

Protocol

This trial protocol has been provided by the authors to give readers additional information about their work.

Protocol for: Trivedi MH, Walker R, Ling W, et al. Bupropion and naltrexone in methamphetamine use disorder.
N Engl J Med 2021;384:140-53. DOI: 10.1056/NEJMoa2020214


Treatment of Methamphetamine Use Disorder with Bupropion and Naltrexone

Protocol Documents

Table of Contents

Final Study Protocol (version 6.0)	page 2 of 221
First Study Protocol (version 1.0)	page 79 of 221
Protocol Change Log (summary of all changes from v1.0 to v6.0)	page 155 of 221
Final Statistical Analysis Plan (version 3.0; contains the first version 0.1 of the Statistical Analysis Plan and summary of SAP changes)	page 168 of 221

Note: Each of the above components contains its own independent table of contents referring to page numbers contained within each of the component documents.



NIDA CTN Protocol 0068

Lead Investigator (LI): Madhukar Trivedi, MD

Version 6.0

January 31, 2019

Details regarding the timing of re-randomization and related statistical analysis (as it contains information about the timing of re-randomization) are omitted from the Protocol to protect the double blind. These details are contained in the confidential Statistical Analysis Plan. The Lead Team will provide the Statistical Analysis Plan directly to the site Institutional Review Board(s) or Independent Ethics Committee.

PROTOCOL DEVELOPMENT TEAM

Lead Investigator:	Madhukar Trivedi, MD Texas Node University of Texas Southwestern Medical Center
Co-Lead Investigator & Project Director:	Robrina Walker, PhD Texas Node University of Texas Southwestern Medical Center
Co-Investigators:	Walter Ling, MD Adriane de la Cruz, MD, PhD
Protocol Development Team:	Linda Chang, MD Mora Kim, MPH
CCTN Project Coordinators:	Udi Ghitza, PhD National Institute on Drug Abuse Petra Jacobs, MD National Institute on Drug Abuse
Clinical Coordinating Center:	Robert Lindblad, MD CCC Principal Investigator Eve Jelstrom, CRNA, MBA CCC Co-Principal Investigator Prashanth Parmar, MS Protocol Specialist
Data Coordinating Center:	Paul Van Veldhuisen, PhD DSC Principal Investigator Gaurav Sharma, PhD DSC Statistician Lauren Yesko DSC Project Manager Ashley Case DSC Data Manager

TABLE OF CONTENTS

1.0	LIST OF ABBREVIATIONS	7
2.0	SCHEMA.....	8
3.0	SYNOPSIS.....	9
4.0	BACKGROUND AND RATIONALE	11
4.1	Background.....	11
4.1.1	Treatment of Stimulant Use Disorder (Amphetamine-type) with Naltrexone	11
4.1.2	Figure 1. Percentages of Urine Samples Negative for MA	12
4.1.3	Treatment of Stimulant Use Disorder (Amphetamine-type) with Bupropion	13
4.1.4	Figure 2. Abstinence for the last two weeks among non-daily MA users	15
4.1.5	Figure 3. Weekly Abstinence Rates for Light Users versus Heavy Users.....	15
4.2	Study Rationale.....	16
4.3	Significance of the Project to the Field	17
5.0	OBJECTIVES.....	18
5.1	Primary Objectives	18
5.2	Secondary Objectives	18
6.0	DESIGN	19
6.1	Overview of Study Design	19
6.2	Duration of Study and Clinic Visit Schedule.....	19
6.3	Participant Selection	20
6.3.1	Inclusion Criteria	20
6.3.2	Exclusion Criteria	21
6.4	Site Selection	22
6.4.1	Site Characteristics	22
6.4.2	Rationale for Site Selection.....	23
6.5	Randomization Plan	23
6.6	Study Intervention	23
6.7	Outcome Measures.....	24
6.7.1	Primary Efficacy Outcome Measure	24
6.7.2	Primary Safety Outcome Measure	24
6.7.3	Secondary Outcome Measures.....	24
7.0	PROCEDURES	26
7.1	Screening and Baseline Phase	26
7.1.1	Pre-screening Assessment	26
7.1.2	Informed Consent	26
7.1.3	Screening and Baseline Assessments	26
7.1.4	Naltrexone Pre-Induction Strategy	27
7.1.5	Final Confirmation of Eligibility	28
7.2	Medication Phase.....	28
7.2.1	Randomization	28

7.2.2	Pharmacotherapy.....	28
7.2.3	Medical Management.....	29
7.2.4	Medication Adherence	29
7.2.5	Participant Medication Withdrawal	29
7.2.6	Medication Phase Visits	31
7.3	Follow-up Phase	31
7.3.1	Oral Study Medication Taper.....	31
7.3.2	Post-Medication Phase Follow-up Visits	31
7.4	Study Medication Management/Drug Accountability.....	31
7.4.1	Documentation.....	31
7.4.2	Storage	31
7.4.3	Packaging	32
7.4.4	Ordering and Dispensing	33
7.4.5	Used/Unused Medication	33
7.4.6	Lost Medication.....	33
7.4.7	Maintaining and Breaking Blind.....	33
7.5	Participant Compensation	34
7.5.1	Table 1. Compensation Schedule	34
8.0	ASSESSMENTS	36
8.1	Table 2. Schedule of Assessments	37
8.2	Screening Measures	38
8.2.1	Pre-Screening Interview Form.....	38
8.2.2	Informed Consent	38
8.2.3	Demographics Form	38
8.2.4	Alcohol and Substance Use History	38
8.2.5	DSM-5 Checklist	38
8.2.6	Psychiatric Diagnostic Screening Questionnaire	38
8.2.7	Self-Report of HIV Testing	38
8.2.8	Medical and Psychiatric History	39
8.3	Safety Measures	39
8.3.1	Physical Examination.....	39
8.3.2	Electrocardiogram (ECG).....	39
8.3.3	Injection Site Examination.....	39
8.3.4	Injection Site Abnormality Log.....	39
8.3.5	Clinical Laboratory Tests.....	39
8.3.6	Concise Health Risk Tracking - Participant Rated Module	40
8.3.7	Pregnancy and Birth Control Assessment.....	40
8.3.8	Vital Signs.....	40
8.3.9	Prior and Concomitant Medications	40
8.3.10	Adverse Events (AEs) and Serious Adverse Events (SAEs)	40
8.3.11	Naloxone Challenge Form	41


8.4	Efficacy Measures.....	41
8.4.1	Urine Drug Screen	41
8.4.2	Timeline Followback	41
8.4.3	Visual Analog Craving Scale	42
8.4.4	Patient Health Questionnaire-9	42
8.4.5	Treatment Effectiveness Assessment	42
8.4.6	Tobacco Use History.....	42
8.4.7	Quality of Life.....	42
8.4.8	Sexual Risk Behaviors	42
8.4.9	Genetic Sampling.....	42
8.5	Adherence Measures	43
8.5.1	Study Medication Dosing Logs.....	43
8.5.2	Injection Administration Form.....	43
8.5.3	Oral Medication Dispensation Form	43
8.5.4	Oral Study Medication Blood Levels.....	43
8.5.5	Video Based Adherence to Oral Study Medication Database.....	43
8.5.6	End of Medication Form.....	43
8.6	Administrative and Other Forms.....	44
8.6.1	Locator Form	44
8.6.2	Eligibility - Randomization	44
8.6.3	Missed Visit Form	44
8.6.4	Protocol Deviation Form.....	44
8.6.5	Protocol Satisfaction Surveys.....	44
8.6.6	Study Completion Form	44
9.0	TRAINING.....	45
10.0	STATISTICAL ANALYSES.....	46
10.1	General Design	46
10.1.1	Study Hypothesis	46
10.1.2	Sample Size.....	46
10.1.3	Primary Outcomes	46
10.1.4	Secondary Outcomes	46
10.2	Interim Analyses	47
10.2.1	Sample Size Re-estimation	47
10.2.2	Interim Monitoring of Primary Efficacy Endpoint.....	48
10.2.3	Safety Interim Analyses	48
10.2.4	Conditional Power and Futility.....	48
10.3	Demographic and Baseline Characteristics.....	49
10.4	Description of Plans to Conduct Analyses of Study Results by Sex and Race/Ethnicity	49
10.5	Safety Analysis	49
11.0	REGULATORY COMPLIANCE, REPORTING AND MONITORING	50

11.1	Statement of Compliance	50
11.2	Institutional Review Board Approval	50
11.3	Research Advisory Panel of California (California sites only)	50
11.4	Informed Consent.....	50
11.5	Health Insurance Portability Accountability Act (HIPAA).....	51
11.6	Investigator Assurances	51
11.7	Financial Disclosure	51
11.8	Confidentiality	52
11.9	IND Requirements.....	52
11.10	Regulatory Files	52
11.11	Study Documentation	53
11.12	Records Retention and Requirements.....	53
11.13	Reporting to Sponsor	53
11.14	Safety Monitoring	53
11.14.1	Adverse Events (AEs)	53
11.14.2	Definitions of Adverse Events and Serious Adverse Events	54
11.14.3	Reportable Adverse Events and Serious Adverse Events	54
11.14.4	Data and Safety Monitoring Board (DSMB)	54
11.14.5	Medical Monitor	54
11.15	Protocol Deviations: Reporting and Management.....	55
11.16	Audits.....	55
11.17	Quality Assurance Monitoring	55
12.0	DATA MANAGEMENT AND PROCEDURES	57
12.1	Design and Development	57
12.2	Site Responsibilities	57
12.3	Data and Statistics Center Responsibilities	57
12.4	Data Collection and Entry.....	57
12.5	Data Monitoring, Cleaning, and Editing	57
12.6	Database Transfer and Lock	58
13.0	PUBLICATIONS AND OTHER RIGHTS	59
14.0	SIGNATURES.....	60
15.0	REFERENCES.....	61
16.0	APPENDIX A - Adverse Event Reporting Definitions and Procedures	67
17.0	APPENDIX B - Data and Safety Monitoring Plan	71
18.0	APPENDIX C - Smartphone App-based Medication Adherence Procedures	76

1.0 LIST OF ABBREVIATIONS

Abbreviation	Definition
AE	Adverse Event
AMC	Active Medication Combination
ALP	Alkaline Phosphatase
ALT	Alanine Aminotransferase
AST	Aspartate Aminotransferase
BL	Blood levels of bupropion and/or metabolite
BUP-XL	Extended-release Bupropion
CAP	College of American Pathologists
CCC	Clinical Coordinating Center
CCTN	Center for the Clinical Trials Network
CHRT	Concise Health Risk Tracking
CLIA	Clinical Laboratory Improvement Amendment of 1988
CNS	Central Nervous System
CRF	Case Report Form
CTN	Clinical Trials Network
DSC	Data and Statistics Center
DSMB	Data and Safety Monitoring Board
DSM-5	Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition
eCRF	Electronic Case Report Form
ECG	Electrocardiogram
EDC	Electronic Data Capture system/Advantage eClinical
FDA	Food and Drug Administration
GCP	Good Clinical Practice
GGT	Gamma-Glutamyl Transpeptidase
HIV	Human Immunodeficiency Virus
ICH	International Council on Harmonisation
IM	Intramuscular
IRB	Institutional Review Board
IND	Investigational New Drug
iPLB	Injectable Placebo
LFT	Liver Function Test
LN	Lead Node
MA	Methamphetamine
Mg	Milligrams
NAL	Naloxone
NDA	New Drug Application
NIDA	National Institute on Drug Abuse
NIH	National Institutes of Health
oPLB	Oral Placebo
PCM	Prior and Concomitant Medications
PDSQ	Psychiatric Diagnostic Screening Questionnaire
PI	Principal Investigator
PLB	Placebo Medication Combination
RAP-C	Research Advisory Panel of California
SRB	Sexual Risk Behaviors
SAE	Serious Adverse Event
SOP	Standard Operating Procedure
TEA	Treatment Effectiveness Assessment
TES	Treatment Effectiveness Score
TLFB	Timeline Followback
UDS	Urine Drug Screen
VAS	Visual Analog Scale
XR-NTX	Extended-Release Naltrexone (as Vivitrol®)

2.0 SCHEMA



Randomization to AMC or PLB occurs the day of successful completion of the naltrexone pre-induction strategy. During the medication phase, participants may or may not be switched (re-randomized) to another arm, as determined by the a priori adaptive aspect of the study design. Participants appearing to respond well to their original treatment assignment will not be switched.

3.0 SYNOPSIS

STUDY OBJECTIVE: The primary objective of this study is to evaluate the efficacy of extended-release naltrexone plus bupropion as a combination pharmacotherapy for methamphetamine use disorder. Secondary objectives include assessing the safety of naltrexone plus bupropion and determining the efficacy of the combination pharmacotherapy on other substance use outcomes, on depression symptom scores, and on quality of life ratings.

STUDY DESIGN: This is a double-blind, placebo-controlled, adaptive randomized clinical trial in which 400 individuals with moderate or severe methamphetamine use disorder will be randomly assigned to the 1) active medication combination (AMC) arm in which injections of extended-release naltrexone (XR-NTX; as Vivitrol®) plus once daily oral extended-release bupropion (BUP-XL) tablets will be provided or the 2) matching placebo (PLB) arm in which injections of placebo (iPLB) and once daily oral placebo (oPLB) tablets will be provided. During the course of the study, participants may or may not be switched to another arm, as determined by the a priori adaptive aspect of the study design. Participants appearing to respond well to their original treatment assignment will not be switched. Overall, approximately 50% of the participants will receive the AMC. After establishing eligibility during a maximum 21-day screening period, participants will begin the 12-week medication phase. Randomization will be stratified by site. At the end of the 12-week medication phase, participants will complete a follow-up phase, including an oral medication taper. Post-medication phase follow-up visits will occur during Weeks 13 and 16.

STUDY PARTICIPANTS: The study sample consists of 400 males and non-pregnant, non-lactating females, ages 18 to 65 years old, who have met all eligibility criteria, including DSM-5 criteria for moderate or severe stimulant use disorder (methamphetamine type), who report using methamphetamine 18 or more days during the 30 days prior to signing consent, and who provide at least 2 methamphetamine-positive urine specimens during screening. Potential participants have up to 3 weeks to meet eligibility criteria after signing consent.

INTERVENTION: The study intervention consists of a 12-week medication phase. Participants randomized to the AMC arm will receive injections of extended-release naltrexone (Vivitrol®) plus 450 mg of once-daily oral extended-release bupropion tablets while participants randomized to the PLB arm will receive placebo injections plus once-daily oral placebo tablets. Injectable study medication will be administered every three weeks (weeks 1, 4, 7, and 10). Take-home oral study medication will be dispensed once weekly for dosing on non-clinic days. Once weekly medical management sessions with the study medical clinician will be provided. Medication adherence procedures will include smartphone app-based videos of daily dosing. Participants will be asked to attend clinic twice weekly for observed oral study medication dosing, collection of urine drug screening samples, and self-report assessments. Compensation will be provided for visit attendance and dosing adherence.

ASSESSMENTS: Screening/baseline assessments include safety and medical measures including a medical and psychiatric history, a physical examination, clinical lab tests (blood chemistry, hematology, and urinalysis), 12-lead electrocardiogram, vital signs, and pregnancy tests (for females). Screening/baseline assessments also include psychological and drug use measures. Methamphetamine use outcome assessments include Urine Drug Screens (UDS), self-reported use via the Timeline Followback (TLFB), and Visual Analog Scale (VAS) craving scores. Other outcome assessments include UDS and TLFB (i.e., alcohol, tobacco, and/or illicit drugs), depression (Patient Health Questionnaire-9), quality of life (QOL), functioning (Treatment Effectiveness Assessment), and clinic attendance. Safety measures include monitoring vital signs, adverse events (AEs), concomitant medications, clinical lab results, and assessments of suicidality. Oral study medication adherence will be assessed by self-report, quantitative blood levels of bupropion and its primary metabolite, and smartphone app-based dosing confirmation procedures.

A blood sample for genetic analysis will be collected from randomized participants who consent to this procedure and the de-identified sample will be sent to a cell and DNA repository.

ANALYSES: The primary analysis will evaluate the impact of the AMC arm, relative to PLB, on methamphetamine use. The primary efficacy outcome is a measurement of treatment response based on MA-negative urine drug screen results obtained during weeks 5 to 6 and weeks 11 to 12 of the medication phase. Outcome variables will be analyzed using appropriate statistical methods for the intention-to-treat (ITT) population and for the evaluable population.

4.0 BACKGROUND AND RATIONALE

4.1 Background

Many years of concerted efforts have produced no effective medication to help initiate and maintain abstinence from methamphetamine (MA). Several promising candidates have shown preliminary clinical utility, including bupropion and naltrexone (Elkashef et al., 2008; Jayaram-Lindström et al., 2008b). Development of a safe and effective pharmacotherapy is an important objective with considerable public health significance.

For many medical conditions, combinations of medications may be routine in clinical practice but are emerging only recently for methamphetamine pharmacotherapy. Well-publicized combination pharmacotherapy studies have tested combination medications for depression (CO-MED, Zisook et al., 2011; STAR-D, Trivedi et al., 2006) made possible by the availability of a number of medications approved for depression. Two notable attempts within the National Institute on Drug Abuse National Drug Abuse Treatment Clinical Trials Network (NIDA CTN) include the *Cocaine Use Reduction with Buprenorphine* (CTN-0048 CURB) trial, a Vivitrol+Suboxone combination trial for cocaine dependence (Ling et al., 2016; Mooney et al., 2013), and the *Accelerated Development of Additive Pharmacotherapy Treatment* (CTN-0054 ADAPT) pilot trial completed in early 2015 that examined the combination pharmacotherapy naltrexone plus bupropion for MA use disorder in an open-label design (Mooney et al., 2016). Findings from the ADAPT pilot study provided a signal sufficient to advise the development of a fully powered, placebo-controlled study to test the efficacy of the combination in producing sustained abstinence from methamphetamine at the end of the study (see below).

4.1.1 Treatment of Stimulant Use Disorder (Amphetamine-type) with Naltrexone

There is modest research to support the individual constituents of the combination pharmacotherapy of naltrexone and bupropion as a putative treatment for MA use disorder.

Naltrexone mechanism of action: An early human laboratory study provided some evidence for modulation of the opioid system as the mechanism of action of naltrexone in its ability to reduce reinforcing effects of amphetamine (Jayaram-Lindström et al., 2005). Although not completely clear, the action of naltrexone that may work to reduce the reinforcing effects of alcohol and other drugs appears to derive from a blockade of effects of endogenous opioid peptides by occupation and binding of opioid receptors. A retrospective pooled data analysis of three studies examining alcohol dependent participants with single nucleotide polymorphism (SNP) A118G (heterozygous or homozygous) found that participants treated with naltrexone were substantially less likely to relapse (Oslin et al., 2003). However, one small randomized trial showed no difference in outcomes along this SNP (A118A vs. A118G) when prospectively assigning individuals to open-label injectable naltrexone treatment for methamphetamine dependence (Pal et al., 2015). More recent controlled human laboratory data show that compared to placebo, steady state naltrexone at 50 mg per day significantly blunted cue-induced craving for methamphetamine and attenuated several of the hedonic subjective effects of methamphetamine, including craving, during administration of 30 mg IV methamphetamine challenge. Specifically, naltrexone decreased subjective ratings of "crave drug," "stimulated," and "would like drug access," decreased the post methamphetamine administration time course of "anxious," and increased ratings of "bad drug effects," as compared to placebo (Ray et al., 2015). There is no aversive response to administration of opioids or alcohol while naltrexone is present at clinical dosages.


Efficacy of naltrexone in treating stimulant use disorders: A study conducted in Sweden (Jayaram-Lindström, 2008b) indicated that naltrexone reduced amphetamine use among human subjects, though this efficacy was tested only for patients who could achieve two weeks of

abstinence during the baseline screening period. Previously, efficacy of naltrexone for stimulant use disorder was found by Schmitz et al. (2001), reporting cocaine use decreased over time among cocaine-dependent patients taking 50 mg oral naltrexone compared to placebo. A question persists as to whether similar reductions can be expected among polydrug users, as the same authors subsequently found no effect on drug use among a sample of alcohol- and cocaine-dependent individuals treated with 50 mg/day (Schmitz et al., 2004). In contrast, Comer et al. (2006), in a study of combination opioid and stimulant abusers, found that cocaine use was reduced among the portion of the sample randomized to 384 mg of sustained-release naltrexone, virtually the same dosage of the extended-release formulation to be used in this protocol.

Efficacy of naltrexone in treating amphetamine dependent individuals: The clinical data emerging from research examining oral naltrexone in amphetamine dependent humans in Sweden provide convincing rationale for the exploration of naltrexone for MA dependence. Jayaram-Lindström and colleagues (2005) established tolerability and feasibility of naltrexone in an open-label trial, finding mild and transient side effects (nausea, headache, abdominal pains) and documenting reduced frequency and quantity of amphetamine use during treatment than before naltrexone treatment. Furthermore, in a double-blind trial, the same Swedish group (Jayaram-Lindström et al., 2008a) found that naltrexone reduced subjective effects of amphetamine. Subsequent work (Jayaram-Lindström et al., 2008b) found that oral naltrexone was effective in suppressing relapse to stimulant use among individuals meeting DSM-IV criteria for amphetamine dependence. While the current study protocol was being developed, a double-blind, randomized, placebo-controlled trial (NCT01449565) of the injectable form of naltrexone was being conducted in San Francisco among methamphetamine dependent men who have sex with men (Coffin et al., 2017). Participants were assigned to extended-release injectable naltrexone (n=50) or matched placebo (n=50), administered every 4 weeks for a 12-week period. All participants reduced their methamphetamine use, as evidenced by urine drug screens, during the primary outcome evaluation period of intervention weeks 2 to 12; however, there were no significant differences by intervention arm. Therefore, this recent study does not provide support for the clinical benefit of the use of naltrexone alone as a treatment for methamphetamine dependence in men who have sex with men and who use methamphetamine during sex. Notably, study participants had excellent medication adherence, which lends support to the acceptability and tolerability of this medication in a methamphetamine dependent sample.

Figure 1, from Jayaram-Lindström et al. (2008b), shows percentages of urine samples negative for MA, presented in the figure on the left in the intention-to-treat sample—for the naltrexone group (diamonds) versus the placebo group (circles)—and for the completer group in the right figure.

4.1.2 **Figure 1. Percentages of Urine Samples Negative for MA**



The rationale for including extended-release injectable naltrexone (XR-NTX) in the original CTN-0054 trial was based on preclinical and clinical pharmacology, as well as on results of clinical trials using oral naltrexone in the treatment of amphetamine dependent individuals. Opiate antagonists, particularly naltrexone, have been shown to reduce amphetamine-induced dopamine

release and amphetamine-induced locomotor activity in rats (Hitzemann et al., 1982), attenuate amphetamine-induced locomotor sensitization in rats (Haggkvist et al., 2011a), reduce cue-induced reinstatement for MA in rats (Anggadiredja et al., 2004), block amphetamine-induced reinstatement of amphetamine self-administration in rats (Haggkvist et al., 2009), reduce the subjective effects of amphetamine in amphetamine-dependent patients (Jayaram-Lindström et al., 2008a), and prevent relapse to amphetamine in a double-blind, placebo-controlled trial (Jayaram-Lindström et al., 2008b). The progression of work logically extends from research on preclinical effects of opiate antagonists, to a clinical pharmacology demonstration of attenuation of amphetamine by naltrexone, to an outpatient efficacy study, then to the CTN-0054 combination medication trial on which the present trial is based.

4.1.3 Treatment of Stimulant Use Disorder (Amphetamine-type) with Bupropion

Bupropion is an antidepressant with stimulant properties that has been proven effective for the treatment of nicotine dependence (Richmond & Zwar, 2003). The antidepressant effects of bupropion may be related to its noradrenergic and dopaminergic mechanisms of action. Bupropion has a favorable side effect profile: it causes fewer anticholinergic, cardiovascular, sedative or adverse sexual effects than tricyclics and does not cause weight gain (Bryant, Guernsey, & Ingram, 1983). Bupropion has been studied as an attractive candidate medication for the treatment of stimulant use disorder, which is associated with dopaminergic dysregulation that may contribute to craving and drug seeking. Restoration of dopamine deficit states, combined with bupropion's ability to alleviate dysphoria observed in early abstinence from stimulants (Newton et al., 2004), may in turn reduce craving and help prevent relapse.

Bupropion has been investigated as a treatment for cocaine use disorder. In a pilot study, Margolin et al. (1991) found that 300 mg/day bupropion substantially reduced cocaine use in four of the five cocaine-dependent, methadone-maintained patients, was well tolerated, and reduced self-reported craving for cocaine. A multicenter placebo-controlled double-blind clinical trial of bupropion for cocaine dependence in methadone-maintained patients indicated efficacy of bupropion for the subgroup of patients with depression at study entry (Margolin et al., 1995).

The results of preclinical studies designed to test the effectiveness of bupropion to block effects of MA support clinical use for the treatment of MA dependence (Kim et al., 2000). Bupropion provides complete protection against MA-induced decrease in dopamine uptake in the striatum in an in vitro model of MA-induced dopamine nerve terminal toxicity. The combination of bupropion's dopaminergic activity and antidepressant properties may enhance its efficacy in the treatment and relief of the signs and symptoms of MA withdrawal and for reduction of relapse.

In a Phase 1 double-blind inpatient clinical laboratory study, 26 subjects with a DSM-IV diagnosis of MA dependence or abuse were randomized to receive either twice-daily bupropion XL (150 mg twice daily) or placebo control and a series of 3 infusions of saline or MA. The first and second infusions were randomized to be either 0 mg or 15 mg of either saline or MA, and the last infusion was always 30 mg of saline or MA (Newton et al., 2006). Of the 26 subjects enrolled, 20 completed the entire study, with 10 subjects in each of the bupropion and placebo control groups. Bupropion treatment was associated with reduced ratings of "any drug effect" ($p = 0.02$), and "high" ($p = 0.02$) as assessed with visual analog scales following MA administration. Bupropion also significantly reduced cue-induced craving [General Craving Scale total score ($p = 0.002$); Behavioral Intention subscale ($p = 0.001$)] (Newton et al., 2006). Bupropion treatment was well tolerated, with the bupropion- and placebo-treated groups reporting similar rates of adverse events. MA administration was associated with expected stimulant cardiovascular effects, and these were not accentuated by bupropion treatment. Instead, there was a trend for bupropion to reduce MA-associated blood pressure increases and a statistically significant reduction in MA-associated heart rate increases (Newton et al., 2005).

Pharmacokinetic analysis revealed that bupropion treatment reduced the plasma clearance of MA and lowered plasma concentrations of the metabolite amphetamine in the plasma (Newton et al., 2005). MA administration did not alter the peak and trough plasma concentrations of bupropion or its metabolites.^{[1][1][1]}

A NIDA Phase 2 efficacy study showed that bupropion significantly decreased MA use in MA-dependent participants who were using MA 18 days or less in the 30-day period prior to the start of screening (Elkashef et al., 2008). This study was a double-blind, placebo-controlled, randomized, two-arm, parallel-group design comparing 150 mg of bupropion to placebo administered twice daily to MA dependent outpatients. Of the 151 participants in the ITT sample, 121 were considered evaluable. Conclusions regarding the efficacy of bupropion include:

- Results of analysis of the primary outcome measure (weekly proportion of participants with all urine specimens free of MA) showed a trend, albeit statistically non-significant, favoring bupropion over placebo for the entire population (GEE, $p = 0.09$).
- Bupropion showed a statistically significant effect for MA-free weeks in participants who used MA ≤ 18 days in the 30 days prior to the start of screening (GEE, $p = 0.03$).
- A higher percentage of participants in the bupropion group than the placebo group reduced their proportion of MA use days to 50% or less of their baseline rate based on self-report only (Chi-square test, $p = 0.02$).
- Bupropion showed a statistically significant effect for MA-free weeks in males (GEE, $p = 0.04$).
- Bupropion showed a trend toward significance favoring bupropion for MA-free weeks in non-depressed participants (GEE, $p = 0.08$).
- Bupropion showed a statistically significant effect for MA-free weeks in participants without attention-deficit disorder (GEE, $p = 0.02$).

Participants were randomized to receive thrice-weekly CBT and either 150 mg twice daily bupropion SR or placebo. Randomization was balanced by frequency of self-reported MA use in the 30 days prior to the start of screening based on two rates of use: 1) low-rate users had 18 or fewer days of MA use; and 2) high-rate users had 19 or more days of MA use. Of the ITT sample, 47% were low-rate users and 53% were high-rate users. A GEE analysis performed on the primary outcome measure for each of these two study subpopulations as well as for the entire ITT sample showed that the low-rate use group administered bupropion had a statistically significant increase (GEE, $p < 0.04$) in the slope of weekly proportion of participants with MA-negative urines compared to the low-rate use group administered placebo. The high rate of MA use appears to reduce the bupropion effect when examining the entire study population.

Figure 2 illustrates the frequency of abstinence over the last two weeks in non-daily MA users in the bupropion study, in which 15 of 63 subjects (23.8%) achieved abstinence as compared to 3 of 53 (5.7%) in the placebo group. This finding was shown to be statistically significant (Chi-square, $p = 0.01$). Although there was a fairly high dropout rate over the course of the study (approximately 50% of the participants completed the study), it is important to note that there were no significant differences in the rate of dropout between the two groups.

4.1.4 **Figure 2.** Abstinence for the last two weeks among non-daily MA users


Group	Abstinence Last 2 Weeks		
	Fail (%)	Success (%)	Total
Bupropion	48 (76.2%)	15 (23.8%)	63
Placebo	50 (94.3%)	3 (5.7%)	53
	98	18	116

P = 0.01 (Chi-Square test)

Bupropion was well tolerated in this study. The only significant treatment emergent adverse event was nausea. Participants receiving bupropion had a significant increase (Chi-square, $p=0.019$) in the incidence of nausea over the intervention period. One participant (a 31-year-old female) in the bupropion group temporarily discontinued taking bupropion during the study due to an adverse event four weeks after commencing study drug, but the investigator determined that the adverse event was not related to the study drug.

Figure 3 is from Elkashef et al., 2008, showing the relative effects on MA use comparing participants who had reported 18 days or less of use per month at baseline (“light users”) against participants who had used more than 18 days per month (“heavy users”).

4.1.5 **Figure 3.** Weekly Abstinence Rates for Light Users versus Heavy Users



To conclude, this study suggested efficacy of bupropion only in participants who had used methamphetamine relatively infrequently at baseline. However, in the Mooney et al. (2016) study, the medication combination of once-daily 450 mg bupropion XL and extended-release injectable naltrexone resulted in a clinically-meaningful outcome in terms of proportion of methamphetamine dependent participants who met “responder” criteria. Unlike in the Elkashef et al. (2008) study, these “responders” were participants who had used methamphetamine frequently, having self-

reported at least 20 days of MA use in the 30 days prior to consent, and having submitted 3 MA-positive urine drug screens out of 4 collected during screening. Thus, the 450 mg dose of bupropion XL used in the Mooney et al. (2016) trial merits further evaluation in a sufficiently powered, randomized, placebo-controlled trial.

4.2 Study Rationale

Interest in the combination of naltrexone with other medications, especially with cognitive enhancers and anti-depressants (e.g., methylphenidate, bupropion, modafinil, mirtazepine), has increased. For example, “a formulation that combines naltrexone with methylphenidate could be a useful pharmaceutical approach to alleviate abuse potential of methylphenidate and other stimulants” (Zhu et al., 2011). The efficacy of naltrexone in reducing stimulant use has been empirically documented (Jayaram-Lindström et al., 2008b). Still, the medication is not wholly effective (e.g., Coffin et al., 2017), which is also true of another medication—bupropion—which has been extensively studied in trials for MA dependence. Bupropion has been found to be somewhat successful at reducing MA use in dependent patients but demonstrates an uneven response across patient types (e.g., many patients did not complete protocols, and participants assessed at baseline as high-frequency users did less well than low-frequency users).

The rationale for combining bupropion and naltrexone, as examined in CTN-0054, is predicated on their potentially complementary effects as shown in clinical research and as postulated in mechanistic arguments for naltrexone (e.g., Hanson, 2004), for bupropion, which may involve noradrenergic and/or dopaminergic effects (e.g., Ascher et al., 1995; Newton et al., 2006), and for the combination, which could regulate the mesolimbic reward pathways (Ornellas & Chavez, 2011). Anecdotal reports derived from research involving opioid addicts who also use stimulants (e.g., Comer et al., 2006) also substantiate the utility of naltrexone for reducing MA use. The combination of naltrexone and bupropion had also been studied in research on the efficacy of the combination pharmacotherapy for controlling obesity (e.g., Greenway et al., 2010; Wadden et al., 2011) leading to the marketing of Contrave® for weight management. In a small (n = 7) clinical pharmacology trial, however, steady state naltrexone (50 mg per day), bupropion (300 mg per day), and their combination showed no statistically significant effect on behavioral responses or subjective effects following 0 mg, 10 mg or 30 mg intranasal methamphetamine (Stoops, Hays, Glaser, & Rush, 2015).

Combination pharmacotherapy, whereby medications exerting effects on different mechanisms of action may complement each other to help reduce stimulant use and to prevent relapse to stimulant use once abstinence has been attained, can be conceived in three ways: (1) one medication may act to enable the effects of other medication(s) as in CTN-0048 where the effect of Vivitrol® allowed buprenorphine to exert the hypothesized therapeutic effect under investigation; (2) one medication may act to enhance therapeutic effects of another, including possibly reducing side effects, as in combining different opioids in clinical pain management; and (3) the two medications may synergistically exert their combined effects as a novel compound and be studied as a single test agent. In this protocol, bupropion may serve to ameliorate some of the anhedonia and dysphoria that characterize early-phase abstinence from MA, and it also may counteract some of the side effects associated with naltrexone.

Some of the best evidence in support of this protocol is from the CTN-0054 pilot trial that was conducted as an open-label study of 49 participants at three sites in two CTN Nodes (Nexus Recovery Center, Inc., Texas Node; Integrated Substance Abuse Programs (ISAP) and University of Hawaii (UH), Pacific Region Node). Treatment-seeking, severe MA users (using an average of 27 days out of the previous 30 prior to enrollment) were given bupropion XL (450 mg) daily and XR-NTX every 4 weeks for 8 weeks. Many procedures being proposed for this phase III RCT were developed and evaluated in the initial pilot trial, including collection of data regarding the tolerability and titration procedures for the 450 mg bupropion in the AMC condition. The intent-to-

treat (ITT) analysis in the pilot trial defined the primary efficacy endpoint as the number of responders, with responders defined as participants who provide at least 6 MA-negative UDS tests during the last four weeks of the active medication phase (weeks 5 – 8), including a MA-negative UDS test at the last clinic visit in week 8. Out of 49 participants, 9 responders were required to indicate that the medication combination has sufficient potential efficacy to warrant a fully-powered phase III, placebo-controlled trial. Findings from the 49 participants included in the analysis of the primary efficacy endpoint indicated that 11 were responders, which met the a priori specified criterion requiring 9 or more responders ($p = 0.0075$). The unbiased estimate of the responder rate was 24%, and the 95% lower confidence limit was 13%. There were no significant site, sex, race or ethnicity differences by responder status. The responder rate was highest at the ISAP site (27.8%) and lowest at the Nexus site (15.8%). Seven (26.9%) males and 4 females (17.4%) were responders. Four (16.7%) whites and 7 others (4 multiracial and 3 others) were responders. Seven responders were not Hispanic or Latino, and 4 were Hispanic or Latino.

These data were used to support development of the current phase III randomized, double-blind, placebo-controlled trial of this combination pharmacotherapy to produce abstinence for participants with methamphetamine use disorder. It is intended that participants randomized to the active medication arm receive the maximum safe dose of both bupropion and naltrexone to maximally enable them to become abstinent within the treatment phase of this study. The recommended dosing regimen of Vivitrol® is every four weeks; however, plasma levels of naltrexone and its metabolite are at a plateau during the first three weeks after administration but fall off in the fourth week. Replenishment of the depot supply of naltrexone at the beginning of the fourth week by re-injecting Vivitrol® should prevent that decline and allow evaluation of the maximum safe dose of the combination medication.

4.3 Significance of the Project to the Field

Identifying an effective medication, or combination of medications, to help achieve abstinence and to prevent relapse to MA use is an important objective with considerable public health significance. The proposed placebo-controlled trial, based on preliminary evidence established in the CTN-0054 ADAPT pilot trial, will advance medication research and potentially confirm the naltrexone plus bupropion combination as the first effective pharmacotherapy for the treatment of stimulant use disorder involving MA.

5.0 OBJECTIVES

The objective of this study is to evaluate an active medication combination (AMC) that comprises extended-release naltrexone (XR-NTX) plus bupropion (BUP-XL) as a potential pharmacotherapy for methamphetamine use disorder.

5.1 Primary Objectives

The primary objective of this study is to evaluate the efficacy of the AMC arm, compared to a matched placebo (PLB) arm, in reducing methamphetamine use in individuals with moderate or severe methamphetamine use disorder seeking to stop or reduce methamphetamine use. It is hypothesized that the AMC arm will be associated with a greater number of “responders,” defined as participants who provide a pre-specified number of MA-negative UDS tests obtained during the evaluation period (i.e., weeks 5 to 6 and weeks 11 to 12) of the 12-week long medication phase, relative to the PLB arm.

5.2 Secondary Objectives

Secondary objectives include evaluating the effect of the AMC arm, compared to the PLB arm, on safety, other substance use outcomes, depression scores, quality of life, overall functioning, clinic attendance, and medication adherence.

6.0 DESIGN

6.1 Overview of Study Design

The primary objective of this study is to assess the efficacy of extended-release naltrexone plus bupropion as a combination pharmacotherapy for methamphetamine use disorder. There will be 400 individuals randomized into the study across 7 -10 clinical sites. Eligibility will be determined during a maximum 21-day screening period. To document an appropriate level of current methamphetamine use, prospective participants must submit at least 2 urine samples positive for methamphetamine of a possible 3 tests to occur within a 10-day period during which clinic visits occur with at least 2 days between visits. In addition, participants must self-report MA use on 18 or more days in the 30-day period prior to consent using the Timeline Followback (TLFB) and meet diagnostic criteria for moderate or severe methamphetamine use disorder per DSM-5 (4 or more criteria) at screening. After screening is completed and eligibility is confirmed, participants will begin the 12-week medication phase of the trial. Participants will be randomized to either the 1) AMC arm and receive injections of extended release naltrexone (XR-NTX; as Vivitrol®) plus once-daily oral extended-release bupropion tablets (BUP-XL) or the 2) matching placebo (PLB) arm and receive injections of placebo (iPLB) plus once-daily oral placebo (oPLB) tablets. This protocol will utilize a sequential parallel comparison design (SPCD), originally proposed by Fava et al. (2003), and later revised by Chen et al. (2011). A feature of this design is that it can reduce the overall placebo response rate. One advantage of the adaptive aspect of the design is that it requires a smaller sample size compared to a standard two group randomized trial design. During the course of the study, participants may or may not be switched to another arm, as determined by the a priori adaptive aspect of the study design. Participants appearing to respond well to their original treatment assignment will not be switched. Overall, approximately 50% of the participants will receive the AMC. Injections will be provided in weeks 1, 4, 7, and 10. Take-home oral study medication will be dispensed weekly for dosing on non-clinic days. Participants will be asked to attend the clinic twice weekly for observed oral medication dosing, assessments, collection of urine samples, and once-weekly medical management. On non-clinic days, participants will participate in smartphone app-based medication adherence activities. Participants will be asked to complete assessments as indicated on the schedule of assessments (see Section 8.0). Following the 12-week medication phase, participants will complete a follow-up phase, including a medication taper and post-medication phase follow-up visits during weeks 13 and 16.

6.2 Duration of Study and Clinic Visit Schedule

Participants will be involved in the study for approximately 19 weeks, including a screening/baseline period of up to 3 weeks (i.e., 21 days), 12 weeks of medication, and a post-medication follow-up phase. The screening phase may differ by participant in the length of time needed to complete preliminary eligibility assessments. Confirmation of opioid-free status (urine drug screen test(s) and optional naloxone challenge) before randomization and medication induction will take approximately 1.5 hours. Twice-weekly visits during the medication phase will range from about 20 to 90 minutes in length depending on scheduled assessments. Once-weekly medical management sessions will require an additional 20 minutes. Medication injection visits will take approximately 2 hours. The post-medication phase follow-up visits will take approximately 1 to 2 hours to complete. A 12-week medication period was selected based on expected time needed to observe clinical benefit and for pragmatic issues related to medication dosing.

Enrollment is expected to take place over a period of approximately 18 months.

6.3 Participant Selection

A total of 400 males and females who meet eligibility criteria will be randomized. Study participants will be recruited using a variety of methods including word-of-mouth, referral, advertising, and study announcement flyers posted in local treatment programs. The study sites should attract a diverse study population. Efforts will be made to recruit a study sample that reflects, or exceeds, the proportion of minorities in the community where the site is located. Recruitment procedures aiming to enhance enrollment of women and/or minorities will be conducted, including linkages with medical sites and/or treatment programs that serve a large number of women and/or minorities, and advertising in media outlets with high female/minority audience. Participants will not receive other formal addiction treatment services while they are participating in the study. Thus, at the time of randomization participants must be willing to have the study intervention serve as their sole treatment during study participation. Mutual help support group attendance will be encouraged throughout the trial. Upon study completion, participants may enroll in behavioral or pharmacological addiction treatment services.

6.3.1 Inclusion Criteria

Study participants **must**:

1. Be 18 to 65 years of age;
2. Be interested in reducing or stopping methamphetamine use;
3. Be able to speak English sufficiently to understand the study procedures and provide written informed consent to participate in the study;
4. Meet DSM-5 criteria for moderate or severe methamphetamine use disorder (4 or more criteria);
5. Self-report methamphetamine use on 18 or more days in the 30-day period prior to consent using the Timeline Followback (TLFB);
6. Provide at least 2 urine samples positive for methamphetamine out of a possible 3 tests to occur within a 10-day period during which clinic visits occur with at least 2 days between visits;
7. If female, agree to use acceptable birth control methods and have periodic urine pregnancy testing done during participation in the study unless documentation of hysterectomy provided;
8. Meet subjective and objective measures of being opioid-free prior to naltrexone induction per study medical clinician's determination;
9. Be willing to comply with all study procedures and medication instructions;
10. Agree to use a smartphone app (downloaded for free to own device or on a study provided smartphone device) to take daily videos of medication dosing.

6.3.2 Exclusion Criteria

Study participants ***must not***:

1. Have an acute medical or psychiatric disorder that would, in the judgment of the study medical clinician, make participation difficult or unsafe;
2. Have suicidal or homicidal ideation that requires immediate attention;
3. Have a history of epilepsy, seizure disorder, or head trauma with neurological sequelae (e.g., loss of consciousness that required hospitalization); current anorexia nervosa or bulimia; or any other conditions that increase seizure risk in the opinion of the study medical clinician;
4. Have evidence of second or third degree heart block, atrial fibrillation, atrial flutter, prolongation of the QTc, or any other finding on the screening ECG that, in the opinion of the study medical clinician, would preclude safe participation in the study;
5. Have Stage 2 hypertension as determined by the study medical clinician (e.g., greater than or equal to 160/100 in 2 out of 3 readings during screening);
6. Have any elevated bilirubin test value per laboratory criteria OR any other liver function test (LFT) value > 5 times the upper limit of normal per laboratory criteria;
7. Have a platelet count <100 x 10³/μL;
8. Have a body habitus that precludes gluteal intramuscular injection of XR-NTX in accordance with the administration equipment (needle) and procedures;
9. Have a known allergy or sensitivity to bupropion, naloxone, naltrexone, PLG (polyactide-co-glycolide), carboxymethylcellulose or any other component of the XR-NTX diluents;
10. Have been in a prior study of pharmacological or behavioral treatment for methamphetamine use disorder within 6 months of study consent;
11. Have taken an investigational drug in another study within 30 days of study consent;
12. Have been prescribed and taken naltrexone or bupropion within 30 days of study consent;
13. Be concurrently enrolled in formal behavioral or pharmacological addiction treatment services;
14. Be receiving ongoing treatment with tricyclic antidepressants, xanthines (i.e., theophylline and aminophylline), systemic corticosteroids, nelfinavir, efavirenz, chlorpromazine, MAOIs, central nervous system stimulants (e.g., Adderall, Ritalin, etc.), or any medication that, in the judgment of the study medical clinician, could interact adversely with study medications;
15. Have a current pattern of alcohol, benzodiazepine, or other sedative hypnotic use which would preclude safe participation in the study as determined by the study medical clinician;
16. Require treatment with opioid-containing medications (e.g., opioid analgesics) during the study period;
17. Have a surgery planned or scheduled during the study period;

18. Are currently in jail, prison or any inpatient overnight facility as required by court of law or have pending legal action or other situation (e.g., unstable living arrangements) that could prevent participation in the study or in any study activities;
19. If female, be currently pregnant, breastfeeding, or planning on conception.

Although not targeted for recruitment, this study obtained authorization from the Office for Human Research Protections (OHRP) to follow-up with study participants who happen to become incarcerated during the trial, as needed and feasible at the individual study sites. Study staff may work with institutions to arrange research visits, and any needed assessments and procedures the institution will allow may be completed. Study medications will be discontinued during incarceration.

6.4 Site Selection

The trial will include 7 -10 sites with each site randomizing approximately 30-70 participants.

6.4.1 Site Characteristics

Participating sites ***must***:

1. Have a physician who can commit the time necessary to take a leadership role and oversee all medical aspects of the study, perform medical assessments, confirm participant eligibility, order and dispense or administer study medications, review adverse events, and appropriately evaluate and respond to adverse reactions that may occur during the course of the study.
2. Have at least one other medical clinician (i.e., physician, physician's assistant, or nurse practitioner) who can, in accordance with the regulations of the state where the site is located, make independent medical decisions and commit the time necessary to perform medical assessments, determine participant eligibility, order and dispense or administer study medications, review adverse events, and appropriately respond to adverse reactions that may occur during the course of the study.
3. Have standard operating procedures in place for handling medical and psychiatric emergencies.
4. Have a physician available to provide after-hours clinical back-up for study-related emergencies.
5. Have access to a phlebotomist or other qualified personnel to complete blood draws.
6. Have the ability to meet storage and dispensing requirements for all study medications, including access to adequate storage space, equipment, and appropriately qualified staff, as directed by the protocol and in accordance with local regulations and NIDA stipulations.
7. Have access to, or the ability to contract with, a local laboratory to process biological specimens (e.g., blood and/or urine) in a timely manner during screening.
8. Have adequate facility space available to conduct study procedures.

6.4.2 Rationale for Site Selection

The sites selected for participation in this trial will be selected, in part, based on the node's interest in participating in the trial, the availability of a sufficient pool of potential study participants in the area, and the presence of an existing team of experienced personnel at the site knowledgeable in clinical trial operations and trained in core CTN assessments. Information on site readiness and capacity will be gathered via a site survey and a coordinated site/investigator selection process will confirm the following:

1. An ability to recruit and randomize 3-4 eligible individuals with methamphetamine use disorder each month.
2. Experienced regulatory personnel capable of the timely preparation of necessary regulatory documents and having the ability to facilitate an expeditious IRB submission, approval, modification, and continuing review processes.
3. Medical staff who can commit the time necessary to oversee all medical aspects of the study, perform medical assessments, confirm participant eligibility, order and administer or dispense study medications, and appropriately respond to possible adverse reactions that may occur during the course of the study.
4. Staff familiar with web-based Electronic Data Capture systems and who have the capacity and discipline to conform to protocol-required direct data entry procedures.
5. Adequate and available space that is suitable for the performance of study procedures.

6.5 Randomization Plan

Eligible participants will be randomized to the AMC and PLB treatment arms, stratifying by site. During the course of the medication phase, participants who provide sufficient UDS for evaluation of outcomes may or may not be switched to another arm. Switching, or re-randomization parameters, were determined a priori and are based on a combination of original treatment assignment, availability of data, and treatment response. Participants appearing to respond to their original treatment assignment will not be switched. Re-randomization will be implemented automatically by computer and will be stratified by site. Overall, approximately 50% of the participants will receive the AMC.

The randomization process will be conducted centrally and electronically by the CTN Data and Statistics Center (DSC) via the Advantage eClinical Electronic Data Capture (EDC) system, and randomization assignments will not be conveyed to staff or participants to maintain the double blind. To ensure the lack of predictability while maintaining the designed randomization fraction, an urn scheme similar to one described in Wei and Lachin (1988) will be used. The DSC statistician will review randomization data on a regular basis to ensure that the scheme is being implemented according to plan. A randomization slot, once used, will not be re-allocated.

6.6 Study Intervention

The study intervention consists of 12 weeks of pharmacotherapy, medical management, and medication adherence procedures. Participants randomized to the AMC treatment arm will receive an injection of extended-release naltrexone (XR-NTX; as Vivitrol®) plus 450 mg of once-daily oral extended-release bupropion tablets (BUP-XL). Participants randomized to the PLB treatment arm will receive matched placebo in the form of injections of placebo (iPLB) plus once-daily oral placebo (oPLB) tablets. Injections of study medications (XR-NTX or iPLB) will be

administered in weeks 1, 4, 7, and 10. All randomized participants will receive weekly medical management sessions with the study medical clinician and will utilize smartphone app-based medication adherence procedures.

6.7 Outcome Measures

The primary outcome measure, as described below, is based on urine drug screen (UDS) test results and is considered a clinically significant improvement in methamphetamine use in this study population. The primary outcome (UDS) has been chosen because it is an objective measure of methamphetamine use. Secondary outcome variables are intended to explore various aspects of response to this medication combination and to identify factors that may be associated with treatment response or non-response. Some of the secondary outcome variables add a measure of clinical relevance to the reduction of use by assessing sustained abstinence, reduced frequency of methamphetamine use, reduction in craving that may be a prelude to relapse, and improvements in mood, quality of life, and overall functioning.

6.7.1 Primary Efficacy Outcome Measure

The primary efficacy outcome measure is a composite of MA-negative UDS test results obtained during weeks 5 to 6 and weeks 11 to 12 of the medication phase and will be compared by treatment group (AMC versus PLB).

6.7.2 Primary Safety Outcome Measure

The safety and tolerability of the AMC arm, relative to the PLB arm, will be determined using participants' reports of adverse events (serious and non-serious) collected at clinic visits or via other contact.

6.7.3 Secondary Outcome Measures

Secondary outcome measures for the impact of the AMC, relative to the PLB arm, on other substance use outcomes, depression scores, quality of life, overall functioning, clinic attendance, and medication adherence will be evaluated as follows:

1. Alternate measures and composites of methamphetamine use including:
 - a) The Treatment Effectiveness Score (TES), as measured by UDS results, during the medication phase;
 - b) Frequency of MA use, as measured by self-report, during the medication phase;
 - c) Severity of MA craving, as measured by Visual Analog Craving Scales (VAS), during the medication phase;
 - d) MA use, as measured by UDS and self-report, during the follow-up period.
2. Quantity and frequency of alcohol, tobacco, and other drug use, as measured by self-report, during the medication phase;
3. Change in depressive symptoms, as measured by the PHQ-9, during the medication phase;
4. Changes in quality of life, as measured by the Quality of Life (QoL), during the medication phase;

5. Changes in overall functioning, as measured by the Treatment Effectiveness Assessment (TEA), during the medication phase;
6. Percentage of participants retained in treatment during the medication phase;
7. Ratings of participant and staff satisfaction with study procedures, including use of the medication adherence app, compensation, and medication.

7.0 PROCEDURES

7.1 Screening and Baseline Phase

Assessments administered during screening will determine whether participants meet eligibility criteria and will provide baseline measures of drug use and other important domains. Screening and baseline assessments will be conducted as shown in Table 2 in section 8.0. Participants who do not complete all screening/baseline assessments within 21 days of signing consent, including the naltrexone pre-induction strategy, or who are otherwise found to be ineligible for participation in the study, will be considered screen fails. With Lead Node approval, screen fails may be allowed to return at a later date to repeat the screening process.

7.1.1 Pre-screening Assessment

Individuals responding to recruitment materials or otherwise referred to the study will be pre-screened on the phone or in person to ascertain preliminary eligibility status. A series of questions (e.g., MA use history, interest in participating in research to investigate medications that have potential to reduce MA use, ability and willingness to participate for the duration of the trial) will determine preliminary eligibility. Full screening appointments will be scheduled for those who meet preliminary eligibility criteria.

7.1.2 Informed Consent

At the start of the screening appointment and before any assessments are administered, qualified study personnel will conduct the informed consent process with prospective participants. The informed consent process will begin with a description of the study, including study procedures and study medications. Potential study participants will be given a copy of the IRB-approved consent form to review either on site or at home, in accordance with IRB requirements. Potential study participants who remain interested after review of the consent form will answer written comprehension questions to ascertain their understanding of the study, including its purpose, procedures involved, and the voluntary nature of participation. For participants who do not correctly answer all comprehension items, research staff will re-explain the study, with a focus on aspects candidates did not understand. Participants may attempt the consent comprehension questions a maximum of three times before they are deemed unable to comprehend the study. Any participant who cannot demonstrate appropriate understanding of the study to research personnel will be ineligible to participate and will be assisted in finding other treatment resources if desired. Study participants who demonstrate understanding of the study and who voluntarily agree to participate will be asked to sign the IRB-approved consent form and, if the consent form is signed, will proceed with the screening assessments. As part of the informed consent process, participants also will be asked if they consent to (1) be contacted for future studies and (2) provide a blood sample for genetic testing.

7.1.3 Screening and Baseline Assessments

Upon signing the IRB-approved consent form, participants enter a maximum 21-day screening phase to complete assessments to determine eligibility and to collect baseline data. Screening/baseline assessment procedures must be completed across at least two screening visits.

During the screening phase, participants must submit at least 2 urine samples positive for methamphetamine out of a possible 3 tests to occur within a 10-day period during which clinic visits occur with at least 2 days between visits. Therefore, all screening visits will have at least 2 days elapse between visits. In addition, participants must self-report MA use on 18 or more days in the 30-day period prior to consent using the Timeline Followback. These criteria will be used to

confirm current MA use and further substantiate a diagnosis of moderate or severe methamphetamine use disorder.

Once the participant completes all screening and baseline assessments, submits 2 MA-positive UDS tests, and is found otherwise eligible for continued participation, the participant may begin the naltrexone pre-induction procedure (see below). All consented participants who do not complete all screening assessments within the 21-day screening period or who are otherwise found to be ineligible for study participation will be considered to be screen fails. Demographic data and the reasons for not meeting eligibility criteria must be documented for all screen fails.

7.1.4 Naltrexone Pre-Induction Strategy

The screening/baseline phase includes a naltrexone pre-induction strategy to be conducted on the final screening visit after all other eligibility criteria have been met. The naltrexone pre-induction strategy is designed to ensure participants meet subjective and objective measures of being opioid-free, per the study medical clinician's determination, on the day of and prior to randomization and induction on the injectable study medication. Required and optional procedures are outlined below:

1. Subjective measures of opioid-free status. Participants must self-report no clinically significant opioid use (i.e., at any level that could constitute a potential risk of precipitating opioid withdrawal upon naltrexone administration) in the 7-10 days prior to the day of randomization, as measured using the TLFB and the Prior and Concomitant Medications (PCM) assessment.
2. Objective measures of opioid-free status. To objectively evaluate opioid-free status, a urine sample must be provided and tested on the day of anticipated randomization. Individuals must have negative results for opioids (on the OPI 2000 and the OPI 300 tests) prior to randomization. Individuals with a positive opioid result on these tests may provide an additional urine sample on a subsequent day if the study medical clinician determines that a second screen is appropriate. The study medical clinician must determine suitability for continuing the pre-induction process for individuals positive for opioids on other opioid tests that may be conducted during Screening.
3. *Optional* naloxone challenge. A naloxone challenge is not required but may be administered for definitive determination of opioid free status at the discretion of the medical clinician. If a naloxone challenge is administered, a minimum 0.8 mg bolus must be given before determining the outcome of the challenge. The study medical clinician will use clinical judgment to determine if the participant passes the naloxone challenge and is safe to continue on to randomization and subsequent XR-NTX or iPLB induction. Evidence of withdrawal signs or symptoms following naloxone administration will result in postponement of randomization until a negative naloxone challenge result is achieved. In other words, if a clinician opts to administer a naloxone challenge and withdrawal is precipitated, a second naloxone challenge must be administered, with no withdrawal observed immediately prior to randomization.

Participants who experience withdrawal symptoms following a naloxone challenge may be treated with ancillary medications, observed until symptoms resolve, and given the opportunity to return another day and be re-challenged if clinically indicated. Participants who are not interested in continuing to participate, or who fail a repeat naloxone challenge, will not be eligible to participate in the study but will be given referrals to local treatment programs, as appropriate.

7.1.5 Final Confirmation of Eligibility

After completing all screening and baseline assessments, including the naltrexone pre-induction strategy, the study physician must review and approve safety and eligibility assessments in order to confirm participant eligibility prior to randomization. Randomization will occur on the day the naltrexone pre-induction strategy is completed (i.e., the participant is determined to be opioid-free) after study eligibility has been confirmed and documented.

7.2 Medication Phase

7.2.1 Randomization

Immediately following the naltrexone pre-induction strategy and final assessment and documentation of eligibility, eligible participants will be randomly assigned to the AMC arm or the matching PLB arm. The randomization procedure will be conducted electronically by the Advantage eClinical system. The switching or re-randomization procedure described previously will occur seamlessly by the electronic system, based on data routinely collected and entered.

7.2.2 Pharmacotherapy

Participants will receive the first intramuscular gluteal injection of study medication (XR-NTX or iPLB) on the day of randomization (Day 1), following confirmation of opioid-free status and final confirmation of study eligibility by the study physician. Subsequent intramuscular gluteal injections (XR-NTX or iPLB) will be administered at the beginning of Weeks 4, 7, and 10 and shall be administered following guidelines in the XR-NTX package insert. Study medical clinicians will evaluate participants to ensure continued suitability for injectable study medication administration. Urine drug screening procedures will help clinicians evaluate participant opioid-free status at the time of study medication injection. A naloxone challenge may be administered prior to any study medication injection at the discretion of the study medical clinician.

Take-home oral study medication will be dispensed weekly. The first dose of oral study medication (BUP-XL or oPLB) will be taken on the day of randomization (Day 1) immediately following administration of the injectable study medication. For each clinic visit, participants will be asked to refrain from taking their dose at home and to bring their oral study medication for in-clinic dosing. On the days in which injectable study medication is administered, oral study medication self-administration will occur immediately following the injection. All in-clinic self-administration of oral study medication will be observed by study staff. Participants will take a dosing video using the study app for all in-clinic and non-clinic self-administrations of oral study medication.

If a participant reports intolerable symptoms or side effects at the full 450 mg dose, ancillary medications may be used and/or a dose reduction may occur if deemed appropriate by the study medical clinician. The study medical clinician, in collaboration with the study physician and site principal investigator, is encouraged to consult with the Lead Investigator(s) in making the decision to reduce a participant's dose. The dose may be reduced to 300 mg daily. Medication packaging will allow for dose reductions without re-dispensing; participants will be instructed to take only the tablets in the first two wells for each day they are on a reduced dose. If intolerable adverse effects continue, the participant may be withdrawn from further medication administration. If intolerable adverse effects resolve after an initial dose reduction or are appropriately addressed with the use of ancillary medications, and if deemed appropriate by the study medical clinician, titration to the full 450 mg target dose may be attempted (i.e., participants will be instructed to take all three tablets for each day) on any visit except visits in which injectable study medication is administered.

7.2.3 Medical Management

Medical management procedures will be conducted as follows. Participants will meet with a study medical clinician once weekly for an individual medical management session that utilizes a structured adherence enhancement manual designed for pharmacotherapy trials with subjects with substance use disorder (adapted from Carroll et al., 1996). The goal of medical management sessions is to achieve high quality supportive treatment that reinforces adherence to study procedures and the study medication regimen. A session will be approximately 20 minutes and focus on:

1. Setting abstinence from methamphetamine as a goal,
2. Participant adherence with study medications and procedures,
- and*
3. Current functioning.

Medical clinicians will also review adverse events, consider potential medication side effects, and discuss other pertinent issues in keeping with sound medical practice. Ancillary medications may be provided for study medication-related adverse events as clinically indicated. A range of prescription and over-the-counter ancillary medications may be used for symptoms such as anxiety, nausea, vomiting, diarrhea, muscle pain, and insomnia. At all medical management sessions, the medical clinician will remind participants about the importance of adhering to the study procedures, including attending scheduled clinic visits and complying with smartphone app-based dosing confirmation procedures. Mutual help support group attendance will be encouraged.

7.2.4 Medication Adherence

Medication adherence procedures will be conducted as follows. To encourage and monitor adherence to oral study medication, procedures include discussing adherence during medical management sessions and twice-weekly observed dosing in the clinic as described previously. Procedures also include the use of a smartphone app to take dosing videos to document oral study medication self-administration on non-clinic days and during clinic visits (while staff observe), including on the taper days in the post-medication follow-up phase. Participants will access the app on either a study provided smartphone device or by downloading the app to their personal device. Further details are outlined in Appendix C. Dosing will be assessed by automated visual recognition software during the video capture to ensure the videos clearly show dosing adherence based on assessment criteria. Participants will be compensated for dosing videos (see section 7.5).

7.2.5 Participant Medication Withdrawal

Participants will be withdrawn from further study medication administration if it is clinically determined that continuation may be unsafe. For example, participants who develop uncontrolled hypertension (160/100 or higher on three consecutive visits) will be withdrawn from further study medication administration. Likewise, women who become pregnant during the medication period will be immediately withdrawn from study medication administration. Participants reporting use of medications that may interact with naltrexone or bupropion will be withdrawn based on clinical judgment. Participants who experience intolerable adverse effects or other physical or psychiatric conditions, regardless of relationship to the study medication, may also be withdrawn from further study medication administration.

The medical clinician may determine that a participant's clinical condition has deteriorated during the course of the study to the extent that now taking study medication may be possibly unsafe or unwise. Examples of clinical deterioration that might trigger a decision to withdraw the participant from study medication include the following:

- New onset of psychiatric or medical conditions that would require intervention and preclude continued participation in the study (e.g., emergence of psychosis, suicide risk, severe cognitive impairment, or dangerous criminal behaviors);
- Worsening of a pre-existing psychiatric or medical condition that would preclude continued safe participation in the study;
- Worsening of substance use disorder or overdose such that a higher level of care is indicated;
- Increase in LFT or decrease in platelet test results at week 6 that may increase participant health risks. This includes any of the following: AST/ALT results > 5 times ULN, total bilirubin > 2 times ULN, or platelets below $75 \times 10^3/\mu\text{L}$.

The study medical clinician, in collaboration with the study physician and site principal investigator, should consult with the Lead Investigator(s) and Study Medical Monitor in making the decision to withdraw a participant from study medications. Also, participants may decide at any time that they no longer wish to continue to receive medication or participate in the study.

In most cases, a taper is not indicated if the study medical clinician determines medication discontinuation is warranted for medical or psychiatric reasons. Generally, a taper of bupropion is not medically necessary as there is no evidence of a physiological dependence or increased incidence of adverse events when this medication is discontinued. However, as down titration is common in clinical practice, clinicians are guided to follow this convention for the majority of study participants. If a taper is believed to be necessary based on clinical judgment, the study medical clinician, in collaboration with the study physician and site principal investigator, should consult with the Lead Investigator(s) and Study Medical Monitor on how to best proceed.

In the event a participant becomes pregnant during the medication period, a taper is not indicated as bupropion is a pregnancy category C medication and the risks of taper outweigh the benefits in pregnant women. The pregnant participant will be immediately discontinued from further study medication administration, referred for medical care, and the pregnancy followed until an outcome is known.

A taper is also not indicated for participants who become incarcerated or for participants who lose study medication during the medication phase of the study. Participants who lose study medication will resume their dosing schedule at the appropriate next study visit; no medication should be dispensed earlier than scheduled.

As the primary aim of this study is to evaluate the efficacy of XR-NTX plus BUP-XL as a combination pharmacotherapy, withdrawal from either study medication will typically lead to discontinuation of the other medication. With Lead Node and Study Medical Monitor approval, participants may be allowed to continue on one medication if discontinued from the other. In the event a participant is withdrawn from further study medication administration, referrals to treatment programs or recommendations for medical care will be provided. Unless consent is officially withdrawn, study staff will encourage participants who are withdrawn from study medications or who opt out of study medications to continue attending twice weekly clinic visits and complete study assessments throughout the duration of the medication phase (weeks 1 – 12) and the follow up phase (weeks 13 and 16).

7.2.6 Medication Phase Visits

Given the requirements across study visits (e.g., meeting with medical clinician, blood draws, injections, assignment of oral medication only after the participant arrives, physical exam, ECG, etc.), the study was designed with the expectation that all visits occur at the study site. However, there may be cases in which off-site visits may be possible with Lead Team approval.

7.3 Follow-up Phase

7.3.1 Oral Study Medication Taper

A taper will occur during the first four days of Week 13 (Days 85 – 88) for participants continuing on oral study medication (BUP-XL or oPLB) through the end of the medication phase. The daily dose will be 300 mg for Days 85 and 86 and 150 mg for Days 87 and 88. This taper schedule will apply to all participants, including any participants already taking a reduced dose.

7.3.2 Post-Medication Phase Follow-up Visits

All enrolled participants will be asked to complete post-medication phase follow-up visits in weeks 13 and 16 according to the schedule of assessments (see Table 2, section 8.0). There may be cases in which off-site visits may be possible with Lead Team approval. Tracking and locating strategies will be used to ensure the highest possible follow-up rates.

7.4 Study Medication Management/Drug Accountability

As set forth in the protocol agreement signed by each site principal investigator (see Section 14, Signatures), study sites are required to observe local, state, and federal regulations regarding receipt, custody, dispensing, administration, and associated documentation of all medications used in this study. Medications used in the study include extended-release bupropion, extended-release injectable naltrexone, oral placebo, and injectable placebo provided by the NIDA contractor as well as naloxone purchased and maintained by each site.

7.4.1 Documentation

Upon receipt, the investigator, pharmacist, or authorized designee at each site is responsible for maintaining written inventory of the investigational agents and naloxone obtained for the study. Appropriately trained and qualified personnel will maintain an accurate and real-time accounting of all medications, which will be available for verification by study monitors. Medication accountability records, including perpetual inventory, will document the amount of study medication ordered, received, transferred between areas of the study site (e.g., from pharmacy to clinic), and medications administered to or dispensed to and returned by an individual participant. Documentation will also record unused medications destroyed on site or returned to the NIDA contractor for destruction. As with all study documentation, medication accountability records must be maintained in accordance with Good Documentation Practices and must be attributable, legible, contemporaneous, original, accurate, and complete.

7.4.2 Storage

All medication used in this study will be stored in compliance with federal, state, and local laws and institutional policy. Study medications will be stored in a locked, secure, limited-access location under the conditions specified by the package insert; XR-NTX and iPLB injectable kits

will be stored in a secure, limited access refrigerator. Temperature logs will show a daily record of medication storage temperature for all medications.

7.4.3 Packaging

Intramuscular gluteal injections (XR-NTX and iPLB) will be supplied in single use kits marked with medication kit numbers which will be used for tracking and inventory purposes. Each active injectable medication kit will contain one 380 mg vial of Vivitrol® microspheres, one vial containing 4 mL (to deliver 3.4 mL) diluent for the suspension of Vivitrol®, one 5 mL prepackaged syringe, one 1-inch 20-gauge needle, two 1.5-inch 20 gauge needles, and two 2-inch 20 gauge needles with needle protection devices. Each injectable placebo medication kit will be prepared to look identical and will contain the same contents as the active medication kits but with no active medication.

Participants will receive once-daily oral study medication (BUP-XL or oPLB). BUP-XL blister cards will contain a daily dose of 300 mg for the up titration days and a daily dose of 450 mg for all other days in the medication phase. BUP-XL blister cards for the taper days (Days 85-88) will contain a daily dose of 300 mg (Days 85 and 86) and 150 mg (Days 87 and 88).

Oral study medication (BUP-XL and oPLB) will be pre-packaged in weekly blister cards that contain 3 tablet wells for each day. The packaging will be designed such that participants will take all 3 tablets each day, including during the up titration and taper periods.

There will be five types of blister cards manufactured to appear identical for both treatment arms. There will be three types of 7 day cards for use in weeks 1 to 12—one for up titration (for AMC only) and two for target dosing (AMC and PLB). Two types of cards will contain a 4-day supply for the week 13 taper period (AMC and PLB).

The up titration AMC card will be dispensed twice during the study: in week 1 for participants randomized to AMC and again when some participants may be re-randomized and assigned to receive AMC. Therefore, the up titration card will be manufactured to contain 3 tablets for each day of the titration in order to appear identical to the target dosing card. The up titration card will contain two active and one placebo tablet each day for days 1 - 3, and it will contain three active tablets each day for days 4 - 7. Packaging the up titration card in this way will help protect the double-blind throughout the trial.

The target dosing cards will contain either active medication or placebo. The AMC taper card will contain two active and one placebo tablet for the first two days and one active and two placebo tablets for the last two days. The PLB taper card will contain three placebo tablets for each of the four days.

Weekly blister cards dispensed to participants will be labeled to include protocol number, study drug information, and blister card number. The label will also include blister card contents, "Caution: New Drug - Limited by Federal Law to Investigational Use. Store at Controlled Room Temperature (20-25°C or 68-77°F)" as well as the manufacturer and distributor information.

Below, the medication packaging plan is summarized visually, whereby P indicates placebo tablet and A indicates active tablet. Weekly blister cards for each treatment arm by the dosing period (up titration, target dosing, and taper) will be dispensed as follows:

Dosing Period during Medication Phase											
Treatment Arm	PLB	Day	Up titration			Target			Taper		
		1	P	P	P	P	P	P	P	P	P
		2	P	P	P	P	P	P	P	P	P
		3	P	P	P	P	P	P	P	P	P
		4	P	P	P	P	P	P	P	P	P
		5	P	P	P	P	P	P			
		6	P	P	P	P	P	P			
		7	P	P	P	P	P	P			
	AMC	1	A	A	P	A	A	A	A	A	P
		2	A	A	P	A	A	A	A	A	P
		3	A	A	P	A	A	A	A	P	P
		4	A	A	A	A	A	A	A	P	P
		5	A	A	A	A	A	A			
		6	A	A	A	A	A	A			
		7	A	A	A	A	A	A			

Key: **A** - Active medication tablet **P** - Placebo tablet

7.4.4 Ordering and Dispensing

All study medications shall be ordered only by delegated licensed medical staff and dispensed by research staff appropriately trained to do so. Injectable medications will be administered by qualified staff during Weeks 1, 4, 7, and 10. Oral medications will be dispensed to the participant weekly in labeled blister cards that will include both in-clinic observed doses and self-administered doses for non-clinic days.

7.4.5 Used/Unused Medication

Unused study medication will be returned and logged into a perpetual inventory. Returned, damaged, expired or otherwise unused study medications will be accurately labeled, securely stored, kept separately, and shall be accounted for prior to disposition. Any unused or expired investigational agent shall be accounted for at all times. Expired naloxone and other ancillary medications obtained for this study will be destroyed on site or sent for destruction per local institutional policies.

7.4.6 Lost Medication

There will be no replacement of any dispensed study medications.

7.4.7 Maintaining and Breaking Blind

This is a double-blind, placebo-controlled trial. With the exception of the data management group overseeing the random assignment schedule and the NIDA-contracted research pharmacist preparing study medications, all other study personnel and participants will remain blinded to medication status until nationwide completion of the trial. A Data and Safety Monitoring Board (DSMB) will review study data throughout the course of the trial. In rare cases, it may be necessary to break the blind for a particular study participant before completion of the trial (e.g.,

pregnancy or other medical necessity). A request to break the study blind for an individual participant must be made by the study physician after consultation with the Lead Investigator. Unblinding the participant should only be done in cases of medical emergency when knowledge of the treatment group assignment may be necessary for clinical management and decision making. The decision to break the blind for a participant will be made jointly by the CCC Medical Monitor and at least one of the Lead Investigators. Any requests for unblinding will be responded to within one business day or less.

7.5 Participant Compensation

Study participants will be provided with study medications, medical management, and a study medication adherence app for use on his/her own device at no cost. Alternatively, a study smartphone device pre-loaded with the medication adherence app will be provided if needed. In addition, participants will receive gift cards or cash (based on local requirements) as compensation for time, travel, parking, and other costs borne by the participant. A total of up to \$50 will be provided for completion of screening/baseline assessments (divided among at least two screening visits). Ten dollars (\$10) will be provided for each additional eligibility phase clinic visit to provide a urine sample. During the medication phase, \$10 will be provided for completion of assessments including a urine sample (\$5 will be provided for assessments without a urine sample); \$5 for bringing the study medication on clinic days and taking a self-dosing video via the smartphone app while staff observe; and \$25 for each injection visit. Participants will be compensated an additional \$40 per visit for completion of the mid-treatment visit (visit 602) and the end of treatment visit (visit 1202), and \$30 for each follow-up visit in weeks 13 and 16. In addition, participants will be compensated \$5 for each dosing video taken on non-clinic days, including the taper in week 13 (see Appendix C for details). Participants may earn a visit attendance bonus of \$20 (received up to 6 times) when they attend each visit expected to occur within each 2-week block of the medication phase. For example, a participant could earn \$20 for attending four visits in weeks 1-2, \$20 for weeks 3-4, and so on until weeks 11-12. Participants may also receive up to \$40 to offset the cost of additional data service needed for the dosing app on their personal device or for return of the study smartphone device (see Appendix C for details). Total compensation possible is \$1,160 as outlined below.

7.5.1 **Table 1.** Compensation Schedule

Visit/Assessment	Amount	# of Payments	Total
Screening Assessments	\$50	1	\$50
Eligibility Phase Clinic Visits	\$10	4	\$40
Injection Visits	\$25	4	\$100
Clinic Visits (12-week Medication Phase)	\$10	23	\$230
In-clinic dosing/med return (2x/wk)	\$5	24	\$120
Mid-Treatment Visit (visit 602) and End-of-Treatment Visit (visit 1202)	\$40	2	\$80
Dosing video (5x/wk+4 taper days)	\$5	64	\$320
Attendance Bonus (attending all expected visits in each 2-week block)	\$20	6	\$120
Follow-up Visits (Weeks 13 and 16)	\$30	2	\$60
Additional data service for dosing app on personal device OR smartphone device return	\$40	1	\$40

Visit/Assessment	Amount	# of Payments	Total
Maximum Compensation Possible			\$ 1,160

8.0 ASSESSMENTS

Study measures were chosen to minimize the research burden on participants yet collect adequate data to support analyses and ensure safety. Importantly, many of the study measures were selected to record vital health information and are similar to other recent and ongoing studies of bupropion and extended-release naltrexone. Additional measures were also selected to obtain information typically assessed in medication studies, including assessments of drug abuse and dependence diagnoses, psychological status, and measures of craving. Safety is assessed at each visit. Additional forms will be used to collect and document information such as dosing and protocol satisfaction. The NIDA endorsed Substance Abuse and Addiction (SAA) common data elements from Core Tier 1 of the PhenX Toolkit (<http://www.phenxtoolkit.org>), which include demographic and other baseline information, will be captured directly or will be populated from the answers to questions from other assessments. Table 2 provides the schedule of study assessments. On average, screening and eligibility assessments will be completed in 6-8 hours. Twice-weekly assessments during the medication phase will be completed in approximately 30 to 90 minutes. Once-weekly medical management sessions will require an additional 20 minutes. The post-medication phase follow-up visits will take approximately 1 to 2 hours.

8.1 Table 2. Schedule of Assessments

Study Phase	Screening/ Baseline	Medication Phase												Follow-up	
Study Week	0	1	2	3	4	5	6	7	8	9	10	11	12	13	16
Screening Measures															
Pre-Screening Interview Form	X*														
Informed Consent	X*														
Demographics Form	X*														
Alcohol and Substance Use History	X*														
DSM-5 Checklist	X*														
Psychiatric Diagnostic Screening Questionnaire	X*														
Sexual Risk Behaviors	X*						X ²						X ²		
Self-Report of HIV Testing	X*														
Medical and Psychiatric History	X*														
Safety Measures															
Physical Examination	X*												X ²		
Electrocardiogram	X*												X		
Injection Site Examination		X ²			X ²			X ²			X ²				
Injection Site Abnormality Log ^A															
Clinical Laboratory Tests	X*												X		
Liver function tests & platelet lab tests							X								
Concise Health Risk Tracking	X*	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Urine Pregnancy Test	X ^E														
Pregnancy and Birth Control Assessment	X*	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Vital Signs	X ^C	X	X	X	X ^C	X	X	X ^C	X	X	X ^C	X	X	X	X
Prior and Concomitant Medications	X+	2X	2X	2X	2X	2X	2X	2X	2X	2X	2X	2X	2X	X	X
Adverse Events and Serious Adverse Events	X ^D	2X	2X	2X	2X	2X	2X	2X	2X	2X	2X	2X	2X	X	X
Naloxone Challenge Form	X ^E				X ^E			X ^E			X ^E				
Efficacy Measures															
Urine Drug Screen	X+	2X	2X	2X	2X	2X	2X	2X	2X	2X	2X	2X	2X	X	X
OPI 300	X**				X**			X**			X**				
Timeline Followback	X+	2X	2X	2X	2X	2X	2X	2X	2X	2X	2X	2X	2X	X	X
Visual Analog Craving Scale	X+	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Patient Health Questionnaire-9	X*	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Treatment Effectiveness Assessment	X*						X ²						X ²		
Tobacco Use History	X*						X ²						X ²		
Quality of Life	X*						X ²						X ²		
Blood draw for genetic testing	X ^F														
Adherence Measures															
Study Medication Dosing Logs	X ^E	2X	2X	2X	2X	2X	2X	2X	2X	2X	2X	2X	2X	X	
Injection Administration Form		X			X			X			X				
Oral Medication Dispensation Form		X	X	X	X	X	X	X	X	X	X	X	2X	X ^E	
Bupropion Blood Levels					X ^B			X ^B			X ^B		X ²		
End of Medication Form ^E														X	
Administrative and Other Forms															
Locator Form	X*			X			X			X			X		
Eligibility - Randomization	X*														
Missed Visit Form ^E															
Protocol Deviation Form ^E															
Protocol Satisfaction Surveys														X	
Study Completion Form															X

NOTES: X* = once during screening/baseline

X** = required prior to randomization and injectable study medication administration, may be collected at other times per Medical Clinician discretion.

X+ = at each screening/baseline visit

X= a procedure or assessment performed once per week and on the first visit of the week, unless otherwise noted.

2X= a procedure or assessment performed twice per week.

X² = collected at the second visit of the week.^A Completed in the event an injection site reaction is reported by a participant or an abnormality is identified during an injection site examination.^B Collected according to schedule of assessments, but must be prior to administration of ANY medications (e.g., naloxone; injectable or oral study medication) in a given visit.^C Collected according to schedule of assessments, including BEFORE and AFTER administration of naloxone challenge(s) as well as BEFORE and AFTER administration of the study medication combination.^D Collected at each visit after consent (i.e. SV02 through the final follow-up visit)^E Completed as applicable^F If consent is provided, collect genetic sample at the end of the day of randomization if possible. Otherwise, collect during any future visit in which a blood draw occurs.

8.2 Screening Measures

8.2.1 Pre-Screening Interview Form

Individuals responding to recruitment materials or otherwise referred to the study will be pre-screened on the phone or in person to ascertain preliminary eligibility status. Prior to administering the IRB-approved Pre-Screening Interview, staff will provide a brief overview of the study and will obtain and document verbal consent. The Pre-Screening Interview consists of questions to assess essential information in determining potential eligibility.

8.2.2 Informed Consent

Prior to beginning any study assessments, all participants will review and sign an IRB-approved consent form and any other related documents in accordance with IRB requirements. The date the IRB-approved consent form was signed will be entered into the electronic data capture system.

8.2.3 Demographics Form

The Demographics Form will collect information about demographic characteristics of the participant at screening including sex, date of birth, ethnicity, race, education, employment pattern, and marital status.

8.2.4 Alcohol and Substance Use History

The Alcohol and Substance Use History will be completed at screening to incorporate PhenX Core Tier 1 items. The participant will be asked whether he/she has ever used alcohol and/or various substances as well as his/her age when the substance was first used. The intent of this measure is to document any alcohol use, illicit drug use (e.g., illegal, more than prescribed, not prescribed), and any marijuana use.

8.2.5 DSM-5 Checklist

The DSM-5 Checklist has been designed as a semi-structured interviewer-administered instrument that provides current diagnoses for substance use disorders based on DSM-5 diagnostic criteria. The DSM-5 Checklist will be completed at screening.

8.2.6 Psychiatric Diagnostic Screening Questionnaire

The Psychiatric Diagnostic Screening Questionnaire (Zimmerman, 2002) is a self-report questionnaire used primarily as a psychiatric disorder screener administered in primary care. The Psychiatric Diagnostic Screening Questionnaire will evaluate symptoms of common psychiatric disorders and will be administered during the screening phase.

8.2.7 Self-Report of HIV Testing

HIV testing status will be assessed via self-report questionnaire using PhenX Core Tier 1 items. Items will assess whether the participant has ever had an HIV test, when the most recent test occurred, the test result, and, if the participant was not tested in the past 12 months, and the most important reason the participant was not tested. This will be administered during the screening phase.

8.2.8 Medical and Psychiatric History

The medical and psychiatric history, collected at screening, will document participants' past and present health conditions to help determine eligibility and to provide baseline information.

8.3 Safety Measures

8.3.1 Physical Examination

A physical examination will be completed at screening to ensure there are no exclusionary medical conditions and to gather baseline information. The physical at screening will also include an examination of the participant's body habitus and the planned injection site(s) to assess appropriateness for intramuscular gluteal injections. The physical examination will be repeated at the end of the medication phase (week 12 visit 2).

8.3.2 Electrocardiogram (ECG)

A 12-lead ECG will be administered at screening to assist in determination of participant eligibility and again at study exit (i.e., week 12 visit 1) to assess safety at termination. The ECG tracings will be reviewed by a qualified medical clinician for accuracy and transmitted to be read by a central cardiologist. Results from the central cardiologist's interpretation will be assessed by a qualified medical clinician at the site.

8.3.3 Injection Site Examination

Appropriate medical personnel will examine the injection site on the visit following each intramuscular gluteal injection. These examinations will usually occur at visits 0102, 0402, 0702, and 1002 but should occur at the next attended visit if any of the aforementioned visits are missed. Additional monitoring may also be required. Well-developed precautionary procedures will be followed to avoid adverse events associated with injectable study medication administration. For example, body habitus will be assessed during the physical exam at screening to assure that intramuscular administration is feasible as an inadvertent subcutaneous injection may increase the likelihood of injection site reactions. Individuals whose body habitus precludes a gluteal intramuscular injection using the needles provided will be excluded from the study.

8.3.4 Injection Site Abnormality Log

Participants will be asked to immediately report any injection site reactions to allow evaluation, monitoring, and possible referral, as needed. A log entry is completed in the event an injection site reaction is reported by a participant or an abnormality is identified during an injection site examination. All injection site reactions should be documented on the Injection Site Abnormality Log. If the abnormality results in a Serious Adverse Event (SAE), the Adverse Event forms must also be completed.

8.3.5 Clinical Laboratory Tests

A comprehensive blood chemistry including liver function tests (LFTs: including AST, ALT, ALP, and bilirubin), hematology panel, and a standard urinalysis will be performed to help determine eligibility at screening. At week 6 visit 1, clinical lab tests to assess LFTs and platelet counts will be repeated for safety monitoring. Clinical labs completed at screening (chemistry, LFTs, hematology, and standard urinalysis) will be repeated during the final week of the medication phase (week 12 visit 1). An accredited local laboratory (College of American Pathologists or

equivalent) that meets CLIA guidelines will perform testing, provide normal values, and provide proof of lab certifications.

8.3.6 Concise Health Risk Tracking - Participant Rated Module

The Concise Health Risk Tracking measure will assess aspects of suicidal ideation and behavior using 16 questions scored on a 5-item Likert scale, including ideation frequency, duration and severity; identifiable deterrents to an attempt; reasons for living/dying; degree of specificity/planning; method availability/opportunity; expectancy of actual attempt; and actual preparation. The Concise Health Risk Tracking measure will be used at screening, every week during the medication phase, and at the week 13 and 16 follow-up visits. Participants who report a significant suicidal/homicidal risk will be assessed by a qualified clinician before leaving the clinic.

8.3.7 Pregnancy and Birth Control Assessment

For females, urine pregnancy test administration, test results, and self-reports of birth control method(s) will be documented during screening unless documentation of hysterectomy is provided. A urine pregnancy test will be performed prior to the naltrexone pre-induction strategy in the screening/baseline phase and may be performed at any other time if clinically indicated or if a woman suspects she is pregnant. If a woman is found to be pregnant at any point during the study, she will be allowed to continue in the study but will be withdrawn from study medications, given an appropriate referral, and followed until resolution of the pregnancy. Self-reports of birth control method(s) will be documented every week during the medication phase.

8.3.8 Vital Signs

Vital signs (e.g., body temperature, blood pressure, pulse, respiration rate) will be collected at least once during screening, as well as before and after any naloxone challenge conducted during the study. During study medication injection clinic visits, vitals will be collected before and after participants receive the combination of the study medications. On non-injection clinic visits, vitals will be collected weekly before oral medication self-dosing. Vital signs can be repeated to confirm the reading or on more frequent intervals, as clinically indicated.

8.3.9 Prior and Concomitant Medications

At screening, the Prior and Concomitant Medications form will collect information about prescription and over-the-counter medications used by participants in the prior 30-day period. At other visits, the form will document medications taken since the previous data collection visit. Participants may be excluded based on medications reported during screening. Participants will be instructed to contact the study medical clinician before taking any non-study medications, including prescription medications, over-the-counter preparations, and herbal supplements, during the course of the study.

8.3.10 Adverse Events (AEs) and Serious Adverse Events (SAEs)

Medical or psychiatric adverse events (AEs) will be collected by inquiring of participants: "How have you been feeling since your last visit?" AEs will be recorded at each visit after consent according to the adverse event reporting definitions and procedures. If an AE or abnormality suggests medical or psychological deterioration, it will be brought to the attention of the study medical clinician for further evaluation. All AEs and SAEs will be medically managed, reported, and followed in accordance with applicable regulatory requirements. Seizures will be reported to the DSMB.

8.3.11 Naloxone Challenge Form

The Naloxone Challenge Form will document the time of administration, total dose, route of administration, and result of each naloxone challenge administered during the study. A naloxone challenge may be conducted at the discretion of the medical clinician prior to any injection of study medication; the Naloxone Challenge Form will be completed for each naloxone challenge.

8.4 Efficacy Measures

8.4.1 Urine Drug Screen

Urine samples will be collected at every clinic visit. Urine drug screen (UDS) testing will be performed on site using an FDA-cleared for use one-step urine drug dip card and/or dipstick following all the manufacturer's recommended procedures.

The UDS will test for the presence of opiates, oxycodone, barbiturates, benzodiazepines, cocaine, amphetamines, methamphetamine, marijuana (THC), methadone, and ecstasy (MDMA). Prior to drug screening, a temperature and validity assessment will be performed on all urine samples collected. The validity assessment will be performed using a commercially available adulterant test strip that indicates normal ranges for creatinine, pH (at minimum), nitrate, glutaraldehyde, specific gravity, bleach and pyridinium chlorochromate. If the temperature or adulterant test falls outside the normal range, the first urine specimen will be considered adulterated and will not be screened. In this case, the first urine sample will be discarded, and the participant will be asked to provide another sample following oral hydration. If the only out of range value from the second sample is a high specific gravity on the adulterant test strip and there are no visible precipitants, this sample may be considered not adulterated and can be drug tested. Any other out of range value on either the temperature strip or adulterant test indicates adulteration and the second sample should not be tested. Study teams at each site may opt to observe the urine collection process either at each collection or as deemed necessary (e.g., recommend observing urine collection if specimen tampering is suspected) according to clinic standard operating procedures.

Throughout the study, urine will be tested to evaluate urine opiate levels at 2000 ng/mL. At Screening/Baseline and prior to each injection of XR-NTX or iPLB, urine will be tested to evaluate urine opiate levels at 300 ng/mL. Additional onsite urine drug testing may occur at Screening/Baseline and during the medication phase to detect urine metabolites of other drugs that are not detected by the previously described tests. Results from any urine drug test intended for forensic use only, or otherwise not cleared by the FDA for use in clinical settings, may not be used in any clinical evaluation and is collected for data purposes only.

8.4.2 Timeline Followback

The Timeline Followback (TLFB) procedure (Sobell & Sobell, 1992; Fals-Stewart, 2000) will be used to elicit the quantity and frequency of the participant's self-reported use of cigarettes, e-cigarettes, alcohol and illicit drug use. At screening, substance use reported by the participant in the 30-day period prior to consent will be assessed. The TLFB will be administered at each study visit throughout the screening phase, the medication phase and the post medication phase follow-up visits to document the participant's self-reported use of substances for each day since the previous TLFB assessment. Adherence to this procedure will ensure that self-reported substance use for the entire study period is documented without gaps.

8.4.3 Visual Analog Craving Scale

Participants' craving for methamphetamine will be documented on a visual analog scale (VAS) that ranges from 0 (no craving) to 100 (most intense craving possible). The VAS will be completed at each screening visit, once weekly throughout the medication phase, and at the week 13 and 16 follow-up visits.

8.4.4 Patient Health Questionnaire-9

The Patient Health Questionnaire-9 (Kroenke et al., 2001) is a well validated self-report tool that measures diagnostic criteria for major depression, severity and frequency of depressive symptoms, presence of suicidal ideation, and functional impairment related to depression. The Patient Health Questionnaire-9 will be collected during screening, weekly during the medication phase, and at the week 13 and 16 follow-up visits.

8.4.5 Treatment Effectiveness Assessment

The Treatment Effectiveness Assessment (Ling, 2012) is a 4-item self-administered assessment that uses a Likert scale (1-10) to document changes in four life domains: substance use, personal responsibilities, health, and community. The Treatment Effectiveness Assessment will be collected at screening, mid-treatment (week 6 visit 2) and end-of-treatment (week 12 visit 2).

8.4.6 Tobacco Use History

The Tobacco Use History assessment will be administered at screening, mid-treatment (week 6 visit 2), and end-of-treatment (week 12 visit 2) to incorporate PhenX Core Tier 1 items. Tobacco use items assessed include lifetime use, 30-day quantity and frequency, and age of first tobacco use.

8.4.7 Quality of Life

Quality of Life will be assessed using items from the PhenX Core Tier 1. Participants will be asked to provide ratings of general health, physical health, and mental health during the past 30 days at screening, mid-treatment (week 6 visit 2), and end-of-treatment (week 12 visit 2).

8.4.8 Sexual Risk Behaviors

The Sexual Risk Behaviors assessment will be administered at screening, mid-treatment (week 6 visit 2), and end-of-treatment (week 12 visit 2) to assess engagement in risky sexual related behaviors in the 30 days prior to each assessment. Participants will answer questions about the number and sex of sexual partners, HIV status of partners, and use of condoms as well as the use of drugs and alcohol during sex.

8.4.9 Genetic Sampling

The NIDA CCTN has requested that blood samples for genetic analysis be obtained for all new CTN pharmacotherapy trials. Randomized participants who consented to the optional genetic testing will have approximately 30 mL (2 tablespoons) of blood drawn at the end of the day of randomization, after all medication administration and monitoring has been completed. However, if the sample cannot be collected on the day of randomization, the sample may be collected at any subsequent visit, ideally at a visit in which a blood draw is scheduled to occur. The blood samples will be coded and only the local investigators will know the identity of the participant

providing the sample. The blood sample will be sent to the Rutgers University Cell and DNA Repository for storage and future analysis.

8.5 Adherence Measures

8.5.1 Study Medication Dosing Logs

Dosing logs will document medication administered in-clinic and dispensed for take-home dosing. Medications to be recorded on dosing logs include naloxone, injectable study medication, and oral study medication. A dosing log will also document return of oral medication blister cards and the participant's self-report of doses taken. Logs will be completed at each visit when medications are dispensed or administered throughout the study.

8.5.2 Injection Administration Form

The Injection Administration Form(s) will document whether injectable study medication is to be administered, it will automatically assign (in real time) an injection kit number for administration, and it will document information related to the administration of the medication (e.g., time of injection). The form is to be completed only after the participant appears in clinic. This form will be completed at each visit in which injectable study medication is administered (i.e., weeks 1, 4, 7, and 10).

8.5.3 Oral Medication Dispensation Form

The Oral Medication Dispensation Form(s) will document whether oral study medication is to be dispensed and it will automatically assign (in real time) a blister card number for dispensation. The first question on this form is to be completed only after the participant appears in clinic, even if oral study medication is not being dispensed.

8.5.4 Oral Study Medication Blood Levels

One of the methods used to evaluate medication adherence requires collecting blood to test for bupropion and hydroxybupropion levels at a central bioanalytical laboratory. Blood will be collected for this purpose prior to study medication administration at visits 0401, 0701, and 1001 and again at the final medication phase visit (week 12 visit 2).

8.5.5 Video Based Adherence to Oral Study Medication Database

Dosing adherence will be assessed in part by automated visual recognition software during the video capture within the AiCure app. The software converts adherence information into data that is automatically entered and stored in the database maintained by AiCure for this study. This database will contain data indicating whether a video was submitted, whether the dosing was deemed valid (i.e., the study participant is clearly ingesting study medication), and whether the dosing was self-reported as opposed to documented via video. Study staff will help ensure information in the AiCure dashboard (the visual representation of the database) is accurate. No additional logs or forms are required for documenting video based adherence.

8.5.6 End of Medication Form

An End of Medication Form will be completed any time a decision is made to discontinue a participant from further medication administration or at the post-medication phase follow-up assessment in Week 13.

8.6 Administrative and Other Forms

8.6.1 Locator Form

A locator form will be used to obtain information to assist in tracking participants during treatment and at follow-up. The locator form will collect information such as participants' current address, email address, social media accounts, and phone numbers, as well as names, addresses, and phone numbers of family/friends who may know how to reach the participants if direct contact efforts are unsuccessful. This information will be collected at screening and updated in weeks 3, 6, 9, and 12 and whenever the participant reports a change in locator information. No identifying information from this form will be used in data analyses.

8.6.2 Eligibility - Randomization

The Enrollment form lists all the study inclusion and exclusion criteria and must be completed for every participant who has signed consent and entered the screening/baseline phase. Eligibility is assessed on an ongoing basis during the screening phase. Only participants who continue to meet study eligibility criteria will be allowed to continue in the screening phase, including the naltrexone pre-induction procedures (e.g., naloxone challenge). The Enrollment form is to be completed in the electronic data capture system after all screening and baseline procedures are complete. Eligible participants will be randomized; ineligible participants will be excluded and deemed screen failures.

8.6.3 Missed Visit Form

This form is designed to capture the reason any study visit was missed. Once the visit window closes without completion of the visit, this Missed Visit Form will be completed directly in the electronic data capture system. Completing this form will remove the requirement for most assessments scheduled for that missed visit. Active tracking and follow-up should be performed for all missed visits.

8.6.4 Protocol Deviation Form

This form should be entered into the electronic data capture system whenever a protocol deviation occurs. This form will document a description of the deviation, how it occurred, the corrective action taken to resolve the specific deviation, as well as a description of the plan implemented to prevent future occurrences of similar deviations.

8.6.5 Protocol Satisfaction Surveys

Satisfaction with medication components, smartphone app, and other study procedures will be recorded on the Protocol Satisfaction Survey completed at the week 13 visit. A survey will be completed by both the participant and a study team member. These forms will be used in data analyses to evaluate secondary objectives including the acceptability of the combination medication and the usefulness of smartphone app-based technology for improving and monitoring medication adherence.

8.6.6 Study Completion Form

Information regarding when and why study visits were stopped for each participant, including whether a participant completed the final follow-up visit in week 16, will be recorded on this form.

9.0 TRAINING

The study staff will be trained as specified in the Training Plan. Required training will include Human Subjects Protection (HSP) and Good Clinical Practice (GCP), as well as protocol-specific training as needed (e.g., assessments, study interventions, safety procedures, data management and collection). Support mechanisms will also be identified as part of the training (e.g., who to contact for aid, questions, resources). All study staff will also complete any additional training per their study site and IRB requirements. An Operations Manual will be provided for this study that will outline study procedures in more detail as necessary for the day-to-day conduct of the trial. The Operations Manual will be used to train study staff, to provide reference for study procedures, and to support quality management activities.

10.0 STATISTICAL ANALYSES

10.1 General Design

10.1.1 Study Hypothesis

The primary hypothesis is that the combination of extended-release depot naltrexone plus extended-release bupropion medication (AMC), relative to the PLB, will be associated with greater MA non-use. Participants will be randomized to one of two conditions, PLB or AMC. Randomization will be stratified by site.

10.1.2 Sample Size

A sample size of 400 is chosen for this study to detect the difference between the two treatment arms. A total of 7 - 10 sites will participate in the trial. It is anticipated that each site will randomize approximately 30 - 70 participants over the recruitment period.

10.1.3 Primary Outcomes

The primary efficacy outcome measure is MA-negative urine drug screen (UDS) test results obtained during weeks 5 to 6 and weeks 11 to 12, which will be compared by treatment group (AMC versus PLB). Participants will be defined as a “responder” if there are at least 75% MA-negative UDS tests during the pre-specified evaluation period. The treatment groups will be compared as to the proportion of responders using a Z test. All treatment comparisons will be performed under the Intent-to-Treat (ITT) criteria.

10.1.4 Secondary Outcomes

Secondary outcomes include methamphetamine and other substance use outcomes in the pre-evaluation period, in the evaluation period, at the follow-up assessment, and any combination of these periods, for responders, non-responders, and other sub-groups. Secondary outcomes also include depression scores, quality of life, overall functioning, clinic attendance, and ratings of participant and staff satisfaction with study procedures, including use of the smartphone app, compensation, and study medication. Secondary safety outcomes will be participants’ reports of treatment emergent adverse events including serious adverse events collected at scheduled clinic visits or via other contact.

Drug use will be measured by several outcomes including but not limited to the Treatment Effectiveness Score (TES; Ling et al., 1997), days of self-reported drug use, number of consecutive negative UDS, and UDS as a binary outcome (positive or negative) across time. The TES is the percentage of the scheduled urine drug screens that were negative for each drug. Mixed-model analysis of repeated measures will be used to explore the presence of time-related medication effects, including severity of cravings. In the models, we will control for baseline MA use and other key demographic and participant variables. Additional analyses will include assessment of drug use in the pre-evaluation period, over the entire medication period and at the follow-up assessment. Changes occurring over the medication period in severity and type of drug-related problems and in quality of life will be analyzed with parametric and nonparametric measures. Participant and staff satisfaction ratings will be summarized. A two-sided test of significance will be used with a p-value less than 0.05 indicating significance.

Analyses of secondary outcomes will be primarily performed on all individuals who are randomized and inducted onto study medications. Secondary analyses will also be performed by examining responses in subgroups with varying characteristics. Adherence with oral study

medication dosing will be measured by participant self-report, smartphone device app dosing videos, and in-clinic observation. A dosing adherent per-protocol analysis will be performed by evaluating response rates in the medication-adherent group. Because per-protocol analyses may be biased (Sheiner and Rubin, 1995) an unbiased complier-adjusted-causal-effects analysis (Jo and Stuart, 2009) may also be used to adjust for adherence. Multiple testing will not be adjusted for in the secondary analyses, since these are not part of the study's primary objective. When multiple tests are conducted, the chance of finding a significant difference in one of the tests, when in fact no difference exists, is greater than the stated Type I error rate. The investigators are aware of the issues associated with multiple testing and will interpret results with caution.

All the above mentioned secondary analyses (except staff satisfaction ratings) will be performed in a similar way as the primary analysis. For continuous outcomes, ordinary least squares and mixed effects model for repeated measures (MMRM) will be used and for binary outcomes, a logistic regression will be used. These will be described in the protocol Statistical Analysis Plan (SAP).

10.2 Interim Analyses

In coordination with the centralized Data and Statistics Center, a DSMB will monitor the progress of the trial. As requested by the DSMB, interim analyses of sample size re-estimation and monitoring of the efficacy and safety data will be performed. However, if ADAPT-2 has a rapid recruitment such that the proportion of Week 12 outcomes realized is small when recruitment is completed or nearly completed, discussion with the DSMB will take place about whether sample size re-estimation and interim analysis of efficacy data is warranted.

10.2.1 Sample Size Re-estimation

Sample size re-estimation analysis will be conducted when approximately half of the participants have been enrolled. This analysis will not reveal the treatment effect observed in the trial at the time of this interim analysis. A sample size re-estimation will be performed to assess the adequacy of the projected study sample size and whether a sample size increase is warranted.

The timing of the sample size re-estimation is based on a number of factors: recruitment rate, timing of the primary outcome, amount of loss to follow-up, and time to perform the sample size re-estimation. The sample size re-estimation will be done only once, and done before any interim analysis of the primary outcome is performed. The results of the sample size re-estimation analysis would be presented in a closed session of the DSMB, who will then provide a recommendation to the NIDA CCTN regarding whether the target sample size should be modified. A decision regarding any such modification would be made subsequently by the CCTN, taking into consideration the recommendation of the DSMB.

Update to the sample size:

The NIDA CTN DSMB reviewed the sample size re-estimation report dated July 23, 2018, prepared by the DSC. Based on the results, the DSMB and NIDA CCTN recommended increasing the originally planned sample size of 370 by 30 additional participants to maintain the targeted 90% power. The CCTN approved the increase in sample size to 400 participants in a letter to the Lead Investigator dated August 13, 2018.

10.2.2 Interim Monitoring of Primary Efficacy Endpoint

Interim monitoring for efficacy will be performed. There will be no interim efficacy monitoring before a sample size re-estimation is performed (or a determination that re-estimation is not needed) because sample size re-estimation could change the target sample size, affecting the alpha spending function used in the interim efficacy monitoring. After sample size re-estimation, interim efficacy monitoring will be performed only once during the recruitment period.

All interim monitoring will use an O'Brien-Fleming-type boundary with information fraction equal to the proportion of the target sample size with primary outcome. This approach spends very little alpha at the interim look, therefore the impact of an interim monitoring on the sample size is negligible. The only criterion for early stopping for efficacy will be based on Z-scores and its relation to O'Brien-Fleming-type boundary.

Before recommending early termination, the DSMB will consider:

- Internal consistency of primary and secondary results.
- Internal consistency of primary and secondary results by subgroups defined by baseline characteristics (e.g., severity of MA use, tobacco use history, treatment effectiveness assessment and visual analog craving scale).
- Distribution of baseline prognostic factors among the two groups.
- Consistency of primary and secondary results across clinical sites and among clinical sites enrolling larger numbers of participants.
- Possible impact of missing data from missed participant visits for assessment of the primary and secondary response variables.
- Possible differences in concomitant interventions or medications.

10.2.3 Safety Interim Analyses

Safety interim looks will be performed for the regular DSMB meetings or at unscheduled times per the DSMB's request. These will include analysis of adverse events and narrative reports on serious adverse events.

Simultaneous with primary interim efficacy monitoring analysis, a "poor efficacy" statistic will be calculated to assess whether the combination of extended-release depot naltrexone plus extended-release bupropion medication (AMC), relative to the PLB, is associated with greater MA use. This analysis will be conducted after the sample size re-estimation. If the "poor efficacy of AMC" statistic crosses its boundary, defined as the response rate for PLB minus AMC being greater than 10%, the DSMB will consider whether to stop the trial early because of poor efficacy of AMC relative to PLB.

10.2.4 Conditional Power and Futility

Unless otherwise requested, a futility/conditional power calculation will be performed every time interim monitoring is performed. If at any DSMB meeting the conditional power falls below 0.3, this will stimulate a discussion among the DSMB members about whether we should stop for futility.

10.3 Demographic and Baseline Characteristics

Baseline demographic and clinical variables will be summarized for participants randomized and inducted on study medications. Descriptive summaries of the distribution of continuous baseline variables will be presented with percentiles (median, 25th and 75th percentiles), and with mean and standard deviation. Categorical variables will be summarized in terms of frequencies and percentages.

10.4 Description of Plans to Conduct Analyses of Study Results by Sex and Race/Ethnicity

The association between specific demographic characteristics and outcome will be studied. The demographic characteristics of potential importance include: age, sex, race, and ethnicity. In accordance with NIH guidelines, analyses will be completed to determine whether treatment response was significantly affected by participant minority/sex status using an interaction term for treatment, time and minority/sex as appropriate.

10.5 Safety Analysis

AEs, including SAEs, will be summarized by body system and preferred term using MedDRA codes (per The Medical Dictionary for Regulatory Activities). AEs will be presented as: (1) the number and proportion of participants experiencing at least one incidence of each event overall; and (2) the total number of each event overall in tabular form. Listings of SAEs will be sorted by body system, and preferred term. Detail in these listings will include severity, relationship to study drug(s), and action taken, as available.

11.0 REGULATORY COMPLIANCE, REPORTING AND MONITORING

11.1 Statement of Compliance

This study will be conducted in compliance with the current version of the study protocol, in accordance with the ethical principles outlined in the Declaration of Helsinki, consistent with current International Conference on Harmonization Good Clinical Practice (GCP) Guidelines, and all other applicable regulatory requirements.

11.2 Institutional Review Board Approval

Participating sites must obtain written approval of the study protocol, consent form(s), other supporting documents, any materials given to the participant, and any advertising for participant recruitment from their Institutional Review Board (IRB) of record or Independent Ethics Committee (IEC) to participate in the study. Prior to initiating the study, site investigators will obtain written IRB approval to conduct the study at their respective site. Any amendments to the protocol or consent must be approved by the Lead Investigator and IRB before implementation. Progress reports, and any required post-approval reports will be submitted to the IRBs either annually or at a frequency requested by each IRB so that continuous study approval is maintained without lapse. The Lead Investigator is responsible for maintaining copies of all performance site(s)' current IRB approval notice(s) and IRB-approved consent document(s), including approvals for all protocol and consent modifications. These materials must be received by the Lead Investigator prior to the initiation of research activities at a given site, must be maintained by the Lead Investigator throughout the course of the trial, and must be available at any time for audit.

11.3 Research Advisory Panel of California (California sites only)

Prior to initiating the study, the sponsor or designee will obtain written approval from the Research Advisory Panel of California (RAP-C). Any planned research project to be conducted in California requiring the use of a Schedule I or Schedule II Controlled Substance as its main study drug as well as research for the treatment of controlled substance addiction or abuse utilizing any drug, scheduled or not, must be submitted to RAP-C for review and approval prior to study start-up. Study approval is based on review of the study protocol, consent form, and other pertinent study documents. Yearly reports will be provided to the RAP-C by the sponsor or designee to maintain continuing study approval. Protocol amendments must also be submitted, and it is required that the Panel be notified of any significant study drug related adverse events that may emerge during conduct of the study at the California sites only.

11.4 Informed Consent

All potential candidates for the study will be given a current IRB-approved consent form in English to read. In accordance with IRB policies, appropriately trained and qualified study personnel will explain all aspects of the study in lay language and answer all the study candidates' questions. Participants who remain interested after receiving an explanation of the study will be given a short quiz to test their understanding of the project including the purpose, procedures involved, and the voluntary nature of participation. Those who cannot successfully answer all quiz items will have the study re-explained by research staff with a focus on aspects they did not understand. Anyone who cannot demonstrate appropriate understanding of the study will be ineligible to participate and will be assisted in finding other treatment resources. Those who demonstrate understanding of the study and voluntarily agree to participate will be asked to sign the IRB-approved consent

form. Participants will not be administered any assessments or participate in study procedures in any way prior to signing and dating the IRB-approved consent form.

Informed consent is a process and not just a document. The informed consent process is a means of providing study information to each prospective participant in understandable language and taking all the time needed to answer all questions to allow for an informed decision about study participation. The IRB-approved consent form must be revised whenever important new information becomes available including whenever the protocol is amended in any way that may affect a study participant's willingness to continue participating in the trial. All study sites must have the study consent forms approved by their IRB(s). Sites must maintain the original signed IRB-approved consent forms for all study participants in a locked, secure location that is in compliance with IRB and institutional policies. Signed/dated IRB-approved consent forms must be accessible for quality assurance review and regulatory compliance at all times. Every study participant will be provided with a copy of the signed/dated consent form that can be used as continual reference for study information including procedures, possible risks and/or side effects, and contact information for questions and/or emergencies. California site participants will also be provided with a California Research Subjects' Bill of Rights. Individuals who refuse to participate or who withdraw from the study will be treated without prejudice.

11.5 Health Insurance Portability Accountability Act (HIPAA)

Study sites may be required by their institutions to obtain authorization from participants for use of protected health information. Releases of participant identifying information that are permitted by the HIPAA regulations, but which are prohibited by other applicable federal regulations and/or state/Commonwealth laws and regulations, are prohibited. Sites will be responsible for communicating with their IRBs or Privacy Boards and obtaining the appropriate approvals or waivers to be in regulatory compliance.

11.6 Investigator Assurances

Each participating site must file (or have previously filed) a Federalwide Assurance (FWA) with the HHS Office for Human Research Protections setting forth the commitment of the organization to adhere to appropriate policies and procedures for the protection of human research subjects. The site's FWA must be current at trial initiation and must be maintained throughout the duration of the study with documentation sent to NIDA or its designee, as requested. Research covered by these regulations cannot proceed in any manner prior to NIDA receipt of certification that the research has been reviewed and approved by the OHRP-registered IRB designated in the assurance (45 CFR 46.103(b) and (f)). Prior to initiating the study, the principal investigator and sub-investigators at each study site will sign a protocol signature page, providing assurances that the study will be performed according to the standards stipulated therein.

11.7 Financial Disclosure

All investigators will comply with the requirements of 42 CFR Part 50, Subpart F to ensure that the design, conduct, and reporting of the research will not be biased by any conflicting financial interest. All study personnel with decision-making responsibilities regarding the protocol must comply with their institution's policy regarding conflict of interest.

11.8 Confidentiality

Confidentiality will be maintained in accordance with all applicable federal regulations and/or state law and regulations. Particular attention is drawn to the regulations promulgated by the Food and Drug Administration (FDA) under the Freedom of Information Act providing, in part, that proprietary information furnished to investigators and Institutional Review Boards will be kept confidential by the FDA only if maintained in confidence by the clinical investigator and Institutional Review Board (IRB). By signing the protocol signature page, the investigator affirms that information furnished to the investigator by NIDA will be maintained in confidence and such information will be divulged to the IRB, Ethical Review Committee, or similar expert committee; affiliated institution; and employees only under an appropriate understanding of confidentiality with such board or committee, affiliated institution and employees.

The Lead Investigator obtained a federal Certificate of Confidentiality (CoC) and distributed it to all sites when it was received. A CoC helps researchers protect the privacy of human research participants enrolled in biomedical, behavioral, clinical and other forms of sensitive health-related research (e.g., drug use). Certificates protect against compulsory legal demands, such as court orders and subpoenas, for identifying information or identifying characteristics of a research participant. The department that issues the CoC will be advised of any changes in the CoC application information that may occur during the study, as required. Participating sites will be notified if CoC revision is necessary.

Participant records will be kept confidential by using study codes for identifying participants on CRFs, secure separate storage of any documents that have participant identifiers, and secure computing procedures for entering and transferring electronic data. All laboratory specimens, eCRFs, reports, and other data records will be identified by the participant identification study code that includes the site number, node number, and participant number. Research records will be stored in a locked cabinet. Only authorized individuals will have access to the study records. Participant information will not be released without written permission, except as necessary for monitoring by the FDA, NIDA-contracted monitors, local node monitors, lead node staff, or NIDA. By signing the protocol signature page, the investigator agrees that within local regulatory restrictions and ethical considerations, NIDA or any regulatory agency may consult and/or copy study documents in order to verify eCRF data.

11.9 IND Requirements

A request for IND exemption was submitted to FDA for this protocol, as described in title 21 of the Code of Federal Regulations, part 312 (21 CFR 312) and the Agency determined that the ADAPT-2 study was exempt from FDA IND regulations, as per Title 21 of the Code of Federal Regulations, Part 312.2.

Though exempt from IND regulation, this study will be conducted in accordance with International Council on Harmonisation Good Clinical Practices (ICH GCPs), all applicable FDA and OHRP Guidance documents, and any state and institutional requirements applicable at the clinical site level.

11.10 Regulatory Files

Essential documents are those documents which individually and collectively permit evaluation of the conduct of a trial and the quality of the data produced. These documents serve to demonstrate the compliance of the investigator, sponsor and monitor with the standards of Good Clinical Practice and with all applicable regulatory requirements. Regulatory files should be maintained throughout the lifecycle of the trial and should contain all required regulatory documents, study-

specific documents, and all important study-related communications. Regulatory files will be checked at each participating site for regulatory document compliance prior to study initiation, throughout the study, as well as at study closure.

11.11 Study Documentation

Study documentation includes, but is not limited to, all data-related forms, workbooks, source documents, monitoring logs and appointment schedules, sponsor-investigator correspondence, signed protocols including amendments, Ethics Review Committee or Institutional Review Board/Committee correspondence, approved current and previous consent forms, and signed participant consent forms. Source documents include all recordings of observations or notations of clinical activities and all reports and records necessary for the evaluation and reconstruction of the clinical research study. All clinical trial information should be recorded, handled, and stored in a way that allows its accurate reporting, interpretation, and verification. The original recording of an observation should be retained as the source document.

11.12 Records Retention and Requirements

Research records for all study participants (e.g., case report forms, source documents, signed consent forms, and regulatory files) are to be maintained by the investigator in a secure location for a minimum of 3 years after the study is completed and closed. These records are also to be maintained in compliance with IRB, state and federal requirements, whichever is longest. The sponsor and Lead Investigator must be notified in writing and acknowledgment must be received by the site prior to the destruction or relocation of research records.

11.13 Reporting to Sponsor

The site principal investigator agrees to submit accurate, complete, legible and timely reports to the sponsor, as required. These include, but are not limited to, reports of any changes that significantly affect the conduct or outcome of the trial or increase risk to study participants. Adverse Event reporting and Serious Adverse Event reporting will occur as described herein. At the completion of the trial, the Lead Investigator will provide a final report to the sponsor.

11.14 Safety Monitoring

11.14.1 Adverse Events (AEs)

All adverse events (medical and/or psychiatric) occurring during the course of the study will be assessed, documented, and reported. AEs occurring during the course of the clinical trial will be collected, documented, and reported by the principal investigator or sub-investigators according to the specific instructions detailed in this section of the protocol and Appendix A. Appropriately qualified and trained medical personnel will elicit participant reporting of AEs and SAEs at each study visit designated to collect AEs (i.e., the first visit following informed consent and at every visit thereafter). Study staff will follow-up on the status of any AEs that remain at the post-medication phase follow-up visit assessment for up to 30 days post last study visit.

An AE is defined as any reaction, side effect, or untoward event that occurs during the course of the clinical trial, whether or not the event is considered investigational product-related or clinically significant. For this study, AEs will include events reported by the participant, as well as clinically significant abnormal findings on physical examinations or laboratory evaluations. A new illness, symptom, sign or clinically significant clinical laboratory abnormality or worsening of a pre-existing

condition or abnormality is considered an AE. Stable chronic conditions, such as arthritis, which are present prior to clinical trial entry and do not worsen are not considered AEs. All AEs must be recorded on the AE log and CRF. The AE log and CRF are also used to record follow-up information for unresolved events reported on previous visits.

Each week, appropriately qualified and trained medical personnel must review the AE log and CRF completed for the previous week for any events that were reported as continuing. All AEs, including clinically significant abnormal findings on laboratory evaluations, regardless of severity, will be followed until satisfactory resolution.

A study medical clinician (MD, DO, PA, or NP) will review or provide consultation for each adverse event. These reviews will include an assessment of the severity and causality to the study drug or study procedures. The study medical clinician, in collaboration with the study physician and site principal investigator, will also make decisions to exclude, refer, or withdraw participants as required. The study staff will be trained to monitor for and report adverse events and serious adverse events.

Each participating site has established practices for managing medical and psychiatric emergencies, and the study staff will continue to utilize these procedures. Study medical clinicians at each site will be responsible for monitoring participants for possible clinical deterioration or other problems, and for implementing appropriate courses of action.

11.14.2 Definitions of Adverse Events and Serious Adverse Events

Full definitions of adverse events and serious adverse events, their identification, and characterization regarding severity and relationship to therapy and processing are described in Appendix A.

11.14.3 Reportable Adverse Events and Serious Adverse Events

For the purpose of this study, all AEs and SAEs will require reporting in the electronic data system. Reporting of AEs and SAEs is described in Appendix A. The local site is responsible for reporting all their local AEs and SAEs to their IRBs per IRB guidelines.

11.14.4 Data and Safety Monitoring Board (DSMB)

This study will utilize the CTN DSMB to oversee ongoing trial progress. The purpose of this board is to determine whether risks emerge during the conduct of the trial that make continuation unethical. This process is intended to assure the IRBs, the sponsor, and investigators that participants are provided with an accurate and ongoing risk evaluation when participating in CTN research trials. Safety monitoring begins with the initial review of the protocol during the study development process. Reports of participant seizures will be provided to the DSMB as they occur. The DSMB will meet as necessary over the study duration.

11.14.5 Medical Monitor

Under the supervision of the NIDA-assigned Medical Monitor, the study Safety Monitor will be responsible for overseeing safety and for evaluating all Adverse Events (AEs). The Safety Monitor will review all Serious Adverse Events (SAEs) within one business day of their reporting in eClinical and all other Adverse Events on a regular basis. The Medical Monitor will review events regularly and will be available at all times for consultation. It is the responsibility of the site principal investigator to provide this information to the Safety Monitor. It is also the site principal investigators' responsibility to inform the IRBs per IRB guidelines.

In addition, the Medical Monitor will independently review the safety data, present it to the DSMB for periodic review, and provide site principal investigators a “Safety Letter” when necessary. The Medical Monitor will determine which safety events require expedited reporting to NIDA, the DSMB, study drug manufacturers, and regulatory authorities. This will include all suspected adverse reactions that are serious and unexpected. Furthermore, in the event of participant seizures, reports will be submitted to the DSMB using the AE form with additional information about the event as deemed appropriate.

11.15 Protocol Deviations: Reporting and Management

Any divergence from procedures and requirements outlined in the protocol will be classified a protocol deviation. A protocol deviation is an action (or inaction) that alone may or may not affect the scientific soundness of the investigation or seriously affect the safety, rights, or welfare of a study participant. In some cases, a protocol deviation may compromise participant safety, participant rights, inclusion/exclusion criteria or the integrity of study data and is cause for corrective action to resolve the departure and to prevent re-occurrence. Protocol deviations will be monitored at each site for (1) significance, (2) frequency, and (3) impact on the study objectives, to ensure that site performance does not compromise the integrity of the trial. The decision about whether a deviation from the protocol will be designated as minor or major will be made by the protocol’s Lead Investigator(s) in conjunction with the Clinical Coordinating Center (CCC). The consequences will be specified and participating sites will be informed.

All protocol deviations will be recorded in the Electronic Data Capture (EDC) system via the Protocol Deviation CRF. Additionally, each site is responsible for tracking and reporting protocol deviations to their IRB, as required. The CCC and the Data and Statistics Center (DSC) and the Lead Investigator must be contacted immediately if an unqualified/ineligible participant is entered into the study.

11.16 Audits

The Sponsor has an obligation to ensure that this trial is conducted according to good research practice guidelines and may perform quality assurance audits for protocol compliance. The Lead Investigator and authorized staff from the Texas Node; the National Institute on Drug Abuse Center for the Clinical Trials Network (NIDA CCTN, the study sponsor); NIDA’s contracted agents, monitors or auditors; and other agencies, such as the Department of Health and Human Services (HHS), the Food and Drug Administration (FDA), the Office for Human Research Protections (OHRP), and the sites’ Institutional Review Boards may inspect research records for verification of data, compliance with federal guidelines on human participant research, and to assess participant safety.

11.17 Quality Assurance Monitoring

Protection of the rights and welfare of study participants will be a vigilant process conducted by the research teams at all sites and at the Lead Node and by the sponsors of the research. Monitoring of the study sites will be conducted on a regular basis using a combination of NIDA-contracted monitors, local node monitors, and lead node staff.

Site investigators will host periodic visits by monitors who will ensure all study procedures are appropriately conducted, and that study data are generated, documented and reported in compliance with the protocol, GCP, and applicable regulations. These monitors will audit, at mutually agreed upon times, regulatory documents, case report forms (CRFs), and corresponding source documents for each participant. NIDA-contracted monitors will assure that submitted data

are accurate and in agreement with source documentation and will also review regulatory/essential documents such as correspondence with the IRB.

Areas of particular concern will be participant signed/dated consents, eligibility for study participation, protocol adherence, safety monitoring, IRB reviews and approvals, regulatory documents, participant records, study drug accountability, and principal investigator supervision and involvement in the trial. Reports will be prepared following the visits and forwarded to the site principal investigator, the Lead Investigator and NIDA CCTN.

Qualified node personnel (Node Protocol Managers and/or QA monitors) will provide site management for each site during the trial to encourage and assess compliance with the study protocol, Good Clinical Practice guidelines, and to ensure the integrity of the trial progress. These visits will take place as specified by the local protocol team, Node PI or Lead Team, and visits will occur as often as needed to help prevent, detect, and correct problems at the study sites. Node staff will ensure that study procedures are properly followed and that site staff are trained and able to conduct the protocol appropriately. If the node staff's review of study documentation indicates that additional training of study personnel is needed, node staff will undertake or arrange for that training.

12.0 DATA MANAGEMENT AND PROCEDURES

12.1 Design and Development

This protocol will utilize a centralized Data and Statistics Center (DSC). The DSC will be responsible for the development of the Case Report Forms (CRFs) and Participant Reported Outcome (PRO) forms, development and validation of the clinical study database, ensuring data integrity, and training site and participating node staff on applicable data management procedures. A web-based distributed data entry model will be implemented. This electronic data capture system (Advantage eClinical) will be developed to ensure that guidelines and regulations surrounding the use of computerized systems used in clinical trials are upheld. The remainder of this section provides an overview of the data management plan associated with this protocol.

12.2 Site Responsibilities

The data management responsibilities of each site will be specified by the Lead Node and the DSC.

12.3 Data and Statistics Center Responsibilities

The DSC will 1) develop and apply data management procedures to ensure the collection of accurate and good-quality data, 2) provide Case Report Forms in electronic (eCRF) and paper (CRF) format, and Participant Reported Outcome forms in electronic (ePRO) and paper (PRO) format for the collection of all data required by the study, 3) develop data dictionaries for each CRF and PRO form that will comprehensively define each data element, 4) prepare instructions for the use of Advantage eClinical and for the completion of forms, 5) conduct ongoing data validation and cleaning activities on study data collected from all participating sites, and 6) perform data validation and cleaning activities prior to any interim analyses and prior to the final study database lock.

12.4 Data Collection and Entry

Data will be collected at the study sites on source documents and entered by the site on the form in Advantage eClinical, or will be collected via direct entry into the eCRF by the site or direct entry into the ePRO by the participant. In the event that Advantage eClinical is not available, the DSC will provide the sites with paper source documents and completion instructions. Data will be entered into Advantage eClinical in accordance with the instructions provided during protocol-specific training and guidelines established by the DSC. Data entry into the forms shall be performed by authorized individuals. Selected eCRFs may also require the investigator's electronic signature.

The principal investigator at the site is responsible for maintaining accurate, complete and up-to-date research records. In addition, the investigator is responsible for ensuring the timely completion of forms for each research participant.

12.5 Data Monitoring, Cleaning, and Editing

Data will be entered into the DSC automated data acquisition and management system (Advantage eClinical). Forms will be monitored for completeness and accuracy throughout the study. Dynamic reports listing missing values and forms are available to sites at all times in

Advantage eClinical. These reports will be monitored regularly by the DSC. In addition, the DSC will identify inconsistencies within forms and between forms and post data clarification requests or queries in Advantage eClinical on a scheduled basis. Sites will resolve data inconsistencies and errors by entering all corrections and changes directly into Advantage eClinical.

The CCC will conduct regular visits to sites, during which audits comparing source documents to the data entered will be performed. Any discrepancies identified between the source document and the eCRF or ePRO will be corrected by the site.

Trial progress and data status reports, which provide information on recruitment, availability of primary outcome, treatment exposure, attendance at follow-up visits, regulatory status, and data quality, will be generated routinely and posted to a secure website. These reports will be available to the site, the corresponding Local Node, the Lead Investigator, the coordinating centers, and NIDA, to monitor the sites' progress on the study.

12.6 Database Transfer and Lock

At the conclusion of data collection for the study, the DSC will perform final data cleaning activities and will “lock” the study database from further modification. The final analysis dataset will be returned to the Lead Investigator and to NIDA, as requested, for storage and archive.

13.0 PUBLICATIONS AND OTHER RIGHTS

Protocol development and implementation in the NIDA CTN is a collaborative process. The planning, preparation, and submission of publications will follow the policies of the CTN Publications Committee. Individuals making substantive contributions to the protocol development and implementation will have opportunities to participate in publications. Other contributors will also be acknowledged. Per NIH policy, the results of the trial are to be made available to the research community and to the public at large. The project will adhere to stipulations in accord with the NIH Public Access Policy (for any articles based on work supported by NIH funding) required for Applications, Proposals, or Reports Submitted After July 1, 2013, as set forth in:

<http://publicaccess.nih.gov/>

<http://publicaccess.nih.gov/FAQ.htm#792>

<http://grants.nih.gov/grants/guide/notice-files/NOT-OD-08-119.html>

14.0 SIGNATURES

SPONSOR'S REPRESENTATIVE (CCTN DESIGNEE)

Udi Ghitza, PhD		
Printed Name	Signature	Date

ACKNOWLEDGEMENT BY INVESTIGATOR:

- I am in receipt of version 6.0 of the protocol and agree to conduct this clinical study in accordance with the design and provisions specified therein.
- I agree to follow the protocol as written except in cases where necessary to protect the safety, rights, or welfare of a participant, an alteration is required, and the sponsor and IRB have been notified prior to the action.
- I will ensure that the requirements relating to obtaining informed consent and institutional review board (IRB) review and approval in 45 CFR 46 are met.
- I agree to personally conduct or supervise this investigation at this site and to ensure that all site staff assisting in the conduct of this study are adequately and appropriately trained to implement this version of the protocol and that they are qualified to meet the responsibilities to which they have been assigned.
- I agree to comply with all the applicable federal, state, and local regulations regarding the obligations of clinical investigators as required by the Department of Health and Human Services (DHHS), the state, and the IRB.

SITE'S PRINCIPAL INVESTIGATOR

Printed Name	Signature	Date

Site Name

Node Affiliation

15.0 REFERENCES

- Anderson, A. L., Li, S. H., Markova, D., Holmes, T. H., Chiang, N., Kahn, R., . . . Elkashef, A. M. (2015). Bupropion for the treatment of methamphetamine dependence in non-daily users: a randomized, double-blind, placebo-controlled trial. *Drug Alcohol Depend*, 150, 170-174. doi:10.1016/j.drugalcdep.2015.01.036
- Anggadiredja, K., Sakimura, K., Hiranita, T., & Yamamoto, T. (2004). Naltrexone attenuates cue- but not drug-induced methamphetamine seeking: a possible mechanism for the dissociation of primary and secondary reward. *Brain Res*, 1021(2), 272-276. doi:10.1016/j.brainres.2004.06.051
- Aron, J. L., & Paulus, M. P. (2007). Location, location: using functional magnetic resonance imaging to pinpoint brain differences relevant to stimulant use. *Addiction*, 102(s1), 33-43.
- Ascher, J. A., Cole, J. O., Colin, J. N., Feighner, J. P., Ferris, R. M., Fibiger, H. C., . . . et al. (1995). Bupropion: a review of its mechanism of antidepressant activity. *J Clin Psychiatry*, 56(9), 395-401.
- Brecht, M.-L., Greenwell, L., & Anglin, M. D. (2005). Methamphetamine treatment: Trends and predictors of retention and completion in a large state treatment system (1992-2002). *Journal of Substance Abuse Treatment*, 29(4), 295-306. doi:10.1016/j.jsat.2005.08.012
- Brensilver, M., Heinzerling, K. G., & Shoptaw, S. (2013). Pharmacotherapy of amphetamine-type stimulant dependence: an update. *Drug Alcohol Rev*, 32(5), 449-460. doi:10.1111/dar.12048
- Brensilver, M., Heinzerling, K. G., Swanson, A. N., & Shoptaw, S. (2012). Placebo-group responders in methamphetamine pharmacotherapy trials: The role of immediate establishment of abstinence. *Exp Clin Psychopharmacol*, 20(5), 430-435. doi:10.1037/a0029210
- Brensilver, M., Heinzerling, K. G., Swanson, A. N., Telesca, D., Furst, B. A., & Shoptaw, S. J. (2013). Cigarette smoking as a target for potentiating outcomes for methamphetamine abuse treatment. *Drug Alcohol Rev*, 32(1), 96-99. doi:10.1111/j.1465-3362.2012.00423.x
- Brensilver, M., Heinzerling, K. G., Swanson, A.-N., & Shoptaw, S. J. (2012). A retrospective analysis of two randomized trials of bupropion for methamphetamine dependence: Suggested guidelines for treatment discontinuation/augmentation. *Drug and Alcohol Dependence*, 125(1-2), 169-172. doi:10.1016/j.drugalcdep.2012.03.027
- Bryant, S. G., Guernsey, B. G., & Ingram, N. B. (1983). Review of bupropion. *Clin Pharm*, 2(6), 525-537.
- Carroll, C. C., & Trappe, T. A. (2006). Personal digital video: a method to monitor drug regimen adherence during human clinical investigations. *Clin Exp Pharmacol Physiol*, 33(12), 1125-1127. doi:10.1111/j.1440-1681.2006.04503.x
- Carroll, K. M., O'Malley, S. S., & Nuro, K. F. (1996). *Compliance Enhancement: A Manual for the Psychopharmacotherapy of Drug Abuse and Dependence*. Retrieved from West Haven, CT:
- Chen, Y. F., Yang, Y., Hung, H. M., & Wang, S. J. (2011). Evaluation of performance of some enrichment designs dealing with high placebo response in psychiatric clinical trials. *Contemp Clin Trials*, 32(4), 592-604. doi:10.1016/j.cct.2011.04.006
- Cherner, M., Suarez, P., Casey, C., Deiss, R., Letendre, S., Marcotte, T., . . . Heaton, R. K. (2010). Methamphetamine use parameters do not predict neuropsychological impairment in currently abstinent dependent adults. *Drug and Alcohol Dependence*, 106(2-3), 154-163.
- Coffin, P. O., Santos, G.-M., Hern, J., Vittinghoff, E., Santos, D., Matheson, T., Colfax, G., Batki, S. L. (2017). Extended-release naltrexone for methamphetamine dependence among

- men who have sex with men: a randomized placebo-controlled trial. *Addiction*, doi:10.1111/add.13950
- Comer, S. D., Sullivan, M. A., Yu, E., Rothenberg, J. L., Kleber, H. D., Kampman, K., . . . O'Brien, C. P. (2006). Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. *Arch Gen Psychiatry*, 63(2), 210-218. doi:10.1001/archpsyc.63.2.210
- Dean, A. C., London, E. D., Sugar, C. A., Kitchen, C. M., Swanson, A. N., Heinzerling, K. G., . . . Shoptaw, S. (2009). Predicting adherence to treatment for methamphetamine dependence from neuropsychological and drug use variables. *Drug Alcohol Depend*, 105(1-2), 48-55. doi:10.1016/j.drugalcdep.2009.06.008
- Diez-Quevedo, C., Rangil, T., Sanchez-Planell, L., Kroenke, K., & Spitzer, R. L. (2001). Validation and utility of the patient health questionnaire in diagnosing mental disorders in 1003 general hospital Spanish inpatients. *Psychosom Med*, 63(4), 679-686.
- Doros, G., Pencina, M., Rybin, D., Meisner, A., & Fava, M. (2013). A repeated measures model for analysis of continuous outcomes in sequential parallel comparison design studies. *Stat Med*, 32(16), 2767-2789. doi:10.1002/sim.5728
- Duarte, N. A., Woods, S. P., Rooney, A., Atkinson, J. H., & Grant, I. (2012). Working memory deficits affect risky decision-making in methamphetamine users with attention-deficit/hyperactivity disorder. *Journal of Psychiatric Research*, 46(4), 492-499. doi:10.1016/j.jpsychires.2012.01.006
- Elkashef, A. M., Rawson, R. A., Anderson, A. L., Li, S. H., Holmes, T., Smith, E. V., . . . Weis, D. (2008). Bupropion for the treatment of methamphetamine dependence. *Neuropsychopharmacology*, 33(5), 1162-1170. doi:10.1038/sj.npp.1301481
- Fals-Stewart, W., O'Farrell, T. J., Freitas, T. T., McFarlin, S. K., & Rutigliano, P. (2000). The timeline followback reports of psychoactive substance use by drug-abusing patients: psychometric properties. *J Consult Clin Psychol*, 68(1), 134-144.
- Fava, M., Evins, A. E., Dorer, D. J., & Schoenfeld, D. A. (2003). The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. *Psychother Psychosom*, 72(3), 115-127. doi:69738
- Fava, M., Memisoglu, A., Thase, M. E., Bodkin, J. A., Trivedi, M. H., de Somer, M., . . . Ehrich, E. (2016). Opioid Modulation With Buprenorphine/Samidorphan as Adjunctive Treatment for Inadequate Response to Antidepressants: A Randomized Double-Blind Placebo-Controlled Trial. *Am J Psychiatry*, 173(5), 499-508. doi:10.1176/appi.ajp.2015.15070921
- Fava, M., Mischoulon, D., Iosifescu, D., Witte, J., Pencina, M., Flynn, M., . . . Pollack, M. (2012). A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study). *Psychother Psychosom*, 81(2), 87-97. doi:10.1159/000332050
- Fernández-Serrano, M. J., Pérez-García, M., & Verdejo-García, A. (2011). What are the specific vs. generalized effects of drugs of abuse on neuropsychological performance? *Neuroscience & Biobehavioral Reviews*, 35(3), 377-406. doi:10.1016/j.neubiorev.2010.04.008
- Greenway, F. L., Fujioka, K., Plodkowski, R. A., Mudaliar, S., Guttadauria, M., Erickson, J., . . . Group, C.-I. S. (2010). Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet*, 376(9741), 595-605. doi:10.1016/S0140-6736(10)60888-4
- Haggkvist, J., Bjorkholm, C., Steensland, P., Lindholm, S., Franck, J., & Schilström, B. (2011). Naltrexone attenuates amphetamine-induced locomotor sensitization in the rat. *Addict Biol*, 16(1), 20-29. doi:10.1111/j.1369-1600.2009.00199.x

- Haggkvist, J., Lindholm, S., & Franck, J. (2009). The opioid receptor antagonist naltrexone attenuates reinstatement of amphetamine drug-seeking in the rat. *Behav Brain Res*, 197(1), 219-224. doi:10.1016/j.bbr.2008.08.021
- Hanson, G. R., Sandoval, V., Riddle, E., & Fleckenstein, A. E. (2004). Psychostimulants and vesicle trafficking: a novel mechanism and therapeutic implications. *Ann N Y Acad Sci*, 1025, 146-150. doi:10.1196/annals.1316.019
- Heinzerling, K. G., Gadzhyan, J., van Oudheusden, H., Rodriguez, F., McCracken, J., & Shoptaw, S. (2013). Pilot randomized trial of bupropion for adolescent methamphetamine abuse/dependence. *J Adolesc Health*, 52(4), 502-505. doi:10.1016/j.jadohealth.2012.10.275
- Heinzerling, K. G., Swanson, A.-N., Hall, T. M., Yi, Y., Wu, Y., & Shoptaw, S. J. (2014). Randomized, placebo-controlled trial of bupropion in methamphetamine-dependent participants with less than daily methamphetamine use. *Addiction*, 109(11), 1878-1886. doi:10.1111/add.12636
- Hillhouse, M. P., Marinelli-Casey, P., Gonzales, R., Ang, A., Rawson, R. A., & Authors, M. T. P. C. (2007). Predicting in-treatment performance and post-treatment outcomes in methamphetamine users. *Addiction*, 102(Suppl. 1), 84-95.
- Hitzemann, R., Curell, J., Hom, D., & Loh, H. (1982). Effects of naloxone on d-amphetamine- and apomorphine-induced behavior. *Neuropharmacology*, 21(10), 1005-1011.
- Jayaram-Lindström, N., Hammarberg, A., Beck, O., & Franck, J. (2008b). Naltrexone for the Treatment of Amphetamine Dependence: A Randomized, Placebo-Controlled Trial. *American Journal of Psychiatry*, 165(11), 1442-1448. doi:doi:10.1176/appi.ajp.2008.08020304
- Jayaram-Lindstrom, N., Konstenius, M., Eksborg, S., Beck, O., Hammarberg, A., & Franck, J. (2008a). Naltrexone Attenuates the Subjective Effects of Amphetamine in Patients with Amphetamine Dependence. *Neuropsychopharmacology*, 33(8), 1856-1863.
- Jayaram-Lindstrom, N., Wennberg, P., Beck, O., & Franck, J. (2005). An open clinical trial of naltrexone for amphetamine dependence: compliance and tolerability. *Nord J Psychiatry*, 59(3), 167-171. doi:10.1080/08039480510023052
- Kim, S., Westphalen, R., Callahan, B., Hatzidimitriou, G., Yuan, J., & Ricaurte, G. A. (2000). Toward development of an in vitro model of methamphetamine-induced dopamine nerve terminal toxicity. *J Pharmacol Exp Ther*, 293(2), 625-633.
- Koffarnus, M. N., & Bickel, W. K. (2014). A 5-trial adjusting delay discounting task: accurate discount rates in less than one minute. *Exp Clin Psychopharmacol*, 22(3), 222-228. doi:10.1037/a0035973
- Ling, W., Farabee, D., Liepa, D., & Wu, L. T. (2012). The Treatment Effectiveness Assessment (TEA): an efficient, patient-centered instrument for evaluating progress in recovery from addiction. *Subst Abuse Rehabil*, 3(1), 129-136. doi:10.2147/SAR.S38902
- Ling, W., Hillhouse, M. P., Saxon, A. J., Mooney, L. J., Thomas, C. M., Ang, A., . . . Rotrosen, J. (2016). Buprenorphine + naloxone plus naltrexone for the treatment of cocaine dependence: the Cocaine Use Reduction with Buprenorphine (CURB) study. *Addiction*, 111(8), 1416-1427. doi:10.1111/add.13375
- Ling, W., Shoptaw, S., Wesson, D., Rawson, R. A., Compton, M., & Klett, C. J. (1997). Treatment effectiveness score as an outcome measure in clinical trials. *NIDA Res Monogr*, 175, 208-220.
- Loftis, J. M., & Sullivan, B. (2013). Cognitive impairments accompanying methamphetamine dependence: Pathologies, clinical implications, and treatment strategies.
- Margolin, A., Kosten, T., Petrakis, I., Avants, S. K., & Kosten, T. (1991). Bupropion reduces cocaine abuse in methadone-maintained patients. *Arch Gen Psychiatry*, 48(1), 87.

- Margolin, A., Kosten, T. R., Avants, S. K., Wilkins, J., Ling, W., Beckson, M., . . . et al. (1995). A multicenter trial of bupropion for cocaine dependence in methadone-maintained patients. *Drug Alcohol Depend*, 40(2), 125-131.
- McCann, D. J., & Li, S. H. (2012). A novel, nonbinary evaluation of success and failure reveals bupropion efficacy versus methamphetamine dependence: reanalysis of a multisite trial. *CNS Neurosci Ther*, 18(5), 414-418. doi:10.1111/j.1755-5949.2011.00263.x
- Mi, M. Y., & Betensky, R. A. (2013). An analysis of adaptive design variations on the sequential parallel comparison design for clinical trials. *Clin Trials*, 10(2), 207-215. doi:10.1177/1740774512468806
- Mooney, L. J., Hillhouse, M. P., Thomas, C., Ang, A., Sharma, G., Terry, G., . . . Ling, W. (2016). Utilizing a Two-stage Design to Investigate the Safety and Potential Efficacy of Monthly Naltrexone Plus Once-daily Bupropion as a Treatment for Methamphetamine Use Disorder. *J Addict Med*. doi:10.1097/ADM.0000000000000218
- Mooney, L. J., Nielsen, S., Saxon, A., Hillhouse, M., Thomas, C., Hasson, A., . . . Ling, W. (2013). Cocaine use reduction with buprenorphine (CURB): rationale, design, and methodology. *Contemp Clin Trials*, 34(2), 196-204. doi:10.1016/j.cct.2012.11.002
- Newton, T. F., Kalechstein, A. D., Duran, S., Vansluis, N., & Ling, W. (2004). Methamphetamine abstinence syndrome: preliminary findings. *Am J Addict*, 13(3), 248-255. doi:10.1080/10550490490459915
- Newton, T. F., Roache, J. D., De La Garza, R., 2nd, Fong, T., Wallace, C. L., Li, S. H., . . . Kahn, R. (2005). Safety of intravenous methamphetamine administration during treatment with bupropion. *Psychopharmacology (Berl)*, 182(3), 426-435. doi:10.1007/s00213-005-0102-8
- Newton, T. F., Roache, J. D., De La Garza, R., 2nd, Fong, T., Wallace, C. L., Li, S. H., . . . Kahn, R. (2006). Bupropion reduces methamphetamine-induced subjective effects and cue-induced craving. *Neuropsychopharmacology*, 31(7), 1537-1544. doi:10.1038/sj.npp.1300979
- Ornellas, T., & Chavez, B. (2011). Naltrexone SR/Bupropion SR (Contrave): A New Approach to Weight Loss in Obese Adults. *P T*, 36(5), 255-262.
- Oslin, D. W., Berrettini, W., Kranzler, H. R., Pettinati, H., Gelernter, J., Volpicelli, J. R., & O'Brien, C. P. (2003). A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. *Neuropsychopharmacology*, 28(8), 1546-1552. doi:10.1038/sj.npp.1300219
- Pal, R., Mendelson, J. E., Flower, K., Garrison, K., Yount, G., Coyle, J. R., & Galloway, G. P. (2015). Impact of prospectively determined A118G polymorphism on treatment response to injectable naltrexone among methamphetamine-dependent patients: an open-label, pilot study. *J Addict Med*, 9(2), 130-135. doi:10.1097/ADM.0000000000000107
- Papakostas, G. I., Shelton, R. C., Zajecka, J. M., Etemad, B., Rickels, K., Clain, A., . . . Fava, M. (2012). L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials. *Am J Psychiatry*, 169(12), 1267-1274. doi:10.1176/appi.ajp.2012.11071114
- Petry, N. M., Peirce, J. M., Stitzer, M. L., Blaine, J. D., Roll, J. M., Cohen, A. J., . . . Saladin, M. E. (2005). Effect of prize-based incentives on outcomes in stimulant abusers in outpatient psychosocial treatment programs. *Archives of General Psychiatry*, 62, 1148-1156.
- Rawson, R. A., Gonzales, R., & Brethen, P. (2002). Treatment of methamphetamine use disorders: an update. *Journal of Substance Abuse Treatment*, 23(2), 145-150.
- Ray, L. A., Bujarski, S., Courtney, K. E., Moallem, N. R., Lunny, K., Roche, D., . . . Miotto, K. (2015). The Effects of Naltrexone on Subjective Response to Methamphetamine in a

- Clinical Sample: a Double-Blind, Placebo-Controlled Laboratory Study. *Neuropsychopharmacology*, 40(10), 2347-2356. doi:10.1038/npp.2015.83
- Richmond, R., & Zwar, N. (2003). Review of bupropion for smoking cessation. *Drug Alcohol Rev*, 22(2), 203-220. doi:10.1080/09595230100100642
- Roll, J. M., Petry, N. M., Stitzer, M. L., Brecht, M. L., Peirce, J. M., McCann, M. J., . . . Kellogg, S. (2006). Contingency management for the treatment of methamphetamine use disorders. *American Journal of Psychiatry*, 163(11), 1993-1999.
- Rose, M. E., & Grant, J. E. (2008). Pharmacotherapy for methamphetamine dependence: a review of the pathophysiology of methamphetamine addiction and the theoretical basis and efficacy of pharmacotherapeutic interventions. *Ann Clin Psychiatry*, 20(3), 145-155. doi:10.1080/10401230802177656
- Salim, Z., Allen, J. S., Patterson, C., & Painter, K. (2007). *Methamphetamine treatment program, Tarrant County, Texas: Final evaluation report, October 2004 - September 2007*. Retrieved from Fort Worth, Texas:
- Salo, R., Nordahl, T. E., Galloway, G. P., Moore, C. D., Waters, C., & Leamon, M. H. (2009). Drug abstinence and cognitive control in methamphetamine-dependent individuals. *Journal of Substance Abuse Treatment*, 37(3), 292-297.
- Schmitz, J. M., Stotts, A. L., Rhoades, H. M., & Grabowski, J. (2001). Naltrexone and relapse prevention treatment for cocaine-dependent patients. *Addict Behav*, 26(2), 167-180.
- Schmitz, J. M., Stotts, A. L., Sayre, S. L., DeLaune, K. A., & Grabowski, J. (2004). Treatment of cocaine-alcohol dependence with naltrexone and relapse prevention therapy. *Am J Addict*, 13(4), 333-341. doi:10.1080/10550490490480982
- Sheehan, D. V., Lecrubier, Y., Sheehan, K. H., Amorim, P., Janavs, J., Weiller, E., . . . Dunbar, G. C. (1998). The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. *J Clin Psychiatry*, 59 Suppl 20, 22-33;quiz 34-57.
- Shoptaw, S., Heinzerling, K. G., Rotheram-Fuller, E., Steward, T., Wang, J., Swanson, A. N., . . . Ling, W. (2008). Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence. *Drug Alcohol Depend*, 96(3), 222-232. doi:10.1016/j.drugalcdep.2008.03.010
- Stoops, W. W., Pike, E., Hays, L. R., Glaser, P. E., & Rush, C. R. (2015). Naltrexone and bupropion, alone or combined, do not alter the reinforcing effects of intranasal methamphetamine. *Pharmacology Biochemistry and Behavior*, 129, 45-50. doi:http://dx.doi.org/10.1016/j.pbb.2014.11.018
- Tamura, R. N., & Huang, X. (2007). An examination of the efficiency of the sequential parallel design in psychiatric clinical trials. *Clin Trials*, 4(4), 309-317. doi:10.1177/1740774507081217
- Trivedi, M. H., Fava, M., Wisniewski, S. R., Thase, M. E., Quitkin, F., Warden, D., . . . Team, S. D. S. (2006). Medication augmentation after the failure of SSRIs for depression. *N Engl J Med*, 354(12), 1243-1252. doi:10.1056/NEJMoa052964
- van der Plas, E. A., Crone, E. A., van den Wildenberg, W. P., Tranel, D., & Bechara, A. (2009). Executive control deficits in substance-dependent individuals: a comparison of alcohol, cocaine, and methamphetamine and of men and women. *J Clin Exp Neuropsychol*, 31(6), 706-719. doi:10.1080/13803390802484797
- Wadden, T. A., Foreyt, J. P., Foster, G. D., Hill, J. O., Klein, S., O'Neil, P. M., . . . Dunayevich, E. (2011). Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. *Obesity (Silver Spring)*, 19(1), 110-120. doi:10.1038/oby.2010.147

- Wei, L. J., & Lachin, J. M. (1988). Properties of the urn randomization in clinical trials. *Control Clin Trials*, 9(4), 345-364.
- Winchell, C., Rappaport, B. A., Roca, R., & Rosebraugh, C. J. (2012). Reanalysis of methamphetamine dependence treatment trial. *CNS Neurosci Ther*, 18(5), 367-368. doi:10.1111/j.1755-5949.2011.00288.x
- Yurcel, M., Lubman, D. I., Solowij, N., & Brewer, W. J. (2007). Understanding drug addiction: a neuropsychological perspective. *Australian & New Zealand Journal of Psychiatry*, 41(12), 957-968.
- Zhu, J., Spencer, T. J., Liu-Chen, L. Y., Biederman, J., & Bhide, P. G. (2011). Methylphenidate and mu opioid receptor interactions: a pharmacological target for prevention of stimulant abuse. *Neuropharmacology*, 61(1-2), 283-292. doi:10.1016/j.neuropharm.2011.04.015
- Zimmerman, M., Posternak, M. A., & Chelminski, I. (2002). Symptom severity and exclusion from antidepressant efficacy trials. *J Clin Psychopharmacol*, 22(6), 610-614.
- Zisook, S., Lesser, I. M., Lebowitz, B., Rush, A. J., Kallenberg, G., Wisniewski, S. R., . . . Trivedi, M. H. (2011). Effect of antidepressant medication treatment on suicidal ideation and behavior in a randomized trial: an exploratory report from the Combining Medications to Enhance Depression Outcomes Study. *J Clin Psychiatry*, 72(10), 1322-1332. doi:10.4088/JCP.10m06724

16.0 APPENDIX A - ADVERSE EVENT REPORTING DEFINITIONS AND PROCEDURES

Each participating site's principal investigator is responsible for study oversight, including ensuring human research subject protection by designating appropriately qualified and trained study personnel to assess, report, and monitor adverse events.

Definition of Adverse Events and Serious Adverse Events

An **adverse event** (AE) is any untoward medical occurrence in humans, whether or not considered study drug/intervention related, which occurs during the conduct of a clinical trial. Any change from baseline clinical status, ECGs, lab results, x-rays, physical examinations, etc., that is considered clinically significant by the study medical clinician are considered AEs.

Suspected adverse reaction is any adverse event for which there is a reasonable possibility that the study drug/intervention caused the adverse event. A reasonable possibility implies that there is evidence that the study drug/intervention caused the event.

Adverse reaction is any adverse event caused by the study drug/intervention.

An **adverse event, suspected adverse reaction, or adverse reaction** is considered "**serious**" (i.e., a serious adverse event, serious suspected adverse reaction or serious adverse reaction) if, in the view of either the study medical clinician or sponsor, it:

1. Results in death: A death occurring during the study or which comes to the attention of the study staff during the protocol-defined follow-up period, whether or not considered caused by the study drug/intervention, must be reported.
2. Is life-threatening: Life-threatening means that the study participant was, in the opinion of the medical clinician or sponsor, at immediate risk of death from the reaction as it occurred and required immediate intervention.
3. Requires inpatient hospitalization or prolongation of existing hospitalization.
4. Results in persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions.
5. Is a congenital abnormality or birth defect.
6. Seizure.
7. Important medical event that may not result in one of the above outcomes, but may jeopardize the health of the study participant or require medical or surgical intervention to prevent one of the outcomes listed in the above definition of serious event.

Definition of Expectedness

Any adverse event is considered "unexpected" if it is not listed in the investigator brochure or the package insert or is not listed at the specificity or severity that has been observed. If neither is available then the protocol and consent are used to determine an unexpected adverse event.

Pregnancy

Any pregnancies that occur to a participant enrolled in the study will be captured on a pregnancy case report form (CRF) and not separately reported as an AE or SAE. Women who become

pregnant during the medication period will be discontinued from further medication administration, referred for medical care, and the pregnancy followed until an outcome is known.

Medical and Psychiatric History

A thorough medical and psychiatric history during the screening/baseline phase should record any chronic, acute, or intermittent preexisting or current illnesses, diseases, symptoms, or laboratory signs of the participant, to avoid reporting pre-existing conditions as new AEs and to assist in the assessment of worsening in intensity or severity of these conditions that would indicate an AE. Stable chronic conditions, such as arthritis, which are present prior to clinical trial entry and do not worsen are not considered AEs.

Site Staff's Role in Eliciting and Reporting Adverse Events

All adverse events (medical and/or psychiatric) occurring during the course of the study will be assessed, documented, and reported. Appropriately qualified and trained medical personnel will elicit participant reporting of AEs and SAEs at each study visit designated to collect AEs (i.e., the first visit following informed consent and at every visit thereafter). Study staff will follow-up on the status of any AEs that remain at the post-medication phase follow-up visit assessment for up to 30 days post last study visit. Study personnel will obtain as much information as possible about the reported AE/SAE in order to complete AE/SAE documentation (i.e., log and CRFs) and will consult with medical clinicians and the Study Medical Monitor as necessary.

Standard reporting, within 7 days of the site staff becoming aware of the event, is required for AEs. Expedited reporting, within 24 hours of their occurrence and/or site staff's knowledge of the event, is required for SAEs (including death and life-threatening events). Site staff is responsible for reporting SAEs to the IRB, per IRB's guidelines.

Site staff is required to enter AEs and SAEs in the eClinical system as soon as they become aware of the event. The AE log and CRF are used to capture AEs (as defined in the protocol). Additional information may need to be gathered to evaluate serious adverse events and to complete the appropriate CRFs and the summary. This process may include obtaining hospital discharge reports, medical records, autopsy records or any other type of records or information necessary to provide a complete and clear picture of the serious event and events preceding and following the event. If the SAE is not resolved or stable at the time of the initial report or if new information becomes available after the initial report, follow-up information must be submitted as soon as possible.

Adverse events will be followed until resolution, stabilization or study end. Any serious adverse reactions will be followed until resolution or stabilization even beyond the end of the study.

Site Staff's Role in Assessing Severity and Causality of Adverse Events

Appropriately qualified and trained medical personnel will conduct an initial assessment of seriousness, severity, and causality when eliciting participant reporting of adverse events. A study medical clinician will review AEs for seriousness, severity, and causality on at least a weekly basis.

Guidelines for Assessing Severity

The severity of an adverse event refers to the intensity of the event.

Grade 1	Mild	Transient or mild discomfort (< 48 hours), no or minimal medical intervention/therapy required, hospitalization not necessary (non-prescription or single-use prescription therapy may be employed to relieve symptoms, e.g., aspirin for simple headache, acetaminophen for post-surgical pain)
Grade 2	Moderate	Mild to moderate limitation in activity, some assistance may be needed; no or minimal intervention/therapy required, hospitalization possible.
Grade 3	Severe	Marked limitation in activity, some assistance usually required; medical intervention/ therapy required, hospitalization possible.

Guidelines for Determining Causality

The study medical clinician will use the following question when assessing causality of an adverse event to study drug/intervention where an affirmative answer designates the event as a suspected adverse reaction:

Is there a reasonable possibility that the study drug/intervention caused the event?

Quality Assurance Staff's Role in Monitoring Adverse Events

Quality assurance monitors (from the node staff and the CRO contract monitor staff) will review safety documentation on a regular basis and will promptly advise site staff to report any previously unreported safety issues and ensure that the reportable safety-related events are being followed to resolution and reported appropriately. Staff education, re-training or appropriate corrective action plan will be implemented at the participating site when unreported or unidentified reportable AEs or serious events are discovered, to help ensure future identification and timely reporting.

Sponsor's Role in Safety Management Procedures of AEs/SAEs

A NIDA-assigned Medical Monitor is responsible for reviewing all serious adverse event reports. All reported SAEs will generate an e-mail notification to the Medical Monitor, Lead Investigator, and designees. All SAEs will be reviewed by the Medical Monitor and, if needed, additional information will be requested. The Medical Monitor will also report events to the sponsor, the Data and Safety Monitoring Board (DSMB), study drug manufacturers, and regulatory authorities. The DSMB will receive summary reports of all adverse events annually, at a minimum. The DSMB or the NIDA assigned Medical Monitor may also request additional and updated information. Details regarding specific adverse events, their treatment and resolution, will be summarized by the Medical Monitor in writing for review by the sponsor and DSMB. Subsequent review by the Medical Monitor, DSMB, and ethics review committee or IRB, the sponsor, or relevant local regulatory authorities may also suspend further trial treatment at a site. The study sponsor and the DSMB retain the authority to suspend additional enrollment and treatments for the entire study as applicable.


Reporting to the Data and Safety Monitoring Board

The DSMB will receive a listing of AEs and summary reports of all SAEs at a frequency requested by the DSMB, but at least annually. Furthermore, the DSMB will be informed of expedited reports of SAEs.

Participant Withdrawal

The study medical clinician must apply his/her clinical judgment to determine whether or not an adverse event is of sufficient severity to require that the participant is withdrawn from further study medication administration. The study medical clinician should consult with the study physician, site principal investigator, the Lead Investigator and/or Medical Monitor as needed. If necessary, a study medical clinician may suspend any trial treatments and institute the necessary medical therapy to protect a participant from any immediate danger. A participant may also voluntarily withdraw from treatment due to what he/she perceives as an intolerable adverse event or for any other reason. If voluntary withdrawal is requested, the participant will be asked to complete an end-of-medication visit to assure safety and to document end-of-medication outcomes and will be given recommendations for medical care and/or referrals to treatment, as necessary. Other reasons for the investigator or sponsor terminating a participant from the study may include, but are not limited to, the participant becoming a threat to self or others, lack of funding, or DSMB early termination of the study for safety or effectiveness reasons.

AE Chart



17.0 APPENDIX B - DATA AND SAFETY MONITORING PLAN

BRIEF STUDY OVERVIEW

This double-blind, placebo-controlled, randomized clinical trial will investigate a combination medication, extended-release injectable naltrexone plus extended-release bupropion, compared to placebo as a potential pharmacotherapy for MA dependence. Screening will occur over a maximum of 21 days. Study medications will be provided during a 12-week medication phase. Participants will be randomized to either the active medication combination (AMC) arm in which injections of extended-release naltrexone (XR-NTX; as Vivitrol®) plus 450 mg / day oral extended-release bupropion (BUP-XL) tablets will be provided or the matching placebo (PLB) arm in which injections of placebo (iPLB) and once daily oral placebo (oPLB) tablets will be provided. Injections will be provided in weeks 1, 4, 7, and 10. Participants will be asked to attend clinic twice weekly for observed oral medication dosing and provision of take-home oral medication, collection of urine samples, assessments, and medical management. Following the 12-week medication phase, participants will complete a follow-up phase, including a medication taper and post-medication phase follow-up visits during Weeks 13 and 16.

Details for the definitions and reporting of safety events are found in Appendix A of the protocol.

OVERSIGHT OF CLINICAL RESPONSIBILITIES

A. Site Principal Investigator

Each participating site's PI is responsible for study oversight, including ensuring human research subject protection by designating appropriately qualified, trained research staff and medical clinicians to assess, report, and monitor adverse events.

Regarding safety, all Adverse Events (AEs) occurring during the course of the clinical trial will be collected, documented, and reported by the investigator or sub-investigators according to the protocol. The assessment of Adverse Events (medical and/or psychiatric) will commence the visit after consent and will continue through all study visits. Study staff will follow-up on the status of any AEs that remain for up to 30 days after the last planned study visit in week 16.

The occurrence of AEs and Serious Adverse Events (SAEs) will be assessed at each clinic visit after consent. All adverse events will be followed until resolution, stabilization or study end. Serious adverse events will be followed until resolved or considered stable, with reporting to the CCC Safety Monitor/Medical Monitor through the follow-up period.

Standard reporting, within 7 days of the site becoming aware of the event, is required for AEs. Expedited reporting (within 24 hours of their occurrence and/or site's knowledge of the event) is required for reportable SAEs (including death and life-threatening events).

B. Medical Monitor/Safety Monitor

The NIDA Clinical Coordinating Center (CCC) Safety Monitor/Medical Monitor is responsible for reviewing all adverse events and serious adverse events reported. All SAEs will be reviewed at the time they are reported in eClinical. The Medical Monitor will also indicate concurrence or not with the details of the report provided by the site. Where further information is needed the Safety Monitor/Medical Monitor will discuss the event with the site. Reviews of SAEs will be conducted

in the Advantage eClinical data system and will be a part of the safety database. All AEs will be reviewed on a regular basis to observe trends or unusual events.

The CCC Safety Monitor/Medical Monitor will in turn report events to the sponsor, study drug manufacturers, and regulatory authorities if the event meets the definition of an expedited event. All SAEs that meet expedited reporting based on federal regulations will be reported to the DSMB in writing within 15 calendar days of notification of the CCC. If the SAE meets the criteria for death or is immediately life-threatening, the CCC will notify the DSMB electronically, by phone or by fax as soon as possible but no later than 7 calendar days of notification of the CCC, with a follow-up written report within 15 calendar days of notification of the CCC. The CCC will prepare an expedited report and copies will be distributed to site investigators.

Reports will be generated and presented for Data and Safety Monitoring Board (DSMB) meetings. The DSMB will receive listings of AEs and summary reports of all SAEs at a frequency requested by the DSMB, but at least annually. Furthermore, the DSMB will be informed of expedited reports of SAEs.

C. Data and Safety Monitoring Board (DSMB)

The NIDA CTN DSMB affiliated with this trial will be responsible for conducting periodic reviews of accumulating safety, trial performance, and outcome data. The DSMB will make recommendations to NIDA as to whether there is sufficient support for continuation of the trial, that study procedures should be changed, or that the trial (or a specific site) should be halted for reasons relating to safety of the study participants or inadequate trial performance (e.g., poor recruitment).

Following each DSMB meeting, the NIDA CCTN will communicate the outcomes of the meeting, including DSMB recommendations, in writing to the study Lead Investigator. Study safety information will be submitted to participating IRBs.

D. Quality Assurance (QA) Monitoring

Monitoring of study sites will be conducted on a regular basis using a combination of NIDA CCC contract monitors, the local node site managers, and lead node staff. The purpose of these visits is to assess compliance with GCP requirements and to document the integrity of the trial progress. Areas of particular concern will be the review of inclusion/exclusion criteria, participant informed consent forms, protocol adherence, safety monitoring, IRB reviews and approvals, regulatory documents, participant records, study drug accountability, and Principal Investigator supervision and involvement in the trial. The Monitors will interact with the site staff to identify issues and re-train the site staff as needed to enhance research quality.

QA Site Visit Reports will be prepared by the NIDA CCC contract monitors following each site visit. These reports will be forwarded to the site Principal Investigator, the study Lead Investigator and NIDA.

E. Management of Risks to Participants

Confidentiality

Confidentiality of participant records will be secured by using study codes for identifying participants on CRFs, secure storage of any documents that have participant identifiers, and secure computing procedures for entering and transferring electronic data. All study data will be stored in a secure location with limited access. Only research staff will have access to the study records. Other parties with access to study data, such as local or central IRBs, will be specified

to the participants per HIPAA regulations. No identifying information will be disclosed in reports, publications or presentations.

Participants' information will not be released without their written permission, except as necessary for monitoring or suspected abuse or violence. The Lead Investigator (LI) will apply for a Certificate of Confidentiality that will cover all sites participating in the study. By participating in this protocol, the local site investigator agrees that within local regulatory restrictions and ethical considerations, any regulatory agency may consult and/or copy study documents to verify study data.

By participating in this protocol, the local site investigator affirms that information furnished to the investigator by the Lead Investigator will be maintained in confidence and such information will be divulged to the IRB, Ethical Review Committee, or similar expert committees, affiliated institutions, and employees only under an appropriate understanding of confidentiality with such boards or committees, affiliated institutions, and employees.

Information Meeting Reporting Requirements

The consent form will specifically state the types of information that are required to be reported and the fact that the information will be reported as required. These include suspected or known sexual or physical abuse of a child or elders, or threatened violence to self and/or others.

Participant Protection

The study physician will evaluate all pertinent screening and baseline assessments prior to participant randomization to ensure that the participant is eligible and safe to enter the study. Adverse events (AEs) and concomitant medications will be assessed and documented at each clinic visit. Individuals who experience an AE that compromises safe participation will be discontinued from further medication administration and provided referrals for other treatment or to specialized care. Study personnel will request that the participant complete an end-of-medication visit to assure safety and to document end-of-medication outcomes.

Pregnancy

Pregnancy is an exclusion criterion for study participation. A positive pregnancy test post-enrollment will result in the cessation of study medication. Participants who discontinue medications will be expected to continue with study visits. Pregnancy test results and related outcome information will be collected on a Pregnancy and Outcome CRF. The site staff will follow the participant until an outcome of the pregnancy is known.

Expected Risks of the Study Medication

For anyone who has opioids in their system, naloxone and naltrexone may cause opioid withdrawal symptoms. As with any study drug, there is also the possibility of an allergic reaction. Participants will be monitored for at least 30 minutes following the naloxone challenge, and at least 15 minutes following each medication induction (co-administration of injectable and oral study medications).

BUPROPION Extended Release: Possible side effects include elevated blood pressure, agitation, irritability, restlessness, sleeplessness, dry mouth, headache/migraine, nausea, vomiting, constipation, and shakiness. At doses of 450 mg daily, there is 1 chance in 1000 that a participant taking bupropion will experience a seizure. Individuals with a history of epilepsy or seizure disorder, current eating disorder, or who are taking certain medications will not be allowed to participate. Although bupropion is used to treat depression, a small percentage of people who take antidepressants have increased thoughts of suicide, particularly during the early weeks of medication.

NALTREXONE for Extended Release (Vivitrol®): Possible side effects include nausea, vomiting, headaches, dizziness, insomnia, dry mouth, and depressed mood. In rare cases people who received naltrexone developed suicidal thoughts, or a type of pneumonia (lung inflammation) caused by an excess of a certain type of white blood cells in the lungs. The most serious side effect of naltrexone is liver (hepatocellular) injury, which has almost always occurred with oral doses of 1400 to 2100 mg per week. Recent study findings show that no evidence of liver injury was found in people receiving once-monthly Vivitrol® injections. For safety, participants with acute symptomatic hepatitis or liver failure will not be allowed to participate.

Vivitrol® injections may cause pain, tenderness, hardening or damage of body tissues, swelling, redness, bruising, itching, or infection at the injection site. Such injection site reactions have been the most common side effects associated with Vivitrol®. The injection site will be monitored after each injection. Participants will be instructed to report any injection site reactions immediately to the study team. Any participants showing signs of injection site reactions such as a localized infection (abscess), skin infection (cellulitis), body tissue damage, or extensive swelling will be monitored by the study medical staff and treated accordingly.

Data Management Procedures

This protocol will utilize a centralized Data and Statistics Center (DSC). A web-based distributed data entry model will be implemented. This electronic data capture system (Advantage eClinical) will be developed to ensure that guidelines and regulations surrounding the use of computerized systems in clinical trials are upheld.

Data and Statistics Center Responsibilities

The DSC will: 1) develop and apply data management procedures to ensure the collection of accurate and good-quality data, 2) provide Case Report Forms in electronic (eCRF) and paper (CRF) format, and Participant Reported Outcome forms in electronic (ePRO) and paper (PRO) format for the collection of all data required by the study, 3) develop data dictionaries for each CRF and PRO form that will comprehensively define each data element, 4) prepare instructions for the use of Advantage eClinical and for the completion of forms, 5) conduct ongoing data validation and cleaning activities on study data collected from all participating sites, and 6) perform data validation and cleaning activities prior to any interim analyses and prior to the final study database lock.

Data Collection and Entry

Data will be collected at the study sites on source documents and entered by the site on the form in Advantage eClinical, or will be collected via direct entry into the eCRF by the site or direct entry into the ePRO by the participant. In the event that Advantage eClinical is not available, the DSC will provide the sites with paper source documents and completion instructions. Data will be entered into Advantage eClinical in accordance with the instructions provided during project-specific training and guidelines established by the DSC. Data entry into the forms shall be performed by authorized individuals. Selected eCRFs may also require the site investigator's electronic signature.

The principal investigator at the site is responsible for maintaining accurate, complete and up-to-date research records. In addition, the site investigator is responsible for ensuring the timely completion of forms for each research participant.

Data Monitoring, Cleaning and Editing

Data will be entered into the DSC automated data acquisition and management system (Advantage eClinical). Forms will be monitored for completeness and accuracy throughout the study. Dynamic reports listing missing values and forms will be available to sites at all times in Advantage eClinical. These reports will be monitored regularly by the DSC. In addition, the DSC will identify inconsistencies within forms and between forms and post data clarification requests or queries in Advantage eClinical on a scheduled basis. Sites will resolve data inconsistencies and errors by entering all corrections and changes directly into Advantage eClinical.

The CCC will conduct regular visits to sites, during which audits comparing source documents to the data entered will be performed. Any discrepancies identified between the source document and the eCRF or ePRO will be corrected by the site.

Trial progress and data status reports, which provide information on recruitment, availability of primary outcome, treatment exposure, attendance at follow-up visits, regulatory status, and data quality, will be generated routinely and posted to a secure website. These reports will be available to the site, the corresponding Local Node, the Lead Investigator, the coordinating centers, and NIDA, to monitor the sites' progress on the study.

Data Lock and Transfer

At the conclusion of data collection for the study, the DSC will perform final data cleaning activities and will "lock" the study database from further modification. The final analysis dataset will be returned to the Lead Investigator and NIDA, as requested, for storage and archive.

18.0 APPENDIX C - SMARTPHONE APP-BASED MEDICATION ADHERENCE PROCEDURES

The smartphone app will be provided by AiCure and will be referred to as the “app” or “study app.”

Technology Training

After eligibility has been established and the participant has been randomized, staff will provide training on the use of the medication adherence app that will monitor and encourage adherence. The AiCure app will be downloaded onto the participant’s personal smartphone or, if unable to be downloaded, a study provided smartphone device will be provided with the app pre-loaded on it. Training will include using the app features and capabilities, security features (e.g., encryption), and taking practice dosing videos.

Medication Adherence App on Participant Personal Smartphone

Participants who choose to use their own smartphone must own a device that is camera-equipped and capable of SMS text messaging and taking videos. Participants who download the app on their personal smartphone devices will be provided an additional \$10 at the beginning of each study month to offset the costs for additional data services needed due to use of the app. Participants who require a study provided smartphone device at any point during the study may be provided one. However, to ensure that participants are compensated equitably, no participant will receive more than \$10 per study month for using either the app or a study provided smartphone device.

Study Provided Smartphone Device

Participants who do not have a personal device or are unable to download the AiCure app will be provided with a smartphone device (and battery charger). Service plans will be included to allow participants to receive text messages and reminders from study staff through the study app and to take dosing videos. The smartphone device equipment will be retained by participants through the end of their participation in the study. A replacement device may be available in the event of unintentional damage or loss. Sites are encouraged to consult with the Lead Team when considering providing replacement study devices for participants who are withdrawn from study medications. If the participant does not require a replacement smartphone device during the course of the study, the participant will be provided up to \$40 payment (i.e., \$10 for each study month) for the safe return of the smartphone device and, ideally, all accompanying accessories (e.g., charger, carrying case). Replacement smartphone devices will be returned at the end of study participation, but no payment will be provided to those participants requiring a replacement device.

Set-up and Maintenance of App (and Smartphone Device, if applicable)

Study staff will activate the AiCure app on participant smartphones or prepare the study provided smartphone for the participant. If a participant is using a study provided smartphone device, study staff will provide appropriate training on how to use the device.

Smartphone Device-Based Procedures and Compensation

Prior to randomization, study personnel will request a signed agreement from participants regarding the use of the smartphone app or study provided device for the purposes of the study. Participants will be informed of the medication adherence procedures, including the requirement to take daily videos of oral study medication ingestion. If a participant fails to bring his/her oral study medication to the clinic so that self-administration of the dose can be observed and a video

can be taken, the participant will be asked to take a video of him/herself taking the dose for that day at home (if the dose has not already been taken). Participants will be compensated \$5 for each dosing video taken on non-clinic days, including the taper in week 13. “Red Alerts” are triggered by AiCure when there is a pattern of problematic behaviors observed during video dosing. AiCure staff will guide site staff in how to re-train participants to appropriately use the app. If a pattern of recurring Red Alerts are triggered by AiCure, this indicates repeated problematic dosing behaviors are occurring, indicating non-adherence to oral study medication. Recurring Red Alerts may result in a participant not being compensated for dosing videos; sites should consult with the Lead Team when repeated Red Alerts occur.

Lost/Stolen/Inoperable Smartphone Devices


The purpose of providing a study smartphone device (to participants unable to use their own) is to monitor and improve medication adherence on non-clinic days as well as provide a means of study staff contacting participants. Participants will be notified that study provided devices will have a tracking tag on the back which allows for lost or stolen devices to be retrieved via a nationwide network and that removal of the tracking tag reveals a “stolen property” embossing on the device. Study provided smartphone devices are operational for study purposes only and are locked down to any other use. A one-time replacement of a lost, stolen, or inoperable study provided smartphone device may be permitted. Study staff should consult with the Lead Team should a second loss/theft of a study smartphone device occur.

Protection of Participant Privacy

Participants will be advised on how to secure their devices with passwords and how the software application will be used to transmit dosing videos to the secure server as an encrypted file. Research staff will only access smartphone device settings as needed to help troubleshoot a problem with the AiCure app and when requested by the participant.

Staff-to-Participant Contact

Staff will send texts from a list of pre-determined messages to participants through the app regarding reminders for clinic visits or dosing requirements. If a participant has not taken the dosing video by an agreed upon time on a take-home dosing day, study staff will contact the participant to ask the participant to take his/her study medication dose via the app as soon as possible.



NIDA CTN Protocol 0068

Lead Investigator (LI): Madhukar Trivedi, MD

Version 1.0

November 4, 2016

Details regarding the timing of re-randomization, the duration and timing of the evaluation period, and related statistical analysis (as it contains information about the timing of re-randomization and the evaluation period) are omitted from the Protocol to protect the double blind. These details are contained in the confidential Statistical Analysis Plan. The Lead Team will provide the Statistical Analysis Plan directly to the site Institutional Review Board(s) or Independent Ethics Committee.

PROTOCOL DEVELOPMENT TEAM

Lead Investigator: Madhukar Trivedi, MD
Texas Node
University of Texas Southwestern Medical Center

Co-Lead Investigator & Project Director: Robrina Walker, PhD
Texas Node
University of Texas Southwestern Medical Center

Co-Investigators: Walter Ling, MD
Adriane dela Cruz, MD, PhD

Protocol Development Team: Linda Chang, MD

CCTN Project Coordinators: Udi Ghitza, PhD
National Institute on Drug Abuse

Petra Jacobs, MD
National Institute on Drug Abuse

Clinical Coordinating Center: Robert Lindblad, MD
CCC Principal Investigator

Eve Jelstrom, CRNA, MBA
CCC Co-Principal Investigator

Matthew Wright, CCRP
Protocol Specialist

Data Coordinating Center: Paul VanVeldhuisen, PhD
DSC Principal Investigator

Gaurav Sharma, PhD
DSC Statistician

Lauren Yesko
DSC Project Manager

Cathryn Mudrick, MPH
DSC Data Manager

TABLE OF CONTENTS

1.0	LIST OF ABBREVIATIONS	7
2.0	SCHEMA.....	8
3.0	SYNOPSIS.....	9
4.0	BACKGROUND AND RATIONALE	11
4.1	Background.....	11
4.1.1	Treatment of Stimulant Use Disorder (Amphetamine-type) with Naltrexone	11
4.1.2	Figure 1. Percentages of Urine Samples Negative for MA.....	12
4.1.3	Treatment of Stimulant Use Disorder (Amphetamine-type) with Bupropion	13
4.1.4	Figure 2. Abstinence for the last two weeks among non-daily MA users	15
4.1.5	Figure 3. Weekly Abstinence Rates for Light Users versus Heavy Users	15
4.2	Study Rationale.....	16
4.3	Significance of the Project to the Field	17
5.0	OBJECTIVES.....	18
5.1	Primary Objectives	18
5.2	Secondary Objectives	18
6.0	DESIGN	19
6.1	Overview of Study Design	19
6.2	Duration of Study and Clinic Visit Schedule.....	19
6.3	Participant Selection	20
6.3.1	Inclusion Criteria	20
6.3.2	Exclusion Criteria	21
6.4	Site Selection	22
6.4.1	Site Characteristics	22
6.4.2	Rationale for Site Selection.....	22
6.5	Randomization Plan	23
6.6	Study Intervention	23
6.7	Outcome Measures.....	23
6.7.1	Primary Efficacy Outcome Measure	24
6.7.2	Primary Safety Outcome Measure	24
6.7.3	Secondary Outcome Measures.....	24
7.0	PROCEDURES	25
7.1	Screening and Baseline Phase	25
7.1.1	Pre-screening Assessment	25
7.1.2	Informed Consent	25
7.1.3	Screening and Baseline Assessments	25
7.1.4	Naltrexone Pre-Induction Strategy	26
7.1.5	Final Confirmation of Eligibility	26
7.2	Medication Phase.....	27
7.2.1	Randomization	27

7.2.2	Pharmacotherapy.....	27
7.2.3	Medical Management.....	27
7.2.4	Medication Adherence	28
7.2.5	Participant Medication Withdrawal	28
7.3	Follow-up Phase	30
7.3.1	Oral Study Medication Taper.....	30
7.3.2	Post-Medication Phase Follow-up Visits	30
7.4	Study Medication Management/Drug Accountability.....	30
7.4.1	Documentation.....	30
7.4.2	Storage	30
7.4.3	Packaging	31
7.4.4	Ordering and Dispensing	32
7.4.5	Used/Unused Medication	32
7.4.6	Lost Medication.....	32
7.4.7	Maintaining and Breaking Blind.....	32
7.5	Participant Compensation	33
7.5.1	Table 1. Compensation Schedule	33
8.0	ASSESSMENTS	34
8.1	Table 2. Schedule of Assessments	35
8.2	Screening Measures	36
8.2.1	Pre-Screening Interview Form.....	36
8.2.2	Informed Consent	36
8.2.3	Demographics Form	36
8.2.4	Alcohol and Substance Use History	36
8.2.5	DSM-5 Checklist	36
8.2.6	Psychiatric Diagnostic Screening Questionnaire	36
8.2.7	Self-Report of HIV Testing	36
8.2.8	Medical and Psychiatric History	37
8.3	Safety Measures	37
8.3.1	Physical Examination.....	37
8.3.2	Electrocardiogram (ECG).....	37
8.3.3	Injection Site Examination.....	37
8.3.4	Injection Site Abnormality Log.....	37
8.3.5	Clinical Laboratory Tests.....	37
8.3.6	Concise Health Risk Tracking- Participant Rated Module	38
8.3.7	Pregnancy and Birth Control Assessment.....	38
8.3.8	Vital Signs.....	38
8.3.9	Prior and Concomitant Medications	38
8.3.10	Adverse Events (AEs) and Serious Adverse Events (SAEs)	38
8.3.11	Naloxone Challenge Form	39
8.4	Efficacy Measures.....	39


8.4.1	Urine Drug Screen (UDS)	39
8.4.2	Timeline Followback (TLFB)	39
8.4.3	Visual Analog Craving Scale (VAS)	39
8.4.4	Patient Health Questionnaire-9	39
8.4.5	Treatment Effectiveness Assessment	40
8.4.6	Tobacco Use History.....	40
8.4.7	Quality of Life.....	40
8.4.8	Sexual Risk Behaviors	40
8.4.9	Genetic Sampling.....	40
8.5	Adherence Measures	40
8.5.1	Study Medication Dosing Logs.....	40
8.5.2	Injection Administration Form.....	41
8.5.3	Oral Medication Dispensation Form	41
8.5.4	Oral Study Medication Blood Levels.....	41
8.5.5	Video Based Adherence to Oral Study Medication Database.....	41
8.5.6	End of Medication Form.....	41
8.6	Administrative and Other Forms.....	41
8.6.1	Locator Form	41
8.6.2	Eligibility - Randomization	42
8.6.3	Missed Visit Form	42
8.6.4	Protocol Deviation Form.....	42
8.6.5	Protocol Satisfaction Surveys.....	42
8.6.6	Study Completion Form	42
9.0	TRAINING	43
10.0	STATISTICAL ANALYSES.....	44
10.1	General Design	44
10.1.1	Study Hypothesis	44
10.1.2	Sample Size.....	44
10.1.3	Primary Outcomes	44
10.1.4	Secondary Outcomes	44
10.2	Interim Analyses	45
10.2.1	Sample Size Re-estimation.....	45
10.2.2	Interim Monitoring of Primary Efficacy Endpoint.....	45
10.2.3	Safety Interim Analyses	46
10.2.4	Conditional Power and Futility.....	46
10.3	Demographic and Baseline Characteristics.....	47
10.4	Description of Plans to Conduct Analyses of Study Results by Gender and Race/Ethnicity	47
10.5	Safety Analysis	47
11.0	REGULATORY COMPLIANCE, REPORTING AND MONITORING	48
11.1	Statement of Compliance	48

11.2	Institutional Review Board Approval	48
11.3	Research Advisory Panel of California (California sites only)	48
11.4	Informed Consent.....	48
11.5	Health Insurance Portability Accountability Act (HIPAA).....	49
11.6	Investigator Assurances	49
11.7	Financial Disclosure	49
11.8	Confidentiality	49
11.9	IND Requirements.....	50
11.10	Regulatory Files	50
11.11	Study Documentation	51
11.12	Records Retention and Requirements.....	51
11.13	Reporting to Sponsor	51
11.14	Safety Monitoring	51
11.14.1	Adverse Events (AEs).....	51
11.14.2	Definitions of Adverse Events and Serious Adverse Events.....	52
11.14.3	Reportable Adverse Events and Serious Adverse Events	52
11.14.4	Data and Safety Monitoring Board (DSMB).....	52
11.14.5	Medical Monitor	52
11.15	Protocol Deviations: Reporting and Management.....	53
11.16	Audits.....	53
11.17	Quality Assurance Monitoring	53
12.0	DATA MANAGEMENT AND PROCEDURES	55
12.1	Design and Development.....	55
12.2	Site Responsibilities	55
12.3	Data and Statistics Center Responsibilities	55
12.4	Data Collection and Entry.....	55
12.5	Data Monitoring, Cleaning, and Editing	55
12.6	Database Transfer and Lock	56
13.0	PUBLICATIONS AND OTHER RIGHTS	57
14.0	SIGNATURES.....	58
15.0	REFERENCES.....	59
16.0	APPENDIX A - Adverse Event Reporting Definitions and Procedures	65
17.0	APPENDIX B - Data and Safety Monitoring Plan	70
18.0	APPENDIX C – Smartphone App-based Medication Adherence Procedures.....	75

19.0 LIST OF ABBREVIATIONS

Abbreviation	Definition
AE	Adverse Event
AMC	Active Medication Combination
ALP	Alkaline Phosphatase
ALT	Alanine Aminotransferase
AST	Aspartate Aminotransferase
BL	Blood levels of bupropion and/or metabolite
BUP-XL	Extended-release Bupropion
CAP	College of American Pathologists
CCC	Clinical Coordinating Center
CCTN	Center for the Clinical Trials Network
CHRT	Concise Health Risk Tracking
CLIA	Clinical Laboratory Improvement Amendment of 1988
CNS	Central Nervous System
CRF	Case Report Form
CTN	Clinical Trials Network
DSC	Data and Statistics Center
DSMB	Data and Safety Monitoring Board
DSM-5	Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition
eCRF	Electronic Case Report Form
ECG	Electrocardiogram
EDC	Electronic Data Capture system/Advantage eClinical
FDA	Food and Drug Administration
GCP	Good Clinical Practice
GGT	Gamma-Glutamyl Transpeptidase
HIV	Human Immunodeficiency Virus
ICH	International Council on Harmonisation
IM	Intramuscular
IRB	Institutional Review Board
IND	Investigational New Drug
iPLB	Injectable Placebo
LFT	Liver Function Test
LN	Lead Node
MA	Methamphetamine
Mg	Milligrams
NAL	Naloxone
NDA	New Drug Application
NIDA	National Institute on Drug Abuse
NIH	National Institutes of Health
oPLB	Oral Placebo
PCM	Prior and Concomitant Medications
PDSQ	Psychiatric Diagnostic Screening Questionnaire
PI	Principal Investigator
PLB	Placebo Medication Combination
RAP-C	Research Advisory Panel of California
SRB	Sexual Risk Behaviors
SAE	Serious Adverse Event
SOP	Standard Operating Procedure
TEA	Treatment Effectiveness Assessment
TES	Treatment Effectiveness Score
TLFB	Timeline Followback
UDS	Urine Drug Screen
VAS	Visual Analog Scale
XR-NTX	Extended-Release Naltrexone (as Vivitrol®)

20.0 SCHEMA



21.0 SYNOPSIS

STUDY OBJECTIVE: The primary objective of this study is to evaluate the efficacy of extended-release naltrexone plus bupropion as a combination pharmacotherapy for methamphetamine use disorder. Secondary objectives include assessing the safety of naltrexone plus bupropion and determining the efficacy of the combination pharmacotherapy on other substance use outcomes, on depression symptom scores, and on quality of life ratings.

STUDY DESIGN: This is a double-blind, placebo-controlled, adaptive randomized clinical trial in which 370 individuals with moderate or severe methamphetamine use disorder will be randomly assigned to the 1) active medication combination (AMC) arm in which injections of extended-release naltrexone (XR-NTX; as Vivitrol®) plus once daily oral extended-release bupropion (BUP-XL) tablets will be provided or the 2) matching placebo (PLB) arm in which injections of placebo (iPLB) and once daily oral placebo (oPLB) tablets will be provided. During the course of the study, participants may or may not be switched to another arm, as determined by the a priori adaptive aspect of the study design. Participants appearing to respond well to their original treatment assignment will not be switched. Overall, approximately 50% of the participants will receive the AMC. After establishing eligibility during a maximum 21 day screening period, participants will begin the 12 week medication phase. Randomization will be stratified by site. At the end of the 12 week medication phase, participants will complete a follow-up phase, including an oral medication taper. Post-medication phase follow-up visits will occur during Weeks 13 and 16.

STUDY PARTICIPANTS: The study sample consists of 370 males and non-pregnant, non-lactating females, ages 18 to 65 years old, who have met all eligibility criteria, including DSM-5 criteria for moderate or severe stimulant use disorder (methamphetamine type), who report using methamphetamine 18 or more days during the 30 days prior to signing consent, and who provide at least 2 methamphetamine-positive urine specimens during screening. Potential participants have up to 3 weeks to meet eligibility criteria after signing consent.

INTERVENTION: The study intervention consists of a 12 week medication phase. Participants randomized to the AMC arm will receive injections of extended-release naltrexone (Vivitrol®) plus 450 mg of once-daily oral extended-release bupropion tablets while participants randomized to the PLB arm will receive placebo injections plus once-daily oral placebo tablets. Injectable study medication will be administered every three weeks (weeks 1, 4, 7, and 10). Take-home oral study medication will be dispensed once weekly for dosing on non-clinic days. Once weekly medical management sessions with the study medical clinician will be provided. Medication adherence procedures will include smartphone app-based videos of daily dosing. Participants will be asked to attend clinic twice weekly for observed oral study medication dosing, collection of urine drug screening samples, and self-report assessments. Compensation will be provided for visit attendance and dosing adherence.

ASSESSMENTS: Screening/baseline assessments include safety and medical measures including a medical and psychiatric history, a physical examination, clinical lab tests (blood chemistry, hematology, and urinalysis), 12-lead electrocardiogram, vital signs, and pregnancy tests (for females). Screening/baseline assessments also include psychological and drug use measures. Methamphetamine use outcome assessments include Urine Drug Screens (UDS), self-reported use via the Timeline Followback (TLFB), and Visual Analog Scale (VAS) craving scores. Other outcome assessments include UDS and TLFB (i.e., alcohol, tobacco, and/or illicit drugs), depression (Patient Health Questionnaire-9), quality of life (QOL), functioning (Treatment Effectiveness Assessment), and clinic attendance. Safety measures include monitoring vital signs, adverse events (AEs), concomitant medications, clinical lab results, and assessments of suicidality. Oral study medication adherence will be assessed by self-report, quantitative blood

levels of bupropion and its primary metabolite, and smartphone app-based dosing confirmation procedures.

A blood sample for genetic analysis will be collected from participants who consent to this procedure and the de-identified sample will be sent to a cell and DNA repository.

ANALYSES: The primary analysis will evaluate the impact of the AMC arm, relative to PLB, on methamphetamine use. The primary efficacy outcome is a measurement of treatment response based on MA-negative urine drug screen results during the medication phase. Outcome variables will be analyzed using appropriate statistical methods for the intention-to-treat (ITT) population and for the evaluable population.

22.0 BACKGROUND AND RATIONALE

22.1 Background

Many years of concerted efforts have produced no effective medication to help initiate and maintain abstinence from methamphetamine (MA). Several promising candidates have shown preliminary clinical utility, including bupropion and naltrexone (Elkashef et al., 2008; Jayaram-Lindström et al., 2008b). Development of a safe and effective pharmacotherapy is an important objective with considerable public health significance.

For many medical conditions, combinations of medications may be routine in clinical practice but are emerging only recently for methamphetamine pharmacotherapy. Well-publicized combination pharmacotherapy studies have tested combination medications for depression (CO-MED, Zisook et al., 2011; STAR-D, Trivedi et al., 2006) made possible by the availability of a number of medications approved for depression. Two notable attempts within the National Institute on Drug Abuse National Drug Abuse Treatment Clinical Trials Network (NIDA CTN) include the *Cocaine Use Reduction with Buprenorphine* (CTN-0048 CURB) trial, a Vivitrol+Suboxone combination trial for cocaine dependence (Ling et al., 2016; Mooney et al., 2013), and the *Accelerated Development of Additive Pharmacotherapy Treatment* (CTN-0054 ADAPT) trial completed in early 2015 that examined the combination pharmacotherapy naltrexone plus bupropion for MA use disorder in an open-label design (Mooney et al., 2016). Findings from this first ADAPT study provided a signal sufficient to advise the development of a fully powered, placebo-controlled study to test the efficacy of the combination in producing sustained abstinence from methamphetamine at the end of the study (see below).

22.1.1 Treatment of Stimulant Use Disorder (Amphetamine-type) with Naltrexone

There is modest research to support the individual constituents of the combination pharmacotherapy of naltrexone and bupropion as a putative treatment for MA use disorder.


Naltrexone mechanism of action: An early human laboratory study provided some evidence for modulation of the opioid system as the mechanism of action of naltrexone in its ability to reduce reinforcing effects of amphetamine (Jayaram-Lindström et al., 2005). Although not completely clear, the action of naltrexone that may work to reduce the reinforcing effects of alcohol and other drugs appears to derive from a blockade of effects of endogenous opioid peptides by occupation and binding of opioid receptors. A retrospective pooled data analysis of three studies examining alcohol dependent participants with single nucleotide polymorphism (SNP) A118G (heterozygous or homozygous) found that participants treated with naltrexone were substantially less likely to relapse (Oslin et al., 2003). However, one small randomized trial showed no difference in outcomes along this SNP (A118A vs. A118G) when prospectively assigning individuals to open-label injectable naltrexone treatment for methamphetamine dependence (Pal et al., 2015). More recent controlled human laboratory data show that compared to placebo, steady state naltrexone at 50 mg per day significantly blunted cue-induced craving for methamphetamine and attenuated several of the hedonic subjective effects of methamphetamine, including craving, during administration of 30 mg IV methamphetamine challenge. Specifically, naltrexone decreased subjective ratings of "crave drug," "stimulated," and "would like drug access," decreased the post methamphetamine administration time course of "anxious," and increased ratings of "bad drug effects," as compared to placebo (Ray et al., 2015). There is no aversive response to administration of opioids or alcohol while naltrexone is present at clinical dosages.

Efficacy of naltrexone in treating stimulant use disorders: A study conducted in Sweden (Jayaram-Lindström, 2008b) indicated that naltrexone reduced amphetamine use among human subjects, though this efficacy was tested only for patients who could achieve two weeks of abstinence during the baseline screening period. Previously, efficacy of naltrexone for stimulant use disorder was found by Schmitz et al. (2001), reporting cocaine use decreased over time among cocaine-dependent patients taking 50 mg oral naltrexone compared to placebo. A question persists as to whether similar reductions can be expected among polydrug users, as the same authors subsequently found no effect on drug use among a sample of alcohol- and cocaine-dependent individuals treated with 50 mg/day (Schmitz et al., 2004). In contrast, Comer et al. (2006), in a study of combination opioid and stimulant abusers, found that cocaine use was reduced among the portion of the sample randomized to 384 mg of sustained-release naltrexone, virtually the same dosage of the extended-release formulation to be used in this protocol.

Efficacy of naltrexone in treating amphetamine dependent individuals: The clinical data emerging from research examining oral naltrexone in amphetamine dependent humans in Sweden provide convincing rationale for the exploration of naltrexone for MA dependence. Jayaram-Lindström and colleagues (2005) established tolerability and feasibility of naltrexone in an open-label trial, finding mild and transient side effects (nausea, headache, abdominal pains) and documenting reduced frequency and quantity of amphetamine use during treatment than before naltrexone treatment. Furthermore, in a double-blind trial, the same Swedish group (Jayaram-Lindström et al., 2008a) found that naltrexone reduced subjective effects of amphetamine. Subsequent work (Jayaram-Lindström et al., 2008b) found that oral naltrexone was effective in suppressing relapse to stimulant use among individuals meeting DSM-IV criteria for amphetamine dependence. An ongoing randomized, placebo-controlled trial (NCT01449565) of the injectable form of naltrexone is being conducted in San Francisco among methamphetamine dependent men who have sex with men and is estimated to be completed in 2016.

Figure 1, from Jayaram-Lindström et al. (2008b), shows percentages of urine samples negative for MA, presented in the figure on the left in the intention-to-treat sample—for the naltrexone group (diamonds) versus the placebo group (circles)—and for the completer group in the right figure.

22.1.2 **Figure 1. Percentages of Urine Samples Negative for MA**



The rationale for including extended-release injectable naltrexone (XR-NTX) in the original CTN-0054 trial was based on preclinical and clinical pharmacology, as well as on results of clinical trials using oral naltrexone in the treatment of amphetamine dependent individuals. Opiate antagonists, particularly naltrexone, have been shown to reduce amphetamine-induced dopamine release and amphetamine-induced locomotor activity in rats (Hitzemann et al., 1982), attenuate amphetamine-induced locomotor sensitization in rats (Haggkvist et al., 2011a), reduce cue-

induced reinstatement for MA in rats (Anggadiredja et al., 2004), block amphetamine-induced reinstatement of amphetamine self-administration in rats (Haggkvist et al., 2009), reduce the subjective effects of amphetamine in amphetamine-dependent patients (Jayaram-Lindström et al., 2008a), and prevent relapse to amphetamine in a double-blind, placebo-controlled trial (Jayaram-Lindström et al., 2008b). The progression of work logically extends from research on preclinical effects of opiate antagonists, to a clinical pharmacology demonstration of attenuation of amphetamine by naltrexone, to an outpatient efficacy study, then to the CTN-0054 combination medication trial on which the present trial is based.

22.1.3 Treatment of Stimulant Use Disorder (Amphetamine-type) with Bupropion

Bupropion is an antidepressant with stimulant properties that has been proven effective for the treatment of nicotine dependence (Richmond & Zwar, 2003). The antidepressant effects of bupropion may be related to its noradrenergic and dopaminergic mechanisms of action. Bupropion has a favorable side effect profile: it causes fewer anticholinergic, cardiovascular, sedative or adverse sexual effects than tricyclics and does not cause weight gain (Bryant, Guernsey, & Ingram, 1983). Bupropion has been studied as an attractive candidate medication for the treatment of stimulant use disorder, which is associated with dopaminergic dysregulation that may contribute to craving and drug seeking. Restoration of dopamine deficit states, combined with bupropion's ability to alleviate dysphoria observed in early abstinence from stimulants (Newton et al., 2004), may in turn reduce craving and help prevent relapse.

Bupropion has been investigated as a treatment for cocaine use disorder. In a pilot study, Margolin et al. (1991) found that 300 mg/day bupropion substantially reduced cocaine use in four of the five cocaine-dependent, methadone-maintained patients, was well tolerated, and reduced self-reported craving for cocaine. A multicenter placebo-controlled double-blind clinical trial of bupropion for cocaine dependence in methadone-maintained patients indicated efficacy of bupropion for the subgroup of patients with depression at study entry (Margolin et al., 1995).

The results of preclinical studies designed to test the effectiveness of bupropion to block effects of MA support clinical use for the treatment of MA dependence (Kim et al., 2000). Bupropion provides complete protection against MA-induced decrease in dopamine uptake in the striatum in an in vitro model of MA-induced dopamine nerve terminal toxicity. The combination of bupropion's dopaminergic activity and antidepressant properties may enhance its efficacy in the treatment and relief of the signs and symptoms of MA withdrawal and for reduction of relapse.

In a Phase 1 double-blind inpatient clinical laboratory study, 26 subjects with a DSM-IV diagnosis of MA dependence or abuse were randomized to receive either twice-daily bupropion XL (150 mg twice daily) or placebo control and a series of 3 infusions of saline or MA. The first and second infusions were randomized to be either 0 mg or 15 mg of either saline or MA, and the last infusion was always 30 mg of saline or MA (Newton et al., 2006). Of the 26 subjects enrolled, 20 completed the entire study, with 10 subjects in each of the bupropion and placebo control groups. Bupropion treatment was associated with reduced ratings of "any drug effect" ($p = 0.02$), and "high" ($p = 0.02$) as assessed with visual analog scales following MA administration. Bupropion also significantly reduced cue-induced craving [General Craving Scale total score ($p = 0.002$); Behavioral Intention subscale ($p = 0.001$)] (Newton et al., 2006). Bupropion treatment was well tolerated, with the bupropion- and placebo-treated groups reporting similar rates of adverse events. MA administration was associated with expected stimulant cardiovascular effects, and these were not accentuated by bupropion treatment. Instead, there was a trend for bupropion to reduce MA-associated blood pressure increases and a statistically significant reduction in MA-associated heart rate increases (Newton et al., 2005).

Pharmacokinetic analysis revealed that bupropion treatment reduced the plasma clearance of MA and lowered plasma concentrations of the metabolite amphetamine in the plasma (Newton et al., 2005). MA administration did not alter the peak and trough plasma concentrations of bupropion or its metabolites.^{[1][1]}

A NIDA Phase 2 efficacy study showed that bupropion significantly decreased MA use in MA-dependent participants who were using MA 18 days or less in the 30-day period prior to the start of screening (Elkashef et al., 2008). This study was a double-blind, placebo-controlled, randomized, two-arm, parallel-group design comparing 150 mg of bupropion to placebo administered twice daily to MA dependent outpatients. Of the 151 participants in the ITT sample, 121 were considered evaluable. Conclusions regarding the efficacy of bupropion include:

- Results of analysis of the primary outcome measure (weekly proportion of participants with all urine specimens free of MA) showed a trend, albeit statistically non-significant, favoring bupropion over placebo for the entire population (GEE, $p = 0.09$).
- Bupropion showed a statistically significant effect for MA-free weeks in participants who used MA ≤ 18 days in the 30 days prior to the start of screening (GEE, $p = 0.03$).
- A higher percentage of participants in the bupropion group than the placebo group reduced their proportion of MA use days to 50% or less of their baseline rate based on self-report only (Chi-square test, $p = 0.02$).
- Bupropion showed a statistically significant effect for MA-free weeks in males (GEE, $p = 0.04$).
- Bupropion showed a trend toward significance favoring bupropion for MA-free weeks in non-depressed participants (GEE, $p = 0.08$).
- Bupropion showed a statistically significant effect for MA-free weeks in participants without attention-deficit disorder (GEE, $p = 0.02$).

Participants were randomized to receive thrice-weekly CBT and either 150 mg twice daily bupropion SR or placebo. Randomization was balanced by frequency of self-reported MA use in the 30 days prior to the start of screening based on two rates of use: 1) low-rate users had 18 or fewer days of MA use; and 2) high-rate users had 19 or more days of MA use. Of the ITT sample, 47% were low-rate users and 53% were high-rate users. A GEE analysis performed on the primary outcome measure for each of these two study subpopulations as well as for the entire ITT sample showed that the low-rate use group administered bupropion had a statistically significant increase (GEE, $p < 0.04$) in the slope of weekly proportion of participants with MA-negative urines compared to the low-rate use group administered placebo. The high rate of MA use appears to reduce the bupropion effect when examining the entire study population.

Figure 2 illustrates the frequency of abstinence over the last two weeks in non-daily MA users in the bupropion study, in which 15 of 63 subjects (23.8%) achieved abstinence as compared to 3 of 53 (5.7%) in the placebo group. This finding was shown to be statistically significant (Chi-square, $p = 0.01$). Although there was a fairly high dropout rate over the course of the study (approximately 50% of the participants completed the study), it is important to note that there were no significant differences in the rate of dropout between the two groups.

22.1.4 **Figure 2.** Abstinence for the last two weeks among non-daily MA users


	Abstinence Last 2 Weeks		
Group	Fail (%)	Success (%)	Total
Bupropion	48 (76.2%)	15 (23.8%)	63
Placebo	50 (94.3%)	3 (5.7%)	53
	98	18	116

P = 0.01 (Chi-Square test)

Bupropion was well tolerated in this study. The only significant treatment emergent adverse event was nausea. Participants receiving bupropion had a significant increase (Chi-square, $p=0.019$) in the incidence of nausea over the intervention period. One participant (a 31-year-old female) in the bupropion group temporarily discontinued taking bupropion during the study due to an adverse event four weeks after commencing study drug, but the investigator determined that the adverse event was not related to the study drug.

Figure 3 is from Elkashef et al., 2008, showing the relative effects on MA use comparing participants who had reported 18 days or less of use per month at baseline (“light users”) against participants who had used more than 18 days per month (“heavy users”).

22.1.5 **Figure 3.** Weekly Abstinence Rates for Light Users versus Heavy Users



To conclude, this study suggested efficacy of bupropion only in participants who had used methamphetamine relatively infrequently at baseline. However, in the Mooney et al. (2016) study, the medication combination of once-daily 450 mg bupropion XL and extended-release injectable naltrexone resulted in a clinically-meaningful outcome in terms of proportion of methamphetamine dependent participants who met “responder” criteria. Unlike in the Elkashef et al. (2008) study,

these “responders” were participants who had used methamphetamine frequently, having self-reported at least 20 days of MA use in the 30 days prior to consent, and having submitted 3 MA-positive urine drug screens out of 4 collected during screening. Thus, the 450 mg dose of bupropion XL used in the Mooney et al. (2016) trial merits further evaluation in a sufficiently powered, randomized, placebo-controlled trial.

22.2 Study Rationale

Interest in the combination of naltrexone with other medications, especially with cognitive enhancers and anti-depressants (e.g., methylphenidate, bupropion, modafinil, mirtazepine), has increased. For example, “a formulation that combines naltrexone with methylphenidate could be a useful pharmaceutical approach to alleviate abuse potential of methylphenidate and other stimulants” (Zhu et al., 2011). The efficacy of naltrexone in reducing stimulant use has been empirically documented (Jayaram-Lindström, 2008b). Still, the medication is not wholly effective, which is also true of another medication—bupropion—which has been extensively studied in trials for MA dependence. Bupropion has been found to be somewhat successful at reducing MA use in dependent patients but demonstrates an uneven response across patient types (e.g., many patients did not complete protocols, and participants assessed at baseline as high-frequency users did less well than low-frequency users).

The rationale for combining bupropion and naltrexone, as examined in CTN-0054, is predicated on their potentially complementary effects as shown in clinical research and as postulated in mechanistic arguments for naltrexone (e.g., Hanson, 2004), for bupropion, which may involve noradrenergic and/or dopaminergic effects (e.g., Ascher et al., 1995; Newton et al., 2006), and for the combination, which could regulate the mesolimbic reward pathways (Ornellas & Chavez, 2011). Anecdotal reports derived from research involving opioid addicts who also use stimulants (e.g., Comer et al., 2006) also substantiate the utility of naltrexone for reducing MA use. The combination of naltrexone and bupropion had also been studied in research on the efficacy of the combination pharmacotherapy for controlling obesity (e.g., Greenway et al., 2010; Wadden et al., 2011) leading to the marketing of Contrave® for weight management. In a small ($n = 7$) clinical pharmacology trial, however, steady state naltrexone (50 mg per day), bupropion (300 mg per day), and their combination showed no statistically significant effect on behavioral responses or subjective effects following 0 mg, 10 mg or 30 mg intranasal methamphetamine (Stoops, Hays, Glaser, & Rush, 2015).

Combination pharmacotherapy, whereby medications exerting effects on different mechanisms of action may complement each other to help reduce stimulant use and to prevent relapse to stimulant use once abstinence has been attained, can be conceived in three ways: (1) one medication may act to enable the effects of other medication(s) as in CTN-0048 where the effect of Vivitrol® allowed buprenorphine to exert the hypothesized therapeutic effect under investigation; (2) one medication may act to enhance therapeutic effects of another, including possibly reducing side effects, as in combining different opioids in clinical pain management; and (3) the two medications may synergistically exert their combined effects as a novel compound and be studied as a single test agent. In this protocol, bupropion may serve to ameliorate some of the anhedonia and dysphoria that characterize early-phase abstinence from MA, and it also may counteract some of the side effects associated with naltrexone.

Some of the best evidence in support of this protocol is from the CTN-0054 pilot trial that was conducted as an open-label study of 49 participants at three sites in two CTN Nodes (Nexus Recovery Center, Inc., Texas Node; Integrated Substance Abuse Programs (ISAP) and University of Hawaii (UH), Pacific Region Node). Treatment-seeking, severe MA users (using an average of 27 days out of the previous 30 prior to enrollment) were given bupropion XL (450 mg) daily and

XR-NTX every 4 weeks for 8 weeks. Many procedures being proposed for this phase III RCT were developed and evaluated in the initial pilot trial, including collection of data regarding the tolerability and titration procedures for the 450 mg bupropion in the AMC condition. The intent-to-treat (ITT) analysis in the pilot trial defined the primary efficacy endpoint as the number of responders, with responders defined as participants who provide at least 6 MA-negative UDS tests during the last four weeks of the active medication phase (weeks 5 – 8), including a MA-negative UDS test at the last clinic visit in week 8. Out of 49 participants, 9 responders were required to indicate that the medication combination has sufficient potential efficacy to warrant a fully-powered phase III, placebo-controlled trial. Findings from the 49 participants included in the analysis of the primary efficacy endpoint indicated that 11 were responders, which met the a priori specified criterion requiring 9 or more responders ($p = 0.0075$). The unbiased estimate of the responder rate was 24%, and the 95% lower confidence limit was 13%. There were no significant site, gender, race or ethnicity differences by responder status. The responder rate was highest at the ISAP site (27.8%) and lowest at the Nexus site (15.8%). Seven (26.9%) males and 4 females (17.4%) were responders. Four (16.7%) whites and 7 others (4 multiracial and 3 others) were responders. Seven responders were not Hispanic or Latino, and 4 were Hispanic or Latino.

These data were used to support development of the current phase III randomized, double-blind, placebo-controlled trial of this combination pharmacotherapy to produce abstinence for participants with methamphetamine use disorder. It is intended that participants randomized to the active medication arm receive the maximum safe dose of both bupropion and naltrexone to maximally enable them to become abstinent within the treatment phase of this study. The recommended dosing regimen of Vivitrol® is every four weeks; however, plasma levels of naltrexone and its metabolite are at a plateau during the first three weeks after administration but fall off in the fourth week. Replenishment of the depot supply of naltrexone at the beginning of the fourth week by re-injecting Vivitrol® should prevent that decline and allow evaluation of the maximum safe dose of the combination medication.

22.3 Significance of the Project to the Field

Identifying an effective medication, or combination of medications, to help achieve abstinence and to prevent relapse to MA use is an important objective with considerable public health significance. The proposed placebo-controlled trial, based on preliminary evidence established in the CTN-0054 ADAPT pilot trial, will advance medication research and potentially confirm the naltrexone plus bupropion combination as the first effective pharmacotherapy for the treatment of stimulant use disorder involving MA.

23.0 OBJECTIVES

The objective of this study is to evaluate an active medication combination (AMC) that comprises extended-release naltrexone (XR-NTX) plus bupropion (BUP-XL) as a potential pharmacotherapy for methamphetamine use disorder.

23.1 Primary Objectives

The primary objective of this study is to evaluate the efficacy of the AMC arm, compared to a matched placebo (PLB) arm, in reducing methamphetamine use in individuals with moderate or severe methamphetamine use disorder seeking to stop or reduce methamphetamine use. It is hypothesized that the AMC arm will be associated with a greater number of “responders,” defined as participants who provide a pre-specified number of MA-negative UDS tests during the evaluation period of the 12 week long medication phase, relative to the PLB arm.

23.2 Secondary Objectives

Secondary objectives include evaluating the effect of the AMC arm, compared to the PLB arm, on safety, other substance use outcomes, depression scores, quality of life, overall functioning, clinic attendance, and medication adherence.

24.0 DESIGN

24.1 Overview of Study Design

The primary objective of this study is to assess the efficacy of extended-release naltrexone plus bupropion as a combination pharmacotherapy for methamphetamine use disorder. There will be 370 individuals randomized into the study across 7 -10 clinical sites. Eligibility will be determined during a maximum 3 week screening period. To document an appropriate level of current methamphetamine use, prospective participants must submit at least two urine samples positive for methamphetamine of a possible three tests to occur within a 10 day period during which clinic visits occur with at least two days between visits. In addition, participants must self-report MA use on 18 or more days in the 30 day period prior to consent using the Timeline Followback (TLFB) and meet diagnostic criteria for moderate or severe methamphetamine use disorder per DSM-5 (4 or more criteria) at screening. After screening is completed and eligibility is confirmed, including successful administration of a naloxone challenge, participants will begin the 12 week medication phase of the trial. Participants will be randomized to either the 1) AMC arm and receive injections of extended release naltrexone (XR-NTX; as Vivitrol®) plus once-daily oral extended-release bupropion tablets (BUP-XL) or the 2) matching placebo (PLB) arm and receive injections of placebo (iPLB) plus once-daily oral placebo (oPLB) tablets. This protocol will utilize a sequential parallel comparison design (SPCD), originally proposed by Fava et al. (2003), and later revised by Chen et al. (2011). A feature of this design is that it can reduce the overall placebo response rate. One advantage of the adaptive aspect of the design is that it requires a smaller sample size compared to a standard two group randomized trial design. During the course of the study, participants may or may not be switched to another arm, as determined by the a priori adaptive aspect of the study design. Participants appearing to respond well to their original treatment assignment will not be switched. Overall, approximately 50% of the participants will receive the AMC. Injections will be provided in weeks 1, 4, 7, and 10. Take-home oral study medication (BUP-XL or oPLB) will be dispensed weekly for dosing on non-clinic days. Participants will be asked to attend the clinic twice weekly for observed oral medication dosing, assessments, collection of urine samples, and once-weekly medical management. On non-clinic days, participants will participate in smartphone app-based medication adherence activities. Participants will be asked to complete assessments as indicated on the schedule of assessments (see Section 8.0). Following the 12 week medication phase, participants will complete a follow-up phase, including a medication taper and post-medication phase follow-up visits during weeks 13 and 16.

24.2 Duration of Study and Clinic Visit Schedule

Participants will be involved in the study for up to 19 weeks, including a screening/baseline period of up to 3 weeks (i.e., 21 days), 12 weeks of medication, and a post-medication follow-up phase to conclude in week 16. The screening phase may differ by participant in the length of time needed to complete preliminary eligibility assessments. Confirmation of opioid-free status (urine drug screen and naloxone challenge) before randomization and medication induction will take approximately 1.5 hours. Twice-weekly clinic visits during the medication phase will range from about 20–60 minutes in length depending on scheduled assessments. Once-weekly medical management sessions will require an additional 30 minutes. Medication injection visits can take up to two hours. The post-medication phase follow-up visits will take approximately 1-2 hours to complete. A 12 week medication period was selected based on expected time needed to observe clinical benefit and for pragmatic issues related to medication dosing.

Enrollment is expected to take place over a period of approximately 18 months.

24.3 Participant Selection

A total of 370 males and females who meet eligibility criteria will be randomized. Study participants will be recruited using a variety of methods including word-of-mouth, referral, advertising, and study announcement flyers posted in local treatment programs. The study sites should attract a diverse study population. Efforts will be made to recruit a study sample that reflects, or exceeds, the proportion of minorities in the community where the site is located. Recruitment procedures aiming to enhance enrollment of women and/or minorities will be conducted, including linkages with medical sites and/or treatment programs that serve a large number of women and/or minorities, and advertising in media outlets with high female/minority audience. Participants will not receive other formal addiction treatment services while they are participating in the study. Thus, participants must be willing to have the study intervention serve as their sole treatment during study participation. Mutual help support group attendance will be encouraged throughout the trial. Upon study completion, participants may enroll in behavioral or pharmacological addiction treatment services.

24.3.1 Inclusion Criteria

Study participants **must**:

11. Be 18 to 65 years of age;
12. Be interested in reducing or stopping methamphetamine use;
13. Be able to speak English sufficiently to understand the study procedures and provide written informed consent to participate in the study;
14. Meet DSM-5 criteria for moderate or severe methamphetamine use disorder (4 or more criteria);
15. Self-report methamphetamine use on 18 or more days in the 30 day period prior to consent using the Timeline Followback (TLFB);
16. Provide at least 2 urine samples positive for methamphetamine out of a possible 3 tests to occur within a 10 day period during which clinic visits occur with at least 2 days between visits;
17. If female of childbearing potential, agree to use acceptable birth control methods and have periodic urine pregnancy testing done during participation in the study unless documentation of hysterectomy provided;
18. Meet subjective and objective measures of being opioid-free prior to naltrexone induction per study medical clinician's determination (including passing a naloxone challenge);
19. Be willing to comply with all study procedures and medication instructions;
20. Agree to use a smartphone app (downloaded for free to own device or on a study provided smartphone device) to take daily videos of medication dosing.

24.3.2 Exclusion Criteria

Study participants **must not**:

20. Have an acute medical or psychiatric disorder that would, in the judgment of the study medical clinician, make participation difficult or unsafe;
21. Have suicidal or homicidal ideation that requires immediate attention;
22. Have a history of epilepsy, seizure disorder, or head trauma with neurological sequelae (e.g., loss of consciousness that required hospitalization); current anorexia nervosa or bulimia; or any other conditions that increase seizure risk in the opinion of the study medical clinician;
23. Have evidence of second or third degree heart block, atrial fibrillation, atrial flutter, prolongation of the QTc, or any other finding on the screening ECG that, in the opinion of the study medical clinician, would preclude safe participation in the study;
24. Have Stage 2 hypertension as determined by the study medical clinician (e.g., greater than or equal to 160/100 in 2 out of 3 readings during screening);
25. Have any elevated bilirubin test value per laboratory criteria OR any other liver function test (LFT) value > 5 times the upper limit of normal per laboratory criteria;
26. Have a platelet count <100 x 10³/μL;
27. Have a body habitus that precludes gluteal intramuscular injection of XR-NTX in accordance with the administration equipment (needle) and procedures;
28. Have a known allergy or sensitivity to bupropion, naloxone, naltrexone, PLG (polyactide-co-glycolide), carboxymethylcellulose or any other component of the XR-NTX diluents;
29. Have been in a prior study of pharmacological or behavioral treatment for methamphetamine use disorder within 6 months of study consent;
30. Have taken an investigational drug in another study within 30 days of study consent;
31. Have been prescribed and taken naltrexone or bupropion within 30 days of study consent;
32. Be concurrently enrolled in formal behavioral or pharmacological addiction treatment services;
33. Be receiving ongoing treatment with tricyclic antidepressants, duloxetine, venlafaxine, xanthines (i.e., theophylline and aminophylline), systemic corticosteroids, nelfinavir, efavirenz, chlorpromazine, MAOIs, central nervous system stimulants (e.g., Adderall, Ritalin, etc.), or any medication that, in the judgment of the study medical clinician, could interact adversely with study medications;
34. Have a current pattern of alcohol, benzodiazepine, or other sedative hypnotic use which would preclude safe participation in the study as determined by the study medical clinician;
35. Require treatment with opioid-containing medications (e.g., opioid analgesics) during the study period;
36. Have a surgery planned or scheduled during the study period;
37. Are currently in jail, prison or any inpatient overnight facility as required by court of law or have pending legal action or other situation (e.g., unstable living arrangements) that could prevent participation in the study or in any study activities;
38. If female, be currently pregnant, breastfeeding, or planning on conception.

24.4 Site Selection

The trial will include 7 -10 sites with each site randomizing approximately 30-55 participants.

24.4.1 Site Characteristics

Participating sites **must**:

9. Have a physician who can commit the time necessary to take a leadership role and oversee all medical aspects of the study, perform medical assessments, confirm participant eligibility, order and dispense or administer study medications, review adverse events, and appropriately evaluate and respond to adverse reactions that may occur during the course of the study.
10. Have at least one other medical clinician (i.e., physician, physician's assistant, or nurse practitioner) who can, in accordance with the regulations of the state where the site is located, make independent medical decisions and commit the time necessary to perform medical assessments, determine participant eligibility, order and dispense or administer study medications, review adverse events, and appropriately respond to adverse reactions that may occur during the course of the study.
11. Have standard operating procedures in place for handling medical and psychiatric emergencies.
12. Have a physician available to provide after-hours clinical back-up for study-related emergencies.
13. Have access to a phlebotomist or other qualified personnel to complete blood draws.
14. Have the ability to meet storage and dispensing requirements for all study medications, including access to adequate storage space, equipment, and appropriately qualified staff, as directed by the protocol and in accordance with local regulations and NIDA stipulations.
15. Have access to, or the ability to contract with, a local laboratory to process biological specimens (e.g., blood and/or urine) in a timely manner during screening.
16. Have adequate facility space available to conduct study procedures.

24.4.2 Rationale for Site Selection

The sites selected for participation in this trial will be selected, in part, based on the node's interest in participating in the trial, the availability of a sufficient pool of potential study participants in the area, and the presence of an existing team of experienced personnel at the site knowledgeable in clinical trial operations and trained in core CTN assessments. Information on site readiness and capacity will be gathered via a site survey and a coordinated site/investigator selection process will confirm the following:

6. An ability to recruit and randomize 3-4 individuals with methamphetamine use disorder (not currently in formal treatment) each month.
7. Experienced regulatory personnel capable of the timely preparation of necessary regulatory documents and having the ability to facilitate an expeditious IRB submission, approval, modification, and continuing review processes.

8. Medical staff who can commit the time necessary to oversee all medical aspects of the study, perform medical assessments, confirm participant eligibility, order and administer or dispense study medications, and appropriately respond to possible adverse reactions that may occur during the course of the study.
9. Staff familiar with web-based Electronic Data Capture systems and who have the capacity and discipline to conform to protocol-required direct data entry procedures.
10. Adequate and available space that is suitable for the performance of study procedures.

24.5 Randomization Plan

Eligible participants will be randomized to the AMC and PLB treatment arms, stratifying by site. During the course of the medication phase, participants who provide sufficient UDS for evaluation of outcomes may or may not be switched to another arm. Switching, or re-randomization parameters, were determined a priori and are based on a combination of original treatment assignment, availability of data, and treatment response. Participants appearing to respond to their original treatment assignment will not be switched. Re-randomization will be implemented automatically by computer and will be stratified by site. Overall, approximately 50% of the participants will receive the AMC.

The randomization process will be conducted centrally and electronically by the CTN Data and Statistics Center (DSC), and randomization assignments will not be conveyed to staff or participants to maintain the double blind. To ensure the lack of predictability while maintaining the designed randomization fraction, an urn scheme similar to one described in Wei and Lachin (1988) will be used. The DSC statistician will review randomization data on a regular basis to ensure that the scheme is being implemented according to plan. A randomization slot, once used, will not be re-allocated.

24.6 Study Intervention

The study intervention consists of 12 weeks of pharmacotherapy, medical management, and medication adherence procedures. Participants randomized to the AMC treatment arm will receive an injection of extended-release naltrexone (XR-NTX; as Vivitrol®) plus 450 mg of once-daily oral extended-release bupropion tablets (BUP-XL). Participants randomized to the PLB treatment arm will receive matched placebo in the form of injections of placebo (iPLB) plus once-daily oral placebo (oPLB) tablets. Injections of study medications (XR-NTX or iPLB) will be administered in weeks 1, 4, 7, and 10. All randomized participants will receive weekly medical management sessions with the study medical clinician and will utilize smartphone app-based medication adherence procedures.

24.7 Outcome Measures

The primary outcome measure, as described below, is based on urine drug screen (UDS) test results and is considered a clinically significant improvement in methamphetamine use in this study population. The primary outcome (UDS) has been chosen because it is an objective measure of methamphetamine use. Secondary outcome variables are intended to explore various aspects of response to this medication combination and to identify factors that may be associated with treatment response or non-response. Some of the secondary outcome variables add a measure of clinical relevance to the reduction of use by assessing sustained abstinence, reduced

quantity and frequency of methamphetamine use, reduction in craving that may be a prelude to relapse, and improvements in mood, quality of life, and overall functioning.

24.7.1 Primary Efficacy Outcome Measure

The primary efficacy outcome measure is a composite of MA-negative UDS test results during the medication phase and will be compared by treatment group (AMC versus PLB).

24.7.2 Primary Safety Outcome Measure

The safety and tolerability of the AMC arm, relative to the PLB arm, will be determined using participants' reports of adverse events (serious and non-serious) collected at clinic visits or via other contact.

24.7.3 Secondary Outcome Measures

Secondary outcome measures for the impact of the AMC, relative to the PLB arm, on other substance use outcomes, depression scores, quality of life, overall functioning, clinic attendance, and medication adherence will be evaluated as follows:

8. Alternate measures and composites of methamphetamine use including:
 - e) The Treatment Effectiveness Score (TES), as measured by UDS results, during the medication phase;
 - f) Frequency of MA use, as measured by self-report, during the medication phase;
 - g) Severity of MA craving, as measured by Visual Analog Craving Scales (VAS), during the medication phase;
 - h) MA use, as measured by UDS and self-report, during the follow-up period.
9. Quantity and frequency of alcohol, tobacco, and other drug use, as measured by self-report, during the medication phase;
10. Change in depressive symptoms, as measured by the PHQ-9, during the medication phase;
11. Changes in quality of life, as measured by the Quality of Life (QoL), during the medication phase;
12. Changes in overall functioning, as measured by the Treatment Effectiveness Assessment (TEA), during the medication phase;
13. Percentage of participants retained in treatment during the medication phase;
14. Ratings of participant and staff satisfaction with study procedures, including use of the medication adherence app, compensation, and medication.

25.0 PROCEDURES

25.1 Screening and Baseline Phase

Assessments administered during screening will determine whether participants meet eligibility criteria and will provide baseline measures of drug use and other important domains. Screening and baseline assessments will be conducted as shown in Table 2 in section 8.0. Participants who do not complete all screening/baseline assessments within 21 days of signing consent, including the naloxone challenge, or who are otherwise found to be ineligible for participation in the study, will be considered screen fails. Screen fails will not be allowed to return at a later date to repeat the screening process.

25.1.1 Pre-screening Assessment

Individuals responding to recruitment materials or otherwise referred to the study will be pre-screened on the phone or in person to ascertain preliminary eligibility status. A series of questions (e.g., MA use history, interest in participating in research to investigate medications that have potential to reduce MA use, ability and willingness to participate for the duration of the trial) will determine preliminary eligibility. Full screening appointments will be scheduled for those who meet preliminary eligibility criteria.

25.1.2 Informed Consent

At the start of the screening appointment and before any assessments are administered, qualified study personnel will conduct the informed consent process with prospective participants. The informed consent process will begin with a description of the study, including study procedures and study medications. Potential study participants will be given a copy of the IRB-approved consent form to review either on site or at home, in accordance with IRB requirements. Potential study participants who remain interested after review of the consent form will be given comprehension questions to ascertain their understanding of the study, including its purpose, procedures involved, and the voluntary nature of participation. For participants who do not correctly answer all comprehension items, research staff will re-explain the study, with a focus on aspects candidates did not understand. Participants may attempt the consent comprehension questions a maximum of three times before they are deemed unable to comprehend the study. Any participant who cannot demonstrate appropriate understanding of the study to research personnel will be ineligible to participate and will be assisted in finding other treatment resources if desired. Study participants who demonstrate understanding of the study and who voluntarily agree to participate will be asked to sign the IRB-approved consent form and will proceed with the screening assessments. As part of the informed consent process, participants also will be asked if they consent to (1) be contacted for future studies and (2) provide a blood sample for genetic testing.

25.1.3 Screening and Baseline Assessments

Upon signing the IRB-approved consent form, participants enter a maximum 21 day screening phase to complete assessments to determine eligibility and to collect baseline data. Screening/baseline assessment procedures must be completed across multiple screening visits.

During the screening phase, participants must submit at least 2 urine samples positive for methamphetamine out of a possible 3 tests to occur within a 10-day period during which clinic visits occur with at least 2 days between visits. In addition, participants must self-report MA use on 18 or more days in the 30 day period prior to consent using the Timeline Followback.

These criteria will be used to confirm current MA use and further substantiate a diagnosis of moderate or severe methamphetamine use disorder.

Once the participant completes all screening and baseline assessments, submits 2 MA-positive UDS tests, and is found otherwise eligible for continued participation, the participant may begin the pre-induction procedure (see below). All consented participants who do not complete all screening assessments within the 21 day screening period or who are otherwise found to be ineligible for study participation will be considered to be screen fails. Demographic data and the reasons for not meeting eligibility criteria must be documented for all screen fails.

25.1.4 Naltrexone Pre-Induction Strategy

The screening/baseline phase includes a naltrexone pre-induction strategy to be conducted on the final screening visit after all other eligibility criteria have been met. The naltrexone pre-induction strategy is designed to ensure participants meet subjective and objective measures of being opioid-free, per the study medical clinician's determination, prior to randomization and induction on the injectable study medication. Necessary procedures are outlined below:

4. Participants must self-report no clinically significant opioid use (i.e., at any level that could constitute a potential risk of precipitating opioid withdrawal upon naloxone administration) in the 7-10 days prior to the naloxone challenge, as measured using the TLFB and the Prior and Concomitant Medications (PCM) assessment.
5. To confirm opioid abstinence, a urine sample provided and tested on the day of the naloxone challenge must be negative for opioids prior to administration of the challenge. Individuals who are negative for opioids will continue the pre-induction process. Individuals who are positive for opioids may provide an additional urine sample on a subsequent day if the study medical clinician determines that a second screen is appropriate.
6. The naloxone challenge will then be administered to those meeting the above criteria. A minimum 0.8 mg bolus must be given before determining the outcome of the challenge. The study medical clinician will use clinical judgment to determine if the participant passes the naloxone challenge and is eligible to continue on to randomization and subsequent XR-NTX or iPLB induction. Evidence of withdrawal signs or symptoms following naloxone administration will result in postponement of randomization until a negative naloxone challenge result is achieved.

Participants who experience withdrawal symptoms following the naloxone challenge may be treated with ancillary medications, observed until symptoms resolve, and given the opportunity to return another day and be re-challenged if clinically indicated. Participants who are not interested in continuing to participate, or who fail a repeat naloxone challenge, will not be eligible to participate in the study but will be given referrals to local treatment programs, as appropriate.

25.1.5 Final Confirmation of Eligibility

After completing all screening and baseline assessments, including the naloxone challenge, the study physician must review and approve safety and eligibility assessments in order to confirm participant eligibility prior to randomization. Randomization will occur on the day of the successful naloxone challenge after study eligibility has been confirmed and documented.

25.2 Medication Phase

25.2.1 Randomization

Immediately following the successful naloxone challenge and final assessment of eligibility, participants will be randomly assigned to the AMC arm or the matching PLB arm. Pharmacotherapy will be provided for 12 weeks with twice-weekly visits. The randomization procedure will be conducted electronically by the CTN Data and Statistics Center (DSC). The switching or re-randomization procedure described previously will occur seamlessly by the electronic system, based on data routinely collected and entered.

25.2.2 Pharmacotherapy

Participants will receive the first intramuscular gluteal injection of study medication (XR-NTX or iPLB) on the day of randomization, following a successful naloxone challenge and confirmation of study eligibility. Subsequent intramuscular gluteal injections (XR-NTX or iPLB) will be administered at the beginning of Weeks 4, 7, and 10 and shall be administered following guidelines in the XR-NTX package insert. Study medical clinicians will evaluate participants to ensure continued suitability for study medication administration. Urine drug screening procedures will help clinicians ensure participant opioid-free status at the time of study medication injection. A naloxone challenge may be administered prior to any study medication injection at the discretion of the study medical clinician.

The first dose of oral study medication (BUP-XL or oPLB) will be given on the day of randomization (Day 1) immediately following administration of the injectable study medication. Take-home oral study medication will be dispensed weekly. On clinic days, participants will be asked to refrain from taking their dose at home and to bring their oral study medication to each clinic visit so that self-administration of the oral medication can be observed by study staff. A daily dose of 300 mg will be dispensed for the up titration period scheduled to occur over three days. A daily dose of 450 mg will be dispensed for the days in which participants are expected to take the full target dose. On the days in which injectable study medication is administered in weeks 4, 7, and 10, oral study medication self-administration will be observed by study staff immediately following the injection.

If a participant reports intolerable symptoms or side effects at the full 450 mg dose, a dose reduction may occur if deemed appropriate by the study medical clinician. The study medical clinician, in collaboration with the study physician and site principal investigator, are encouraged to consult with the Lead Investigator(s) and Study Medical Monitor in making the decision to reduce a participant's dose. The dose may be reduced to 300 mg daily. Medication packaging will allow for dose reductions without re-dispensing; participants will be instructed to take only the tablets in the first two wells for each day they are on a reduced dose. If intolerable adverse effects continue, the participant may be withdrawn from further medication administration. If intolerable adverse effects resolve after an initial dose reduction, and if deemed appropriate by the study medical clinician, titration to the full 450 mg target dose may be attempted (i.e., participants will be instructed to take all three tablets for each day) on any visit except visits in which injectable medication is administered.

25.2.3 Medical Management

Medical management procedures will be conducted as follows. Participants will meet with a study medical clinician once weekly for an individual medical management session that utilizes a structured compliance enhancement manual designed for pharmacotherapy trials with subjects

with substance use disorder (Carroll et al., 1996). The goal of compliance enhancement therapy is to achieve high quality supportive treatment that reinforces adherence to study procedures and the study medication regimen. A session will be approximately 30 minutes and focus on:

4. Setting abstinence from methamphetamine as a goal,
5. Participant compliance with study medications and procedures,
and
6. Current functioning.

Medical clinicians will also review adverse events, consider potential medication side effects, and discuss other pertinent issues in keeping with sound medical practice. Ancillary medications may be provided for study medication-related adverse events as clinically indicated. A range of prescription and over-the-counter ancillary medications may be used for symptoms such as anxiety, nausea, vomiting, diarrhea, muscle pain, and insomnia. At all medical management sessions, the medical clinician will remind participants about the importance of adhering to the study procedures, including attending scheduled clinic visits and complying with smartphone app-based dosing confirmation procedures. Mutual help support group attendance will be encouraged.

25.2.4 Medication Adherence

Medication adherence procedures will be conducted as follows. To monitor and encourage adherence to oral study medication, procedures include twice-weekly observed dosing in the clinic as described previously. Procedures also include the use of a smartphone app to take dosing videos to document oral study medication self-administration on non-clinic days and during clinic visits (while staff observe), including on the taper days in the post-medication follow-up phase. Participants will access the app on either a study provided smartphone device or by downloading the app to their personal device. Further details are outlined in Appendix C. Dosing will be assessed by automated visual recognition software during the video capture to ensure the videos clearly show dosing adherence based on assessment criteria. Participants will be compensated for each video determined to adequately show dosing adherence.

25.2.5 Participant Medication Withdrawal

Participants will be withdrawn from further study medication administration if it is clinically determined that continuation may be unsafe. For example, participants who develop uncontrolled hypertension (160/100 or higher on three consecutive visits) will be withdrawn from further study medication administration. Likewise, women who become pregnant during the medication period will be immediately withdrawn from study medication administration. Participants reporting use of medications that may interact with naltrexone or bupropion will be withdrawn based on clinical judgment. Participants who experience intolerable adverse effects or other physical or psychiatric conditions, regardless of relationship to the study medication, may also be withdrawn from further study medication administration.

The medical clinician may determine that a participant's clinical condition has deteriorated during the course of the study to the extent that now taking study medication may be possibly unsafe or unwise. Examples of clinical deterioration that might trigger a decision to withdraw the participant from study medication include the following:

- New onset of psychiatric or medical conditions that would require intervention and preclude continued participation in the study (e.g., emergence of psychosis, suicide risk, severe cognitive impairment, or dangerous criminal behaviors);
- Worsening of a pre-existing psychiatric or medical condition that would preclude continued safe participation in the study;
- Worsening of substance use disorder or overdose such that a higher level of care is indicated;
- Increase in LFT or platelet test results at week 6 that may increase participant health risks. This includes any of the following: AST/ALT results > 5 times ULN, total bilirubin > 2 times ULN, or platelets below $75 \times 10^3/\mu\text{L}$.

The study medical clinician, in collaboration with the study physician and site principal investigator, should consult with the Lead Investigator(s) and Study Medical Monitor in making the decision to withdraw a participant from study medications. Also, participants may decide at any time that they no longer wish to continue to receive medication or participate in the study.

In most cases, a taper is not indicated if the study medical clinician determines medication discontinuation is warranted for medical or psychiatric reasons. Generally, a taper of bupropion is not medically necessary as there is no evidence of a physiological dependence or increased incidence of adverse events when this medication is discontinued. However, down titration is common in clinical practice, therefore clinicians are guided to follow this convention for the majority of study participants. If a taper is believed to be necessary based on clinical judgment, the study medical clinician, in collaboration with the study physician and site principal investigator, should consult with the Lead Investigator(s) and Study Medical Monitor on how to best proceed.

In the event a participant becomes pregnant during the medication period, a taper is not indicated as bupropion is a pregnancy category C medication and the risks of taper outweigh the benefits in pregnant women. The pregnant participant will be immediately discontinued from further study medication administration, referred for medical care, and the pregnancy followed until an outcome is known.

A taper is also not indicated for participants who become incarcerated or for participants who lose study medication during the active medication phase of the study. Participants who lose study medication will resume their dosing schedule at the appropriate next study visit.

As the primary aim of this study is to evaluate the efficacy of XR-NTX plus BUP-XL as a combination pharmacotherapy, withdrawal from either study medication will lead to discontinuation of the other medication. In the event a participant is withdrawn from further study medication administration, referrals to treatment programs or recommendations for medical care will be provided. Unless consent is officially withdrawn, study staff will encourage participants who are withdrawn from study medications or who opt out of study medications to continue attending twice weekly clinic visits and complete study assessments throughout the duration of the medication phase (weeks 1 – 12).

25.3 Follow-up Phase

25.3.1 Oral Study Medication Taper

A taper will occur during the first four days of Week 13 (Days 85 – 88) for participants continuing on oral study medication (BUP-XL or oPLB) through the end of the medication phase. The daily dose will be 300 mg for Days 85 and 86 and 150 mg for Days 87 and 88. This taper schedule will apply to all participants, including any participants already taking a reduced dose.

25.3.2 Post-Medication Phase Follow-up Visits

All enrolled participants will be asked to complete post-medication phase follow-up visits in weeks 13 and 16 according to the schedule of assessments (see Table 2, section 8.0). Tracking and locating strategies will be used to ensure the highest possible follow-up rates.

25.4 Study Medication Management/Drug Accountability

As set forth in the protocol agreement signed by each site principal investigator (see Section 14, Signatures), study sites are required to observe local, state, and federal regulations regarding receipt, custody, dispensing, administration, and associated documentation of all medications used in this study. Study medications include extended-release bupropion, extended-release injectable naltrexone, oral placebo, and injectable placebo provided by the NIDA contractor as well as naloxone purchased and maintained by each site.

25.4.1 Documentation

Upon receipt, the investigator, pharmacist, or authorized designee at each site is responsible for maintaining written inventory of the investigational agents. Appropriately trained and qualified personnel will maintain an accurate and real-time accounting of all study medications, which will be available for verification by study monitors. Medication accountability records, including perpetual inventory, will document the amount of study medication ordered, received, transferred between areas of the study site (e.g., from pharmacy to clinic), and medications dispensed to and returned by an individual participant. Documentation will also record unused medications returned to the NIDA contractor for destruction. As with all study documentation, medication accountability records must be maintained in accordance with Good Documentation Practices and must be attributable, legible, contemporaneous, original, and accurate.

25.4.2 Storage

All medication used in this study will be stored in compliance with federal, state, and local laws and institutional policy. Study medications will be stored in a locked, secure, limited-access location under the conditions specified by the package insert; XR-NTX and iPLB kits will be stored in a secure, limited access refrigerator. Temperature logs will show a daily record of medication storage temperature.

25.4.3 Packaging

Intramuscular gluteal injections (XR-NTX and iPLB) will be supplied in single use packages marked with medication kit numbers. Each active injectable medication package will contain one 380 mg vial of Vivitrol® microspheres, one vial containing 4 mL (to deliver 3.4 mL) diluent for the suspension of Vivitrol®, one 5 mL prepackaged syringe, one 1-inch 20 gauge needle, two 1.5-inch 20 gauge needles, and two 2-inch 20 gauge needles with needle protection devices. Each injectable placebo medication package will be prepared to look identical and will contain the same contents as the active medication packages but with no active medication. Lot number and medication expiration date will be included on the package labels supplied by the manufacturer.

Participants will receive once-daily oral study medication (BUP-XL or oPLB). A daily dose of 300 mg will be dispensed for the up titration period. A daily dose of 450 mg will be dispensed on all other days in the medication phase. The taper will occur during the first four days of Week 13 (Days 85-88).

Oral study medication (BUP-XL and oPLB) will be pre-packaged in weekly blister packs that contain 3 tablet wells for each day. The packaging will be designed such that participants will take all 3 tablets each day, including during the up titration and taper periods.

There will be five types of blister packs manufactured to appear identical for both treatment arms. There will be three types of 7 day packs for use in weeks 1 to 12—one for up titration (for AMC only) and two for target dosing (AMC and PLB). Two types of packs will contain a 4 day supply for the week 13 taper period (AMC and PLB).

The up titration AMC pack will be dispensed twice during the study: in week 1 for participants randomized to AMC and again when some participants may be re-randomized and assigned to receive AMC. Therefore, the up titration pack will be manufactured to contain 3 tablets for each day of the titration in order to appear identical to the target dosing pack. The up titration pack will contain two active and one placebo tablet each day for days 1 - 3, and it will contain three active tablets each day for days 4 - 7. Packaging the up titration pack in this way will help protect the double-blind throughout the trial.

The target dosing packs will contain either active medication or placebo. The AMC taper pack will contain two active and one placebo tablet for the first two days and one active and two placebo tablets for the last two days. The PLB taper pack will contain three placebo tablets for each of the four days.

Weekly blister packs dispensed to participants will be labeled to include protocol number, study drug information, and blister pack number. The label will also include "Caution: New Drug - Limited by Federal Law to Investigational Use. Store at Controlled Room Temperature (20-25°C or 68-77°F)" as well as the manufacturer and distributor information.

Below, the medication packaging plan is summarized visually, whereby P indicates placebo tablet and A indicates active tablet. Weekly blister packs for each treatment arm by the dosing period (up titration, target dosing, and taper) will be dispensed as follows:

Dosing Period during Medication Phase											
Treatment Arm	PLB	Day	Up-titration			Target			Taper		
		1	P	P	P	P	P	P	P	P	P
		2	P	P	P	P	P	P	P	P	P
		3	P	P	P	P	P	P	P	P	P
		4	P	P	P	P	P	P	P	P	P
		5	P	P	P	P	P	P			
		6	P	P	P	P	P	P			
		7	P	P	P	P	P	P			
	AMC	1	A	A	P	A	A	A	A	A	P
		2	A	A	P	A	A	A	A	A	P
		3	A	A	P	A	A	A	A	P	P
		4	A	A	A	A	A	A	A	P	P
		5	A	A	A	A	A	A			
		6	A	A	A	A	A	A			
		7	A	A	A	A	A	A			

Key: **A** - Active medication combination tablet **P** - Placebo tablet

25.4.4 Ordering and Dispensing

All study medications shall be ordered only by delegated licensed medical staff and dispensed by research staff appropriately trained to do so. Injectable medications will be administered by qualified staff during Weeks 1, 4, 7, and 10. Oral medications will be provided to the participant weekly in labeled blister packs that will include both in-clinic observed doses and self-administered doses for non-clinic days.

25.4.5 Used/Unused Medication

Unused study medication will be returned and logged into a perpetual inventory. Returned, damaged, expired or otherwise unused study medications will be accurately labeled, securely stored, kept separately, and shall be accounted for prior to destruction. Any unused or expired investigational agent shall be accounted for at all times. Expired naloxone and other ancillary medications obtained for this study will be destroyed on site or sent for destruction per local institutional policies.

25.4.6 Lost Medication

There will be no replacement of any dispensed study medications.

25.4.7 Maintaining and Breaking Blind

This is a double-blind, placebo-controlled trial. With the exception of the data management group overseeing the random assignment schedule and the NIDA-contracted research pharmacist preparing study medications, all other study personnel and participants will remain blinded to

medication status until nationwide completion of the trial. A Data and Safety Monitoring Board (DSMB) will review study data throughout the course of the trial. In rare cases it may be necessary to break the blind for a particular study participant before completion of the trial (e.g., pregnancy or other medical necessity). A request to break the study blind for an individual participant must be made by the study physician after consultation with the Lead Investigator. Unblinding the participant should only be done in cases of medical emergency when knowledge of the treatment group assignment may be necessary for clinical management and decision making. The decision to break the blind for a participant will be made jointly by the CCC Medical Monitor and at least one of the Lead Investigators. Any requests for unblinding will be responded to within one business day or less.

25.5 Participant Compensation

Study participants will be provided with study medications, medical management, and a study medication adherence app for use on his/her own device at no cost. Alternatively, a study smartphone device pre-loaded with the medication adherence app will be provided if needed. In addition, participants will receive gift cards or cash (based on local requirements) as compensation for time, travel, parking, and other costs borne by the participant. A total of up to \$50 will be provided for completion of screening/baseline assessments (divided among multiple screening visits if required). Ten dollars (\$10) will be provided for each additional eligibility phase clinic visit to provide a urine sample. During the medication phase, \$10 will be provided for completion of assessments including a urine sample (\$5 will be provided for assessments without a urine sample); \$3 for bringing the study medication on clinic days and taking a self-dosing video via the smartphone app while staff observe; and \$20 for each injection visit. Participants will be compensated \$40 per visit for completion of the mid-treatment visit (visit 602) and the end of treatment visit (visit 1202), and \$30 for each follow-up visit in weeks 13 and 16. In addition, participants will be compensated \$3 for each of the video-confirmed self-administration dosing events on non-clinic days, including the taper in week 13. Participants may also receive up to \$40 to offset the cost of additional data service needed for the dosing app on their personal device or for return of the study smartphone device. Total compensation possible is \$844 as outlined below.

25.5.1 **Table 1.** Compensation Schedule

Visit/Assessment	Amount	# of Payments	Total
Screening Assessments	\$50	1	\$50
Eligibility Phase Clinic Visits	\$10	4	\$40
Injection Visits	\$20	4	\$80
Clinic Visits (12 week Medication Phase)	\$10	23	\$230
In-clinic dosing/med return (2x/wk)	\$3	24	\$72
Mid-Treatment Visit (visit 602) and End-of-Treatment Visit (visit 1202)	\$40	2	\$80
Follow-up Visits (Weeks 13 and 16)	\$30	2	\$60
Dosing video (5x/wk+4 taper days)	\$3	64	\$192
Additional data service for dosing app on personal device OR smartphone device return	\$40	1	\$40
Maximum Compensation Possible			\$ 844

26.0 ASSESSMENTS

Study measures were chosen to minimize the research burden on participants yet collect adequate data to support analyses and ensure safety. Importantly, many of the study measures were selected to record vital health information and are similar to other recent and ongoing studies of bupropion and extended-release naltrexone. Additional measures were also selected to obtain information typically assessed in medication studies, including assessments of drug abuse and dependence diagnoses, psychological status, and measures of craving. Safety is assessed at each visit. Additional forms will be used to collect and document information such as dosing and protocol satisfaction. The NIDA endorsed Substance Abuse and Addiction (SAA) common data elements from Core Tier 1 of the PhenX Toolkit (www.phenxtoolkit.org), which include demographic and other baseline information, will be captured directly or will be populated from the answers to questions from other assessments. Table 2 provides the schedule of study assessments. On average, screening and eligibility assessments will be completed in 6-8 hours. Twice-weekly assessments during the medication phase will be completed in approximately 20 to 60 minutes. Once-weekly medical management sessions will require an additional 30 minutes. The post-medication phase follow-up visits will take approximately 1-2 hours.

26.1 Table 2. Schedule of Assessments

Study Phase	Screening/ Baseline	Medication Phase												Follow-up	
Study Week	0	1	2	3	4	5	6	7	8	9	10	11	12	13	16
Screening Measures															
Pre-Screening Interview Form	X*														
Informed Consent	X*														
Demographics Form	X*														
Alcohol and Substance Use History	X*														
DSM-5 Checklist	X*														
Psychiatric Diagnostic Screening Questionnaire	X*														
Sexual Risk Behaviors	X*						X						X		
Self-Report of HIV Testing	X*														
Medical and Psychiatric History	X*														
Safety Measures															
Physical Examination	X*												X ²		
Electrocardiogram	X*												X ²		
Injection Site Examination		X ²			X ²			X ²			X ²				
Injection Site Abnormality Log ^A															
Clinical Laboratory Tests	X*												X		
Liver function tests & platelet lab tests							X								
Concise Health Risk Tracking	X*	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Urine Pregnancy Test	X ^B														
Pregnancy and Birth Control Assessment	X*	X	X	X	X	X	X	X	X	X	X	X	X		
Vital Signs	X ^C	X	X	X	X ^C	X	X	X ^C	X	X	X ^C	X	X		
Prior and Concomitant Medications	X+	2X	2X	2X	2X	2X	2X	2X	2X	2X	2X	2X	2X	X	X
Adverse Events and Serious Adverse Events	X ^D	2X	2X	2X	2X	2X	2X	2X	2X	2X	2X	2X	2X	X	X
Naloxone Challenge Form	X*				X ^E			X ^E			X ^E				
Efficacy Measures															
Urine Drug Screen	X+	2X	2X	2X	2X	2X	2X	2X	2X	2X	2X	2X	2X	X	X
Timeline Followback	X+	2X	2X	2X	2X	2X	2X	2X	2X	2X	2X	2X	2X	X	X
Visual Analog Craving Scale	X+	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Patient Health Questionnaire-9	X*		X		X		X		X		X		X		
Treatment Effectiveness Assessment	X*						X ²						X ²		
Tobacco Use History	X*						X ²						X ²		
Quality of Life	X*						X ²						X ²		
Blood draw for genetic testing	X ^F														
Adherence Measures															
Study Medication Dosing Logs	X ^E	2X	2X	2X	2X	2X	2X	2X	2X	2X	2X	2X	2X	X	
Injection Administration Form		X			X			X			X				
Oral Medication Dispensation Form		X	X	X	X	X	X	X	X	X	X	X	X	X	
Bupropion Blood Levels					X ^B			X ^B			X ^B		X ²		
End of Medication Form ^E														X	
Administrative and Other Forms															
Locator Form	X*			X			X			X			X		
Eligibility - Randomization	X*														
Missed Visit Form ^E															
Protocol Deviation Form ^E															
Protocol Satisfaction Surveys														X	
Study Completion Form															X

NOTES: *X* = once during screening/baseline; *X+* = at each screening/baseline visit; *X* = a procedure or assessment performed once per week and on the first visit of the week, unless otherwise noted; *2X* = a procedure or assessment performed twice per week; *X²* collected at the second visit of the week.

^A Completed in the event an injection site reaction is reported by a participant or an abnormality is identified during an injection site examination.

^B Collected according to schedule of assessments, including PRIOR TO naloxone challenge and injectable medication (XR-NTX or iPLB) administration.

^C Collected according to schedule of assessments, including BEFORE and AFTER administration of naloxone challenge and injectable study medication (XR-NTX or iPLB).

^D Collected at each visit after consent (i.e. SV02 through the final follow-up visit)

^E Completed as applicable

^F Collected if consent is provided at the end of the day of randomization

26.2 Screening Measures

26.2.1 Pre-Screening Interview Form

Individuals responding to recruitment materials or otherwise referred to the study will be pre-screened on the phone or in person to ascertain preliminary eligibility status. Prior to administering the IRB-approved Pre-Screening Interview, staff will provide a brief overview of the study and will obtain and document verbal consent. The Pre-Screening Interview consists of questions to assess essential information in determining potential eligibility.

26.2.2 Informed Consent

Prior to beginning any study assessments, all participants will review and sign an IRB-approved consent form and any other related documents in accordance with IRB requirements. The date the IRB-approved consent form was signed will be entered into the electronic data capture system.

26.2.3 Demographics Form

The demographics form will collect information about demographic characteristics of the participant at screening including sex, date of birth, ethnicity/race, education, employment pattern, and marital status.

26.2.4 Alcohol and Substance Use History

The Alcohol and Substance Use History will be completed at screening to incorporate PhenX Core Tier 1 items. The participant will be asked whether he/she has ever used alcohol and/or various substances as well as his/her age when the substance was first used.

26.2.5 DSM-5 Checklist

The DSM-5 Checklist has been designed as a semi-structured interviewer-administered instrument that provides current diagnoses for substance use disorders based on DSM-5 diagnostic criteria. The DSM-5 Checklist will be completed at screening.

26.2.6 Psychiatric Diagnostic Screening Questionnaire

The Psychiatric Diagnostic Screening Questionnaire (Zimmerman, 2002) is a self-report questionnaire used primarily as a psychiatric disorder screener administered in primary care. The Psychiatric Diagnostic Screening Questionnaire will evaluate symptoms of common psychiatric disorders and will be administered during the screening phase.

26.2.7 Self-Report of HIV Testing

HIV testing status will be assessed using PhenX Core Tier 1 items. Participants will be asked whether the participant has ever had an HIV test, when the most recent test occurred, the test result, and, if the participant was not tested in the past 12 months, the most important reason the participant was not tested

26.2.8 Medical and Psychiatric History

The medical and psychiatric history, collected at screening, will document participants' past and present health conditions to help determine eligibility and to provide baseline information.

26.3 Safety Measures

26.3.1 Physical Examination

A physical examination will be completed at screening to ensure there are no exclusionary medical conditions and to gather baseline information. The physical at screening will also include an examination of the participant's body habitus and the planned injection site(s) to assess appropriateness for intramuscular gluteal injections. The physical examination will be repeated at the end of the medication phase (visit 2 in week 12).

26.3.2 Electrocardiogram (ECG)

A 12-lead ECG will be administered at screening to assist in determination of participant eligibility and again at study exit (i.e., visit 1202) to assess safety at termination. The ECGs will ideally be read by a central cardiologist, but may also be read by a qualified medical clinician at the site.

26.3.3 Injection Site Examination

Appropriate medical personnel will examine the injection site on the visit following each intramuscular gluteal injection. These examinations will usually occur at visits 102, 402, 702, and 1002 but should occur at the next attended visit if any of the aforementioned visits are missed. Additional monitoring may also be required. Well-developed precautionary procedures will be followed to avoid adverse events associated with XR-NTX or PLB administration. For example, body habitus will be assessed during the physical exam at screening to assure that intramuscular administration is feasible as an inadvertent subcutaneous injection may increase the likelihood of injection site reactions. Individuals whose body habitus precludes a gluteal intramuscular injection using the needles provided will be excluded from the study.

26.3.4 Injection Site Abnormality Log

Participants will be asked to immediately report any injection site reactions to allow evaluation, monitoring, and possible referral, as needed. A log entry is completed in the event an injection site reaction is reported by a participant or an abnormality is identified during an injection site examination. All injection site reactions should be documented on the Injection Site Abnormality Log. If the abnormality results in a Serious Adverse Event (SAE), the Adverse Event forms must also be completed.

26.3.5 Clinical Laboratory Tests

A comprehensive blood chemistry including liver function tests (LFTs: including AST, ALT, ALP, and bilirubin), hematology panel, and a standard urinalysis will be performed to help determine eligibility at screening. At week 6 visit 1 (V601), clinical lab tests to assess LFTs and platelet counts will be repeated for safety monitoring. Clinical labs completed at screening (chemistry, LFTs, hematology, and standard urinalysis) will be repeated during the final week of the medication phase (week 12). An accredited central laboratory (College of American Pathologists or equivalent) that meets CLIA guidelines will perform testing, provide normal values, and provide proof of lab certifications.

26.3.6 Concise Health Risk Tracking- Participant Rated Module

The Concise Health Risk Tracking measure will assess aspects of suicidal ideation and behavior using 16 questions scored on a 5-item Likert scale, including ideation frequency, duration and severity; identifiable deterrents to an attempt; reasons for living/dying; degree of specificity/planning; method availability/opportunity; expectancy of actual attempt; and actual preparation. The Concise Health Risk Tracking measure will be used at screening, every week during the medication phase, and at the week 13 and 16 follow-up visits. Participants who report a significant suicidal/homicidal risk will be assessed by a qualified clinician before leaving the clinic.

26.3.7 Pregnancy and Birth Control Assessment

For females, urine pregnancy test administration, test results, and self-reports of birth control method(s) will be documented during screening unless documentation of hysterectomy is provided. A urine pregnancy test will be performed prior to the naloxone challenge in the screening/baseline phase and may be performed at any other time if a woman suspects she is pregnant. If a woman is found to be pregnant at any point during the study, she will be allowed to continue in the study but will be withdrawn from study medications, given an appropriate referral, and followed until resolution of the pregnancy. Self-reports of birth control method(s) will be documented every week during the medication phase.

26.3.8 Vital Signs

Vital signs (e.g., body temperature, blood pressure, pulse, respiration rate) will be collected at screening and once weekly thereafter, before and after the naloxone challenge in the screening/baseline phase and any subsequent naloxone challenges, and before and after intramuscular gluteal injection(s). Vital signs can be repeated to confirm the reading or on more frequent intervals, as clinically indicated.

26.3.9 Prior and Concomitant Medications

At screening, the Prior and Concomitant Medications form will collect information about prescription and over-the-counter medications used by participants in the prior 30 day period. At other visits, the form will document medications taken since the previous data collection visit. Exclusionary medications include tricyclic antidepressants, duloxetine, venlafaxine, MAOIs, chlorpromazine, stimulants, xanthines, systemic steroids (which may lower the seizure threshold), and nelfinavir and efavirenz (which may alter bupropion levels). The study medical clinician may also exclude any participant who is taking medications that could interact adversely with study medications. Participants will be instructed to contact the study medical clinician before taking any non-study medications, including prescription medications, over-the-counter preparations, and herbal supplements, during the course of the study.

26.3.10 Adverse Events (AEs) and Serious Adverse Events (SAEs)

Medical or psychiatric adverse events (AEs) will be collected by inquiring of participants: "How have you been feeling since your last visit?" AEs will be recorded at each visit after consent according to the adverse event reporting definitions and procedures. If an AE or abnormality suggests medical or psychological deterioration, it will be brought to the attention of the study medical clinician for further evaluation. All AEs and SAEs will be medically managed, reported, and followed in accordance with applicable regulatory requirements. Seizures will be reported to the DSMB.

26.3.11 Naloxone Challenge Form

The Naloxone Challenge Form will document the time of administration, total dose, route of administration, and result of each naloxone challenge administered during the study. During screening, a naloxone challenge is required to confirm the absence of physiological dependence on opioids during the Final Screening Visit (FSV) prior to randomization. Randomization will only occur once a participant successfully completes the naloxone challenge. During the active medication phase, additional naloxone challenges may be conducted at the discretion of the medical clinician; the Naloxone Challenge Form will be completed for each naloxone challenge.

26.4 Efficacy Measures

26.4.1 Urine Drug Screen (UDS)

Urine samples will be collected at every clinic visit. Urine drug screen testing will be performed on site using an FDA-cleared for use one-step urine drug test card following all of the manufacturer's recommended procedures.

The UDS will test for the presence of opiates, oxycodone, barbiturates, benzodiazepines, cocaine, amphetamines, methamphetamine, marijuana (THC), methadone, and ecstasy (MDMA). Prior to drug screening, a temperature and validity assessment will be performed on all urine samples collected. The validity assessment will be performed using a commercially available adulterant test strip that indicates normal ranges for creatinine, pH (at minimum), nitrate, glutaraldehyde, specific gravity, bleach and pyridinium chlorochromate. If the temperature or adulterant test is positive and/or falls outside the normal range, the urine specimen will be considered adulterated and will not be screened. The adulterated urine sample will be discarded, and the participant will be asked to provide another sample. Study teams at each site may opt to observe the urine collection process either at each collection or as deemed necessary (e.g., if specimen tampering is suspected) according to clinic standard operating procedures.

26.4.2 Timeline Followback (TLFB)

The Timeline Followback procedure (Sobell & Sobell, 1992; Fals-Stewart, 2000) will be used to elicit the quantity and frequency of the participant's self-reported use of alcohol and illicit substances. At screening, substance use reported by the participant in the 30 day period prior to consent will be assessed. The TLFB will be administered at each study visit throughout the screening phase, the medication phase and the post medication phase follow-up visits to document the participant's self-reported use of substances for each day since the previous TLFB assessment. Adherence to this procedure will ensure that self-reported substance use for the entire study period is documented without gaps.

26.4.3 Visual Analog Craving Scale (VAS)

Participants' craving for methamphetamine will be documented on a visual analog scale (VAS) that ranges from 0 (no craving) to 100 (most intense craving possible). The VAS will be completed at each screening visit, once weekly throughout the medication phase, and at the week 13 and 16 follow-up visits.

26.4.4 Patient Health Questionnaire-9

The Patient Health Questionnaire-9 (Kroenke et al., 2001) is a well validated self-report tool that measures diagnostic criteria for major depression, severity and frequency of depressive

symptoms, presence of suicidal ideation, and functional impairment related to depression. The Patient Health Questionnaire-9 will be collected during screening and in weeks 2, 4, 6, 8 10, and 12.

26.4.5 Treatment Effectiveness Assessment

The Treatment Effectiveness Assessment (Ling, 2012) is a 4 item self-administered assessment that uses a Likert scale (1-10) to document changes in four life domains: substance use, personal responsibilities, health, and community. The Treatment Effectiveness Assessment will be collected at screening, mid-treatment (week 6 visit 2) and end-of-treatment (week 12 visit 2).

26.4.6 Tobacco Use History

The Tobacco Use History assessment will be administered at screening, mid-treatment (week 6 visit 2), and end-of-treatment (week 12 visit 2) to incorporate PhenX Core Tier 1 items. Tobacco use items assessed include lifetime use, 30 day quantity and frequency, and age of first tobacco use.

26.4.7 Quality of Life

Quality of Life will be assessed using items from the PhenX Core Tier 1. Participants will be asked to provide ratings of general health, physical health, and mental health during the past 30 days at screening, mid-treatment (week 6 visit 2), and end-of-treatment (week 12 visit 2).

26.4.8 Sexual Risk Behaviors

The Sexual Risk Behaviors assessment will be administered at screening, mid-treatment (week 6 visit 2), and end-of-treatment (week 12 visit 2) to assess engagement in risky sexual related behaviors in the 30 days prior to each assessment. Participants will be asked about the number and sex of sexual partners, HIV status of partners, and use of condoms as well as the use of drugs and alcohol during sex.

26.4.9 Genetic Sampling

The NIDA CCTN has requested that blood samples for genetic analysis be obtained for all new CTN pharmacotherapy trials. Participants who consented to the optional genetic testing will have approximately 10 mL (2 teaspoons) of blood drawn at the end of the day of randomization, after all medication administration and monitoring has been completed. However, if the sample cannot be collected on the day of randomization, the sample may be collected at any visit after written consent is obtained, ideally at a visit in which a blood draw is scheduled to occur. The blood samples will be coded and only the local investigators will know the identity of the participant providing the sample. The blood sample will be sent to the Rutgers University Cell and DNA Repository for storage and future analysis.

26.5 Adherence Measures

26.5.1 Study Medication Dosing Logs

Dosing logs will document medication administered in-clinic, dispensed for take-home dosing, and the participant's self-report of doses taken. Medications to be recorded on dosing logs include naloxone, injected study medication, and oral study medication. Logs will be completed at each visit for each dose dispensed or administered throughout the study.

26.5.2 Injection Administration Form

The Injection Administration Form will document whether injectable study medication is to be administered, it will automatically assign (in real time) an injection kit number for administration, and it will document information related to the administration of the medication (e.g., time of injection). The form is to be completed once the participant appears in clinic. This form will be completed at each visit in which injectable study medication is administered (i.e., weeks 1, 4, 7, and 10) or an injection was expected but not administered (e.g., due to incarceration).

26.5.3 Oral Medication Dispensation Form

The Oral Medication Dispensation Form will document whether oral study medication is to be administered and it will automatically assign (in real time) a blister pack number for dispensation. The form is to be completed once the participant appears in clinic. This form will be completed at each study visit in which oral study medication is dispensed.

26.5.4 Oral Study Medication Blood Levels

One of the methods used to evaluate medication adherence requires collecting blood to test for bupropion and hydroxybupropion levels at a central bioanalytical laboratory. Blood will be collected for this purpose prior to study medication administration at visits 401, 701, and 1001 and again at the final medication phase visit (week 12 visit 2).

26.5.5 Video Based Adherence to Oral Study Medication Database

Dosing adherence will be assessed by automated visual recognition software during the video capture within the AiCure app. The software converts adherence information into data that is automatically entered and stored in the database maintained by AiCure for this study. This database will contain data indicating whether a video was submitted, whether the dosing was deemed valid (i.e., the study participant is clearly ingesting study medication), and whether the dosing was self-reported as opposed to documented via video. Study staff will help ensure information in the AiCure dashboard (the visual representation of the database) is accurate. No additional logs or forms are required for documenting video based adherence.

26.5.6 End of Medication Form

An End of Medication Form will be completed any time a decision is made to discontinue a participant from further medication administration or at the post-medication phase follow-up assessment in Week 13.

26.6 Administrative and Other Forms

26.6.1 Locator Form

A locator form will be used to obtain information to assist in tracking participants during treatment and at follow-up. The locator form will collect information such as participants' current address, email address, social media accounts, and phone numbers, as well as names, addresses, and phone numbers of family/friends who may know how to reach the participants if direct contact efforts are unsuccessful. This information will be collected at screening and updated in weeks 3, 6, 9, and 12 and whenever the participant reports a change in locator information. No identifying information from this form will be used in data analyses.

26.6.2 Eligibility - Randomization

This form lists all of the study inclusion and exclusion criteria and must be completed for every participant who has signed consent and entered the screening/baseline phase. Eligibility is assessed on an ongoing basis during the screening phase. Only participants who continue to meet study eligibility criteria will be allowed to continue in the screening phase, including the naltrexone pre-induction procedures (e.g., naloxone challenge). This form is to be completed in the electronic data capture system after all screening and baseline procedures are complete. Eligible participants will be randomized; ineligible participants will be excluded and deemed screen failures.

26.6.3 Missed Visit Form

This form is designed to capture the reason any study visit was missed. Once the visit window closes without completion of the visit, this Missed Visit Form will be completed directly in the electronic data capture system. Completing this form will remove the requirement for all assessments scheduled for that missed visit. Active tracking and follow-up should be performed for all missed visits.

26.6.4 Protocol Deviation Form

This form should be entered into the electronic data capture system whenever a protocol deviation occurs. This form will document a description of the deviation, how it occurred, the corrective action taken to resolve the specific deviation, as well as a description of the plan implemented to prevent future occurrences of similar deviations.

26.6.5 Protocol Satisfaction Surveys

Satisfaction with medication components, smartphone app, and other study procedures will be recorded on the Satisfaction Survey completed at the week 13 visit. A survey will be completed by both the participant and a study team member. These forms will be used in data analyses to evaluate secondary objectives including the acceptability of the combination medication and the usefulness of smartphone app-based technology for improving and monitoring medication adherence.

26.6.6 Study Completion Form

Information regarding when and why study visits were stopped for every participant, including whether a participant completed the final follow-up visit in week 16, will be recorded on this form.

27.0 TRAINING

The study staff will be trained as specified in the Training Plan. Required training will include Human Subjects Protection (HSP) and Good Clinical Practice (GCP), as well as protocol-specific training as needed (e.g., assessments, study interventions, safety procedures, data management and collection). Support mechanisms will also be identified as part of the training (e.g., who to contact for aid, questions, resources). All study staff will also complete any additional training per their study site and IRB requirements. An Operations Manual will be provided for this study that will outline study procedures in more detail as necessary for the day-to-day conduct of the trial. The Operations Manual will be used to train study staff, to provide reference for study procedures, and to support quality management activities.

28.0 STATISTICAL ANALYSES

28.1 General Design

28.1.1 Study Hypothesis

The primary hypothesis is that the combination of extended-release depot naltrexone plus extended-release bupropion medication (AMC), relative to the PLB, will be associated with greater MA non-use. Participants will be randomized to one of two conditions, PLB or AMC. Randomization will be stratified by site.

28.1.2 Sample Size

A sample size of 370 is chosen for this study to detect the difference between the two treatment arms. A total of 7 - 10 sites will participate in the trial. It is anticipated that each site will randomize approximately 30 - 55 participants over the 18-month recruitment period.

28.1.3 Primary Outcomes

The primary efficacy outcome measure is MA-negative urine drug screen (UDS) test results over the course of twice-weekly visits, which will be compared by treatment group (AMC versus PLB). Participants will be defined as a “responder” if there are at least 75% MA-negative UDS tests during the pre-specified evaluation period. The treatment groups will be compared as to the proportion of responders using a Z test. All treatment comparisons will be performed under the Intent-to-Treat (ITT) criteria.

28.1.4 Secondary Outcomes

Secondary outcomes include methamphetamine and other substance use outcomes in the pre-evaluation period, in the evaluation period, and at the follow-up assessment for responders, non-responders, and other sub-groups. Secondary outcomes also include depression scores, quality of life, overall functioning, clinic attendance, and ratings of participant and staff satisfaction with study procedures, including use of the smartphone app, compensation, and study medication. Secondary safety outcomes will be participants’ reports of treatment emergent adverse events including serious adverse events collected at scheduled clinic visits or via other contact.

Drug use will be measured by several outcomes including but not limited to the Treatment Effectiveness Score (TES; Ling et al., 1997), days of self-reported drug use, number of consecutive negative UDS, and UDS as a binary outcome (positive or negative) across time. The TES is the percentage of the scheduled urine drug screens that were negative for each drug. Mixed-model analysis of repeated measures will be used to explore the presence of time-related medication effects, including severity of cravings. In the models, we will control for baseline MA use and other key demographic and participant variables. Additional analyses will include assessment of drug use in the pre-evaluation period, over the entire medication period and at the follow-up assessment. Changes occurring over the medication period in severity and type of drug-related problems and in quality of life will be analyzed with parametric and nonparametric measures. Participant and staff satisfaction ratings will be summarized. A two-sided test of significance will be used with a p-value less than 0.05 indicating significance.

Analyses of secondary outcomes will be primarily performed on all individuals who are randomized and inducted onto study medication. Secondary analyses will also be performed by

examining responses in subgroups with varying characteristics. Adherence with oral study medication dosing will be measured by smartphone device app dosing videos and in-clinic observation. A dosing adherent per-protocol analysis will be performed by evaluating response rates in the medication-adherent group. Because per-protocol analyses may be biased (Sheiner and Rubin, 1995) an unbiased complier-adjusted-causal-effects analysis (Jo and Stuart, 2009) may also be used to adjust for adherence. Multiple testing will not be adjusted for in the secondary analyses, since these are not part of the study's primary objective. When multiple tests are conducted, the chance of finding a significant difference in one of the tests, when in fact no difference exists, is greater than the stated Type I error rate. The investigators are aware of the issues associated with multiple testing and will interpret results with caution.

All the above mentioned secondary analyses (except staff satisfaction ratings) will be performed in a similar way as the primary analysis. For continuous outcome ordinary least squares and mixed effects model for repeated measures (MMRM) will be used and for binary outcomes a logistic regression will be used. These will be described in the protocol Statistical Analysis Plan (SAP).

28.2 Interim Analyses

In coordination with the centralized Data and Statistics Center, a DSMB will monitor the progress of the trial. As requested by the DSMB, interim analyses of sample size re-estimation and monitoring of the efficacy and safety data will be performed. However, if ADAPT-2 has a rapid recruitment such that the proportion of Week 12 outcomes realized is small when recruitment is completed or nearly completed, discussion with the DSMB will take place whether sample size re-estimation and interim analysis of efficacy data is warranted.

28.2.1 Sample Size Re-estimation

Sample size re-estimation analysis will be conducted when approximately half of the participants have been enrolled. This analysis will not reveal the treatment effect observed in the trial at the time of this interim analysis. A sample size re-estimation will be performed to assess the adequacy of the projected study sample size and whether a sample size increase is warranted.

The timing of the sample size re-estimation is based on a number of factors: recruitment rate, timing of the primary outcome, amount of loss to follow-up, and time to perform the sample size re-estimation. The sample size re-estimation will be done only once, and done before any interim analysis of the primary outcome is performed. The results of the sample size re-estimation analysis would be presented in a closed session of the DSMB, who will then provide a recommendation to the NIDA CCTN regarding whether the target sample size should be modified. A decision regarding any such modification would be made subsequently by the CCTN, taking into consideration the recommendation of the DSMB.

28.2.2 Interim Monitoring of Primary Efficacy Endpoint

Interim monitoring for efficacy will be performed. There will be no interim efficacy monitoring before a sample size re-estimation is performed (or a determination that re-estimation is not needed) because sample size re-estimation could change the target sample size, affecting the alpha spending function used in the interim efficacy monitoring. After sample size re-estimation, interim efficacy monitoring will be performed only once during the recruitment period.

All interim monitoring will use an O'Brien-Fleming-type boundary with information fraction equal to the proportion of the target sample size with primary outcome. This approach spends very little

alpha at the interim look, therefore the impact of an interim monitoring on the sample size is negligible. The only criterion for early stopping for efficacy will be based on Z-scores and its relation to O'Brien-Fleming-type boundary.

Before recommending early termination, the DSMB will consider:

- Internal consistency of primary and secondary results.
- Internal consistency of primary and secondary results by subgroups defined by baseline characteristics (e.g., severity of MA use, tobacco use history, treatment effectiveness assessment and visual analog craving scale).
- Distribution of baseline prognostic factors among the two groups.
- Consistency of primary and secondary results across clinical sites and among clinical sites enrolling larger numbers of participants.
- Possible impact of missing data from missed participant visits for assessment of the primary and secondary response variables.
- Possible differences in concomitant interventions or medications.

28.2.3 Safety Interim Analyses

Safety interim looks will be performed for the regular DSMB meetings or at unscheduled times per the DSMB's request. These will include analysis of adverse events and narrative report on serious adverse events.

Simultaneous with primary interim efficacy monitoring analysis, a "poor efficacy" statistic will be calculated to assess whether the combination of extended-release depot naltrexone plus extended-release bupropion medication (AMC), relative to the PLB, is associated with greater MA use. This analysis will be conducted after the sample size re-estimation. If the "poor efficacy of AMC" statistic crosses its boundary, defined as the response rate for PLB minus AMC being greater than 10%, the DSMB will consider whether to stop the trial early because of poor efficacy of AMC relative to PLB.

28.2.4 Conditional Power and Futility

Unless otherwise requested, a futility/conditional power calculation will be performed every time interim monitoring is performed. If at any DSMB meeting the conditional power falls below 0.3, this will stimulate a discussion among the DSMB members about whether we should stop for futility.

28.3 Demographic and Baseline Characteristics

Baseline demographic and clinical variables will be summarized for participants randomized and inducted on study medication. Descriptive summaries of the distribution of continuous baseline variables will be presented with percentiles (median, 25th and 75th percentiles), and with mean and standard deviation. Categorical variables will be summarized in terms of frequencies and percentages.

28.4 Description of Plans to Conduct Analyses of Study Results by Gender and Race/Ethnicity

The association between specific demographic characteristics and outcome will be studied. The demographic characteristics of potential importance include: age, gender, race, and ethnicity. In accordance with NIH guidelines, analyses will be completed to determine whether treatment response was significantly affected by participant minority/gender status using an interaction term for treatment, time and minority/gender as appropriate.

28.5 Safety Analysis

AEs, including SAEs, will be summarized by body system and preferred term using MedDRA codes (per The Medical Dictionary for Regulatory Activities). AEs will be presented as: (1) the number and proportion of participants experiencing at least one incidence of each event overall; and (2) the total number of each event overall in tabular form. Listings of SAEs will be sorted by body system, and preferred term. Detail in these listings will include severity, relationship to study drug(s), and action taken, as available.

29.0 REGULATORY COMPLIANCE, REPORTING AND MONITORING

29.1 Statement of Compliance

This study will be conducted in compliance with the current version of the study protocol, in accordance with the ethical principles outlined in the Declaration of Helsinki, consistent with current International Conference on Harmonization Good Clinical Practice (GCP) Guidelines, and all other applicable regulatory requirements.

29.2 Institutional Review Board Approval

Participating sites must obtain written approval of the study protocol, consent form(s), other supporting documents, any materials given to the participant, and any advertising for participant recruitment from their local Institutional Review Board (IRB) or Independent Ethics Committee (IEC) in order to participate in the study. Prior to initiating the study, site investigators will obtain written IRB approval to conduct the study at their respective site. Any amendments to the protocol or consent must be approved by the Lead Investigator and IRB before implementation. Progress reports, and any required post-approval reports will be submitted to the IRBs either annually or at a frequency requested by each IRB so that continuous study approval is maintained without lapse. The Lead Investigator is responsible for maintaining copies of all performance site(s) current IRB approval notice(s) and IRB-approved consent document(s), including approvals for all protocol and consent modifications. These materials must be received by the Lead Investigator prior to the initiation of research activities at a given site, must be maintained by the Lead Investigator throughout the course of the trial, and must be available at any time for audit.

29.3 Research Advisory Panel of California (California sites only)

Prior to initiating the study, the sponsor or designee will obtain written approval from the Research Advisory Panel of California (RAP-C). Any planned research project to be conducted in California requiring the use of a Schedule I or Schedule II Controlled Substance as its main study drug as well as research for the treatment of controlled substance addiction or abuse utilizing any drug, scheduled or not must be submitted to RAP-C for review and approval prior to study start-up. Study approval is based on review of the study protocol, consent form, and other pertinent study documents. Yearly reports will be provided to the RAP-C by the sponsor or designee in order to maintain continuing study approval.

29.4 Informed Consent

All potential candidates for the study will be given a current IRB-approved consent form in English to read. In accordance with IRB policies, appropriately trained and qualified study personnel will explain all aspects of the study in lay language and answer all of the study candidates' questions. Participants who remain interested after receiving an explanation of the study will be given a short quiz to test their understanding of the project including the purpose, procedures involved, and the voluntary nature of participation. Those who cannot successfully answer all quiz items will have the study re-explained by research staff with a focus on aspects they did not understand. Anyone who cannot demonstrate appropriate understanding of the study will be ineligible to participate and will be assisted in finding other treatment resources. Those who demonstrate understanding of the study and voluntarily agree to participate will be asked to sign the IRB-approved consent form. Participants will not be administered any assessments or participate in study procedures in any way prior to signing and dating the IRB-approved consent form.

Informed consent is a process and not just a document. The informed consent process is a means of providing study information to each prospective participant in understandable language and taking all the time needed to answer all questions to allow for an informed decision about study participation. The IRB-approved consent form must be revised whenever important new information becomes available including whenever the protocol is amended in any way that may affect a study participant's willingness to continue participating in the trial. All study sites must have the study consent forms approved by their IRB(s). Sites must maintain the original signed IRB-approved consent forms for all study participants in a locked, secure location that is in compliance with IRB and institutional policies. Signed/dated IRB-approved consent forms must be accessible for quality assurance review and regulatory compliance at all times. Every study participant will be provided with a copy of the signed/dated consent form that can be used as continual reference for study information including procedures, possible risks and/or side effects, and contact information for questions and or emergencies. Individuals who refuse to participate or who withdraw from the study will be treated without prejudice.

29.5 Health Insurance Portability Accountability Act (HIPAA)

Study sites may be required by their institutions to obtain authorization from participants for use of protected health information. Releases of participant identifying information that are permitted by the HIPAA regulations, but which are prohibited by other applicable federal regulations and/or state/Commonwealth laws and regulations, are prohibited. Sites will be responsible for communicating with their IRBs or Privacy Boards and obtaining the appropriate approvals or waivers to be in regulatory compliance.

29.6 Investigator Assurances

Each participating site must file (or have previously filed) a Federalwide Assurance (FWA) with the HHS Office for Human Research Protections setting forth the commitment of the organization to adhere to appropriate policies and procedures for the protection of human research subjects. The site's FWA must be current at trial initiation and must be maintained throughout the duration of the study with documentation sent to NIDA or its designee, as requested. Research covered by these regulations cannot proceed in any manner prior to NIDA receipt of certification that the research has been reviewed and approved by the OHRP-registered IRB designated in the assurance (45 CFR 46.103(b) and (f)). Prior to initiating the study, the principal investigator and sub-investigators at each study site will sign a protocol signature page, providing assurances that the study will be performed according to the standards stipulated therein.

29.7 Financial Disclosure

All investigators will comply with the requirements of 42 CFR Part 50, Subpart F to ensure that the design, conduct, and reporting of the research will not be biased by any conflicting financial interest. All study personnel with decision-making responsibilities regarding the protocol must comply with their institution's policy regarding conflict of interest.

29.8 Confidentiality

Confidentiality will be maintained in accordance with all applicable federal regulations and/or state law and regulations. Particular attention is drawn to the regulations promulgated by the Food and Drug Administration (FDA) under the Freedom of Information Act providing, in part, that proprietary information furnished to investigators and Institutional Review Boards will be kept

confidential by the FDA only if maintained in confidence by the clinical investigator and Institutional Review Board (IRB). By signing the protocol signature page the investigator affirms that information furnished to the investigator by NIDA will be maintained in confidence and such information will be divulged to the IRB, Ethical Review Committee, or similar expert committee; affiliated institution; and employees only under an appropriate understanding of confidentiality with such board or committee, affiliated institution and employees.

The Lead Investigator will obtain a federal Certificate of Confidentiality (CoC) and will distribute it to all sites when received. A CoC helps researchers protect the privacy of human research participants enrolled in biomedical, behavioral, clinical and other forms of sensitive health-related research (e.g., drug use). Certificates protect against compulsory legal demands, such as court orders and subpoenas, for identifying information or identifying characteristics of a research participant. The department that issues the CoC will be advised of any changes in the CoC application information that may occur during the study, as required. Participating sites will be notified if CoC revision is necessary.

Participant records will be kept confidential by the use of study codes for identifying participants on CRFs, secure separate storage of any documents that have participant identifiers, and secure computing procedures for entering and transferring electronic data. All laboratory specimens, eCRFs, reports, and other data records will be identified by the participant identification study code that includes the site number, node number, and participant number. Research records will be stored in a locked cabinet. Only authorized individuals will have access to the study records. Participant information will not be released without written permission, except as necessary for monitoring by the FDA, NIDA-contracted monitors, local node monitors, lead node staff, or NIDA. By signing the protocol signature page the investigator agrees that within local regulatory restrictions and ethical considerations, NIDA or any regulatory agency may consult and/or copy study documents in order to verify eCRF data.

29.9 IND Requirements

An IND application will be submitted to FDA for this protocol, as described in title 21 of the Code of Federal Regulations, part 312 (21 CFR 312). Accordingly, all protocol amendments will be submitted to this IND as amendments. This study will be conducted in accordance with International Council on Harmonisation Good Clinical Practices (ICH GCPs), all applicable FDA and OHRP Guidance documents, and any state and institutional requirements applicable at the clinical site level.

29.10 Regulatory Files

Essential documents are those documents which individually and collectively permit evaluation of the conduct of a trial and the quality of the data produced. These documents serve to demonstrate the compliance of the investigator, sponsor and monitor with the standards of Good Clinical Practice and with all applicable regulatory requirements. Regulatory files should be maintained throughout the lifecycle of the trial and should contain all required regulatory documents, study-specific documents, and all important study-related communications. Regulatory files will be checked at each participating site for regulatory document compliance prior to study initiation, throughout the study, as well as at study closure.

29.11 Study Documentation

Study documentation includes, but is not limited to, all data-related forms, workbooks, source documents, monitoring logs and appointment schedules, sponsor-investigator correspondence, signed protocols including amendments, Ethics Review Committee or Institutional Review Board/Committee correspondence, approved current and previous consent forms, and signed participant consent forms. Source documents include all recordings of observations or notations of clinical activities and all reports and records necessary for the evaluation and reconstruction of the clinical research study. All clinical trial information should be recorded, handled, and stored in a way that allows its accurate reporting, interpretation, and verification. The original recording of an observation should be retained as the source document.

29.12 Records Retention and Requirements

Research records for all study participants (e.g., case report forms, source documents, signed consent forms, and regulatory files) are to be maintained by the investigator in a secure location for a minimum of 3 years after the study is completed and closed. These records are also to be maintained in compliance with IRB, state and federal requirements, whichever is longest. The sponsor and Lead Investigator must be notified in writing and acknowledgment must be received by the site prior to the destruction or relocation of research records.

29.13 Reporting to Sponsor

The site principal investigator agrees to submit accurate, complete, legible and timely reports to the sponsor, as required. These include, but are not limited to, reports of any changes that significantly affect the conduct or outcome of the trial or increase risk to study participants. Adverse Event reporting and Serious Adverse Event reporting will occur as described herein. At the completion of the trial, the Lead Investigator will provide a final report to the sponsor.

29.14 Safety Monitoring

29.14.1 Adverse Events (AEs)

All adverse events (medical and/or psychiatric) occurring during the course of the study will be assessed, documented, and reported. AEs occurring during the course of the clinical trial will be collected, documented, and reported by the principal investigator or sub-investigators according to the specific instructions detailed in this section of the protocol and Appendix A. Appropriately qualified and trained medical personnel will elicit participant reporting of AEs and SAEs at each study visit designated to collect AEs (i.e., the first visit following informed consent and at every visit thereafter). Study staff will follow-up on the status of any AEs that remain at the post-medication phase follow-up visit assessment for up to 30 days post last study visit.

An AE is defined as any reaction, side effect, or untoward event that occurs during the course of the clinical trial, whether or not the event is considered investigational product-related or clinically significant. For this study, AEs will include events reported by the participant, as well as clinically significant abnormal findings on physical examinations or laboratory evaluations. A new illness, symptom, sign or clinically significant clinical laboratory abnormality or worsening of a pre-existing condition or abnormality is considered an AE. Stable chronic conditions, such as arthritis, which are present prior to clinical trial entry and do not worsen are not considered AEs. All AEs must be recorded on the AE log and CRF. The AE log and CRF are also used to record follow-up information for unresolved events reported on previous visits.

Each week, appropriately qualified and trained medical personnel must review the AE log and CRF completed for the previous week for any events that were reported as continuing. All AEs, including clinically significant abnormal findings on laboratory evaluations, regardless of severity, will be followed until satisfactory resolution.

A study medical clinician (MD, DO, PA, or NP) will review or provide consultation for each adverse event. These reviews will include an assessment of the severity and causality to the study drug or study procedures. The study medical clinician, in collaboration with the study physician and site principal investigator, will also make decisions to exclude, refer, or withdraw participants as required. The study staff will be trained to monitor for and report adverse events and serious adverse events.

Each participating site has established practices for managing medical and psychiatric emergencies, and the study staff will continue to utilize these procedures. Study medical clinicians at each site will be responsible for monitoring participants for possible clinical deterioration or other problems, and for implementing appropriate courses of action.

29.14.2 Definitions of Adverse Events and Serious Adverse Events

Full definitions of adverse events and serious adverse events, their identification, and characterization regarding severity and relationship to therapy and processing are described in Appendix A.

29.14.3 Reportable Adverse Events and Serious Adverse Events

For the purpose of this study, all AEs and SAEs will require reporting in the electronic data system. Reporting of AEs and SAEs is described in Appendix A. The local site is responsible for reporting all of their local AEs and SAEs to their IRBs per IRB guidelines.

29.14.4 Data and Safety Monitoring Board (DSMB)

This study will utilize the CTN DSMB to oversee ongoing trial progress. The purpose of this board is to determine whether risks emerge during the conduct of the trial that make continuation unethical. This process is intended to assure the IRBs, the sponsor, and investigators that participants are provided with an accurate and ongoing risk evaluation when participating in CTN research trials. Safety monitoring begins with the initial review of the protocol during the study development process. Reports of participant seizures will be provided to the DSMB as they occur. The DSMB will meet as necessary over the study duration.

29.14.5 Medical Monitor

Under the supervision of the NIDA-assigned Medical Monitor, the study Safety Monitor will be responsible for overseeing safety and for evaluating all Adverse Events (AEs). The Safety Monitor will review all Serious Adverse Events (SAEs) within one business day of their reporting in the eClinical and all other Adverse Events on a regular basis. The Medical Monitor will review events regularly and will be available at all times for consultation. It is the responsibility of the site principal investigator to provide this information to the Safety Monitor. It is also the site principal investigators' responsibility to inform the IRBs per IRB guidelines.

In addition, the Medical Monitor will independently review the safety data, present it to the DSMB for periodic review, and provide site principal investigators a "Safety Letter" when necessary. The

Medical Monitor will determine which safety events require expedited reporting to NIDA, the DSMB, study drug manufacturers, and regulatory authorities. This will include all suspected adverse reactions that are serious and unexpected. Furthermore, in the event of participant seizures, reports will be submitted to the DSMB using the AE form with additional information about the event as deemed appropriate.

29.15 Protocol Deviations: Reporting and Management

Any divergence from procedures and requirements outlined in the protocol will be classified a protocol deviation. A protocol deviation is an action (or inaction) that alone may or may not affect the scientific soundness of the investigation or seriously affect the safety, rights, or welfare of a study participant. In some cases, a protocol deviation may compromise participant safety, participant rights, inclusion/exclusion criteria or the integrity of study data and is cause for corrective action to resolve the departure and to prevent re-occurrence. Protocol deviations will be monitored at each site for (1) significance, (2) frequency, and (3) impact on the study objectives, to ensure that site performance does not compromise the integrity of the trial. The decision about whether a deviation from the protocol will be designated as minor or major will be made by the protocol's Lead Investigator(s) in conjunction with the Clinical Coordinating Center (CCC). The consequences will be specified and participating sites will be informed.

All protocol deviations will be recorded in the Electronic Data Capture (EDC) system via the Protocol Deviation CRF. Additionally, each site is responsible for tracking and reporting protocol deviations to their IRB, as required. The CCC and the Data and Statistics Center (DSC) and the Lead Investigator must be contacted immediately if an unqualified/ineligible participant is entered into the study.

29.16 Audits

The Sponsor has an obligation to ensure that this trial is conducted according to good research practice guidelines and may perform quality assurance audits for protocol compliance. The Lead Investigator and authorized staff from the Texas Node; the National Institute on Drug Abuse Center for the Clinical Trials Network (NIDA CCTN, the study sponsor); NIDA's contracted agents, monitors or auditors; and other agencies such as the Department of Health and Human Services (HHS), the Food and Drug Administration (FDA), the Office for Human Research Protections (OHRP), and the sites' Institutional Review Boards may inspect research records for verification of data, compliance with federal guidelines on human participant research, and to assess participant safety.

29.17 Quality Assurance Monitoring

Protection of the rights and welfare of study participants will be a vigilant process conducted by the research teams at all sites and at the Lead Node and by the sponsors of the research. Monitoring of the study sites will be conducted on a regular basis using a combination of NIDA-contracted monitors, local node monitors, and lead node staff.

Site investigators will host periodic visits by monitors who will ensure all study procedures are appropriately conducted, and that study data are generated, documented and reported in compliance with the protocol, GCP, and applicable regulations. These monitors will audit, at mutually agreed upon times, regulatory documents, case report forms (CRFs), and corresponding source documents for each participant. NIDA-contracted monitors will assure that submitted data are accurate and in agreement with source documentation and will also review regulatory/essential documents such as correspondence with the IRB.

Areas of particular concern will be participant signed/dated consents, eligibility for study participation, protocol adherence, safety monitoring, IRB reviews and approvals, regulatory documents, participant records, study drug accountability, and principal investigator supervision and involvement in the trial. Reports will be prepared following the visits and forwarded to the site principal investigator, the Lead Investigator and NIDA CCTN.

Qualified node personnel (Node Protocol Managers and/or QA monitors) will provide site management for each site during the trial to encourage and assess compliance with the study protocol, Good Clinical Practice guidelines, and to ensure the integrity of the trial progress. These visits will take place as specified by the local protocol team, Node PI or Lead Team, and visits will occur as often as needed to help prevent, detect, and correct problems at the study sites. Node staff will ensure that study procedures are properly followed and that site staff are trained and able to conduct the protocol appropriately. If the node staff's review of study documentation indicates that additional training of study personnel is needed, node staff will undertake or arrange for that training.

30.0 DATA MANAGEMENT AND PROCEDURES

30.1 Design and Development

This protocol will utilize a centralized Data and Statistics Center (DSC). The DSC will be responsible for the development of the case report forms (CRFs), development and validation of the clinical study database, ensuring data integrity, and training site and participating node staff on applicable data management procedures. A web-based distributed data entry model will be implemented. This electronic data capture system (Advantage eClinical) will be developed to ensure that guidelines and regulations surrounding the use of computerized systems used in clinical trials are upheld. The remainder of this section provides an overview of the data management plan associated with this protocol.

30.2 Site Responsibilities

The data management responsibilities of each site will be specified by the lead node and the DSC.

30.3 Data and Statistics Center Responsibilities

The DSC will 1) develop and apply data management procedures to ensure the collection of accurate and good-quality data, 2) provide final Case Report Forms (CRFs) and electronic CRFs (eCRFs) for the collection of all data required by the study, 3) develop data dictionaries for each CRF that will comprehensively define each data element, 4) prepare instructions for the use of Advantage eClinical and for the completion of CRFs, 5) conduct ongoing data validation and cleaning activities on study data collected from all study sites, and 6) perform data validation and cleaning activities prior to any interim analyses and prior to the final study database lock.

30.4 Data Collection and Entry

Data will be collected at the study sites on source documents and entered by the site into eCRFs in Advantage eClinical, or will be collected via direct entry into the eCRF. In the event that Advantage eClinical is not available, the DSC will provide the sites with paper CRF source documents and completion instructions. Data will be entered into Advantage eClinical in accordance with the instructions provided during protocol-specific training and guidelines established by the DSC. Data entry into the eCRFs shall be performed by authorized individuals. Selected eCRFs may also require the investigator's electronic signature.

The principal investigator at the site is responsible for maintaining accurate, complete and up-to-date research records. In addition, the investigator is responsible for ensuring the timely completion of eCRFs for each research participant.

30.5 Data Monitoring, Cleaning, and Editing

Data will be entered into the DSC automated data acquisition and management system (Advantage eClinical). eCRFs will be monitored for completeness and accuracy throughout the study. Dynamic reports listing missing values and forms are available to sites at all times in Advantage eClinical. These reports will be monitored regularly by the DSC. In addition, the DSC will identify inconsistencies within eCRFs and between eCRFs and post data clarification requests

or queries in Advantage eClinical on a scheduled basis. Sites will resolve data inconsistencies and errors by entering all corrections and changes directly into Advantage eClinical.

The CCC will conduct regular on-site and remote visits, during which audits comparing source documents to the data entered on the eCRF will be performed. Any discrepancies identified between the source document and the eCRF will be corrected by the site.

Trial progress and data status reports, which provide information on recruitment, availability of primary outcome, treatment exposure, regulatory status, and data quality, will be generated daily and posted to a secure website. These reports are available to the site, the corresponding node, the lead node, the coordinating centers, and NIDA to monitor study progress overall and at each individual participating site.

30.6 Database Transfer and Lock

At the conclusion of data collection for the study, the DSC will perform final cleaning activities and will “lock” the study database from further modification. The final analysis dataset will be returned to the Lead Investigator and to NIDA, as requested, for storage and archive.

31.0 PUBLICATIONS AND OTHER RIGHTS

Protocol development and implementation in the NIDA CTN is a collaborative process. The planning, preparation, and submission of publications will follow the policies of the CTN Publications Committee. Individuals making substantive contributions to the protocol development and implementation will have opportunities to participate in publications. Other contributors will also be acknowledged. Per NIH policy, the results of the proposed trial are to be made available to the research community and to the public at large. The project will adhere to stipulations in accord with the NIH Public Access Policy (for any articles based on work supported by NIH funding) required for Applications, Proposals, or Reports Submitted After July 1, 2013, as set forth in:

<http://publicaccess.nih.gov/>

<http://publicaccess.nih.gov/FAQ.htm#792>

<http://grants.nih.gov/grants/guide/notice-files/NOT-OD-08-119.html>

32.0 SIGNATURES

SPONSOR'S REPRESENTATIVE (CCTN DESIGNEE)

Printed Name	Signature	Date
--------------	-----------	------

ACKNOWLEDGEMENT BY INVESTIGATOR:

- I am in receipt of version 1.0 of the protocol and agree to conduct this clinical study in accordance with the design and provisions specified therein.
- I agree to follow the protocol as written except in cases where necessary to protect the safety, rights, or welfare of a participant, an alteration is required, and the sponsor and IRB have been notified prior to the action.
- I will ensure that the requirements relating to obtaining informed consent and institutional review board (IRB) review and approval in 45 CFR 46 are met.
- I agree to personally conduct or supervise this investigation at this site and to ensure that all site staff assisting in the conduct of this study are adequately and appropriately trained to implement this version of the protocol and that they are qualified to meet the responsibilities to which they have been assigned.
- I agree to comply with all the applicable federal, state, and local regulations regarding the obligations of clinical investigators as required by the Department of Health and Human Services (DHHS), the state, and the IRB.

SITE'S PRINCIPAL INVESTIGATOR

Printed Name	Signature	Date
--------------	-----------	------

Site Name

Node Affiliation

33.0 REFERENCES

- Anderson, A. L., Li, S. H., Markova, D., Holmes, T. H., Chiang, N., Kahn, R., . . . Elkashef, A. M. (2015). Bupropion for the treatment of methamphetamine dependence in non-daily users: a randomized, double-blind, placebo-controlled trial. *Drug Alcohol Depend*, 150, 170-174. doi:10.1016/j.drugalcdep.2015.01.036
- Anggadiredja, K., Sakimura, K., Hiranita, T., & Yamamoto, T. (2004). Naltrexone attenuates cue- but not drug-induced methamphetamine seeking: a possible mechanism for the dissociation of primary and secondary reward. *Brain Res*, 1021(2), 272-276. doi:10.1016/j.brainres.2004.06.051
- Aron, J. L., & Paulus, M. P. (2007). Location, location: using functional magnetic resonance imaging to pinpoint brain differences relevant to stimulant use. *Addiction*, 102(s1), 33-43.
- Ascher, J. A., Cole, J. O., Colin, J. N., Feighner, J. P., Ferris, R. M., Fibiger, H. C., . . . et al. (1995). Bupropion: a review of its mechanism of antidepressant activity. *J Clin Psychiatry*, 56(9), 395-401.
- Brecht, M.-L., Greenwell, L., & Anglin, M. D. (2005). Methamphetamine treatment: Trends and predictors of retention and completion in a large state treatment system (1992-2002). *Journal of Substance Abuse Treatment*, 29(4), 295-306. doi:10.1016/j.jsat.2005.08.012
- Brensilver, M., Heinzerling, K. G., & Shoptaw, S. (2013). Pharmacotherapy of amphetamine-type stimulant dependence: an update. *Drug Alcohol Rev*, 32(5), 449-460. doi:10.1111/dar.12048
- Brensilver, M., Heinzerling, K. G., Swanson, A. N., & Shoptaw, S. (2012). Placebo-group responders in methamphetamine pharmacotherapy trials: The role of immediate establishment of abstinence. *Exp Clin Psychopharmacol*, 20(5), 430-435. doi:10.1037/a0029210
- Brensilver, M., Heinzerling, K. G., Swanson, A. N., Telesca, D., Furst, B. A., & Shoptaw, S. J. (2013). Cigarette smoking as a target for potentiating outcomes for methamphetamine abuse treatment. *Drug Alcohol Rev*, 32(1), 96-99. doi:10.1111/j.1465-3362.2012.00423.x
- Brensilver, M., Heinzerling, K. G., Swanson, A.-N., & Shoptaw, S. J. (2012). A retrospective analysis of two randomized trials of bupropion for methamphetamine dependence: Suggested guidelines for treatment discontinuation/augmentation. *Drug and Alcohol Dependence*, 125(1-2), 169-172. doi:10.1016/j.drugalcdep.2012.03.027
- Bryant, S. G., Guernsey, B. G., & Ingram, N. B. (1983). Review of bupropion. *Clin Pharm*, 2(6), 525-537.
- Carroll, C. C., & Trappe, T. A. (2006). Personal digital video: a method to monitor drug regimen adherence during human clinical investigations. *Clin Exp Pharmacol Physiol*, 33(12), 1125-1127. doi:10.1111/j.1440-1681.2006.04503.x
- Carroll, K. M., O'Malley, S. S., & Nuro, K. F. (1996). *Compliance Enhancement: A Manual for the Psychopharmacotherapy of Drug Abuse and Dependence*. Retrieved from West Haven, CT:
- Chen, Y. F., Yang, Y., Hung, H. M., & Wang, S. J. (2011). Evaluation of performance of some enrichment designs dealing with high placebo response in psychiatric clinical trials. *Contemp Clin Trials*, 32(4), 592-604. doi:10.1016/j.cct.2011.04.006
- Cherner, M., Suarez, P., Casey, C., Deiss, R., Letendre, S., Marcotte, T., . . . Heaton, R. K. (2010). Methamphetamine use parameters do not predict neuropsychological impairment in currently abstinent dependent adults. *Drug and Alcohol Dependence*, 106(2-3), 154-163.
- Comer, S. D., Sullivan, M. A., Yu, E., Rothenberg, J. L., Kleber, H. D., Kampman, K., . . . O'Brien, C. P. (2006). Injectable, sustained-release naltrexone for the treatment of opioid

- dependence: a randomized, placebo-controlled trial. *Arch Gen Psychiatry*, 63(2), 210-218. doi:10.1001/archpsyc.63.2.210
- Dean, A. C., London, E. D., Sugar, C. A., Kitchen, C. M., Swanson, A. N., Heinzerling, K. G., . . . Shoptaw, S. (2009). Predicting adherence to treatment for methamphetamine dependence from neuropsychological and drug use variables. *Drug Alcohol Depend*, 105(1-2), 48-55. doi:10.1016/j.drugalcdep.2009.06.008
- Diez-Quevedo, C., Rangil, T., Sanchez-Planell, L., Kroenke, K., & Spitzer, R. L. (2001). Validation and utility of the patient health questionnaire in diagnosing mental disorders in 1003 general hospital Spanish inpatients. *Psychosom Med*, 63(4), 679-686.
- Doros, G., Pencina, M., Rybin, D., Meisner, A., & Fava, M. (2013). A repeated measures model for analysis of continuous outcomes in sequential parallel comparison design studies. *Stat Med*, 32(16), 2767-2789. doi:10.1002/sim.5728
- Duarte, N. A., Woods, S. P., Rooney, A., Atkinson, J. H., & Grant, I. (2012). Working memory deficits affect risky decision-making in methamphetamine users with attention-deficit/hyperactivity disorder. *Journal of Psychiatric Research*, 46(4), 492-499. doi:10.1016/j.jpsychires.2012.01.006
- Elkashef, A. M., Rawson, R. A., Anderson, A. L., Li, S. H., Holmes, T., Smith, E. V., . . . Weis, D. (2008). Bupropion for the treatment of methamphetamine dependence. *Neuropsychopharmacology*, 33(5), 1162-1170. doi:10.1038/sj.npp.1301481
- Fals-Stewart, W., O'Farrell, T. J., Freitas, T. T., McFarlin, S. K., & Rutigliano, P. (2000). The timeline followback reports of psychoactive substance use by drug-abusing patients: psychometric properties. *J Consult Clin Psychol*, 68(1), 134-144.
- Fava, M., Evins, A. E., Dorer, D. J., & Schoenfeld, D. A. (2003). The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. *Psychother Psychosom*, 72(3), 115-127. doi:69738
- Fava, M., Memisoglu, A., Thase, M. E., Bodkin, J. A., Trivedi, M. H., de Somer, M., . . . Ehrich, E. (2016). Opioid Modulation With Buprenorphine/Samidorphan as Adjunctive Treatment for Inadequate Response to Antidepressants: A Randomized Double-Blind Placebo-Controlled Trial. *Am J Psychiatry*, 173(5), 499-508. doi:10.1176/appi.ajp.2015.15070921
- Fava, M., Mischoulon, D., Iosifescu, D., Witte, J., Pencina, M., Flynn, M., . . . Pollack, M. (2012). A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study). *Psychother Psychosom*, 81(2), 87-97. doi:10.1159/000332050
- Fernández-Serrano, M. J., Pérez-García, M., & Verdejo-García, A. (2011). What are the specific vs. generalized effects of drugs of abuse on neuropsychological performance? *Neuroscience & Biobehavioral Reviews*, 35(3), 377-406. doi:10.1016/j.neubiorev.2010.04.008
- Greenway, F. L., Fujioka, K., Plodkowski, R. A., Mudaliar, S., Guttadauria, M., Erickson, J., . . . Group, C.-I. S. (2010). Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet*, 376(9741), 595-605. doi:10.1016/S0140-6736(10)60888-4
- Haggkvist, J., Bjorkholm, C., Steensland, P., Lindholm, S., Franck, J., & Schilström, B. (2011). Naltrexone attenuates amphetamine-induced locomotor sensitization in the rat. *Addict Biol*, 16(1), 20-29. doi:10.1111/j.1369-1600.2009.00199.x
- Haggkvist, J., Lindholm, S., & Franck, J. (2009). The opioid receptor antagonist naltrexone attenuates reinstatement of amphetamine drug-seeking in the rat. *Behav Brain Res*, 197(1), 219-224. doi:10.1016/j.bbr.2008.08.021
- Hanson, G. R., Sandoval, V., Riddle, E., & Fleckenstein, A. E. (2004). Psychostimulants and

- vesicle trafficking: a novel mechanism and therapeutic implications. *Ann N Y Acad Sci*, 1025, 146-150. doi:10.1196/annals.1316.019
- Heinzerling, K. G., Gadzhyan, J., van Oudheusden, H., Rodriguez, F., McCracken, J., & Shoptaw, S. (2013). Pilot randomized trial of bupropion for adolescent methamphetamine abuse/dependence. *J Adolesc Health*, 52(4), 502-505. doi:10.1016/j.jadohealth.2012.10.275
- Heinzerling, K. G., Swanson, A.-N., Hall, T. M., Yi, Y., Wu, Y., & Shoptaw, S. J. (2014). Randomized, placebo-controlled trial of bupropion in methamphetamine-dependent participants with less than daily methamphetamine use. *Addiction*, 109(11), 1878-1886. doi:10.1111/add.12636
- Hillhouse, M. P., Marinelli-Casey, P., Gonzales, R., Ang, A., Rawson, R. A., & Authors, M. T. P. C. (2007). Predicting in-treatment performance and post-treatment outcomes in methamphetamine users. *Addiction*, 102(Suppl. 1), 84-95.
- Hitzemann, R., Curell, J., Hom, D., & Loh, H. (1982). Effects of naloxone on d-amphetamine- and apomorphine-induced behavior. *Neuropharmacology*, 21(10), 1005-1011.
- Jayaram-Lindström, N., Hammarberg, A., Beck, O., & Franck, J. (2008b). Naltrexone for the Treatment of Amphetamine Dependence: A Randomized, Placebo-Controlled Trial. *American Journal of Psychiatry*, 165(11), 1442-1448. doi:doi:10.1176/appi.ajp.2008.08020304
- Jayaram-Lindstrom, N., Konstenius, M., Eksborg, S., Beck, O., Hammarberg, A., & Franck, J. (2008a). Naltrexone Attenuates the Subjective Effects of Amphetamine in Patients with Amphetamine Dependence. *Neuropsychopharmacology*, 33(8), 1856-1863.
- Jayaram-Lindstrom, N., Wennberg, P., Beck, O., & Franck, J. (2005). An open clinical trial of naltrexone for amphetamine dependence: compliance and tolerability. *Nord J Psychiatry*, 59(3), 167-171. doi:10.1080/08039480510023052
- Kim, S., Westphalen, R., Callahan, B., Hatzidimitriou, G., Yuan, J., & Ricaurte, G. A. (2000). Toward development of an in vitro model of methamphetamine-induced dopamine nerve terminal toxicity. *J Pharmacol Exp Ther*, 293(2), 625-633.
- Koffarnus, M. N., & Bickel, W. K. (2014). A 5-trial adjusting delay discounting task: accurate discount rates in less than one minute. *Exp Clin Psychopharmacol*, 22(3), 222-228. doi:10.1037/a0035973
- Ling, W., Farabee, D., Liepa, D., & Wu, L. T. (2012). The Treatment Effectiveness Assessment (TEA): an efficient, patient-centered instrument for evaluating progress in recovery from addiction. *Subst Abuse Rehabil*, 3(1), 129-136. doi:10.2147/SAR.S38902
- Ling, W., Hillhouse, M. P., Saxon, A. J., Mooney, L. J., Thomas, C. M., Ang, A., . . . Rotrosen, J. (2016). Buprenorphine + naloxone plus naltrexone for the treatment of cocaine dependence: the Cocaine Use Reduction with Buprenorphine (CURB) study. *Addiction*, 111(8), 1416-1427. doi:10.1111/add.13375
- Ling, W., Shoptaw, S., Wesson, D., Rawson, R. A., Compton, M., & Klett, C. J. (1997). Treatment effectiveness score as an outcome measure in clinical trials. *NIDA Res Monogr*, 175, 208-220.
- Loftis, J. M., & Sullivan, B. (2013). Cognitive impairments accompanying methamphetamine dependence: Pathologies, clinical implications, and treatment strategies.
- Margolin, A., Kosten, T., Petrakis, I., Avants, S. K., & Kosten, T. (1991). Bupropion reduces cocaine abuse in methadone-maintained patients. *Arch Gen Psychiatry*, 48(1), 87.
- Margolin, A., Kosten, T. R., Avants, S. K., Wilkins, J., Ling, W., Beckson, M., . . . et al. (1995). A multicenter trial of bupropion for cocaine dependence in methadone-maintained patients. *Drug Alcohol Depend*, 40(2), 125-131.

- McCann, D. J., & Li, S. H. (2012). A novel, nonbinary evaluation of success and failure reveals bupropion efficacy versus methamphetamine dependence: reanalysis of a multisite trial. *CNS Neurosci Ther*, 18(5), 414-418. doi:10.1111/j.1755-5949.2011.00263.x
- Mi, M. Y., & Betensky, R. A. (2013). An analysis of adaptive design variations on the sequential parallel comparison design for clinical trials. *Clin Trials*, 10(2), 207-215. doi:10.1177/1740774512468806
- Mooney, L. J., Hillhouse, M. P., Thomas, C., Ang, A., Sharma, G., Terry, G., . . . Ling, W. (2016). Utilizing a Two-stage Design to Investigate the Safety and Potential Efficacy of Monthly Naltrexone Plus Once-daily Bupropion as a Treatment for Methamphetamine Use Disorder. *J Addict Med*. doi:10.1097/ADM.0000000000000218
- Mooney, L. J., Nielsen, S., Saxon, A., Hillhouse, M., Thomas, C., Hasson, A., . . . Ling, W. (2013). Cocaine use reduction with buprenorphine (CURB): rationale, design, and methodology. *Contemp Clin Trials*, 34(2), 196-204. doi:10.1016/j.cct.2012.11.002
- Newton, T. F., Kalechstein, A. D., Duran, S., Vansluis, N., & Ling, W. (2004). Methamphetamine abstinence syndrome: preliminary findings. *Am J Addict*, 13(3), 248-255. doi:10.1080/10550490490459915
- Newton, T. F., Roache, J. D., De La Garza, R., 2nd, Fong, T., Wallace, C. L., Li, S. H., . . . Kahn, R. (2005). Safety of intravenous methamphetamine administration during treatment with bupropion. *Psychopharmacology (Berl)*, 182(3), 426-435. doi:10.1007/s00213-005-0102-8
- Newton, T. F., Roache, J. D., De La Garza, R., 2nd, Fong, T., Wallace, C. L., Li, S. H., . . . Kahn, R. (2006). Bupropion reduces methamphetamine-induced subjective effects and cue-induced craving. *Neuropsychopharmacology*, 31(7), 1537-1544. doi:10.1038/sj.npp.1300979
- Ornellas, T., & Chavez, B. (2011). Naltrexone SR/Bupropion SR (Contrave): A New Approach to Weight Loss in Obese Adults. *P T*, 36(5), 255-262.
- Oslin, D. W., Berrettini, W., Kranzler, H. R., Pettinati, H., Gelernter, J., Volpicelli, J. R., & O'Brien, C. P. (2003). A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. *Neuropsychopharmacology*, 28(8), 1546-1552. doi:10.1038/sj.npp.1300219
- Pal, R., Mendelson, J. E., Flower, K., Garrison, K., Yount, G., Coyle, J. R., & Galloway, G. P. (2015). Impact of prospectively determined A118G polymorphism on treatment response to injectable naltrexone among methamphetamine-dependent patients: an open-label, pilot study. *J Addict Med*, 9(2), 130-135. doi:10.1097/ADM.0000000000000107
- Papakostas, G. I., Shelton, R. C., Zajecka, J. M., Etemad, B., Rickels, K., Clain, A., . . . Fava, M. (2012). L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials. *Am J Psychiatry*, 169(12), 1267-1274. doi:10.1176/appi.ajp.2012.11071114
- Petry, N. M., Peirce, J. M., Stitzer, M. L., Blaine, J. D., Roll, J. M., Cohen, A. J., . . . Saladin, M. E. (2005). Effect of prize-based incentives on outcomes in stimulant abusers in outpatient psychosocial treatment programs. *Archives of General Psychiatry*, 62, 1148-1156.
- Rawson, R. A., Gonzales, R., & Brethen, P. (2002). Treatment of methamphetamine use disorders: an update. *Journal of Substance Abuse Treatment*, 23(2), 145-150.
- Ray, L. A., Bujarski, S., Courtney, K. E., Moallem, N. R., Lunny, K., Roche, D., . . . Miotto, K. (2015). The Effects of Naltrexone on Subjective Response to Methamphetamine in a Clinical Sample: a Double-Blind, Placebo-Controlled Laboratory Study. *Neuropsychopharmacology*, 40(10), 2347-2356. doi:10.1038/npp.2015.83
- Richmond, R., & Zwar, N. (2003). Review of bupropion for smoking cessation. *Drug Alcohol*

- Rev, 22(2), 203-220. doi:10.1080/09595230100100642
- Roll, J. M., Petry, N. M., Stitzer, M. L., Brecht, M. L., Peirce, J. M., McCann, M. J., . . . Kellogg, S. (2006). Contingency management for the treatment of methamphetamine use disorders. *American Journal of Psychiatry*, 163(11), 1993-1999.
- Rose, M. E., & Grant, J. E. (2008). Pharmacotherapy for methamphetamine dependence: a review of the pathophysiology of methamphetamine addiction and the theoretical basis and efficacy of pharmacotherapeutic interventions. *Ann Clin Psychiatry*, 20(3), 145-155. doi:10.1080/10401230802177656
- Salim, Z., Allen, J. S., Patterson, C., & Painter, K. (2007). *Methamphetamine treatment program, Tarrant County, Texas: Final evaluation report, October 2004 - September 2007*. Retrieved from Fort Worth, Texas:
- Salo, R., Nordahl, T. E., Galloway, G. P., Moore, C. D., Waters, C., & Leamon, M. H. (2009). Drug abstinence and cognitive control in methamphetamine-dependent individuals. *Journal of Substance Abuse Treatment*, 37(3), 292-297.
- Schmitz, J. M., Stotts, A. L., Rhoades, H. M., & Grabowski, J. (2001). Naltrexone and relapse prevention treatment for cocaine-dependent patients. *Addict Behav*, 26(2), 167-180.
- Schmitz, J. M., Stotts, A. L., Sayre, S. L., DeLaune, K. A., & Grabowski, J. (2004). Treatment of cocaine-alcohol dependence with naltrexone and relapse prevention therapy. *Am J Addict*, 13(4), 333-341. doi:10.1080/10550490490480982
- Sheehan, D. V., Lecrubier, Y., Sheehan, K. H., Amorim, P., Janavs, J., Weiller, E., . . . Dunbar, G. C. (1998). The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. *J Clin Psychiatry*, 59 Suppl 20, 22-33;quiz 34-57.
- Shoptaw, S., Heinzerling, K. G., Rotheram-Fuller, E., Steward, T., Wang, J., Swanson, A. N., . . . Ling, W. (2008). Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence. *Drug Alcohol Depend*, 96(3), 222-232. doi:10.1016/j.drugalcdep.2008.03.010
- Stoops, W. W., Pike, E., Hays, L. R., Glaser, P. E., & Rush, C. R. (2015). Naltrexone and bupropion, alone or combined, do not alter the reinforcing effects of intranasal methamphetamine. *Pharmacology Biochemistry and Behavior*, 129, 45-50. doi:http://dx.doi.org/10.1016/j.pbb.2014.11.018
- Tamura, R. N., & Huang, X. (2007). An examination of the efficiency of the sequential parallel design in psychiatric clinical trials. *Clin Trials*, 4(4), 309-317. doi:10.1177/1740774507081217
- Trivedi, M. H., Fava, M., Wisniewski, S. R., Thase, M. E., Quitkin, F., Warden, D., . . . Team, S. D. S. (2006). Medication augmentation after the failure of SSRIs for depression. *N Engl J Med*, 354(12), 1243-1252. doi:10.1056/NEJMoa052964
- van der Plas, E. A., Crone, E. A., van den Wildenberg, W. P., Tranel, D., & Bechara, A. (2009). Executive control deficits in substance-dependent individuals: a comparison of alcohol, cocaine, and methamphetamine and of men and women. *J Clin Exp Neuropsychol*, 31(6), 706-719. doi:10.1080/13803390802484797
- Wadden, T. A., Foreyt, J. P., Foster, G. D., Hill, J. O., Klein, S., O'Neil, P. M., . . . Dunayevich, E. (2011). Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. *Obesity (Silver Spring)*, 19(1), 110-120. doi:10.1038/oby.2010.147
- Wei, L. J., & Lachin, J. M. (1988). Properties of the urn randomization in clinical trials. *Control Clin Trials*, 9(4), 345-364.
- Winchell, C., Rappaport, B. A., Roca, R., & Rosebraugh, C. J. (2012). Reanalysis of methamphetamine dependence treatment trial. *CNS Neurosci Ther*, 18(5), 367-368.

doi:10.1111/j.1755-5949.2011.00288.x

- Yurcel, M., Lubman, D. I., Solowij, N., & Brewer, W. J. (2007). Understanding drug addiction: a neuropsychological perspective. *Australian & New Zealand Journal of Psychiatry*, 41(12), 957-968.
- Zhu, J., Spencer, T. J., Liu-Chen, L. Y., Biederman, J., & Bhide, P. G. (2011). Methylphenidate and mu opioid receptor interactions: a pharmacological target for prevention of stimulant abuse. *Neuropharmacology*, 61(1-2), 283-292. doi:10.1016/j.neuropharm.2011.04.015
- Zimmerman, M., Posternak, M. A., & Chelminski, I. (2002). Symptom severity and exclusion from antidepressant efficacy trials. *J Clin Psychopharmacol*, 22(6), 610-614.
- Zisook, S., Lesser, I. M., Lebowitz, B., Rush, A. J., Kallenberg, G., Wisniewski, S. R., . . . Trivedi, M. H. (2011). Effect of antidepressant medication treatment on suicidal ideation and behavior in a randomized trial: an exploratory report from the Combining Medications to Enhance Depression Outcomes Study. *J Clin Psychiatry*, 72(10), 1322-1332. doi:10.4088/JCP.10m06724

34.0 APPENDIX A - ADVERSE EVENT REPORTING DEFINITIONS AND PROCEDURES

Each participating site's principal investigator is responsible for study oversight, including ensuring human research subject protection by designating appropriately qualified and trained study personnel to assess, report, and monitor adverse events.

Definition of Adverse Events and Serious Adverse Events

An **adverse event** (AE) is any untoward medical occurrence in humans, whether or not considered study drug/intervention related, which occurs during the conduct of a clinical trial. Any change from baseline clinical status, ECGs, lab results, x-rays, physical examinations, etc., that is considered clinically significant by the study medical clinician are considered AEs.

Suspected adverse reaction is any adverse event for which there is a reasonable possibility that the study drug/intervention caused the adverse event. A reasonable possibility implies that there is evidence that the study drug/intervention caused the event.

Adverse reaction is any adverse event caused by the study drug/intervention.

An **adverse event, suspected adverse reaction, or adverse reaction** is considered "**serious**" (i.e., a serious adverse event, serious suspected adverse reaction or serious adverse reaction) if, in the view of either the study medical clinician or sponsor, it:

8. Results in death: A death occurring during the study or which comes to the attention of the study staff during the protocol-defined follow-up period, whether or not considered caused by the study drug/intervention, must be reported.
9. Is life-threatening: Life-threatening means that the study participant was, in the opinion of the medical clinician or sponsor, at immediate risk of death from the reaction as it occurred and required immediate intervention.
10. Requires inpatient hospitalization or prolongation of existing hospitalization.
11. Results in persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions.
12. Is a congenital abnormality or birth defect.
13. Seizure.
14. Important medical event that may not result in one of the above outcomes, but may jeopardize the health of the study participant or require medical or surgical intervention to prevent one of the outcomes listed in the above definition of serious event.

Definition of Expectedness

Any adverse event is considered “unexpected” if it is not listed in the investigator brochure or the package insert or is not listed at the specificity or severity that has been observed. If neither is available then the protocol and consent are used to determine an unexpected adverse event.

Pregnancy

Any pregnancies that occur to a participant enrolled in the study will be captured on a pregnancy case report form (CRF) and not separately reported as an AE or SAE. Women who become pregnant during the medication period will be discontinued from further medication administration, referred for medical care, and the pregnancy followed until an outcome is known.

Medical and Psychiatric History

A thorough medical and psychiatric history during the screening/baseline phase should record any chronic, acute, or intermittent preexisting or current illnesses, diseases, symptoms, or laboratory signs of the participant, to avoid reporting pre-existing conditions as new AEs and to assist in the assessment of worsening in intensity or severity of these conditions that would indicate an AE. Stable chronic conditions, such as arthritis, which are present prior to clinical trial entry and do not worsen are not considered AEs.

Site Staff’s Role in Eliciting and Reporting Adverse Events

All adverse events (medical and/or psychiatric) occurring during the course of the study will be assessed, documented, and reported. Appropriately qualified and trained medical personnel will elicit participant reporting of AEs and SAEs at each study visit designated to collect AEs (i.e., the first visit following informed consent and at every visit thereafter). Study staff will follow-up on the status of any AEs that remain at the post-medication phase follow-up visit assessment for up to 30 days post last study visit. Study personnel will obtain as much information as possible about the reported AE/SAE in order to complete AE/SAE documentation (i.e., log and CRFs) and will consult with medical clinicians and the Study Medical Monitor as necessary.

Standard reporting, within 7 days of the site staff becoming aware of the event, is required for AEs. Expedited reporting, within 24 hours of their occurrence and/or site staff’s knowledge of the event is required for SAEs (including death and life-threatening events). Site staff is responsible for reporting SAEs to the IRB, per IRB’s guidelines.

Site staff is required to enter AEs and SAEs in the eClinical system as soon as they become aware of the event. The AE log and CRF are used to capture AEs (as defined in the protocol). Additional information may need to be gathered to evaluate serious adverse events and to complete the appropriate CRFs and the summary. This process may include obtaining hospital discharge reports, medical records, autopsy records or any other type records or information necessary to provide a complete and clear picture of the serious event and events preceding and following the event. If the SAE is not resolved or stable at the time of the initial report or if new information becomes available after the initial report, follow-up information must be submitted as soon as possible.

Adverse events will be followed until resolution, stabilization or study end. Any serious adverse reactions will be followed until resolution or stabilization even beyond the end of the study.

Site Staff's Role in Assessing Severity and Causality of Adverse Events

Appropriately qualified and trained medical personnel will conduct an initial assessment of seriousness, severity, and causality when eliciting participant reporting of adverse events. A study medical clinician will review AEs for seriousness, severity, and causality on at least a weekly basis.

Guidelines for Assessing Severity

The severity of an adverse event refers to the intensity of the event.

Grade 1	Mild	Transient or mild discomfort (< 48 hours), no or minimal medical intervention/therapy required, hospitalization not necessary (non-prescription or single-use prescription therapy may be employed to relieve symptoms, e.g., aspirin for simple headache, acetaminophen for post-surgical pain)
Grade 2	Moderate	Mild to moderate limitation in activity some assistance may be needed; no or minimal intervention/therapy required, hospitalization possible.
Grade 3	Severe	Marked limitation in activity, some assistance usually required; medical intervention/ therapy required hospitalization possible.

Guidelines for Determining Causality

The study medical clinician will use the following question when assessing causality of an adverse event to study drug/intervention where an affirmative answer designates the event as a suspected adverse reaction:

Is there a reasonable possibility that the study drug/intervention caused the event?

Quality Assurance Staff's Role in Monitoring Adverse Events

Quality assurance monitors (from the node staff and the CRO contract monitor staff) will review safety documentation on a regular basis and will promptly advise site staff to report any previously unreported safety issues and ensure that the reportable safety-related events are being followed to resolution and reported appropriately. Staff education, re-training or appropriate corrective action plan will be implemented at the participating site when unreported or unidentified reportable AEs or serious events are discovered, to help ensure future identification and timely reporting.

Sponsor's Role in Safety Management Procedures of AEs/SAEs

A NIDA-assigned Medical Monitor is responsible for reviewing all serious adverse event reports. All reported SAEs will generate an e-mail notification to the Medical Monitor, Lead Investigator, and designees. All SAEs will be reviewed by the Medical Monitor and, if needed, additional information will be requested. The Medical Monitor will also report events to the sponsor, the Data and Safety Monitoring Board (DSMB), study drug manufacturers, and regulatory authorities. The DSMB will receive summary reports of all adverse events annually, at a minimum. The DSMB or the NIDA assigned Medical Monitor may also request additional and updated information. Details regarding specific adverse events, their treatment and resolution, will be summarized by the Medical Monitor in writing for review by the sponsor and DSMB. Subsequent review by the Medical Monitor, DSMB, FDA, and ethics review committee or IRB, the sponsor, or relevant local regulatory authorities may also suspend further trial treatment at a site. The study sponsor and


the DSMB retain the authority to suspend additional enrollment and treatments for the entire study as applicable.

Reporting to the Data and Safety Monitoring Board: The DSMB will receive a listing of AEs and summary reports of all SAEs at a frequency requested by the DSMB, but at least annually. Furthermore, the DSMB will be informed of expedited reports of SAEs.

Participant Withdrawal

The study medical clinician must apply his/her clinical judgment to determine whether or not an adverse event is of sufficient severity to require that the participant is withdrawn from further study medication administration. The study medical clinician should consult with the study physician, site principal investigator, the Lead Investigator and/or Medical Monitor as needed. If necessary, a study medical clinician may suspend any trial treatments and institute the necessary medical therapy to protect a participant from any immediate danger. A participant may also voluntarily withdraw from treatment due to what he/she perceives as an intolerable adverse event or for any other reason. If voluntary withdrawal is requested, the participant will be asked to complete an end-of-medication visit to assure safety and to document end-of-medication outcomes and will be given recommendations for medical care and/or referrals to treatment, as necessary. Other reasons for the investigator or sponsor terminating a participant from the study may include, but are not limited to, the participant becoming a threat to self or others, lack of funding, or DSMB early termination of the study for safety or effectiveness reasons.

AE Chart



BRIEF STUDY OVERVIEW

This double-blind, placebo-controlled, randomized clinical trial will investigate a combination medication, extended-release injectable naltrexone plus extended-release bupropion, compared to placebo as a potential pharmacotherapy for MA dependence. Screening will occur over a maximum of 21 days. Study medications will be provided during a 12 week medication phase. Participants will be randomized to either the active medication combination (AMC) arm in which injections of extended-release naltrexone (XR-NTX; as Vivitrol®) plus 450 mg / day oral extended-release bupropion (BUP-XL) tablets will be provided or the matching placebo (PLB) arm in which injections of placebo (iPLB) and once daily oral placebo (oPLB) tablets will be provided. Injections will be provided in weeks 1, 4, 7, and 10. Participants will be asked to attend clinic twice weekly for observed oral medication dosing and provision of take-home oral medication, collection of urine samples, assessments, and medical management. Following the 12 week medication phase, participants will complete a follow-up phase, including a medication taper and post-medication phase follow-up visits during Weeks 13 and 16.

Details for the definitions and reporting of safety events are found in Appendix A of the protocol.

OVERSIGHT OF CLINICAL RESPONSIBILITIES

F. Site Principal Investigator

Each participating site's PI is responsible for study oversight, including ensuring human research subject protection by designating appropriately qualified, trained research staff and medical clinicians to assess, report, and monitor adverse events.

Regarding safety, and in accordance with FDA reporting requirements, all Adverse Events (AEs) occurring during the course of the clinical trial will be collected, documented, and reported by the investigator or sub-investigators according to the protocol. The assessment of Adverse Events (medical and/or psychiatric) will commence the visit after consent and will continue through all study visits. Study staff will follow-up on the status of any AEs that remain for up to 30 days after the last planned study visit in week 16.

The occurrence of AEs and Serious Adverse Events (SAEs) will be assessed at each clinic visit after consent. All adverse events will be followed until resolution, stabilization or study end. Serious adverse events will be followed until resolved or considered stable, with reporting to the CCC Safety Monitor/Medical Monitor through the follow-up period.

Standard reporting, within 7 days of the site becoming aware of the event, is required for AEs. Expedited reporting (within 24 hours of their occurrence and/or site's knowledge of the event) is required for reportable SAEs (including death and life-threatening events).

G. Medical Monitor/Safety Monitor

The NIDA Clinical Coordinating Center (CCC) Safety Monitor/Medical Monitor is responsible for reviewing all adverse events and serious adverse events reported. All SAEs will be reviewed at the time they are reported in eClinical. The Medical Monitor will also indicate concurrence or not with the details of the report provided by the site PI. Where further information is needed the Safety Monitor/Medical Monitor will discuss the event with the site. Reviews of SAEs will be conducted in the Advantage eClinical data system and will be a part of the safety database. All AEs will be reviewed on a weekly basis to observe trends or unusual events.

The CCC Safety Monitor/Medical Monitor will in turn report events to the sponsor, study drug manufacturers, and regulatory authorities if the event meets the definition of an expedited event. All SAEs that meet expedited reporting based on federal regulations will be reported to the DSMB in writing within 15 calendar days of notification of the CCC. If the SAE meets the criteria for death or immediately life-threatening, the CCC will notify the DSMB electronically, by phone or by fax as soon as possible but no later than 7 calendar days of notification of the CCC, with a follow-up written report within 15 calendar days of notification of the CCC. The CCC will prepare an expedited report and copies will be distributed to site investigators.

Reports will be generated and presented for Data and Safety Monitoring Board (DSMB) meetings. The DSMB will receive listings of AEs and summary reports of all SAEs at a frequency requested by the DSMB, but at least annually. Furthermore, the DSMB will be informed of expedited reports of SAEs.

H. Data and Safety Monitoring Board (DSMB)

The NIDA CTN DSMB affiliated with this trial will be responsible for conducting periodic reviews of accumulating safety, trial performance, and outcome data. The DSMB will make recommendations to NIDA as to whether there is sufficient support for continuation of the trial, that study procedures should be changed, or that the trial (or a specific site) should be halted for reasons relating to safety of the study participants or inadequate trial performance (e.g., poor recruitment).

Following each DSMB meeting, the NIDA CCTN will communicate the outcomes of the meeting, including DSMB recommendations, in writing to the study Lead Investigator. Study safety information will be submitted to participating IRBs.

I. Quality Assurance (QA) Monitoring

Monitoring of study sites will be conducted on a regular basis using a combination of NIDA CCC contract monitors, the local node site managers, and lead node staff. The purpose of these visits is to assess compliance with GCP requirements and to document the integrity of the trial progress. Areas of particular concern will be the review of inclusion/exclusion criteria, participant informed consent forms, protocol adherence, safety monitoring, IRB reviews and approvals, regulatory documents, participant records, study drug accountability, and Principal Investigator supervision and involvement in the trial. The Monitors will interact with the site staff to identify issues and re-train the site staff as needed to enhance research quality.

QA Site Visit Reports will be prepared by the NIDA CCC contract monitors following each site visit. These reports will be and forwarded to the site Principal Investigator, the study Lead Investigator and NIDA.

J. Management of Risks to Participants

Confidentiality

Confidentiality of participant records will be secured by the use of study codes for identifying participants on CRFs, secure storage of any documents that have participant identifiers, and secure computing procedures for entering and transferring electronic data. All study data will be stored in a secure location with limited access. Only research staff will have access to the study records. Other parties with access to study data, such as local or central IRBs, will be specified to the participants per HIPAA regulations. No identifying information will be disclosed in reports, publications or presentations.

Participants' information will not be released without their written permission, except as necessary for monitoring or suspected abuse or violence. The Lead Investigator (LI) will apply for a Certificate of Confidentiality that will cover all sites participating in the study. By participating in this protocol, the local site investigator agrees that within local regulatory restrictions and ethical considerations, any regulatory agency may consult and/or copy study documents to verify study data.

By participating in this protocol, the local site investigator affirms that information furnished to the investigator by the Lead Investigator will be maintained in confidence and such information will be divulged to the IRB, Ethical Review Committee, or similar expert committees, affiliated institutions, and employees only under an appropriate understanding of confidentiality with such boards or committees, affiliated institutions, and employees.

Information Meeting Reporting Requirements

The consent form will specifically state the types of information that are required to be reported and the fact that the information will be reported as required. These include suspected or known sexual or physical abuse of a child or elders, or threatened violence to self and/or others.

Participant Protection

The study physician will evaluate all pertinent screening and baseline assessments prior to participant randomization to ensure that the participant is eligible and safe to enter the study. Adverse events (AEs) and concomitant medications will be assessed and documented at each clinic visit. Individuals who experience an AE that compromises safe participation will be discontinued from further medication administration and provided referrals for other treatment or to specialized care. Study personnel will request that the participant complete an end-of-medication visit to assure safety and to document end-of-medication outcomes.

Pregnancy

Pregnancy is an exclusion criterion for study participation. A positive pregnancy test post-enrollment will result in the cessation of study medication. Participants who discontinue medications will be expected to continue with study visits. Pregnancy test results and related outcome information will be collected on a Pregnancy and Outcome CRF. The site staff will follow the participant until an outcome of the pregnancy is known.

Expected Risks of the Study Medication

For anyone who has opioids in their system, naloxone and naltrexone may cause opioid withdrawal symptoms. As with any study drug, there is also the possibility of an allergic reaction. Participants will be monitored for at least one hour following the first bupropion dose, naloxone challenge, and study medication induction.

BUPROPION: Possible side effects include agitation, irritability, restlessness, sleeplessness, dry mouth, headache/migraine, nausea, vomiting, constipation, and shakiness. At doses of 450 mg daily, there is 1 chance in 1000 that a participant taking bupropion will experience a seizure. Individuals with a history of epilepsy or seizure disorder, acute eating disorder, or who are taking certain medications will not be allowed to participate. Although bupropion is used to treat depression, a small percentage of people who take antidepressants have increased thoughts of suicide, particularly during the early weeks of medication.

NALTREXONE: Possible side effects include nausea, vomiting, headaches, dizziness, insomnia, dry mouth, and depressed mood. In rare cases people who received naltrexone developed suicidal thoughts, or a type of pneumonia (lung inflammation) caused by an excess of a certain type of white blood cells in the lungs. The most serious side effect of naltrexone is liver (hepatocellular) injury, which has almost always occurred with oral doses of 1400 to 2100 mg per week. Recent study findings show that no evidence of liver injury was found in people receiving once-monthly Vivitrol® injections. For safety, participants with acute symptomatic hepatitis or liver failure will not be allowed to participate.

VIVITROL®: Vivitrol® injections may cause pain, tenderness, hardening or damage of body tissues, swelling, redness, bruising, itching, or infection at the injection site. Such injection site reactions have been the most common side effects associated with Vivitrol®. The injection site will be monitored after each injection. Participants will be instructed to report any injection site reactions immediately to the study team. Any participants showing signs of injection site reactions such as a localized infection (abscess), skin infection (cellulitis), body tissue damage, or extensive swelling will be monitored by the study medical staff and treated accordingly.

Data management procedures

This protocol will utilize a centralized Data and Statistics Center (DSC). A web-based distributed data entry model will be implemented. This electronic data capture system (Advantage eClinical) will be developed to ensure that guidelines and regulations surrounding the use of computerized systems in clinical trials are upheld.

Data and statistics center responsibilities

The DSC will: 1) develop and apply data management procedures to ensure the collection of accurate and good-quality data, 2) provide source documents and electronic Case Report Forms (eCRFs) for the collection of all data required by the study, 3) develop data dictionaries for each eCRF that will comprehensively define each data element, 4) prepare instructions for the use of Advantage eClinical and for the completion of eCRFs, 5) conduct ongoing monitoring activities on study data collected from all participating sites, 6) perform data cleaning activities prior to any interim analyses and prior to the final study database lock.

Data collection and entry

Data will be collected at the study sites on source documents and entered by the site into eCRFs in Advantage eClinical, or will be collected via direct entry into the eCRF. In the event that Advantage eClinical is not available, the DSC will provide the sites with paper source documents and completion instructions. Data will be entered into Advantage eClinical in accordance with the instructions provided during project-specific training and guidelines established by the DSC. Data entry into the eCRFs shall be performed by authorized individuals. Selected eCRFs may also require the site investigator's electronic signature.

The principal investigator at the site is responsible for maintaining accurate, complete and up-to-date research records. In addition, the site investigator is responsible for ensuring the timely completion of eCRFs for each research participant.

Data monitoring, cleaning and editing

eCRFs will be monitored for completeness and accuracy throughout the study. Dynamic reports listing missing values and forms will be available to sites at all times in Advantage eClinical. These reports will be monitored regularly by the DSC. In addition, the DSC will identify inconsistencies within eCRFs and between eCRFs and post queries in Advantage eClinical on a scheduled basis. Sites will resolve data inconsistencies and errors by entering all corrections and changes directly into Advantage eClinical.

As described above, the CCC will conduct regular visits to sites, during which, audits comparing source documents to the data entered on the eCRF will be performed. Any discrepancies identified between the source document and the eCRF will be corrected by the site.

Trial progress and data status reports, which provide information on recruitment, availability of primary outcome, treatment exposure, attendance at long term follow-up visits, regulatory status, and data quality, will be generated daily and posted to a secure website. These reports will be available to the site, the corresponding Local Node, the Lead Investigator, the coordinating centers, and NIDA, to monitor the sites' progress on the study.

Data lock and transfer

At the conclusion of data collection for the study, the DSC will perform final data cleaning activities and will "lock" the study database from further modification. The final analysis dataset will be returned to the Lead Investigator and NIDA, as requested, for storage and archive.

36.0 APPENDIX C – SMARTPHONE APP-BASED MEDICATION ADHERENCE PROCEDURES

The smartphone app will be provided by AiCure and will be referred to as the “app” or “study app”.

Technology Training

After eligibility has been established and the participant has been randomized, staff will provide training on the use of the medication adherence app that will monitor and encourage adherence. The AiCure app will be downloaded onto the participant’s personal smartphone or, if unable to be downloaded, a study provided smartphone device. Training will include using the app features and capabilities, security features (e.g., encryption), and taking practice dosing videos. This training will also be completed for the study provided smartphone devices.

Medication Adherence App on Participant Personal Smartphone

Participants who download the app on their personal smartphone devices will be provided an additional \$10 at the beginning of each month to offset the costs for additional data services needed due to use of the app. Participants who require a study provided smartphone device at any point during the study will be provided one. However, the additional \$10 per month for extra data costs will not be pro-rated to ensure that participants using either the study app or a study provided smartphone are treated equitably and that no participant will receive more than \$10 per month for using either the app or a study provided smartphone device. Participants who choose to use their own smartphone must own a device that is camera-equipped and capable of SMS text messaging and taking videos.

Study Provided Smartphone Device

Participants who do not have a personal device or are unable to download the AiCure app will be provided with a smartphone device (and battery charger). Service plans will be included to allow participants to communicate via SMS text messages with study staff and to take dosing videos. The smartphone device equipment will be retained by participants through the end of their participation in the study. A replacement device may be available in the event of unintentional damage or loss. If the participant does not require a replacement smartphone device during the course of the study, the participant will be provided up to \$40 payment for the safe return of the smartphone device and all accompanying accessories. Replacement smartphone devices will be returned at the end of study participation, but no payment will be provided to those participants.

Set-up and Maintenance of App and Smartphone Device (if applicable)

Study staff will activate the AiCure app on participant smartphones or prepare the study provided smartphone for the participant. If a participant is using a study provided smartphone device, study staff will provide appropriate training on how to use the device.

Smartphone Device-based Procedures

Prior to randomization, study personnel will request a signed agreement from participants regarding the use of the smartphone app or study provided device for the purposes of the study. Participants will be informed of the medication adherence procedures, including the requirement to take daily videos of oral study medication ingestion at home. If a participant fails to bring his/her oral study medication to the clinic so that self-administration of the dose can be observed and videoed, the participant will be asked to take a video of him/herself taking the dose for that day at home (if the dose has not already been taken). If a dosing video showing appropriate adherence

is transmitted and confirmed, he/she will be compensated appropriately. The primary purpose of providing study smartphone devices is to monitor and improve medication adherence. However, study smartphones may assist in communicating with participants who do not own a personal smartphone. Sites are encouraged to consult with the Lead Team when considering providing replacement study devices for participants who withdraw from study medications.

Lost/Stolen/Inoperable Smartphone Devices

The purpose of providing a study smartphone device (to participants unable to use their own) is to monitor and improve medication adherence on non-clinic days as well as provide a means of contacting study staff. Participants will be notified that study provided devices will have a tracking tag on the back which allows for lost or stolen devices to be retrieved via a nationwide network and that removal of the tracking tag reveals a “stolen property” embossing on the device. Study provided smartphone devices are operational for study purposes only and are locked down to any other use. A one-time replacement of a lost, stolen, or inoperable study provided smartphone device may be permitted. Study staff should consult with the Lead Team should a second loss/theft of a study smartphone device occur.

Protection of Participant Privacy

Participants will be advised on how to secure their devices with passwords and how the software application will be used to transmit dosing videos to the secure server as an encrypted file. Research staff will only access smartphone device settings as needed to help troubleshoot a problem with the AiCure app and when requested by the participant.

Staff-to-Participant Contact

Staff will send texts as regular reminders for clinic visits or dosing requirements. If a participant has not taken the dosing video by an agreed upon time on a take-home dosing day, study staff will contact the participant to ask the participant to take his/her study medication dose and document it via the app as soon as possible.

NIDA CTN Protocol 0068

PROTOCOL CHANGE LOG

Protocol Version 1.0 (11/04/2016) to 2.0 (03/03/2017)		
Section No.	Description of Changes	Rationale
Throughout protocol	<ol style="list-style-type: none"> Removed any references to “lot number” and “blister pack”. Replaced “blister pack” with “blister card”. Updated time estimates of study visits. 	<ol style="list-style-type: none"> This is the more accurate description of the oral study medication packaging. Lot number is not used for any of the study medications. To give a more accurate time estimate required to complete visits for staff and participants.
Schedule of Assessments	<ol style="list-style-type: none"> Patient Health Questionnaire (PHQ-9) was changed from being assessed every two weeks to weekly and at the last study visit. Sexual Risk Behaviors assessment moved from week 6 visit 1 and week 12 visit 1 to week 6 visit 2 and week 12 visit 2. Added separate row to clarify OPI 300 drug test to be used at screening, week 4, 7, and 10. 	<ol style="list-style-type: none"> To assess depressive symptoms more frequently. Originally intended to be assessed at week 6 visit 2 and week 12 visit 2 but was mistakenly entered in schedule of assessments at visit 1 of weeks 6 and 12. To make clear that the OPI 300 is a separate urine dip stick from the standard 10-panel Urine Drug Screen panel. This is not a change in procedure.
Genetic Sampling	Changed the total amount of blood to be collected for genetics from 2 teaspoons to 2 tablespoons.	This is the correct amount of blood to be collected for genetics.
7.1 Screening and Baseline Phase	<u>Changed:</u> <i>With Lead Node approval,</i> s Screen fails may not be allowed to return at a later date to repeat the screening process.	This will allow participants who fail in-person screening to re-screen at a later date for the study. People may fail pre-screening on eligibility criteria that may be modifiable or treatable but are otherwise good study candidates. For example, people with uncontrolled

		blood pressure may learn of this during screening, be screen failed, seek treatment, and later be safe to participate upon re-screening.
7.2.5 Participant Medication Withdrawal (last bullet)	<u>Added:</u> Increase in LFT or <i>decrease in</i> platelet test results at week 6 that may increase participant health risks. This includes any of the following: AST/ALT results > 5 times ULN, total bilirubin > 2 times ULN, or platelets below $75 \times 10^3/\mu\text{L}$.	To clarify safety parameters around medication withdrawal regarding platelets counts.
7.2.5 Participant Medication Withdrawal (last paragraph, page 29)	<u>Added:</u> As the primary aim of this study is to evaluate the efficacy of XR-NTX plus BUP-XL as a combination pharmacotherapy, withdrawal from either study medication will <i>typically</i> lead to discontinuation of the other medication. <i>With Lead Node approval, participants may be allowed to continue on one medication if discontinued from the other.</i>	To allow some participants to remain on one study medication if discontinued on the other. If it can be determined with reasonable certainty which medication (oral or injectable) is the likely cause of intolerable side effects, we wish to allow sites to discontinue participants from the intolerable medication and continue the other medication.
8.5.1 Study Medication Dosing Logs	<u>Added:</u> <i>A dosing log will also document return of oral medication blister cards and the participant's self-report of doses taken.</i>	To clarify oral medication adherence procedures.
11.9 IND Requirements	<u>Deleted:</u> An IND application will be submitted to FDA for this protocol, as described in title 21 of the Code of Federal Regulations, part 312 (21 CFR 312). Accordingly, all protocol amendments will be submitted to this IND as amendments. This study will be conducted in accordance with International Council on Harmonisation Good Clinical Practices (ICH GCPs), all applicable FDA and OHRP Guidance documents, and any state and institutional requirements applicable at the clinical site level. <u>Replaced with:</u> A request for IND exemption was submitted to FDA for	Updated paragraph to reflect current IND exemption status.

	<p>this protocol, and the Agency determined that the ADAPT-2 study was exempt from FDA IND regulations, as per Title 21 of the Code of Federal Regulations, Part 312.2.</p> <p>Though exempt from IND regulation, this study will be conducted in accordance with International Council on Harmonisation Good Clinical Practices (ICH GCPs), all applicable FDA and OHRP Guidance documents, and any state and institutional requirements applicable at the clinical site level.</p>	
Protocol Version 2.0 (03/03/2017) to 3.0 (11/10/2017)		
Section No.	Description of Changes	Rationale
Section 4.1.1	<u>Added:</u> Details of a study for background literature about the use of naltrexone for methamphetamine use disorder.	Results from publication became available since last protocol version was approved.
Section 6.2	<u>Added:</u> Confirmation of opioid-free status (urine drug screen, <i>single strip OPI-300 test</i> , and naloxone challenge) before randomization and medication induction will take approximately 1.5 hours.	With this protocol modification, two additional opioid tests were added. Here, we specify the OPI-300 test is the only test that is required to be negative in order to proceed to naloxone challenge. This is a clarification and not a change in procedure.
Section 6.3	<u>Added:</u> Thus, <i>at the time of randomization</i> participants must be willing to have the study intervention serve as their sole treatment during study participation.	Further clarifies when participants must express willingness for the study to be their sole treatment.
Section 6.3.1	<u>Removed from Inclusion Criterion 6:</u> If female of childbearing potential, agree to use acceptable birth control methods and have periodic urine pregnancy testing done during participation in the study unless documentation of hysterectomy provided;	Deletion of this phrase is to make criterion consistent with other protocol sections. This change does not change how the criterion is implemented. Deletion more clearly reflects how this criterion has been operationalized since start of study.
Section 6.3.2	<u>Removed from Exclusion Criterion 14:</u> Be receiving ongoing treatment	Based on updated package inserts for both study

	with tricyclic antidepressants, duloxetine, venlafaxine, xanthines (i.e., theophylline and aminophylline), systemic corticosteroids, nelfinavir, efavirenz, chlorpromazine, MAOIs, central nervous system stimulants (e.g., Adderall, Ritalin, etc.), or any medication that, in the judgment of the study medical clinician, could interact adversely with study medications;	medications and a review of the current literature, there is minimal concern for medication interactions. DSMB approved deletion of these two medications from this exclusion criterion, as confirmed via email to the Lead Team on 9/11/17.
Section 6.3.2 After the list of exclusion criteria	<u>Added:</u> Although not targeted for recruitment, this study obtained authorization from the Office for Human Research Protections (OHRP) to follow-up with study participants who happen to become incarcerated during the trial, as needed and feasible at the individual study sites. Study staff may work with institutions to arrange research visits, and any needed assessments and procedures the institution will allow may be completed. Study medications will be discontinued during incarceration.	Added to further clarify study procedures for participants who become incarcerated during the study. This is not a change in procedure, but rather adds to the protocol a brief summary of procedures that were previously only described in the Manual of Operations.
Section 7.1.2	<u>Added:</u> Study participants who demonstrate understanding of the study and who voluntarily agree to participate will be asked to sign the IRB-approved consent form and, <i>if the consent form is signed</i> , will proceed with the screening assessments.	To further clarify consent process.
Section 7.1.4	<u>Revised procedure #2 of Naltrexone Pre-Induction Strategy:</u> To confirm <i>objectively evaluate</i> opioid-free status abstinence , a urine sample provided and tested on the day of the naloxone challenge must be negative for opioids <i>on the UDS (the 10-panel urine drug screen) and the OPI-300 test</i> prior to administration of the challenge. Individuals who are <i>with a negative result for</i> on these opioid tests will continue the pre-	Revised wording to more accurately describe urine sample testing is objective and only evaluates opioid-free status at the time of testing. Due to the addition of two new opioid-related tests, this paragraph's edits are to clearly show which tests <u>must</u> be negative prior to naloxone challenge. This is a clarification and is not a change in procedure.

	induction process. Individuals who are with a positive for opioid <i>results on these tests</i> may provide an additional urine sample on a subsequent day if the study medical clinician determines that a second screen is appropriate. <i>The study medical clinician must determine suitability for continuing the pre-induction process for individuals positive for opioids on any other opioid test that may be conducted during Screening.</i>	The last sentence was added to address the two new opioid-related tests that were added with the intention of collecting additional opioid related data. The protocol sets no specific requirements for the results of these tests but rather leaves it to the medical judgment of the site medical clinicians.
Section 7.2.2	<ol style="list-style-type: none"> 1. <u>Changed:</u> Urine drug screening procedures will help clinicians ensure <i>evaluate</i> participant opioid-free status at the time of study medication injection. 2. <u>Added:</u> If a participant reports intolerable symptoms or side effects at the full 450 mg dose, <i>ancillary medications may be used and/or</i> a dose reduction may occur if deemed appropriate by the study medical clinician. 	<ol style="list-style-type: none"> 1. Clarification that urine drug screening is one part of evaluating opioid status. It cannot “ensure” that a participant is opioid-free. 2. Clarifying earlier in this paragraph that ancillary medications can also be used to address side effects. The use of ancillary medications was previously only described in the last sentence of this paragraph.
8.3.5	<u>Changed:</u> An accredited central <i>local</i> laboratory (College of American Pathologists or equivalent) that meets CLIA guidelines will perform testing, provide normal values, and provide proof of lab certifications.	Updated to reflect study procedures. Sites use their local laboratories and not a central lab.
8.4.1	<u>Changed:</u> If the temperature or adulterant test is positive and/or falls outside the normal range, the <i>first</i> urine specimen will be considered adulterated and will not be screened. <i>In this case, the first urine sample</i> will be discarded, and the participant will be asked to provide another sample <i>following oral hydration of the participant. If the second sample's only out of range value is a high specific gravity on the adulterant test</i>	Revised urine drug testing procedures when the first urine sample is untestable. This change resulted from several sites experiencing elevated specific gravity on the adulterant test strip in severely dehydrated participants, leading to the investigative team and sponsor reevaluating

	<p><i>strip and there are no visible precipitants, this sample may be considered not adulterated and can be drug tested.</i></p> <p><u>Added:</u> Study teams at each site may opt to observe the urine collection process either at each collection or as deemed necessary (e.g., <i>recommend observing</i> if specimen tampering is suspected) according to clinic standard operating procedures.</p>	adulterant testing procedures.
8.4.1	<p><u>Changed:</u> An additional FDA-cleared single-strip test to detect urine opiate levels at 300 ng/mL (OPI-300) will be performed at Screening/Baseline and prior to each injection of XR-NTX or iPLB. <i>Additional onsite urine drug testing may occur at Screening/Baseline and during the medication phase to detect urine metabolites of other drugs in the opioid family that are not detected by the previously described tests.</i></p>	With this protocol modification, two additional opioid tests were added to collect more data about the extent of opioid use in our study sample.
8.4.9	<p><u>Changed:</u> However, if the sample cannot be collected on the day of randomization, the sample may be collected at any <i>subsequent</i> visit after written consent is obtained, ideally at a visit in which a blood draw is scheduled to occur.</p>	This phrase unintentionally contradicted previous sentences and implied that the genetics blood draw could occur after consent and before randomization. Clarified that blood draw should only occur after randomization.
8.5.2	<p><u>Deleted:</u> This form will be completed at each visit in which injectable study medication is administered (i.e., weeks 1, 4, 7, and 10) or an injection was expected but not administered (e.g., due to incarceration).</p>	Deleted to accurately reflect current study procedures. The requirements for completion of this form changed since protocol version 2.0 was approved.
8.5.3	<p><u>Changed:</u> The <i>first question on this form</i> is to be completed only after the participant appears in clinic, This form will be completed at each study visit, even if in which oral study medication is <i>not being</i> dispensed.</p>	Updated to reflect current study procedures. The functionality of this form changed since protocol version 2.0 was approved.
10.1.4	<p><u>Changed:</u> Secondary outcomes include methamphetamine and other substance use outcomes in the pre-</p>	To more accurately describe how secondary outcomes will be analyzed.

	evaluation period, in the evaluation period, and at the follow-up assessment, <i>and any combination of these periods</i> , for responders, non-responders, and other sub-groups.	
12.0 – Entire section	<u>Updated:</u> Case Report Forms (CRFs), Participant Reported Outcome forms (PRO), and electronic forms (eCRFs and ePRO)	Added text to distinguish between the different types of forms used in the study and which are participant self-report forms.
12.5	<u>Updated:</u> Trial progress and data status reports, which provide information on recruitment, availability of primary outcome, treatment exposure, <i>attendance at follow-up visits</i> , regulatory status, and data quality, will be generated daily routinely and posted to a secure website. <i>These reports will be available to the site, the corresponding Local Node, the Lead Investigator, the coordinating centers, and NIDA, to monitor the sites' progress on the study. These reports are available to the site, the corresponding node, the lead node, the coordinating centers, and NIDA to monitor study progress overall and at each individual participating site.</i>	Clarified what information was included in trial progress and data status reports and to whom those reports are available.
17.0 - Data and Statistics Center Responsibilities - Data Collection and Entry - Data monitoring, Cleaning, and Editing	Updated sections to distinguish between the different types of forms used in the study and which are participant self-report forms.	Revisions more accurately reflect study procedures.
18.0	<ol style="list-style-type: none"> <u>Paragraph 1, Added:</u> The AiCure app will be downloaded onto the participant's personal smartphone..... a study provided smartphone device <i>will be provided with the app pre-loaded on it.</i> <u>Moved sentence from end of paragraph 5 to paragraph 3:</u> <i>Sites are encouraged to consult with the Lead Team when considering providing replacement study devices for</i> 	Provided additional clarification and instruction on how the study app has worked since the study began.

	<p><i>participants who are withdrawn from study medications.</i></p> <p>3. <u>Paragraph 3, Added:</u> If the participant does not require a replacement smartphone device during the course of the study, the participant will be provided up to \$40 payment (<i>i.e.</i>, \$10 for each month) for the safe return...</p> <p>4. <u>Paragraph 5, Added to title:</u> Smartphone Device-Based Procedures and Compensation</p> <p>5. <u>Changed:</u> <i>Participants will be compensated \$3 for each dosing video taken on non-clinic days, including the taper in week 13. "Red Alerts" are triggered by AiCure when there is a pattern of problematic behaviors observed during video dosing. AiCure staff will guide site staff in how to re-train participants to appropriately use the app. If a pattern of recurring Red Alerts are triggered by AiCure, this indicates repeated problematic dosing behaviors are occurring, indicating non-adherence to oral study medication. Recurring Red Alerts may result in a participant not being compensated for dosing videos; sites should consult with the Lead Team when repeated Red Alerts occur. a dosing video showing appropriate adherence is confirmed, the participant will be compensated appropriately.</i></p>	
Protocol Version 3.0 (11/10/2017) to 4.0 (05/01/2018)		
Section No.	Description of Changes	Rationale
Protocol cover page	<p><u>Changed:</u> Details regarding the timing of re-randomization, the duration and timing of the evaluation period, and related statistical analysis (as it contains information about the timing of re-randomization and the evaluation period) are omitted from the Protocol to protect</p>	<p>Included the duration and timing of the primary outcome evaluation period,</p>

	the double blind. These details are contained in the confidential Statistical Analysis Plan. The Lead Team will provide the Statistical Analysis Plan directly to the site Institutional Review Board(s) or Independent Ethics Committee.	as approved by the DSMB. This information is being shared with site staff so they may strategically use this information when tracking and locating participants. Revealing this information does not compromise the integrity of the double-blind or the timing of re-randomization.
Section 3.0 SYNOPSIS – Analyses	<u>Added:</u> The primary efficacy outcome is a measurement of treatment response based on MA-negative urine drug screen results <i>obtained during weeks 5 to 6 and weeks 11 to 12</i> of the medication phase.	
Section 5.1 Primary Objectives	<u>Added:</u> It is hypothesized that the AMC arm will be associated with a greater number of “responders,” defined as participants who provide a pre-specified number of MA-negative UDS tests <i>obtained during the evaluation period (i.e., weeks 5 to 6 and weeks 11 to 12)</i> of the 12 week long medication phase, relative to the PLB arm.	
Section 6.7.1 Primary Efficacy Outcome Measure	<u>Added:</u> The primary efficacy outcome measure is a composite of MA-negative UDS test results <i>obtained during weeks 5 to 6 and weeks 11 to 12</i> of the medication phase...	
Section 10.1.3 STATISTICAL ANALYSES – Primary Outcomes	<u>Changed:</u> The primary efficacy outcome measure is MA-negative urine drug screen (UDS) test results <i>obtained during weeks 5 to 6 and weeks 11 to 12 over the course of twice weekly visits,...</i>	
Section 6.3.1 Inclusion Criteria	<u>Revised Inclusion Criteria #8:</u> Meet subjective and objective measures of being opioid-free prior to naltrexone induction per study medical clinician’s determination (including passing a naloxone challenge)	Removed the required naloxone challenge at screening as our data has shown that the need for a naloxone challenge to confirm opioid free status for all participants appears unnecessary in this sample. Other study procedures used to confirm opioid free status during screening are
Sections: 6.1, 6.2, 7.1, 7.1.3, 7.1.4, 7.1.5, 7.2.1,	<u>Summary of changes:</u> <ul style="list-style-type: none"> Rephrased “naloxone challenge” to “naltrexone pre-induction strategy” in certain places to refer to the process of confirming opioid free status leading up to and on the day of randomization and study medication induction. 	


7.2.2, 8.3.7, 8.3.8, 8.3.11	<p>These steps (i.e., UDS, TLFB, PCM) and requirements are unchanged from Protocol v3.0.</p> <ul style="list-style-type: none"> Removed language indicating the naloxone challenge is 'required' to confirm eligibility in order to match updated inclusion criteria #8. Added language indicating the naloxone challenge at screening is now 'optional and at clinician discretion.' If a clinician opts to administer a naloxone challenge at screening, procedures for conducting the challenge, interpreting the results, and next steps remain unchanged. 	appropriately excluding participants who use opioids. Those procedures will be continued. Clinicians may still conduct a naloxone challenge if needed to confirm opioid free status but this is no longer required by the protocol. Removal of the required naloxone challenge at screening was approved by the DSMB.
8.1 Schedule of Assessments	The Schedule of Assessments was updated to reflect removal of the naloxone challenge requirement during screening.	
Section 7.1.3 Screening and Baseline Assessments	<u>Added:</u> <i>Therefore, all screening visits will have at least 2 days elapse between visits.</i>	To further clarify and reinforce that all study visits in screening must have 2 days elapse in between.
7.2.6 Medication Phase Visits	<u>Added new section:</u> <i>Given the requirements across study visits (e.g., meeting with medical clinician, blood draws, injections, assignment of oral medication only after the participant arrives, physical exam, ECG, etc.), the study was designed with the expectation that all visits occur at the study site. However, there may be cases in which off-site visits may be possible with Lead Team approval.</i>	To allow for more flexibility when working with participants who may be unable or unwilling to come in to study sites to complete research visits.
7.3.2 Post-Medication Phase Follow-up Visits	<u>Added:</u> <i>There may be cases in which off-site visits may be possible with Lead Team approval.</i>	To allow for more flexibility when working with participants who may be unable or unwilling to come in to study sites to complete research visits.
7.5 Participant Compensation	<p><u>Changed:</u> changed table and text to reflect new study compensation amounts.</p> <ul style="list-style-type: none"> Injection visits increased from \$20 to \$25 	Compensation was increased to improve study retention. Compensation was increased strategically, focusing on study activities that were most burdensome

	<ul style="list-style-type: none">• In-clinic dosing and dosing videos increased from \$3 to \$5• Added an attendance bonus for 2 week blocks of time: \$20 per two week block of perfect attendance	and likely to have the most beneficial impact on key study metrics.
18.0	Updated text to reflect new compensation plan and added clarifying language on the study app capabilities.	Updates reflect current procedures.
Protocol Version 4.0 (05/01/2018) to 5.0 (11/12/2018)		
Section No.	Description of Changes	Rationale
Protocol Development Team	<u>Changed:</u> Protocol Specialist: Matthew Wright , CCRP Prashanth Parmar DSC Data Manager: Cathryn Mudrick , MPH Ashley Case	Updated names of protocol team as there were staffing changes.
Throughout protocol	<u>Changed:</u> sample size from 370 to 400 <u>Changed:</u> numbers of randomization for each site from 30-55 participants to 30-70 participants.	Updated sample size and recruitment period throughout the protocol to reflect the July 2018 DSMB review recommendations.
Throughout protocol	<u>Removed:</u> "...18 month recruitment period."	
Section 10.2.1	<u>Added:</u> <u>Update to the sample size:</u> The NIDA CTN DSMB reviewed the sample size re-estimation report dated July 23, 2018, prepared by the DSC. Based on the results, the DSMB and NIDA CCTN recommended increasing the originally planned sample size of 370 by 30 additional participants to maintain the targeted 90% power. The CCTN approved the increase in sample size to 400 participants in a letter to the Lead Investigator dated August 13, 2018.	
Protocol Version 5.0 (11/12/2018) to Final Version 6.0 (01/31/2019)		

Section No.	Description of Changes	Rationale
6.2 Duration of Study and Clinic Visit Schedule	1. Removed “10-panel” and “single strip OPI-300” and now only state “urine drug screen test(s)” when describing methods to confirm opioid-free status	Due to a change in the manufacturer of the urine drug tests, the protocol was updated to reflect the new UDS devices now available. The devices evaluate the same drugs, but an opioid that was previously tested by the “10-panel” has now changed to the “single strip” and vice versa. The protocol previously provided exact details but those details have now been either corrected (where the exact detail was needed for understanding) or made less specific (procedures retained in operations documents).
7.1.4 Naltrexone Pre-Induction Strategy	Changed sentence to (italics=added; marked out=deleted): Individuals must have negative results for opioids (on the <i>OPI-2000</i> 10-panel urine drug screen and the OPI-300 test) prior to randomization.	To only include drug tests performed and avoid describing testing device.
8.4.1 Urine Drug Screen	Added (in italics): Urine drug screen (UDS) testing will be performed on site using an FDA-cleared for use one-step urine drug test card <i>and/or test strip(s)</i> following all the manufacturer's recommended procedures.	To more accurately describe urine drug testing devices that may be used.
8.4.1 Urine Drug Screen	Changed sentence to (italics=added; marked out=deleted): <i>Throughout the study, urine will be tested to evaluate urine opiate levels at 2000 ng/mL. At Screening/Baseline and prior to each injection of XR-NTX or iPLB, urine will be tested</i> An FDA-cleared single-strip test to detect evaluate urine opiate levels at 300 ng/mL (OPI-300) will be performed at Screening/Baseline and prior to each injection of XR-NTX or iPLB.	To refer to drugs tests and avoid language about testing devices.

CTN-0068 Protocol Change Log

	<p>Additional onsite urine drug testing may occur at Screening/Baseline and during the medication phase to detect urine metabolites of other drugs in the opioid family that are not detected by the previously described tests. Results from any urine opioid drug test intended for forensic use only, or otherwise not cleared by the FDA for use in clinical settings, may not be used in any clinical evaluation and is collected for data purposes only.</p>	
--	--	--



Statistical Analysis Plan for NIDA CTN-0068 Protocol

**Accelerated Development of Additive
Pharmacotherapy Treatment (ADAPT-2)
for Methamphetamine Use Disorder**

Lead Investigator: Madhukar Trivedi, MD

**Version 3.0
September 13, 2019**

Prepared by:
NIDA CTN Data and Statistics Center

TABLE OF CONTENTS

1.0	SUMMARY OF STUDY DESIGN AND PROCESS	1
1.1	Study Objective	1
1.2	Study Design and Procedures	1
1.2.1	Study Design	1
1.2.2	Study Procedures	1
1.2.3	Randomization	2
1.3	Inclusion and Exclusion Criteria	2
1.3.1	Inclusion Criteria	2
1.3.2	Exclusion Criteria	3
2.0	GENERAL DEFINITIONS AND PROCEDURES	4
2.1	Pre-screened Population	4
2.2	Screened Population	4
2.3	Randomized Population	4
2.4	Intent-to-Treat Population	4
2.5	Per Protocol Population	4
2.6	Safety Population	4
2.7	Study Day Definition	5
2.8	First Dose Date	5
2.9	Last Dose Date	5
2.10	Treatment Period	5
2.11	Follow-up Period	5
2.12	Safety Window	5
2.13	Treatment Emergence	5
2.14	Summary Table Conventions	5
2.15	Data and Statistics Center Responsibilities	5
3.0	ENROLLMENT, PARTICIPANT DISPOSITION, AND FOLLOW-UP	6
4.0	ANALYSIS OF PARTICIPANT CHARACTERISTICS	6
5.0	CONCOMITANT MEDICATIONS	6
6.0	STUDY MEDICATION ADHERENCE	7
6.1	Early Medication Terminations	7
6.2	Treatment Exposure	7
6.3	Video Confirmed Oral Medication Dosing	7
6.4	Oral Medication Blood Levels	8
7.0	ANALYSIS OF EFFICACY OUTCOME MEASURES	8
7.1	Definition of Primary Outcome Measure	8
7.2	Analysis of Primary Outcome Measure	8
7.3	Supportive Analyses of Primary Outcome Measure	9
7.4	Secondary Outcome Measures	10
7.5	Secondary Outcome Analyses	11

8.0	OTHER STATISTICAL CONSIDERATIONS	13
8.1	Handling Missing Data	13
8.2	Significance Testing	13
8.3	Sample Size and Power Calculations	13
8.4	Interim Analyses	16
8.4.1	Sample Size Re-Estimation	16
8.4.1.1	Sample Size Re-Estimation Results	17
8.4.2	Interim Monitoring of Primary Efficacy Endpoint	18
8.4.3	Safety Interim Analyses	19
8.4.4	Conditional Power and Futility	20
8.4.5	Results of Interim Monitoring for Efficacy and Safety	20
8.5	Software to be Used for Analyses	20
9.0	ANALYSIS OF SAFETY OUTCOME MEASURES	20
9.1	Adverse Events	20
9.2	Serious Adverse Events	21
9.3	Injection Site Abnormalities	21
9.4	Laboratory Values	21
9.5	Electrocardiogram	23
9.6	Suicide Risk	23
9.7	Pregnancy	23
9.8	Deaths	23
10.0	DATA QUALITY	23
10.1	Data Audits	23
10.2	Protocol Deviations	23
11.0	UPDATES TO THE STATISTICAL ANALYSIS PLAN	23
12.0	REFERENCES	24
13.0	LIST OF PROPOSED TABLES, FIGURES, AND LISTINGS	25
14.0	APPENDICES	28
14.1	SAP Version 0.1	29
14.2	Change Log for SAP Version 0.1 to SAP Version 2.0	42

LIST OF ABBREVIATIONS

AE	Adverse Event
ALT	Alanine Aminotransferase
AST	Aspartate Aminotransferase
AMC	Active Medication Combination
ATC	Anatomical Therapeutic Chemical
CCTN	Center for Clinical Trials Network
CHRT	Concise Health Risk Tracking
DSC	Data and Statistics Center
DSM-5	Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition
DSMB	Data and Safety Monitoring Board
ECG	Electrocardiogram
EOM	End of Medication form
FSR	Final Study Report
IN2	Injection Administration 2 form
ITT	Intent-to-Treat
LFT	Liver Function Test
NIDA	National Institute on Drug Abuse
NNT	Number Needed to Treat
ODL	Oral Study Medication Dosing Log form
PHQ-9	Patient Health Questionnaire-9
PLB	Placebo
QOL	Quality of Life
SAE	Serious Adverse Event
SAP	Statistical Analysis Plan
SOC	System Organ Class
SPCD	Sequential Parallel Comparison Design
STC	Study Completion form
TEA	Treatment Effectiveness Assessment
TES	Treatment Effectiveness Score
TLFB	TimeLine Followback
UDS	Urine Drug Screen
VAS	Visual Analog Craving Scale
WHO	World Health Organization
XR-NTX	Extended-Release Naltrexone (as Vivitrol®)

1.0 SUMMARY OF STUDY DESIGN AND PROCESS

1.1 Study Objective

The primary objective of this study is to evaluate the efficacy of extended-release naltrexone plus bupropion as a combination pharmacotherapy for methamphetamine use disorder. Secondary objectives include assessing the safety of naltrexone plus bupropion and determining the efficacy of the combination pharmacotherapy on other substance use outcomes, on depression symptom scores, and on quality of life ratings.

1.2 Study Design and Procedures

1.2.1 Study Design

This is a double-blind, placebo-controlled, adaptive randomized clinical trial in which 400 individuals with moderate or severe methamphetamine use disorder will be randomly assigned to either 1) active medication combination (AMC) arm in which injections of extended-release naltrexone (XR-NTX; as Vivitrol®) plus once daily oral extended-release bupropion tablets or the 2) matching Placebo (PLB) arm in which injections of placebo and once daily oral placebo tablets will be provided during a 12 week medication phase.

This protocol will utilize a two-stage sequential parallel comparison design (SPCD), originally proposed by Fava et al. (2003), and later revised by Chen et al. (2011). Participants will be randomized to Placebo:AMC in the ratio of **0.74:0.26** in Stage 1 of the study and only Stage 1 placebo non-responders will be re-randomized at the beginning of Stage 2 in a 1:1 ratio. The 12-week medication phase is divided into two stages of approximately equal treatment duration.

The original designed sample size for this study was 370. After the pre-specified sample size re-estimation, the Center for Clinical Trials Network (CCTN) approved the increase of the sample size to 400 participants (See Section 8.4.1.1).

1.2.2 Study Procedures

Participants randomized to the AMC arm will receive injections of extended-release naltrexone (Vivitrol®) plus 450 mg of once-daily oral extended-release bupropion tablets while participants randomized to the Placebo arm will receive placebo injections plus once-daily oral placebo tablets. Injectable study medications will be administered every three weeks (Weeks 1, 4, 7, and 10). Take-home oral study medication will be dispensed once weekly for daily dosing. Once weekly medical management sessions with the study medical clinician will be provided. Medication adherence procedures will include smartphone app-confirmation of daily oral study medication dosing using AiCure. Participants will be asked to attend clinic twice weekly for observed oral study medication dosing, collection of urine drug screening samples, and self-report assessments. Compensation will be provided for visit attendance and dosing via AiCure.

Screening/baseline assessments include safety and medical measures including a medical and psychiatric history, a physical examination, clinical lab tests (blood chemistry, hematology, and urinalysis), 12-lead electrocardiogram, vital signs, and pregnancy tests (for females). Screening/baseline assessments also include psychological and drug use measures. Methamphetamine use outcome assessments include Urine Drug Screens (UDS), self-reported use via the Timeline Followback (TLFB), and Visual Analog Scale (VAS) craving scores. Other outcome assessments include UDS and TLFB (i.e., alcohol, tobacco, and/or illicit drugs), depression (Patient Health Questionnaire-9), quality of life (QOL), functioning (Treatment Effectiveness Assessment), and clinic attendance. Safety measures include monitoring vital signs, adverse events (AEs), concomitant medications, clinical lab results, and assessments of suicidality. Oral study medication adherence will be assessed by self-report, quantitative blood

levels of bupropion and its primary metabolite, and smartphone device-based dosing confirmation procedures. A blood sample for genetic analysis will be collected from participants who consent to this procedure and the deidentified sample will be sent to a cell and DNA repository.

At the end of the 12-week medication phase, participants will complete a follow-up phase, including an oral medication taper. Post-medication phase follow-up visits will occur during Weeks 13 and 16. Participants may be withdrawn from study medication for safety reasons due to the discretion of medical clinician. The participant will terminate study medication if there is an increase in liver function tests or a decrease in platelet test results. Refer to Protocol Section 7.2.5 for further information.

1.2.3 Randomization

Eligible participants will be randomized in Stage 1 of the medication phase in a **0.74:0.26** fashion following the SPCD, which is approximately 296:104 participants to the Placebo and AMC treatment arms, respectively (total target N = 400), stratifying by site. Participants who have not been withdrawn from study medication by medical staff will remain eligible to participate in Stage 2. Eligible Stage 1 participants assigned to Placebo and who did not meet the specified definition of responder (i.e., Placebo non-responders) and who attend a visit in the re-randomization window will be re-randomized in a 1:1 ratio to either the Placebo or AMC arm in Stage 2, stratifying by site. All other eligible Stage 1 participants, including participants who did not attend a visit during the re-randomization window, Placebo responders, and AMC participants, will remain in the same treatment arm during Stage 2 as was assigned in Stage 1.

The window for re-randomization opens on Week 7 Day 1 and closes on Week 8 Day 2. If a participant does not attend a visit on or between Week 7 Day 1 and Week 8 Day 2, the participant will not be re-randomized in Stage 2 and will continue receiving the treatment assigned in Stage 1. Re-randomization at Stage 2 helps ensure treatment balance in the two treatment groups within the Stage 2 population.

1.3 Inclusion and Exclusion Criteria

1.3.1 Inclusion Criteria

1. 18 to 65 years of age.
2. Interested in reducing or stopping methamphetamine use.
3. Able to speak English sufficiently to understand the study procedures and provide written informed consent to participate in the study.
4. Meet DSM-5 criteria for moderate or severe methamphetamine use disorder (4 or more criteria.)
5. Self-report methamphetamine use on 18 or more days in the 30-day period prior to consent on TLFB.
6. Provide at least 2 urine samples positive for methamphetamine out of a possible 3 tests to occur within a 10-day period during which clinic visits occur with at least 2 days between visits.
7. If female, agree to use acceptable birth control methods and have periodic urine pregnancy testing done during participation in the study unless documentation of hysterectomy provided.
8. Meet subjective and objective measures of being opioid-free prior to naltrexone induction per study medical clinician's determination.

9. Willing to comply with all study procedures and medication instructions.
10. Agree to use a smartphone app (downloaded for free to own device or on a study provided smartphone device) to take daily videos of medication dosing.

1.3.2 Exclusion Criteria

39. Have an acute medical or psychiatric disorder that would, in the judgment of the study medical clinician, make participation difficult or unsafe.
40. Have suicidal or homicidal ideation that requires immediate attention.
41. Have a history of epilepsy, seizure disorder, or head trauma with neurological sequelae (e.g., loss of consciousness that required hospitalization); current anorexia nervosa or bulimia; or any other conditions that increase seizure risk in the opinion of the study medical clinician.
42. Have evidence of second- or third-degree heart block, atrial fibrillation, atrial flutter, prolongation of the QTc, or any other finding on the screening electrocardiogram (ECG) that, in the opinion of the study medical clinician, would preclude safe participation in the study.
43. Have Stage 2 hypertension as determined by the study medical clinician (e.g., greater than or equal to 160/100 in 2 out of 3 readings during screening.)
44. Have any elevated bilirubin test value per laboratory criteria OR any other liver function test (LFT) value > 5 times the upper limit of normal per laboratory criteria.
45. Have a platelet count < 100 x 10³/μL.
46. Have a body habitus that precludes gluteal intramuscular injection of XR-NTX in accordance with the administration equipment (needle) and procedures.
47. Have a known allergy or sensitivity to bupropion, naloxone, naltrexone, PLG (polyactide-co-glycolide), carboxymethylcellulose or any other component of the XR-NTX diluents.
48. Have been in a prior study of pharmacological or behavioral treatment for methamphetamine use disorder within 6 months of study consent.
49. Have taken an investigational drug in another study within 30 days of study consent.
50. Have been prescribed and taken naltrexone or bupropion within 30 days of study consent.
51. Concurrently enrolled in formal behavioral or pharmacological addiction treatment services.
52. Receiving ongoing treatment with tricyclic antidepressants, xanthines (i.e., theophylline and aminophylline), systemic corticosteroids, nelfinavir, efavirenz, chlorpromazine, MAOIs, central nervous system stimulants (e.g., Adderall, Ritalin, etc.), or any medication that, in the judgment of the study medical clinician, could interact adversely with study medications.
53. Have a current pattern of alcohol, benzodiazepine, or other sedative hypnotic use which would preclude safe participation in the study as determined by the study medical clinician.
54. Require treatment with opioid-containing medications (e.g., opioid analgesics) during the study period.

- 55. Have a surgery planned or scheduled during the study period.
- 56. Are currently in jail, prison or any inpatient overnight facility as required by court of law or have pending legal action or other situation (e.g., unstable living arrangements) that could prevent participation in the study or in any study activities.
- 57. If female, be currently pregnant, breastfeeding, or planning on conception.

2.0 GENERAL DEFINITIONS AND PROCEDURES

2.1 Pre-screened Population

The pre-screened population consists of all participants who provided verbal consent for the pre-screen process.

2.2 Screened Population

The screened population consists of all participants who provided informed consent at the initiation of the screening process.

2.3 Randomized Population

The Randomized population consists of all participants randomized in Stage 1.

2.4 Intent-to-Treat Population

The Intent-to-Treat (ITT) population consists of all randomized participants in Stage 1. For Stage 2, the ITT population includes all participants who were re-randomized.

2.5 Per Protocol Population

The Per Protocol (PP) population is a subgroup of the ITT population. The PP population consists of participants who have not taken bupropion outside of the study medication, have not taken the incorrect treatment assignment, do not terminate study medication early, meet all entry criteria, complete the treatment period as defined in Section 2.10, and meet treatment exposure requirements. Four PP populations will be defined using the following treatment exposure criteria:

1. For each stage, participants who have greater than or equal to 75% treatment exposure for oral study medication and receive 2 injections. Each stage will have its own PP population.
2. For each stage, participants who have greater than or equal to 50% treatment exposure for oral study medication and receive at least one injection during the stage. Each stage will have its own PP population.
3. For each stage, participants who are greater than or equal to 50% compliant to oral study medication using AiCure confirmed dosing.
4. Participants randomized to AMC in Stage 1 who have 2 oral medication blood levels collected during Stage 1 which indicate bupropion dosing, as defined in Section 6.4, and participants re-randomized to AMC in Stage 2 who have 2 oral medication blood levels collected which indicate bupropion dosing. Each stage will have its own PP population.

2.6 Safety Population

The safety population includes all participants who completed informed consent during the screening visit.

2.7 Study Day Definition

Study Day 1 is defined as the day of randomization.

2.8 First Dose Date

The first dose date for oral study medication is the first date on the Oral Study Medication Dosing Log (ODL) on which it is indicated that tablets were taken. The first dose for injectable study medication is the first date an injection was administered on the Injection Administration 2 (IN2) form.

2.9 Last Dose Date

The last dose date for oral study medication is the last day on the ODL form on which it is indicated that tablets were taken. The last dose for injectable study medication is the last date an injection was administered on the IN2 form.

2.10 Treatment Period

The treatment period consists of Study Days 1-84, coinciding with the 12-week medication phase.

2.11 Follow-up Period

The follow-up period consists of two study visits during the post-medication phase occurring at Week 13 and Week 16.

2.12 Safety Window

The safety window begins at the first dose date of either oral or injectable study medication, whichever comes first, and ends either 7 days after the last oral medication dose or 28 days after the last injectable medication, whichever comes last.

2.13 Treatment Emergence

Treatment emergent AEs are defined as AEs with a start date during the safety window.

2.14 Summary Table Conventions

All analyses described in this document for the intent-to-treat population will be summarized over all randomized participants by stages (Stage 1 and 2) and treatment arm. Additionally, some analyses for the intent-to-treat population will also be summarized by site. For all summaries of ITT population, participants will be analyzed according to the treatment arm to which they were randomized regardless of the subsequent sequence of events regarding study drug exposure.

Descriptive summaries of the distribution of continuous variables will be presented with percentiles (median, 25th and 75th percentiles), and with mean, standard deviation, minimum and maximum. Categorical variables will be summarized in terms of frequencies and/or percentages.

Listings presented by treatment arm will include groups for non-re-randomized Placebo and AMC participants, and re-randomized Placebo and AMC participants (Placebo, Placebo/Placebo, Placebo/AMC, AMC).

2.15 Data and Statistics Center Responsibilities

The CTN's DSC will conduct analyses for the Final Study Report, including those related to the primary outcome measure and the supportive analyses listed in Section 7.3, and the analysis for the primary outcome paper, as discussed by and decided upon by the Lead Node, DSC, and Center for Clinical Trials Network (CCTN). The Lead Node will be responsible for the all secondary outcomes and analyses, the AiCure app-confirmed oral medication dosing described in Section

6.3, and the Per Protocol Population definition #3 detailed in Section 2.5 which uses AiCure treatment exposure information.

3.0 ENROLLMENT, PARTICIPANT DISPOSITION, AND FOLLOW-UP

The number of pre-screens and screens completed and the reasons for ineligibility on pre-screening and screening will be summarized by site. Note that participants might be screened twice. For participants who were screened twice, they will only be considered for the second screening.

The distribution of treatment assignments by site and stage will be presented. The trajectory of actual randomizations versus the expected number of randomizations according to the first date of randomization and under the assumption that three participants are expected to be randomized per month per site will be graphed by site and overall. Proposed versus actual randomizations will be summarized by site in a tabular fashion.

Participants are defined as study completers if the Week 16 Follow-up Visit is completed as indicated on the Study Completion (STC) form, and are considered as early study terminations if this visit is not completed. Participant disposition will be summarized by site, treatment arm, and stage for the number of participants completing the study, the number of participants early terminating from the study, and the reasons for early study termination. Early study terminations, using the date of last data collection or date of withdrawn consent on the STC form, will be attributed to Stage 1 if the termination occurred prior to the end of Week 6 (Day 42). Study terminations occurring from Day 43 to Day 84 will be considered to occur in Stage 2, and study terminations occurring after Day 84 will be considered to occur during follow-up.

The CONSORT flow diagram will be generated (Moher et al., 2010).

The number and percentage of participants who attend the bi-weekly treatment period study visits during Weeks 1-12 will be presented by treatment arm and stage, and the Week 13 and 16 follow-up visits will be presented by treatment arm. Information on missed visits during the treatment period and the follow-up period will be presented by treatment arm and stage, including the number of missed visits, the number of participants with at least one missed visit, and the reasons for the missed visits. The expected number of visits during the treatment period is calculated based on the general rule that two visits per week are expected per participant for a total of 12 expected visits per stage, and two visits are expected during the follow-up period. The average number of missed visits per participant will be calculated by dividing the number of missed visits by the number of participants. For early study terminations, visits are only considered missed during active study participation if they occur before the study termination date.

4.0 ANALYSIS OF PARTICIPANT CHARACTERISTICS

Baseline demographics and characteristics including sex, age, ethnicity, race, education level, marital status, employment status, and the number of methamphetamine use days in the 30 days prior to informed consent reported on TLFB will be summarized by site, treatment arm, and stage. Because randomization is expected to produce balance at baseline between the two arms of the trial, statistical comparisons of treatment groups with respect to baseline characteristics will be informal. If differences between treatments arms are suspected, statistical testing will be performed.

5.0 CONCOMITANT MEDICATIONS

Concomitant medications taken during the treatment period will be coded using the WHO Drug Dictionary. Summaries by treatment arm will be presented by Anatomical Therapeutic Chemical

(ATC) Class level 1 and ATC Class level 2 and will include the number and percentage of participants receiving each drug class during the safety window defined in Section 2.12.

6.0 STUDY MEDICATION ADHERENCE

Exposure to study medication will be assessed by oral medication dosing, including self-report and AiCure app-confirmed dosing, injection administration, and medication blood levels.

6.1 Early Medication Terminations

Participants may terminate early from either oral study medication or injectable study medication, or from both study medications. Participants will be considered early oral medication terminations as of the date of last oral medication dose entered on the End of Medication (EOM) form. For injectable study medication the date of early medication termination is not collected, and participants will be considered to terminate from the medication for the injection number after the last injection administered on the IN2 form. Early injection termination participants receiving no injections or injection #1 only will be considered early injection terminations in Stage 1, and participants last receiving injection #2 or #3 will be considered early injection terminations in Stage 2. Note there is one exception that participants terminating the study or terminating both study medications on or before Day 42 (end of Week 6) who received both injection #1 and #2 will be considered as early injectable study medication terminations in Stage 1. Early oral study medication terminations occurring before the date of re-randomization or Day 43 for participants who are not re-randomized are considered to occur in Stage 1, and early oral study medications occurring on or after the date of re-randomization are assigned to Stage 2.

The number of participants terminating early from each study medications and the reasons for termination will be presented by site and by stage and treatment arm.

6.2 Treatment Exposure

During the treatment period (Days 1-84), 3 tablets per study day are expected and 4 injections should be administered. Oral study medication dosing is recorded on the ODL form and injection administration is recorded on the IN2 form. Treatment exposure is defined as the average of the percentage of expected oral study medication taken and the percentage of expected injections received. Oral medication taken after the end of the treatment period Day 84 will not be considered. Treatment exposure will be summarized by site, and by site, treatment arm and stage. Oral medication expected to be taken before the date of re-randomization or Study Day 43 for non-re-randomized participants is considered Stage 1, and oral medication expected to be taken on or after the date of re-randomization or Study Day 43 for non-re-randomized participants is considered Stage 2. Injections #1 and #2 are allocated to Stage 1 and injections #3 and #4 are in Stage 2.

A summary of the number of injections administered out of the 4 expected injections by site and by treatment arm and stage will be presented. Two injections are expected in each stage.

6.3 Video Confirmed Oral Medication Dosing

Exposure to oral medication will also be calculated using information from the smartphone app-based dosing confirmation procedures developed by AiCure. Video confirmed dosing adherence data is to be interpreted as an objective indicator of the lowest medication adherence rate participants achieve. Video confirmed adherence is defined as the percentage of expected oral study medication taken, with taken medication including dosing confirmed via video, confirmed by the site, and confirmed in the clinic. Oral medication taken after the end of the treatment period Day 84 will not be considered. Video confirmed adherence will be summarized by site and by treatment arm and stage.

6.4 Oral Medication Blood Levels

Exposure to bupropion will be assessed at Weeks 4, 7, 10, and 12 for participants randomized to AMC and Weeks 10 and 12 for participants re-randomized to AMC by examining quantitative blood levels of bupropion and its primary metabolite hydroxybupropion. Bupropion blood levels greater than 0.500 ng/mL (limit of detection) and hydroxybupropion blood levels greater than 1.00 ng/mL (limit of detection) will indicate adherence to oral bupropion dosing. A summary table of AMC participants adherent to bupropion dosing by stage will be provided.

7.0 ANALYSIS OF EFFICACY OUTCOME MEASURES

7.1 Definition of Primary Outcome Measure


The evaluation period is the final two weeks of the medication phase in Stage 1 (Weeks 5-6) for all participants and Stage 2 (Weeks 11-12) for participants that have been re-randomized. The primary efficacy outcome is a measurement of treatment response at a specified threshold (3 of 4 UDS negative for methamphetamine during the two-week period). Thus, a participant will meet responder criterion by providing 3 or 4 methamphetamine-negative UDS tests during the final two weeks of each stage of the treatment period. All other participants without 3 or 4 methamphetamine-negative UDS will be considered non-responders.

It is hypothesized that the AMC arm will be associated with a greater number of responders, relative to the Placebo arm. The treatment groups will be compared as to the proportion of responders in Stage 1 and Stage 2. The treatment effect will be defined as a weighted combination of the response rates in the two stages. The weight was chosen to optimize the test under the alternative hypothesis as described below. In addition, clinically it is expected that a larger treatment effect will be observed in Stage 2 due to the exclusion of placebo responders from Stage 1. All treatment comparisons will be performed under the Intent-to-Treat (ITT) criteria.

7.2 Analysis of Primary Outcome Measure

Figure 1 shows the design parameters of the SPCD.

Figure 1: SPCD: Defining the Outcome



Let p_1 , q_1 be the response rates for AMC and Placebo in Stage 1; and p_2 , q_2 be the response rates of AMC and Placebo in Stage 2, that is, among Placebo non-responders. Assume that s is the rate of continuation into Stage 2 among Placebo non-responders, (i.e., $1-s$ is the Stage 1 drop-out rate). The primary analysis alternative hypothesis is that the AMC group has higher response rate than Placebo in the full population (Stage 1) OR in the sub-population of Placebo non-responders (Stage 2). The following null (H_0) vs alternate hypothesis (H_1) will be tested:

$$H_0: p_1 \leq q_1 \text{ AND } p_2 \leq q_2$$

$$H_1: p_1 > q_1 \text{ OR } p_2 > q_2$$

The randomization fraction, **a** and the weight, **w** are the parameters of the SPCD that are chosen to maximize the power of the test, based on the alternative hypothesis. Fava (2003) recommends that both **a** and **w** be chosen *a priori* based on the alternative hypothesis of interest. For the alternative hypothesis of this study, it is assumed **p1=0.24**, **q1=0.15** (response rates for AMC and Placebo, respectively, in Stage 1) and **p2=0.24**, **q2=0.10** (response rates for AMC and Placebo, respectively, in Stage 2), and **s=0.85** (rate of continuation into Stage 2 of the trial among Placebo non-responders). These assumptions lead to the conclusion that the randomization fraction, **a=0.37** and the weight, **w=0.43** will maximize the power of the test. The primary outcome analysis will be performed as described in Tamura and Huang (2007) using the Wald type test statistic $Z = h/se(h)$, where

$$h = w(p_{1,obs} - q_{1,obs}) + (1 - w)(p_{2,obs} - q_{2,obs})$$

$$var(h) = \frac{w^2 p_{1,obs}(1 - p_{1,obs})}{n(1 - 2a)} + \frac{\left(\left(\frac{w^2}{4} \right) q_{1,obs}(1 - q_{1,obs}) + \frac{(1 - w)^2 q_{2,obs}(1 - q_{2,obs})}{s_{obs}(1 - q_{1,obs})} \right)}{na}$$

$$+ \frac{\left(\left(\frac{w^2}{4} \right) q_{1,obs}(1 - q_{1,obs}) + \frac{(1 - w)^2 p_{2,obs}(1 - p_{2,obs})}{s_{obs}(1 - q_{1,obs})} \right)}{na}$$

$$\text{and } se(h) = \sqrt{var(h)}$$

Note that Schoenfeld corrected the Tamura and Huang formula for the variance.

In the above test statistic both **a** and **w** are chosen *a priori* as 0.37 and 0.43; n is the sample size and the quantities $p_{1,obs}$, $q_{1,obs}$, s_{obs} , $p_{2,obs}$ and $q_{2,obs}$ will be estimated from the data. The null hypothesis will be rejected if $Z > \text{boundary}$ (one-sided), where the boundary for interim and final analysis is defined as the O'Brien-Fleming boundary as described in Section 8.4.2. A one-sided p-value for the test of primary outcome will be presented. One-sided lower bound confidence limit for the responder rate will be calculated using $h - \text{boundary} \times se(h)$. See Section 8.2 for the boundary and cumulative alpha spent to be used at interim analysis and final analysis.

The Number Needed to Treat (NNT) will be calculated as $1/h$. UDS availability and results in the evaluation periods will be summarized by treatment arm and stage. A graph of the percentage of negative methamphetamine UDS results during the treatment and follow-up periods will be presented.

7.3 Supportive Analyses of Primary Outcome Measure

The analysis will be repeated with the inclusion of selected covariates, for example, age of onset of methamphetamine use, baseline number of methamphetamine use days self-reported on Timeline Followback (TLFB) in the 30 days prior to informed consent, severity of methamphetamine use (presence or absence of using methamphetamine via injection route of administration on TLFB in the 30 days prior to informed consent; number of DSM-5 criteria met during screening), tobacco use (number of days using cigarettes or e-cigarette on TLFB during 30 days prior to informed consent), Treatment Effectiveness Assessment score at screening,

average of all Visual Analog Craving scale scores collected during screening, and site. A generalized linear mixed effect model will be used to assess the covariate adjusted treatment effects to use in the equation in Section 7.2 to compute h .

Subgroup analysis for sex, race, ethnicity and age will be performed as required by the NIH (NIH, 2016). A generalized linear mixed effect model will be used to assess the subgroup-by-stage-by-treatment interaction. A contrast will be written using the pre-specified weight ($w=0.43$) to test the difference in the primary hypothesis by subgroup.

The primary hypothesis is the difference in the weighted treatment effect in Stage 1 and 2. For example, the difference in the primary hypothesis by sex (Female = F, Male = M) is obtained by a contrast using the weighted treatment effects within males (h_M) and females (h_F) which are given by the following equations:

$$h_M = \{w(p_{1,M} - q_{1,M}) + (1 - w)(p_{2,M} - q_{2,M})\}$$

$$h_F = \{w(p_{1,F} - q_{1,F}) + (1 - w)(p_{2,F} - q_{2,F})\}$$

The estimates for the responder rate and standard error for males and females will be obtained using an LSMESTIMATE statement and the p-value for the comparison will be obtained using a CONTRAST statement in the SAS code below.

```
proc glimmix data=final method=quad;
  class sex stage trt patid;
  model responder = sex*stage*trt/noint solution;
  random intercept /subject=patid;
  contrast "MvsF" sex*stage*trt -.43 .43 -.57 .57 .43 -.43 .57 -.57;
  lsestimate sex*stage*trt "Male" -.43 .43 -.57 .57;
  lsestimate sex*stage*trt "Female" 0 0 0 0 -.43 .43 -.57 .57;
run;
```

Similarly, the subgroup analysis for site, race, ethnicity, and age will be conducted. If there are more than 2 levels of a subgroup e.g. race (black, white and other) an overall p-value will be reported and appropriate post-hoc testing will be conducted. Summary tables of primary outcome results by site and in the subgroups for sex, race, ethnicity, and age will be provided by treatment arm.

Responder rates in the Randomized Population and the Per Protocol Populations will be presented by treatment arm.

A sensitivity analysis using $w=0.5$ will be performed for the ITT Population.

7.4 Secondary Outcome Measures

Secondary outcome measures for the impact of the AMC, relative to the Placebo arm, on other substance use outcomes, depression scores, quality of life, overall functioning, clinic attendance, and medication adherence will be evaluated as follows.

15. Alternate measures and composites of methamphetamine use including:

- i) The Treatment Effectiveness Score (TES) (Ling et al., 1997), as measured by UDS results, during the treatment period. The TES is the percentage of the expected urine drug screens that were negative for each drug. Twelve urine drug screens are expected within each stage.
- j) Methamphetamine use, as measured by UDS, during the treatment period. Outcomes include UDS results in the pre-evaluation period (Weeks 1-4 for Stage 1 and Weeks 7-10 in Stage 2), the maximum number of consecutive negative UDS

- (missing and positive UDS will reset the count to zero), and number of study weeks during the treatment period with two methamphetamine-negative UDS.
- k) Frequency of methamphetamine use, as measured by self-report on TLFB, during the treatment period. The self-reported number of days abstinent from methamphetamine use will be assessed during the evaluation periods during Stage 1 and Stage 2 and over the entire treatment period.
 - l) Severity of methamphetamine craving, as measured by Visual Analog Craving Scales (VAS), during the treatment period. VAS scores range from 0 (no craving) to 100 (most intense craving possible). The VAS is completed at screening, once a week during the treatment period, and at the follow-up visits.
 - m) Methamphetamine use as measured by UDS and methamphetamine use self-reported on TLFB during the follow-up period. UDS results and the self-reported number of days abstinent from methamphetamine use during the follow-up will be assessed.
16. Other substance use, as measured by UDS, during the treatment period. Opioid use will also be assessed using the Opioid 2000 ng tests on the UDS.
17. Quantity and frequency of alcohol, quantity and frequency of cigarettes, frequency of e-cigarettes, and frequency of other drug use, as measured by self-report on TLFB during the treatment period.
18. Depressive symptoms, as measured by the PHQ-9, during the treatment period. The PHQ-9 is collected at screening, once a week during the treatment period, and at the follow-up visits.
19. Quality of life (QoL), as measured by the PhenX Core Tier 1 instrument and collected on the Quality of Life (QLP) form, during the treatment period. Ratings of general health, physical health, and mental health during the past 30 days at screening, mid-treatment (Week 6 Visit 2), and end-of-treatment (Week 12 Visit 2) are collected.
20. Overall functioning, as measured by the Treatment Effectiveness Assessment (TEA), during the treatment period. The Treatment Effectiveness Assessment (Ling, 2012) is a 4-item self-administered assessment that uses a Likert scale (1-10) to document changes in four life domains: substance use, health, lifestyle, and community and is collected at screening, mid-treatment (Week 6 Visit 2) and end-of-treatment (Week 12 Visit 2).
21. Percentage of participants who completed a visit in Week 12.
22. Ratings of participant and staff satisfaction with study procedures, including use of the medication adherence app, compensation, and medication.

The Lead Node will provide summary tables by treatment arm and stage for the above secondary outcomes.

7.5 Secondary Outcome Analyses

All secondary analyses described below will be conducted by the Lead Node. The secondary outcomes listed in Section 7.4 are classified in Table 1.

Table 1: Secondary Outcomes by Type of Outcome for SPCD Analysis		
Type of Outcome	Frequency of Measurement	Outcomes
Binary Cross-Sectional	one measurement per stage	Meth use from UDS (1.b, 1.e) Other substance use from UDS (2)
Ordinal	one measurement	Ratings of participant and staff satisfaction (8)
Ordinal Cross-Sectional	one measurement per stage	QOL (general health) (5)
Count	one measurement per stage	Number of weeks with meth-negative UDS (1.b) Number of consecutive meth-negative UDS (1.b) Number of meth-abstinent TLFB days (1.c, 1.e) Number of alcohol, cigarettes, e-cigarettes, and other substance use TLFB days (3)
Continuous	one measurement	Treatment completion (7)
Continuous Cross-Sectional	one measurement per stage	TES (1.a) Quantity of alcohol and cigarettes used from TLFB (3) QOL (physical health, mental health) (5) TEA (substance use, health, lifestyle, community) (6)
Continuous Repeated Measures	multiple measurements per stage	Severity of meth craving measured by VAS (1.d) PHQ-9 (4)

Binary cross-sectional outcomes will be analyzed using the same model as for the primary outcome. All repeated measures will be analyzed using the method of Doros et al, 2012. The mixed effects repeated measures models will control for baseline methamphetamine use days self-reported on TLFB and other key demographic and participant variables such as severity of methamphetamine use, tobacco use history, and visual analog craving scale. Nonparametric analyses will be used if the assumptions of the mixed effects analysis cannot be met. Participant and staff satisfaction ratings will be summarized. Analyses of secondary outcomes will be primarily performed on all individuals who are in the ITT population and inducted onto both study medications.

The analysis approach described in Doros et al, 2012 is preferred, however the approach defined in Chen (2011) may also be used, as appropriate (i.e., for continuous outcome ordinary least squares and mixed effects models for repeated measures (MMRM). Logistic regression may also be used for binary outcomes. The same weights as primary outcome will be used to calculate the weighted combination of the estimated treatment effects in the two stages for the secondary analyses.

Secondary analyses of outcomes not specified in Section 7.4 will also be performed. Adherence to oral study medication dosing will be measured by smartphone app-confirmation of daily oral study medication dosing and as recorded on the dosing log (ODL). In addition, per protocol analyses will be conducted using the Per Protocol population definitions in Section 2.5. Because

per protocol analyses may be biased (Sheiner and Rubin, 1995), an unbiased complier-adjusted causal effects analysis (Stuart and Jo, 2015) may also be used to adjust for adherence.

Additionally, methamphetamine and other substance use outcomes may be assessed for responders, non-responders, and other subgroups.

8.0 OTHER STATISTICAL CONSIDERATIONS

8.1 Handling Missing Data

Any participant who drops out before the last week in each evaluation period is, by definition, a non-responder. Therefore, any participant who drops out before Week 6 is a Stage 1 non-responder. In the SPCD design, Stage 1 Placebo non-responders are to be randomized again in Stage 2, but re-randomization is impossible if the participant has dropped out. Thus, Stage 1 dropouts will not contribute to the analysis in Stage 2. In Stage 2, dropouts (i.e., any participant who drops out before Week 12) are again considered to be non-responders by definition, and this causes no further complication in the SPCD computation.

It is unknown *a priori* how many participants will drop out in Stage 1 of the study, thus the 15% attrition rate ($s=0.85$) was chosen as a conservative estimate. Also, as described above, an assumption was made that participants who dropped out early in a given stage will be considered as non-responders in that stage. Therefore, it is important to assess the impact of these missing data assumptions on the primary outcome analysis of the study. A series of sensitivity analyses will be performed to determine how the missing data affects the primary results. Analysis by imputing missing UDS as negative will be conducted, as well as a complete case analysis which includes all participants who have 4 UDS collected in the evaluation period for each stage. Based on the literature review on novel missing data methodology for SPCD, additional secondary analysis may be performed to support the primary outcome analysis.

8.2 Significance Testing

The primary outcome will be evaluated using a one-sided test with a type I error rate of $\alpha=0.025$, adjusted based on O'Brien-Fleming boundaries for the interim analysis as described in Section 8.4.2. The boundary and the cumulative alpha spent used for interim and final analysis are noted below in Table 2.

Table 2: Primary Outcome Analysis Boundary and Cumulative Alpha Spent		
Timepoint	Boundary for Declaring Statistical Significance	Alpha Level (Cumulative alpha spent)
Interim analysis	2.9626	0.00153
Final analysis	1.9686	0.025

The secondary outcomes will use a two-sided test with 5% error rate. There are several secondary outcomes; however, multiple testing will not be adjusted for in the secondary analyses, since these are not part of the study's primary objective. When multiple tests are conducted, the chance of finding a significant difference in one of the tests, when in fact no difference exists, is greater than the stated type I error rate. The investigators are aware of the issues associated with multiple testing and will interpret results with caution.

8.3 Sample Size and Power Calculations

The sample size calculation was conducted as described in Tamura and Huang (2007), with the randomization ratio for Placebo:AMC defined as $2a:(1-2a)$, where a is defined as the

randomization fraction. Table 2 shows the impact of various design assumptions on the parameters of the SPCD, the randomization fraction \mathbf{a} , and the weight \mathbf{w} on the sample size. It is important to note that when the rate of discontinuation is 0% ($\mathbf{s}=1$), the sample size calculation based on Tamura and Huang (2007) gives the same results as Fava et al. (2003) SPCD sample size calculations.

As described in Section 7.2 for the alternate hypothesis, it is assumed $\mathbf{p1=0.24}$, $\mathbf{q1=0.15}$ (response rates for AMC and Placebo, respectively, in Stage 1) and $\mathbf{p2=0.24}$, $\mathbf{q2=0.10}$ (response rates for AMC and Placebo, respectively, in Stage 2), and $\mathbf{s=0.85}$ (rate of continuation into Stage 2 of the trial among placebo non-responders). Corresponding to these, the randomization fraction $\mathbf{a=0.37}$ and the weight $\mathbf{w=0.43}$ would maximize the power of the test (Table 3). A sample size of 370 is chosen for this study and will provide 90% power to detect the weighted difference between the two treatment arms. In Stage 1, the random allocation to Placebo:AMC would be 274:96. Based on the above assumptions, it would be expected that:

- Of the 274 assigned to PLB, 15% ($\mathbf{q1=0.15}$) would be Placebo responders while 85% (or 233) would be Placebo non-responders.
- 198 (85% of 233, $\mathbf{s=0.85}$) participants would continue to Stage 2.
- In Stage 2, the random allocation to Placebo:AMC would be 99:99.
- During the course of the entire study 195 participants will receive the AMC, with 96 in Stage 1 and 99 in Stage 2.

See Section 8.4.1.1 for an update to the sample size after the sample size re-estimation was conducted.

Table 3: Sample Size Calculation								
SPCD Design Assumptions					Impact of Assumptions on			
Response Rates				Rate of Continuation in Stage 2				
AMC		PLB			Parameters		Sample Size for	
Stage 1 (p1)	Stage 2 (p2)	Stage 1 (q1)	Stage 2 (q2)	s	a	w	80% Power	90% Power
0.29	0.29	0.15	0.15	1	0.28	0.67	187	250
0.29	0.29	0.15	0.10	1	0.35	0.46	134	179
0.29	0.29	0.10	0.15	1	0.23	0.8	105	141
0.29	0.29	0.10	0.10	1	0.26	0.68	89	119
0.29	0.24	0.15	0.15	1	0.24	0.78	225	301
0.29	0.24	0.15	0.10	1	0.29	0.61	174	232
0.29	0.24	0.10	0.10	1	0.23	0.75	102	136
0.24	0.29	0.15	0.15	1	0.36	0.45	283	379
0.24	0.29	0.10	0.15	1	0.25	0.73	160	214
0.24	0.29	0.10	0.10	1	0.32	0.54	120	161
0.24	0.24	0.15	0.15	1	0.28	0.67	417	558
0.24	0.24	0.15	0.10	1	0.4	0.33	246	329
0.24	0.24	0.10	0.15	1	0.23	0.82	187	250
0.24	0.24	0.10	0.10	1	0.27	0.67	151	201
0.29	0.29	0.15	0.15	0.85	0.27	0.72	196	262
0.29	0.29	0.15	0.10	0.85	0.33	0.54	147	196
0.29	0.29	0.10	0.15	0.85	0.22	0.82	108	144
0.29	0.29	0.10	0.10	0.85	0.25	0.72	94	125
0.29	0.24	0.15	0.15	0.85	0.24	0.81	230	308
0.29	0.24	0.15	0.10	0.85	0.28	0.66	184	246
0.29	0.24	0.10	0.10	0.85	0.23	0.79	105	140
0.24	0.29	0.15	0.15	0.85	0.34	0.54	313	419
0.24	0.29	0.10	0.15	0.85	0.25	0.77	167	223
0.24	0.29	0.10	0.10	0.85	0.3	0.61	131	175
0.24	0.24	0.15	0.15	0.85	0.27	0.71	439	587
0.24	0.24	0.15	0.10	0.85	0.37	0.43	276	370
0.24	0.24	0.10	0.15	0.85	0.22	0.84	190	254
0.24	0.24	0.10	0.10	0.85	0.26	0.72	158	212


8.4 Interim Analyses

8.4.1 Sample Size Re-Estimation

Sample size re-estimation analysis will be conducted when approximately half of the participants have been enrolled and have passed the last day available for re-randomization, Week 8 Day 2, and will focus on the nuisance parameter s (rate of continuation into Stage 2 of the trial among Placebo non-responders). This analysis will not reveal the treatment effect observed in the trial at the time of this interim analysis. Fava (2003) suggested that both a and w be *a priori* chosen to maximize the power of the test based on the alternative hypothesis of interest, and therefore a and w will not be re-estimated. Under the design assumptions of $p1=0.24$, $q1=0.15$, $p2=0.24$, $q2=0.10$, the randomization fraction $a=0.37$, and the weight $w=0.43$, a sample size re-estimation will be performed using the estimated parameter s , keeping the other parameters fixed, to assess the adequacy of the projected study sample size and whether a sample size increase is warranted.

The timing of the sample size re-estimation is based on a number of factors: recruitment rate, timing of the primary outcome, amount of loss to follow-up, and time to perform the sample size re-estimation. ADAPT-2 will use the graphical tool presented in Figure 2 to assist in assessing the appropriate timing of sample size re-estimation. To illustrate, Figure 2 shows the timing of re-estimation when 50% of the participants have completed Stage 1 in the study (0.5 on the red line), assuming enrollment (blue line) in ADAPT-2 of 370 participants over an 18-month period. The time point to perform the sample size re-estimation corresponds to 10.7 months (9 months to enroll 50% participants plus completion of end of re-randomization window at Week 8 Day 2) after enrollment into ADAPT-2 has started, at which point, the study will have enrolled about 58% of the target sample size. If recruitment takes more or less time than expected, modifications can be made to the timing of the sample size re-estimation. The sample size re-estimation will be done only once and done before any interim analysis of the primary outcome is performed. The results of the sample size re-estimation analysis would be presented in a closed session of the DSMB, who will then provide a recommendation to the NIDA CCTN regarding whether the target sample size should be modified. A decision regarding any such modification would be made subsequently by the CCTN, taking into consideration the recommendation of the DSMB.

Figure 2: Completed Stage 1 and Fraction of Target Enrollment for Proposed Sample Size Re-Estimation Based on Months from Start of Enrollment



8.4.1.1 Sample Size Re-Estimation Results

The NIDA CTN DSMB reviewed the sample size re-estimation report dated July 23, 2018, prepared by the DSC. In this report, the sample size re-estimation was presented under the design assumptions of $p_1=0.24$, $q_1=0.15$, $p_2=0.24$, $q_2=0.10$, the randomization fraction $a=0.37$, the weight $w=0.43$, and using the estimated parameter $s=0.75758$, keeping the other parameters fixed. The s parameter was estimated using the first 185 participants randomized. Table 4 shows the results of the sample size re-estimation.

Table 4: Sample Size Re-Estimation Results			
Sample Size Calculation	s	N	Power
Original design	0.85	276	80%
	0.85	370	90%
Power with current sample size and updated s parameter	0.75758	276	76.8%
	0.75758	370	87.7%
Maintaining original power with increased sample size using updated s parameter	0.75758	298	80%
	0.75758	399	90%

Based on the above results, the DSMB and NIDA CCTN concurred that although the loss of power compared to the original power calculations was negligible, the dropout rate that will occur in Stage 2 of the study is also unknown and recommended increasing the sample size by 30 additional participants ($N = 400$) to maintain the targeted 90% power. The CCTN approved the increase the sample size to 400 participants in a letter to the Lead Investigator dated August 13, 2018.

8.4.2 Interim Monitoring of Primary Efficacy Endpoint

Interim monitoring for efficacy will be performed of the primary alternative hypothesis that the AMC, relative to the Placebo, is associated with greater methamphetamine non-use. There will be no interim efficacy monitoring before a sample size re-estimation is performed (or a determination that re-estimation is not needed) because sample size re-estimation could change the target sample size, affecting the alpha spending function used in the interim efficacy monitoring. After sample size re-estimation, interim efficacy monitoring will be performed only once during the recruitment period. Because the Lan-DeMets approach (DeMets and Lan, 1994) requires an independent increments process, care must be taken in defining the population that will be used in the interim analysis. For example, including participants in an interim look who completed 6 weeks of Stage 1 and are Placebo non-responders, but have not yet had the opportunity to contribute Stage 2 responses, violates the independent-increments requirement. To avoid this, the following rule will be obeyed:

- For a look at study time t months, include only those participants who were randomized to Stage I no later than $t-3$ months (i.e., have the opportunity to complete the 12 weeks (or 3 months) on study at the time of the analysis). The size of that sample, when divided by the target sample size, becomes the information fraction for the look at calendar time t .

Based on the above rule and using designed parameters, the Lan-DeMets alpha-spending approach to interim monitoring for SPCD trials was investigated by simulation. Enrollment was assumed to be constant over an 18-month period. Under the null hypothesis, (p_1, p_2) are set equal to $(q_1, q_2) = (0.15, 0.10)$, while under the alternative, $(p_1, p_2) = (0.24, 0.24)$ a 2-look scenario, in which information fraction = $(0.5, 1.0)$, was simulated.

Table 5 gives the simulated probability of rejecting the null hypothesis at $\alpha = 0.025$, 1-tailed, for each of these scenarios. More specifically, 10,000 time series of SPCD z-values were simulated, each with 2 values (when there are 2 looks) for each scenario. In each scenario, the proportion of time series that ever cross the relevant boundary is presented in Table 6. It shows that after using the O'Brien-Fleming-type boundaries the test size under the null and power under the alternative are as desired.

Table 5: Simulated Probability of Rejecting the Null Hypothesis at $\alpha = 0.025$, 1-tailed		
	Null Hypothesis	Alternative Hypothesis
O'Brien-Fleming type	0.0237	0.90

All interim monitoring will use an O'Brien-Fleming-type boundary with information fraction equal to the proportion of the target sample size with primary outcome, and $\alpha = 0.025$, one-tailed. This approach spends very little alpha at the interim look, therefore the impact of an interim monitoring on the sample size is negligible. Table 6 shows an example of boundary (Z-score) to stop early for efficacy and cumulative alpha spent at interim analysis with 0.5 information fraction.

Table 6: Boundary to Stop Early for Efficacy and Cumulative Alpha Spent at Interim Analysis			
Information Fraction	Boundary	Alpha Spent	Cumulative Alpha Spent
0.5 (Half-way)	2.9626	0.00153	0.00153
1 (End of study)	1.9686	0.02347	0.025

In addition, the observed parameters and number of participants assigned to each treatment arm in the two stages will be monitored against the designed parameters (**$p1=0.24$, $q1=0.15$, $p2=0.24$, $q2=0.10$, $s=0.85$**) and expected assignment. The only criterion for early stopping for efficacy will be based on Z-scores and its relation to O'Brien-Fleming-type boundary.

Before recommending early termination, the DSMB should consider:

- Internal consistency of primary and secondary results.
- Internal consistency of primary and secondary results by subgroups defined by baseline characteristics (e.g., number of baseline MA use days on TLFB, severity of MA use, tobacco use history, treatment effectiveness assessment and visual analog craving scale).
- Distribution of baseline prognostic factors among the two groups.
- Consistency of primary and secondary results across clinical sites and among clinical sites enrolling larger numbers of participants.
- Possible impact of missing data from missed participant visits for assessment of the primary and secondary response variables.
- Possible differences in concomitant interventions or medications.

8.4.3 Safety Interim Analyses

Safety interim looks will be performed for the regular DSMB meetings or at unscheduled times per the DSMB's request. These will include analysis of adverse events and narrative report on serious adverse events.

Further, because the primary outcome analysis is a one-sided test to assess whether AMC is more efficacious than Placebo, simultaneous with primary interim efficacy monitoring analysis, a poor efficacy statistic will be calculated to assess whether the AMC, relative to the Placebo, is associated with greater methamphetamine use i.e., whether compared to AMC, the response rate

is greater in Placebo in both stages. This analysis will be conducted after the sample size re-estimation. If the poor efficacy of AMC statistic crosses its boundary, defined by the minimum of $q1 - p1$ and $q2 - p2$ being greater than 10%, the DSMB will consider whether to stop the trial early because of poor efficacy of AMC relative to Placebo. When reporting results of the trial, the one-sided superiority test will be considered the primary outcome, with the other tail considered as part of the poor efficacy analysis intended for the DSMB to monitor for safety. That is, as in a more usual trial design, the possibility of exit in the safety/poor efficacy tail will not be considered as possibly affecting the type I or type II error of the primary outcome statistical test.

8.4.4 Conditional Power and Futility

Unless otherwise requested, a futility/conditional power calculation will be performed when interim monitoring is performed. If at any DSMB meeting the conditional power falls below 0.3 (when hypothetical future observations are generated under the design alternative ($p1=0.24$, $q1=0.15$, $p2=0.24$, $q2=0.10$) but tested under the null), this will stimulate a discussion among the DSMB members about whether the trial should stop for futility.

8.4.5 Results of Interim Monitoring for Efficacy and Safety

The NIDA CTN DSMB met on October 24, 2018 to review the interim efficacy and safety analyses prepared by the DSC using the first 200 enrollment participants. The DSMB recommended the study should continue until 400 participants complete as determined by the sample size re-estimation.

8.5 Software to be Used for Analyses

The O'Brien-Fleming boundaries and the p-value for the primary outcome will be calculated in WinLD (Reboussin 2000). The interim analyses for sample size re-estimation and conditional power will be conducted in R Versions 3.4.2 and 3.5.1. All other analyses performed by the DSC and the Lead Node will use SAS® Version 9.4 software, including the calculation of the Wald type test statistic Z for the primary outcome. The Lead Node may also conduct analyses using R Versions 3.4.2 and 3.5.1.

9.0 ANALYSIS OF SAFETY OUTCOME MEASURES

9.1 Adverse Events

Treatment emergent adverse events (AEs) as defined in Section 2.13 will be summarized by presenting the number of events, number of participants experiencing AEs, and the severity and relatedness of adverse events by treatment arm and stage. Stage 1 events include AEs occurring before the date of re-randomization for re-randomized participants and in Weeks 1-6 for non-re-randomized participants, and Stage 2 AEs include events occurring on or after the date of re-randomization for re-randomized participants and in Weeks 7 or greater for non-re-randomized participants.

All adverse events will be coded using MedDRA® dictionary version 22.0 and higher and the number of participants experiencing each treatment emergent AE and the incidence rate will be provided by treatment arm and stage. Treatment emergent adverse event incidence rates will be summarized by System Organ Class (SOC) and Preferred Term (PT). The incidence rate of an AE is calculated as the number of participants who experience the event at least once during the safety window divided by the number of participants at risk times 100. Incidence rates will be calculated at the preferred term level, at the SOC level, and for participants with at least one treatment emergent adverse event. If a participant experiences multiple episodes of an event, then the event is only counted once. Detailed listings of treatment emergent adverse events and non-treatment emergent events in the safety population by treatment arm will be provided.

Treatment arm differences will be monitored by the DSMB.

9.2 Serious Adverse Events

Treatment emergent Serious Adverse Events (SAEs) will be summarized by presenting the number of events, number of participants experiencing SAEs, and the relatedness and type of SAEs by treatment arm and stage. SAEs will be presented by stage as described in Section 9.1. A summary of treatment emergent MedDRA[®] coded serious adverse events using incidence rates will be provided by treatment arm and stage. Incidence rates, as defined in Section 9.1, will be calculated at the preferred term level, at the SOC level, and for participants with at least one treatment emergent serious adverse event. A detailed listing of SAEs, including treatment emergent SAEs and non-treatment emergent SAEs, will be provided by treatment arm. Narratives for all serious adverse events will be included in the Final Study Report.

9.3 Injection Site Abnormalities

The injection site is examined by medical personnel at the next study visit following the injection administration. Injections #1 and #2 occur in Stage 1 and injections #3 and #4 occur in Stage 2. Injection site abnormalities will be summarized by presenting the number of abnormalities, number of participants experiencing abnormalities, type of abnormality, and the severity of the abnormality by treatment arm and stage. A detailed listing of injection site abnormalities for injections by treatment arm will be provided.

9.4 Laboratory Values

Laboratory values are collected at Screening, Week 6, and Week 12. Elevated liver function tests (LFTs) consisting of alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin and decreased platelets are monitored by the safety and medical monitors at the CCC. There are multiple site- and sex-based normal ranges amongst the eight sites for the ALT, AST and total Bilirubin parameters. For practicality, the safety team reviewed these parameters and generated a global threshold for each: ALT and AST 250 IU/L, total bilirubin 2.2 mg/dL, and platelets below $75 \times 10^3/\mu\text{L}$. Table 7 provides the normal ranges for all study sites for LFTs and platelets.

Listings of elevated LFTs and decreased platelets will be presented by treatment arm.

Table 7: Normal Ranges by Site

Lab	SC BHS	WS CODA, Inc.	GNV SURC - Columbia	NS Hennepin County	WS SURU - SFDPH	TX UCLA CBAM	TX UT Health CNRA	TX UTSW
ALT	female 14-54 IU/L male 17-63 IU/L	Female 16-19 yrs 5-32 U/L Female 20+ yrs 6-29 U/L Male 16-19 yrs 8-46 U/L Male 20+ yrs 9-46 U/L	Female 1-31 IU/L Male 1-40 IU/L	Female up to 33 U/L Male up to 41 U/L	Female 7-35 U/L Male 10-40 U/L	8-64 units/L	Female 0-32 IU/L Male 0-44 IU/L	9-46 U/L
AST	15-41 IU/L	Female 7-19 yrs 12-32 U/L Female 20-49 yrs 10-30 U/L Female 50+ yrs 10-35 U/L Male 7-19 yrs 12-32 U/L Male 20-49 yrs 10-40 U/L Male 50+ yrs 10-35 U/L	Female 1-31 IU/L Male 1-37 IU/L	5-40 U/L	2-60 yrs 10-41 U/L 60-90 yrs 10-48 U/L	13-47 units/L	0-40 IU/L	10-40 U/L
Total Bilirubin	0.3-1.2 mg/dL	Female 10-19 yrs 0.2-1.1 mg/dL Female 20+ yrs 0.2-1.2 mg/dL Male 10-19 yrs 0.2-1.1 mg/dL Male 20+ yrs 0.2-1.2 mg/dL	0.1-1.1 mg/dL	0.0-1.2 mg/dL	0-60 years 0.1-1.2 mg/dL 60-90 yrs 0.1-1.1 mg/dL	0.1-1.2 mg/dL	0.0-1.2 mg/dL	0.2-1.2 mg/dL
Platelets	130-450 x thousand cells/ μ L	140-400 thousand/ μ L	130-400 K/ mm^3	150-400 x 10^3 μ L	150,000-400,000/mcL	143-398 x 10^3 / μ L	150-379 x 10^3 / μ L	140-400 x 10^3 μ L

9.5 Electrocardiogram

Electrocardiograms (ECG) are conducted at screening and at Week 12. A summary table displaying the count and frequency of participants with elevated QTc intervals greater than and equal to 500 milliseconds and changes from baseline will be presented by treatment arm. Participants experiencing second or third degree AV block at Week 12 will be listed by treatment arm.

9.6 Suicide Risk

The Concise Health Risk Tracking (CHRT) and Patient Health Questionnaire-9 (PHQ-9) surveys are conducted at screening, weekly during the treatment period, and at follow-up visits to assess suicide risk. A summary table of participants endorsing suicidality on either assessment during the treatment period will be presented by treatment arm and stage. A listing of visits where suicidality was endorsed by a participant will be generated.

Endorsement for the CHRT is defined as answering agree or strongly agree to any of the following: (1) I have been having thoughts of killing myself, (2) I have thoughts about how I might kill myself, or (3) I have a plan to kill myself. On the PHQ-9, a participant is considered to have endorsed suicidality if they indicate several days, more than half the days, and nearly every day having thoughts they are better off dead or of hurting themselves.

9.7 Pregnancy

A listing of pregnancies and pregnancy outcomes in randomized participants will be generated. Narratives will also be provided.

9.8 Deaths

A listing of deaths and narratives of deaths will be provided.

10.0 DATA QUALITY

10.1 Data Audits

A summary of data audit results from site interim monitoring visits conducted by CCC monitors will be presented by site.

10.2 Protocol Deviations

Protocol deviations will be summarized by site and will include the number of deviations reported, the number of participants each deviation affects, frequencies for the types of protocol deviations, and information on whether the protocol deviation was deemed minor or major. A detailed listing of protocol deviations by deviation category will be provided.

11.0 UPDATES TO THE STATISTICAL ANALYSIS PLAN

The Statistical Analysis Plan (SAP) Version 0.1 was reviewed by the IRB and DSMB prior to the initiation of the study and contains unblinded information on the study design not included in the protocol. SAP Version 0.1 is included in Appendix 14.1. SAP Version 1.0 was updated to include all information necessary for interim analyses to be conducted and was finalized on July 5, 2018. SAP Version 2.0, which included a correction to the formula for standard error for the primary outcome analysis, was finalized on September 6, 2018 before interim analyses were conducted for the October 24, 2018 DSMB meeting. A detailed Change Log from SAP Version 0.1 to SAP Version 2.0 is located in Appendix 14.2. SAP Version 3.0 was finalized prior to data lock to include the remaining information necessary to analyze the study.

12.0 REFERENCES

- Chen, Y. F., Yang, Y., Hung, H. M., & Wang, S. J. (2011). Evaluation of performance of some enrichment designs dealing with high placebo response in psychiatric clinical trials. *Contemp Clin Trials*, 32(4), 592-604. doi:10.1016/j.cct.2011.04.006.
- DeMets DL, Lan KK. (1994). Interim analysis: the alpha spending function approach. *Stat Med*, 13:1341-1356.
- Doros, G., Pencina, M., Rybin, D., Meisner, A., Fava, M. (2013). A repeated measures model for analysis of continuous outcomes in sequential parallel comparison design studies, *Statistics in Medicine*, 32:2767-2789.
- Fava, M., Evins, A. E., Dorer, D. J., & Schoenfeld, D. A. (2003). The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. *Psychother Psychosom*, 72(3), 115-127. doi:69738.
- Ling, W., Shoptaw, S., Wesson, D., Rawson, R. A., Compton, M., & Klett, C. J. (1997). Treatment effectiveness score as an outcome measure in clinical trials. *NIDA Res Monogr*, 175, 208-220.
- Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG. (2010). CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. *J Clin Epi*, 63(8): e1-e37.
- National Institutes of Health (NIH). (2016). Guidelines for the Review of Inclusion on the Basis of Sex/Gender, Race, Ethnicity, and Age in Clinical Research. https://grants.nih.gov/grants/peer/guidelines_general/Review_Human_subjects_Inclusion.pdf.
- Reboussin DM, DeMets DL, Kim KM, Lan KK. (2000). Computations for group sequential boundaries using the Lan-DeMets spending function method. *Control Clin Trials*, 2000 Jun;21(3):190-207.
- Schoenfeld D. Power calculator for a Sequential Parallel Comparison Design (SPCD). <http://hedwig.mgh.harvard.edu/biostatistics/node/43>
- Shiener, L.B., Rubin, D.B. (1995). Intention-to-treat analysis and the goals of clinical trials. *Clinical Pharmacology and Therapeutics*, 57(1):6-15.
- Stuart, E.A., Jo, B. (2015). Assessing the sensitivity of methods for estimating principal causal effects, *Statistical Methods in Medical Research*. 24(6) (2015) 657-674.
- Tamura, R. N., & Huang, X. (2007). An examination of the efficiency of the sequential parallel design in psychiatric clinical trials. *Clin Trials*, 4(4), 309-317.

13.0 LIST OF PROPOSED TABLES, FIGURES, AND LISTINGS

The listing of tables below contains the tables, figures, and listings which will be provided by the DSC.


Section	Title	Population
Enrollment, Participant Disposition, and Follow-up	Summary of Pre-screens by Site	Pre-screened
	Summary of Screen Failures by Site	Screened
	Summary of Pre-screens, Screening, and Randomization by Site	Pre-screened
	Randomizations by Site, Stage and Treatment Arm	ITT
	Figure of Expected versus Actual Randomizations Overall	Randomized
	Figure of Expected versus Actual Randomizations by Site	Randomized
	Proposed and Actual Randomizations by Site	Randomized
	Summary of Disposition by Site	Randomized
	Summary of Disposition by Treatment Arm in Stage 1	Randomized
	Summary of Disposition by Treatment Arm in Stage 2	Randomized
	Summary of Disposition by Treatment Arm in Follow-up Period	Randomized
	CONSORT Flow Diagram	Pre-screened
	Summary of Attendance at Treatment Period Visits by Treatment Arm in Stage 1	Randomized
	Summary of Attendance at Treatment Period Visits by Treatment Arm in Stage 2	Randomized
	Summary of Attendance at Follow-up Visits by Treatment Arm	Randomized
	Summary of Missed Visits by Treatment Arm in Stage 1	Randomized
	Summary of Missed Visits by Treatment Arm in Stage 2	Randomized
	Summary of Missed Visits by Treatment Arm in Follow-up Period	Randomized
Participant Characteristics at Baseline	Summary of Baseline Characteristics by Site	Randomized
	Summary of Baseline Characteristics by Stage and Treatment Arm	Randomized
Concomitant Medications	Summary of Concomitant Medications by Treatment Arm	Randomized
Treatment Exposure	Summary of Early Medication Terminations by Site	Randomized
	Summary of Early Medication Terminations by Treatment Arm in Stage 1	Randomized
	Summary of Early Medication Terminations by Treatment Arm in Stage 2	Randomized
	Summary of Treatment Exposure by Site	Randomized

Section	Title	Population
	Summary of Treatment Exposure by Site, Stage and Treatment Arm	Randomized
	Summary of Injections by Site	Randomized
	Summary of Injections by Stage and Treatment Arm	Randomized
	Summary of Oral Medication Blood Levels in AMC Participants by Stage	Randomized
Primary Outcome	Summary of Primary Outcome Availability by Stage and Treatment Arm	ITT
	Summary of Primary Outcome Analysis by Stage and Treatment Arm	ITT
	Figure of UDS Results by Stage and Treatment Arm	ITT
	Summary of Primary Outcome Sensitivity Analyses by Stage and Treatment Arm	ITT
	Summary of Primary Outcome Availability by Stage and Site	ITT
	Summary of Primary Outcome by Site, Stage, and Treatment Arm	ITT
	Summary of Primary Outcome by Sex, Stage, and Treatment Arm	ITT
	Summary of Primary Outcome by Race, Stage, and Treatment Arm	ITT
	Summary of Primary Outcome by Ethnicity, Stage, and Treatment Arm	ITT
	Summary of Primary Outcome by Age, Stage, and Treatment Arm	ITT
	Primary Outcome Covariate Adjusted Analysis Results	ITT
	Summary of UDS Availability by Stage and Treatment Arm	Randomized
	Summary of Methamphetamine Negative UDS Results by Treatment Arm in Stage 1	Randomized
	Summary of Methamphetamine Negative UDS Results by Treatment Arm in Stage 2	Randomized
	Summary of Methamphetamine Negative UDS Results by Treatment Arm in Follow-up Period	Randomized
	Summary of Primary Outcome Sensitivity Analyses by Stage and Treatment Arm in the Randomized Population	Randomized
	Figure of UDS Results by Stage and Treatment Arm in Randomized Population	Randomized
	Summary of Primary Outcome by Stage and Treatment Arm in Per Protocol Populations	Per Protocol
Safety Outcomes	Summary of Treatment Emergent Adverse Events by Treatment Arm in Stage 1	Safety
	Summary of Treatment Emergent Adverse Events by Treatment Arm in Stage 2	Safety

Section	Title	Population
	Summary of Treatment Emergent MedDRA Coded Adverse Events by Treatment Arm in Stage 1	Safety
	Summary of Treatment Emergent MedDRA Coded Adverse Events by Treatment Arm in Stage 2	Safety
	Listing of Treatment Emergent Adverse Events by Treatment Arm	Safety
	Listing of Non-Treatment Emergent Adverse Events in Randomized Participants by Treatment Arm	Safety
	Listing of Non-Treatment Emergent Adverse Events in Screen Failure Participants	Safety
	Summary of Treatment Emergent Serious Adverse Events by Treatment Arm in Stage 1	Safety
	Summary of Treatment Emergent Serious Adverse Events by Treatment Arm in Stage 2	Safety
	Summary of Treatment Emergent MedDRA Coded Serious Adverse Events by Treatment Arm in Stage 1	Safety
	Summary of Treatment Emergent MedDRA Coded Serious Adverse Events by Treatment Arm in Stage 2	Safety
	Listing of Serious Adverse Events by Treatment Arm	Safety
	Summary of Injection Site Abnormalities by Treatment Arm in Stage 1	Safety
	Summary of Injection Site Abnormalities by Treatment Arm in Stage 2	Safety
	Listing of Injection Site Abnormalities by Treatment Arm	Safety
	Listing of Elevated LFTs by Treatment Arm	Safety
	Listing of Decreased Platelets by Treatment Arm	Safety
	Summary of Elevated QTc Intervals by Treatment Arm	Safety
	Listing of AV Block ECG Abnormalities by Treatment Arm	Safety
	Summary of Suicide Risk by Treatment Arm in Stage 1	Safety
	Summary of Suicide Risk by Treatment Arm in Stage 2	Safety
	Summary of Suicide Risk by Treatment Arm in Follow-up Period	Safety
	Listing of Suicide Risk by Treatment Arm	Safety
	Listing of Pregnancies by Treatment Arm	Safety
	Listing of Deaths by Treatment Arm	Safety
Data Quality	Summary of Data Audits	N/A
Protocol Deviations	Summary of Protocol Deviations	N/A
	Listing of Protocol Deviations	N/A

14.0 APPENDICES

14.1 SAP Version 0.1



Statistical Analysis Plan for NIDA CTN-0068 Protocol

Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder

Lead Investigator (LI): Madhukar Trivedi, MD

Version 0.1

September 13, 2016

TABLE OF CONTENTS

1.0	Randomization Plan	33
2.0	Statistical Analyses	34
2.1	Primary Efficacy Outcome Measure	34
2.2	Statistical Methods for Primary Outcome	34
2.1	Secondary Outcomes.....	35
2.2	Statistical Methods for Secondary Outcomes	35
2.3	Sample Size and Statistical Power	36
2.3.1	Table 1: Sample Size Calculation	37
2.4	Significance Testing	38
2.5	Handling Missing Data and Dropouts	38
2.6	Interim Analyses	38
2.6.1	Sample Size Re-estimation.....	38
2.6.2	Interim Monitoring of Primary Efficacy Endpoint.....	39
2.6.3	Safety Interim Analyses	41
2.6.4	Conditional Power and Futility.....	41

Confidentiality Agreement

The CTN-0068 Protocol provided to site investigators contains all of the information required to safely conduct the study. The protocol contains a disclaimer stating that some design features are omitted because, if they are revealed to site investigators, the double blind will be broken. The disclaimer indicates the following details are omitted: the timing of re-randomization, the duration and timing of the evaluation period, and related statistical analysis (as it contains information about re-randomization and the evaluation period). Those details are contained in this document, the Statistical Analysis Plan or SAP. Some information contained in the protocol is repeated in the SAP to facilitate understanding. Information from the protocol is indicated with an underline.

The Lead Team will provide the SAP directly to the Institutional Review Board(s) or Independent Ethics Committee for review and approval. Those in receipt of the SAP will be asked to keep its contents confidential. As such, the SAP should be viewed as a confidential supplement to the protocol, intended for use only by the Lead Team, Institutional Review Board(s), and Sponsor. The SAP should not be provided to site investigators.

The Individual and/or Institutional Recipient agrees not to disclose, in any medium, the confidential information contained herein unless given written permission from the Study PI, Madhukar H. Trivedi.

37.0 RANDOMIZATION PLAN

Note: Some information contained in the protocol is repeated in the SAP to facilitate understanding. Information from the protocol is indicated with an underline.

This protocol will utilize a sequential parallel comparison design (SPCD), originally proposed by Fava et al. (2003), and later revised by Chen et al. (2011). During the course of the study, participants may or may not be switched to another arm, as determined by the a priori adaptive aspect of the study design. Participants appearing to respond well to their original treatment assignment will not be switched. The 12 week medication phase is divided into two stages of equal treatment duration.

Eligible participants will be randomized to stage 1 of the medication phase in an approximately 96: 274 ratio to the active medication combination (AMC) and placebo (PLB) treatment arms, stratifying by site. Randomization to PLB or AMC in stage 1 will occur in a **2a: (1-2a)** fashion. Participants who have not been withdrawn from study medication administration by medical staff will remain eligible to participate in stage 2. Eligible stage 1 participants assigned to PLB and who did not meet the specified definition of responder (i.e., PLB non-responders) will be re-randomized in a 1:1 ratio to either the PLB or AMC arm in stage 2, stratifying by site. All other eligible stage 1 participants (i.e., PLB responders and AMC participants) will remain in the same treatment arm during stage 2 as was assigned in stage 1. The window for re-randomization opens on week 7 day 1 and closes on week 8 day 2. If a participant does not attend a visit between week 7 day 1 and week 8 day 2, the participant will not be re-randomized in stage 2 and will continue receiving the treatment assigned in stage 1. Re-randomization at stage 2 helps ensure treatment balance in the two treatment groups within the stage 2 population. The stage 1 randomization procedure and the stage 2 re-randomization / treatment continuation procedure will be conducted electronically by the CTN Data and Statistics Center (DSC) to maintain the double blind.

38.0 STATISTICAL ANALYSES

38.1 Primary Efficacy Outcome Measure

The evaluation period is the final two weeks of the medication phase in stage 1 (weeks 5 - 6) for all participants and stage 2 (weeks 11 - 12) for participants that have been re-randomized. The primary efficacy outcome is a measurement of treatment response at a specified threshold (3 of 4 UDS negative for methamphetamine). Thus, a participant will meet “responder” criterion by providing 3 of 4 methamphetamine-negative UDS tests during the final two weeks of each stage of the medication phase.


It is hypothesized that the AMC arm will be associated with a greater number of “responders,” defined as participants who provide at least 3 of 4 MA-negative UDS tests during the final two weeks in stage 1 (weeks 5 - 6) and stage 2 (weeks 11 - 12), relative to the PLB arm.

The treatment groups will be compared as to the proportion of responders in stage 1 and stage 2. The treatment effect will be defined as a weighted combination of the response rates in the two stages. The weight was chosen to optimize the test under the alternative hypothesis as described below. All treatment comparisons will be performed under the Intent-to-Treat (ITT) criteria.

38.2 Statistical Methods for Primary Outcome

The following schema shows the design parameters of the SPCD.

SPCD: Defining the Outcome



Let p_1, q_1 be the response rates for AMC and PLB in stage 1; and p_2, q_2 be the response rates of AMC and PLB in stage 2, that is, among PLB non-responders. Assume that s is the rate of continuation into stage 2 among PLB non-responders, (i.e. $1-s$ is the stage 1 drop-out rate). The primary analysis alternative hypothesis is that the AMC group has higher response rate than PLB in the full population (stage 1) OR in the sub-population of placebo non-responders (stage 2). Statistically speaking, we want to test following null (H_0) vs alternate hypothesis (H_1).

$$H_0: p_1 = q_1 \text{ AND } p_2 = q_2$$

$$H_1: p_1 > q_1 \text{ OR } p_2 > q_2$$

The randomization fraction, **a** and the weight, **w** are the parameters of the SPCD that are chosen to maximize the power of the test, based on the alternative hypothesis. Fava (2003) recommends that both **a** and **w** be chosen *a priori* based on the alternative hypothesis of interest. For the alternative hypothesis of this study, we assume **p1=0.24**, **q1=0.15** (response rates for AMC and PLB, respectively, in stage 1) and **p2=0.24**, **q2=0.10** (response rates for AMC and PLB, respectively, in stage 2), and **s=.85** (rate of continuation into stage 2 of the trial among placebo non-responders). These assumptions lead to the conclusion that the randomization fraction, **a=.37** and the weight, **w=0.43** will maximize the power of the test. The primary outcome analysis will be performed as described in Tamura and Huang (2007) using the Wald type test statistic $Z = h/se(h)$, where

$$h = w(p_{1,obs} - q_{1,obs}) + (1 - w)(p_{2,obs} - q_{2,obs})$$

$$se(h) = \frac{w^2 p_{1,obs} (1 - p_{1,obs})}{n(1 - 2a)} + \frac{\left(\left(\frac{w^2}{4} \right) q_{1,obs} (1 - q_{1,obs}) + \frac{(1 - w)^2 q_{2,obs} (1 - q_{2,obs})}{s_{obs} (1 - q_{1,obs})} \right)}{na} + \frac{\left(\left(\frac{w^2}{4} \right) q_{1,obs} (1 - q_{1,obs}) + \frac{(1 - w)^2 p_{2,obs} (1 - p_{2,obs})}{s_{obs} (1 - q_{1,obs})} \right)}{na}$$

In the above test statistic both **a** and **w** are chosen *a priori* as 0.37 and 0.43; **n** is the sample size and the quantities $p_{1,obs}$, $q_{1,obs}$, s_{obs} , $p_{2,obs}$ and $q_{2,obs}$ will be estimated from the data. The null hypothesis will be rejected if $Z > Z_{\alpha/2}$, where $Z_{\alpha/2}$ is the upper critical value from the normal distribution. A one-sided p-value for the test of primary outcome will be obtained, and the null hypothesis of no treatment effect will be rejected, if this p-value is less than 0.025. We will also investigate repeating the analysis with the inclusion of selected covariates (e.g., age of onset of methamphetamine use) if possible.

38.3 Secondary Outcomes

Secondary outcomes include methamphetamine and other substance use outcomes in the pre-evaluation period (weeks 1 - 4 for stage 1 and weeks 7 - 10 in stage 2), in the evaluation period (weeks 5 - 6 for stage 1 and weeks 11 - 12 in stage 2), in each 6 week stage, over the entire 12 week medication phase, and at the follow-up assessment for responders, non-responders, and other sub-groups. Secondary outcomes also include depression scores, quality of life, overall functioning, clinic attendance and ratings of participant and staff satisfaction with study procedures, including use of the smartphone app, compensation, and study medication. Secondary safety outcomes will be participants' reports of treatment emergent adverse events including serious adverse events collected at scheduled clinic visits or via other contact.

38.4 Statistical Methods for Secondary Outcomes

Drug use will be measured by several outcomes including but not limited to the Treatment Effectiveness Score (TES; Ling et al., 1997), days of self-reported drug use, number of consecutive negative UDS, and UDS as a binary outcome (positive or negative) across time. The TES is the percentage of the scheduled urine drug screens that were negative for each drug. Mixed-model analysis of repeated measures will be used to explore the presence of time-related medication effects, including severity of cravings. The models will control for baseline MA use and other key demographic and participant variables. Additional analyses will include assessment of drug use in the pre-evaluation period (weeks 1 - 4 for stage 1 and weeks 7 - 10 in stage 2), over the entire medication period, and at the follow-up assessment. Changes occurring over the

medication period in severity and type of drug-related problems and in quality of life will be analyzed with parametric and nonparametric measures. Participant and staff satisfaction ratings will be summarized. A two-sided test of significance will be used with a p-value less than 0.05 indicating significance.

Analyses of secondary outcomes will be primarily performed on all individuals who are randomized and inducted onto study medication. Secondary analyses will also be performed by examining responses in subgroups with varying characteristics. Response rates and associated confidence intervals in each stage will be assessed for the participants who initiate the evaluation period and who receive the second injection of medication. Adherence with oral study medication dosing will be measured by smartphone app-based take-home dosing videos and in-clinic observation. A dosing adherent per-protocol analysis will be performed by evaluating response rates in the medication-adherent group, namely, all participants receiving both injections and with $\geq 80\%$ adherence with prescribed daily doses of oral medication confirmed by video or observation in clinic. Because per-protocol analyses may be biased (Sheiner and Rubin, 1995) an unbiased complier-adjusted-causal-effects analysis (Jo and Stuart, 2009) may also be used to adjust for adherence.

All the above mentioned secondary analyses (except staff satisfaction ratings) will be performed in a similar way as the primary analysis for SPCD, that is, by weighted combination of the estimated treatment effects in the two stages. The analysis approach described in Chen (2011) will be followed; for continuous outcome ordinary least squares and mixed effects model for repeated measures (MMRM) will be used and for binary outcomes a logistic regression will be used. The same weights as primary outcome will be used to calculate the weighted combination of the estimated treatment effects in the two stages for the secondary analyses.

38.5 Sample Size and Statistical Power

The sample size calculation has been conducted as described in Tamura (2007). Table 3 below shows the impact of various design assumptions on the parameters of the randomization fraction, a and the weight, w and the sample size for the study. It is important to note that when the rate of discontinuation is 0% ($s=1$), the sample size calculation based on Tamura and Huang (2007) gives the same results as Fava et al.'s (2003) SPCD sample size calculations.

As described above for the alternate hypothesis, we assume $p1=0.24$, $q1=0.15$ (response rates for AMCan and PLB, respectively, in stage 1) and $p2=0.24$, $q2=0.10$ (response rates for AMCan and PLB, respectively, in stage 2), and $s=.85$ (rate of continuation into stage 2 of the trial among placebo non-responders). Corresponding to these, the randomization fraction $a=.37$ and the weight $w=0.43$ would maximize the power of the test. A sample size of 370 is chosen for this study and will provide 90% power to detect the weighted difference between the two treatment arms. In stage 1, the random allocation to PLB: AMC would be 274: 96. Based on the above assumptions, it would be expected that:

- Of the 274 assigned to PLB, 15% ($q1=0.15$) would be PLB responders while 85% (or 233) would be PLB non-responders.
- 198 (85% of 233, $s=.85$) participants would continue to stage 2.
- In stage 2, the random allocation to PLB: AMC would be 99: 99.
- During the course of the entire study 195 participants will receive the AMC, with 96 in stage 1 and 99 in stage 2.

38.5.1 Table 1: Sample Size Calculation

SPCD Design Assumptions								
Response Rates				Rate of Continuation in Stage 2				
					Impact of Assumptions on			
AMC		PLB		s	Parameters		Sample Size for	
Stage 1 (p1)	Stage 2 (p2)	Stage 1 (q1)	Stage 2 (q2)		a	w	80% Power	90% Power
0.29	0.29	0.15	0.15	1	0.28	0.67	187	250
0.29	0.29	0.15	0.10	1	0.35	0.46	134	179
0.29	0.29	0.10	0.15	1	0.23	0.8	105	141
0.29	0.29	0.10	0.10	1	0.26	0.68	89	119
0.29	0.24	0.15	0.15	1	0.24	0.78	225	301
0.29	0.24	0.15	0.10	1	0.29	0.61	174	232
0.29	0.24	0.10	0.10	1	0.23	0.75	102	136
0.24	0.29	0.15	0.15	1	0.36	0.45	283	379
0.24	0.29	0.10	0.15	1	0.25	0.73	160	214
0.24	0.29	0.10	0.10	1	0.32	0.54	120	161
0.24	0.24	0.15	0.15	1	0.28	0.67	417	558
0.24	0.24	0.15	0.10	1	0.4	0.33	246	329
0.24	0.24	0.10	0.15	1	0.23	0.82	187	250
0.24	0.24	0.10	0.10	1	0.27	0.67	151	201
0.29	0.29	0.15	0.15	0.85	0.27	0.72	196	262
0.29	0.29	0.15	0.10	0.85	0.33	0.54	147	196
0.29	0.29	0.10	0.15	0.85	0.22	0.82	108	144
0.29	0.29	0.10	0.10	0.85	0.25	0.72	94	125
0.29	0.24	0.15	0.15	0.85	0.24	0.81	230	308
0.29	0.24	0.15	0.10	0.85	0.28	0.66	184	246
0.29	0.24	0.10	0.10	0.85	0.23	0.79	105	140
0.24	0.29	0.15	0.15	0.85	0.34	0.54	313	419
0.24	0.29	0.10	0.15	0.85	0.25	0.77	167	223
0.24	0.29	0.10	0.10	0.85	0.3	0.61	131	175
0.24	0.24	0.15	0.15	0.85	0.27	0.71	439	587
0.24	0.24	0.15	0.10	0.85	0.37	0.43	276	370
0.24	0.24	0.10	0.15	0.85	0.22	0.84	190	254
0.24	0.24	0.10	0.10	0.85	0.26	0.72	158	212

38.6 Significance Testing

The primary outcome will be evaluated using a one-sided test with a type I error rate of 2.5% while the secondary outcomes will use a two-sided test with 5% error rate. There are several secondary outcomes; however, multiple testing will not be adjusted for in the secondary analyses, since these are not part of the study's primary objective. When multiple tests are conducted, the chance of finding a significant difference in one of the tests, when in fact no difference exists, is greater than the stated Type I error rate. The investigators are aware of the issues associated with multiple testing and will interpret results with caution.

38.7 Handling Missing Data and Dropouts

In stage 1 “responders” are defined as participants who provide at least 3 of 4 MA-negative UDS tests during the final two weeks of the stage 1 phase (weeks 5 – 6). Any participant who drops out before the last week in each evaluation period is, by definition, a non-responder. Therefore, any participant who drops out before week 6 is a stage 1 non-responder. In the SPCD design, stage 1 PLB non-responders are to be randomized again in stage 2, but re-randomization is impossible if the participant has dropped out. Thus, stage 1 dropouts will not contribute to the analysis in stage 2. In stage 2, dropouts (i.e., any participant who drops out before week 12) are again considered to be non-responders by definition, and this causes no further complication in the SPCD computation.

It is unknown *a priori* how many participants will drop out in stage 1 of the study, thus the 15% attrition rate ($s=0.85$) was chosen as a conservative estimate. Also, as described above, an assumption was made that participants who dropped out early in a given stage will be considered as non-responders in that stage. Therefore, it is important to assess the impact of these missing data assumptions on the primary outcome analysis of the study. A series of sensitivity analyses will be performed to determine how the missing data affects the primary results.

38.8 Interim Analyses


38.8.1 Sample Size Re-estimation

Sample size re-estimation analysis will be conducted when approximately half of the participants have been enrolled and have completed stage 1 of the study, and will focus on the nuisance parameter s (rate of continuation into stage 2 of the trial among PLB non-responders). This analysis will not reveal the treatment effect observed in the trial at the time of this interim analysis. Fava (2003) suggested that both a and w be *a priori* chosen to maximize the power of the test based on the alternative hypothesis of interest, and therefore a and w will not be re-estimated. Under the design assumptions of $p1=0.24$, $q1=0.15$, $p2=0.24$, $q2=0.10$, the randomization fraction $a=.37$, and the weight $w=0.43$, a sample size re-estimation will be performed using the estimated parameter s to assess the adequacy of the projected study sample size and whether a sample size increase is warranted.

The timing of the sample size re-estimation is based on a number of factors: recruitment rate, timing of the primary outcome, amount of loss to follow-up, and time to perform the sample size re-estimation. ADAPT-2 will use the graphical tool presented in Figure A to assist in assessing the appropriate timing of sample size re-estimation. To illustrate, Figure A shows in a picture the timing of re-estimation when 50% of the participants have completed stage 1 in the study (0.5 on the red line), assuming enrollment (blue line) in ADAPT-2 of 370 participants over an 18 month period. The time point to perform the sample size re-estimation corresponds to 10.5 months (9 months to enroll 50% participants plus completion of 6 weeks in Stage 1) after enrollment into ADAPT-2 has started, at which point, the study will have enrolled about 58% of the target sample size. If recruitment takes more or less time than expected, modifications can be made to the timing of the sample size re-estimation. The sample size re-estimation will be done only once, and done before any interim analysis of the primary outcome is performed. The results of the sample size

re-estimation analysis would be presented in a closed session of the DSMB, who will then provide a recommendation to the NIDA CCTN regarding whether the target sample size should be modified. A decision regarding any such modification would be made subsequently by the CCTN, taking into consideration the recommendation of the DSMB.

Figure A. Completed Stage 1 and Fraction of Target Enrollment for Proposed Sample Size Re-Estimation Based on Months from Start of Enrollment



38.8.2 Interim Monitoring of Primary Efficacy Endpoint

Interim monitoring for efficacy will be performed of the primary alternative hypothesis that the AMC, relative to the PLB, is associated with greater MA non-use. There will be no interim efficacy monitoring before a sample size re-estimation is performed (or a determination that re-estimation is not needed) because sample size re-estimation could change the target sample size, affecting the alpha spending function used in the interim efficacy monitoring. After sample size re-estimation, interim efficacy monitoring will be performed only once during the recruitment period. Because the Lan-DeMets approach requires an independent increments process, care must be taken in defining the population that will be used in the interim analysis. For example, including participants in an interim look who completed 6 weeks of stage 1 and are placebo non-responders, but have not yet had the opportunity to contribute stage 2 responses, violates the independent-increments requirement. To avoid this, we will obey the following rule:

- For a look at study time t months, include only those participants who were randomized to stage I no later than $t-3$ months (i.e., have the opportunity to complete the 12 weeks (or 3

months) on study at the time of the analysis). The size of that sample, when divided by the target sample size, becomes the information fraction for the look at calendar time t .

Based on the above rule and using designed parameters, we investigated by simulation the Lan-DeMets alpha-spending approach to interim monitoring for SPCD trials. Enrollment was assumed to be constant over an 18-month period. Under the null hypothesis, (p_1, p_2) are set equal to $(q_1, q_2) = (0.15, 0.10)$, while under the alternative, $(p_1, p_2) = (0.24, 0.24)$ a 2-look scenario, in which information fraction = $(0.5, 1.0)$, was simulated.

Table 2 gives the simulated probability of rejecting the null hypothesis at $\alpha = 0.025$, 1-tailed, for each of these scenarios. More specifically, 10,000 time series of SPCD z-values were simulated, each with 2 values (when there are 2 looks) for each scenario. In each scenario, the proportion of time series that ever cross the relevant boundary is presented in Table 2. It shows that after using the O'Brien-Fleming-type boundaries the test size under the null and power under the alternative are as desired.

Table 2: Simulated probability of rejecting the null hypothesis at $\alpha = 0.025$, 1-tailed

	Null Hypothesis	Alternative Hypothesis
O'Brien-Fleming type	0.0237	0.90

All interim monitoring will use an O'Brien-Fleming-type boundary with information fraction equal to the proportion of the target sample size with primary outcome, and $\alpha = 0.025$, one-tailed. This approach spends very little alpha at the interim look, therefore the impact of an interim monitoring on the sample size is negligible. Table 3 shows an example of boundary (Z-score) to stop early for efficacy and cumulative alpha spent at interim analysis with 0.5 information fraction.

Table 3: Boundary to stop early for efficacy and cumulative alpha spent at interim analysis

Information Fraction	Boundary	Alpha Spent	Cumulative Alpha Spent
0.5 (Half-way)	2.9626	0.00153	0.00153
1 (End of study)	1.9686	0.02347	0.025

In addition, the observed parameters and number of participants assigned to each treatment arm in the two stages will be monitored against the designed parameters ($p1=0.24$, $q1=0.15$, $p2=0.24$, $q2=0.10$, $s=.85$) and expected assignment. The only criterion for early stopping for efficacy will be based on Z-scores and its relation to O'Brien-Fleming-type boundary.

Before recommending early termination, the DSMB will consider:

- Internal consistency of primary and secondary results.
- Internal consistency of primary and secondary results by subgroups defined by baseline characteristics (e.g., severity of MA use, tobacco use history, treatment effectiveness assessment and visual analog craving scale).
- Distribution of baseline prognostic factors among the two groups.
- Consistency of primary and secondary results across clinical sites and among clinical sites enrolling larger numbers of participants.
- Possible impact of missing data from missed participant visits for assessment of the primary and secondary response variables.
- Possible differences in concomitant interventions or medications.

38.8.3 Safety Interim Analyses

Safety interim looks will be performed for the regular DSMB meetings or at unscheduled times per the DSMB's request. These will include analysis of adverse events and narrative report on serious adverse events.

Further, because the primary outcome analysis is a one-sided test to assess whether AMC is more efficacious than PLB, simultaneous with primary interim efficacy monitoring analysis, a "poor efficacy" statistic will be calculated to assess whether the AMC, relative to the PLB, is associated with greater MA use i.e. whether compared to AMC, the response rate is greater in PLB in both stages. This analysis will be conducted after the sample size re-estimation. If the "poor efficacy of AMC" statistic crosses its boundary, defined by the minimum of $q1 - p1$ and $q2 - p2$ being greater than 10%, the DSMB will consider whether to stop the trial early because of poor efficacy of AMC relative to PLB. When reporting results of the trial, the one-sided superiority test will be considered the primary outcome, with the other tail considered as part of the poor efficacy analysis intended for the DSMB to monitor for safety. That is, as in a more usual trial design, the possibility of exit in the safety/poor efficacy tail will not be considered as possibly affecting the type I or type II error of the primary outcome statistical test.

38.8.4 Conditional Power and Futility

Unless otherwise requested, a futility/conditional power calculation will be performed when interim monitoring is performed. If at any DSMB meeting the conditional power falls below 0.3 (when hypothetical future observations are generated under the design alternative ($p1=0.24$, $q1=0.15$, $p2=0.24$, $q2=0.10$) but tested under the null), this will stimulate a discussion among the DSMB members about whether the trial should stop for futility.

14.2 Change Log for SAP Version 0.1 to SAP Version 2.0

See SAP Version 3.0, Section 11.0 for summary of changes and dates.

Administrative Changes

Administrative, grammatical, and clarifying changes				
Section	Location	Original text	Revision	Rationale
Throughout	N/A	We	Revised text to remove usage of “we”	Emmes project standards for SAPs
Throughout	N/A	Instances of: s=.85 a=.37	s= 0.85 , a= 0.37	Added leading 0 to all decimals for consistency
Confidentiality Agreement	Paragraph 1	The disclaimer indicates the following details are omitted: the timing of re-randomization, the duration and timing of the evaluation period, and related statistical analysis (as it contains information about re-randomization and the evaluation period).	The disclaimer indicates the following details are omitted: the timing of re-randomization, the duration and timing of the evaluation period , and related statistical analysis (as it contains information about re-randomization and the evaluation period).	Protocol Amendment v4.0 unmasked this information from sites by adding it to the protocol
Confidentiality Agreement	Paragraph 2	The Lead Team will provide the SAP directly to the Institutional Review Board(s) or Independent Ethics Committee for review and approval.	The Lead Team provided the SAP directly to the Institutional Review Board(s) or Independent Ethics Committee for review and approval before the study was initiated .	Revised text to from future tense to reflect the SAP had been submitted to IRB prior to study initiation.
List of Abbreviations	N/A	N/A	ITT Intent-to-Treat SAP Statistical Analysis Plan TLFB Timeline Followback	These abbreviations are referenced in the document
Sections 1.0, 2.2, 2.3, 2.4, 2.6, 2.7	N/A	stage 1, stage 2	Stage 1, Stage 2	Capitalized for consistency with DSMB tables
Section 1.0	Paragraph 3	the active medication combination (AMC) and placebo (PLB) treatment arms	the active medication combination (AMC) and placebo medication combination (PLB) treatment arms	Consistency with protocol

Administrative, grammatical, and clarifying changes				
Section	Location	Original text	Revision	Rationale
Section 2.1	Paragraph 1	(3 of 4 UDS negative for methamphetamine). Thus, a participant will meet “responder” criterion by providing 3 of 4 methamphetamine-negative UDS tests	(3 of 4 UDS negative for methamphetamine (MA)). Thus, a participant will meet “responder” criterion by providing 3 of 4 MA-negative UDS tests	Added definition of MA abbreviation
Section 2.2	Formula after Paragraph 3	$se(h) =$	$var(h) =$	The formula provided is the variance and not the standard error. Refer to Tamura and Huang (2007).
Section 2.2	Formula after Paragraph 3	N/A	$and\ se(h) = \sqrt{var(h)}$	Included the formula to calculate the standard error, which is needed to compute the test statistic Z
Section 2.2	Paragraph 4	null hypothesis will be rejected if $Z > z_{\alpha/2}$, where $z_{\alpha/2}$ is the upper critical value	null hypothesis will be rejected if $Z > z_{\alpha}$ (one-sided), where z_{α} is the upper critical value	Clarification that test is one-sided
Section 2.2	Paragraph 4	if this p-value is less than 0.025	if this p-value is less than α	Clarified that alpha could be less than 0.025 because of interim analysis in Section 2.7.2
Section 2.2	Paragraph 4	N/A	One-sided lower bound confidence limit for the responder rate will be calculated using $h - z_{\alpha} * se(h)$.	Added definition for calculation of confidence interval
Section 2.2	Paragraph 4	N/A	Because an interim analysis will be conducted to assess the efficacy of the study, p-value cutoffs will be adjusted based on O'Brien Fleming boundaries. See Section 2.7.2 for alpha values at interim analysis and final analysis.	Clarified the value of alpha being affected by interim analysis in Section 2.7.2

Administrative, grammatical, and clarifying changes				
Section	Location	Original text	Revision	Rationale
Section 2.2	Paragraph 5	We will also investigate repeating the analysis with the inclusion of selected covariates (e.g., age of onset of methamphetamine use) if possible.	The analysis will be repeated with the inclusion of selected covariates, for example , age of onset of methamphetamine use, baseline methamphetamine use days self-reported on Timeline Followback (TLFB), severity of methamphetamine use, tobacco use history, treatment effectiveness score, visual analog craving scale, and site if possible.	Included more covariates to be considered
Section 2.4	Paragraph 1	the parameters of the randomization fraction, a and the weight, w and the sample size for the study	the parameters of the SPCD , the randomization fraction, a , and the weight, w , and on the sample size for the study	Revised for clarity
Section 2.4	Paragraph 1	Table 3 below shows	Table 1 below shows	Corrected table number and removed reference to below because it is not found on the same page
Section 2.4	Paragraph 2	maximize the power of the test	maximize the power of the test (Table 1)	Added reference to Table 1
Section 2.4	N/A	N/A	See Section 2.7.1 for an update to the samples size after the sample size re-estimation was conducted.	Added information in the SAP to document when the sample size was increased. Protocol v5.0 contains language about the increased sample size.

Administrative, grammatical, and clarifying changes				
Section	Location	Original text	Revision	Rationale
Section 2.4 in v0.1 SAP	N/A	N/A	Entire section removed	This section ('Statistical Methods for Secondary Outcomes') will be revised and included in future version of the SAP
Section 2.5	Paragraph 1	one-sided test with a type I error rate of 2.5%	one-sided test with a type I error rate of α 2.5% as described in section 2.7.2	Clarified that alpha could be less than 0.25 because of interim analysis in Section 2.7.2
Section 2.7.1	Paragraph 1	a sample size re-estimation will be performed using the estimated parameter s to assess the adequacy	a sample size re-estimation will be performed using the estimated parameter s , keeping the other parameters fixed, to assess the adequacy	Clarified how sample-size re-estimation will be conducted
Section 2.7.1	Paragraph 1	have completed stage 1 of the study	have completed stage 1 of the study passed the last day available for re-randomization, week 8 day 2	Revised timing of sample size re-estimation to allow the participants time to re-randomize, using the end of the window for re-randomization
Section 2.7.1	Paragraph 2	Figure A	Figure A1	Updated figure name to be consistent with table naming
Section 2.7.1	Paragraph 2	Figure A shows in a picture	Figure A1 shows in a picture	Redundant wording removed
Section 2.7.1	Paragraph 2	10.5 months (9 months to enroll 50% participants plus completion of 6 weeks in Stage 1)	10. 57 months (9 months to enroll 50% participants plus completion of 6 weeks in Stage 1 end of re-randomization window at week 8 day 2)	Revised timing of sample size re-estimation to allow the participants time to re-randomize, using the end of the window for re-randomization

Administrative, grammatical, and clarifying changes				
Section	Location	Original text	Revision	Rationale
Section 2.7.1	Paragraph 3	N/A	<p><u>Update to the sample size:</u></p> <p>The NIDA CTN DSMB reviewed the sample size re-estimation report dated July 23, 2018, prepared by the DSC. In this report, the sample size re-estimation was presented under the design assumptions of $p1=0.24$, $q1=0.15$, $p2=0.24$, $q2=0.10$, the randomization fraction $a=0.37$, the weight $w=0.43$, and using the estimated parameter $s=0.75758$, keeping the other parameters fixed. The s parameter was estimated using the first 185 participants randomized. Table 2 shows the results of the sample size re-estimation.</p>	Added information in the SAP to summarize how and when the sample size re-estimation was conducted.
Section 2.7.1	Paragraph 4	N/A	<p>Based on the above results, DSMB and NIDA CCTN concurred that although the loss of power compared to the original power calculations was negligible, the dropout rate that will occur in Stage 2 of the study is also unknown and recommended increasing the sample size by 30 additional participants (N = 400) to maintain the targeted 90% power. The CCTN approved the increase the sample size to 400 in a memo to the Lead Investigator on August 13, 2018.</p>	DSMB and NIDA CCTN decision to increase the sample size to 400. Added information to document why and when the sample size was increased. Protocol v5.0 contains language about the increased sample size.

Administrative, grammatical, and clarifying changes				
Section	Location	Original text	Revision	Rationale
Section 2.7.1	Table 2	N/A	Table 2: Sample Size Re-estimation results	The table displays results of the sample size re-estimation
Section 2.7.2	Throughout	Table 2	Table 3	Updated table numbering with insertion of Table 2 Sample Size Re-estimation results
Section 2.7.2	Throughout	Table 3	Table 4	Updated table numbering with insertion of Table 2 Sample Size Re-estimation results
Figure 1	N/A	N/A	Updated Figure	Revised to allow the participants time to re-randomize, using the end of the window for re-randomization
Section 2.7.2	Paragraph 1	Because the Lan-DeMets approach requires	Because the Lan-DeMets approach (DeMets and Lan, 1994) requires	Provided a reference for Lan-DeMets approach which includes O'Brien-Fleming boundary
Section 2.7.2	Paragraph 7	e.g., severity of MA use	e.g., number of baseline MA use days on TLFB, severity of MA use	Include TLFB for DSMB consideration of early termination
Section 3.0	N/A		Added references	Finalized version of SAP should include reference section